{"PMC7160437": [["Establishing a programme for staff testing at Sheffield Teaching Hospitals NHS Foundation TrustSheffield Teaching Hospitals NHS Foundation Trust (STH) is one of the UK\u2019s largest foundation trusts, employing ca 17,000 individuals and providing a range of hospital and community services.", [["staff testing", "TEST", 29, 42]]], ["On 17 March 2020, STH commenced testing of symptomatic staff for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), coordinated by the Occupational Health department.", [["acute respiratory syndrome coronavirus", "DISEASE", 72, 110], ["severe acute respiratory syndrome coronavirus", "SPECIES", 65, 110], ["SARS-CoV-2", "SPECIES", 114, 124], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 65, 110], ["severe", "OBSERVATION_MODIFIER", 65, 71], ["acute", "OBSERVATION_MODIFIER", 72, 77], ["respiratory syndrome", "OBSERVATION", 78, 98]]], ["Staff members presenting with an influenza-like illness (defined as a reported fever AND one of: cough, sore throat, runny nose, myalgia, headache) or persistent cough, were directed to self-swab in the on-site assessment pods previously used for testing of ambulatory patients in the community.", [["influenza-like illness", "DISEASE", 33, 55], ["fever", "DISEASE", 79, 84], ["cough", "DISEASE", 97, 102], ["sore throat", "DISEASE", 104, 115], ["runny nose", "DISEASE", 117, 127], ["myalgia", "DISEASE", 129, 136], ["headache", "DISEASE", 138, 146], ["cough", "DISEASE", 162, 167], ["nose", "ORGANISM_SUBDIVISION", 123, 127], ["patients", "ORGANISM", 269, 277], ["patients", "SPECIES", 269, 277], ["an influenza-like illness", "PROBLEM", 30, 55], ["fever", "PROBLEM", 79, 84], ["cough", "PROBLEM", 97, 102], ["sore throat", "PROBLEM", 104, 115], ["runny nose", "PROBLEM", 117, 127], ["myalgia", "PROBLEM", 129, 136], ["headache", "PROBLEM", 138, 146], ["persistent cough", "PROBLEM", 151, 167], ["influenza", "OBSERVATION", 33, 42], ["persistent", "OBSERVATION_MODIFIER", 151, 161], ["cough", "OBSERVATION", 162, 167]]], ["Written and pictorial instructions were provided to staff to self-swab the back of the oropharynx and then insert the same swab 4\u20136 cm to the back of the nasopharynx.Establishing a programme for staff testing at Sheffield Teaching Hospitals NHS Foundation TrustThe Sigma-Virocult swabs (Medical Wire, Corsham, UK), containing viral transport medium, were transported to the hospital laboratory at least four times daily.", [["oropharynx", "ANATOMY", 87, 97], ["back", "ANATOMY", 142, 146], ["nasopharynx", "ANATOMY", 154, 165], ["back", "ORGANISM_SUBDIVISION", 75, 79], ["oropharynx", "ORGAN", 87, 97], ["nasopharynx", "ORGAN", 154, 165], ["the same swab", "TREATMENT", 114, 127], ["staff testing", "TEST", 195, 208], ["oropharynx", "ANATOMY", 87, 97], ["back", "ANATOMY_MODIFIER", 142, 146], ["nasopharynx", "ANATOMY", 154, 165]]], ["Nucleic acid extraction was performed using MagNA Pure 96 (Roche Life Sciences, Basel, Switzerland).", [["Nucleic acid", "CHEMICAL", 0, 12], ["Nucleic acid", "SIMPLE_CHEMICAL", 0, 12], ["Nucleic acid extraction", "TREATMENT", 0, 23]]], ["Real-time RT-PCR was performed using the ABI LightCycler (Applied Biosystems, Foster City, United States) with primers and probes specific for both RNA-dependent RNA polymerase (RdRP) and envelope (E) genes [2].", [["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 148, 176], ["RdRP", "GENE_OR_GENE_PRODUCT", 178, 182], ["envelope (E)", "GENE_OR_GENE_PRODUCT", 188, 200], ["RNA-dependent RNA polymerase", "PROTEIN", 148, 176], ["RdRP", "PROTEIN", 178, 182], ["envelope (E) genes", "DNA", 188, 206], ["the ABI LightCycler", "TEST", 37, 56], ["primers", "TREATMENT", 111, 118]]], ["Samples with positive amplification curves for both RdRP and E, or samples with an E amplification curve alone and a cycle threshold less than 35, were considered positive.", [["Samples", "ANATOMY", 0, 7], ["samples", "ANATOMY", 67, 74], ["RdRP", "DNA", 52, 56], ["E", "DNA", 61, 62], ["Samples", "TEST", 0, 7], ["positive amplification curves", "TEST", 13, 42], ["an E amplification curve", "TEST", 80, 104], ["a cycle threshold", "TEST", 115, 132]]], ["Samples with E amplification alone but a cycle threshold of 35 or greater were considered indeterminate and sent away for further testing.", [["Samples", "ANATOMY", 0, 7], ["E amplification", "TREATMENT", 13, 28], ["a cycle threshold", "TEST", 39, 56], ["further testing", "TEST", 122, 137], ["indeterminate", "OBSERVATION_MODIFIER", 90, 103]]], ["RNAaseP was used as an internal control to ensure good cellular content of the sample.Establishing a programme for staff testing at Sheffield Teaching Hospitals NHS Foundation TrustThe majority of test results were communicated to staff on the same or the next day.", [["cellular", "ANATOMY", 55, 63], ["sample", "ANATOMY", 79, 85], ["RNAaseP", "CHEMICAL", 0, 7], ["RNAaseP", "SIMPLE_CHEMICAL", 0, 7], ["cellular", "CELL", 55, 63], ["RNAaseP", "PROTEIN", 0, 7], ["RNAaseP", "TREATMENT", 0, 7], ["an internal control", "TREATMENT", 20, 39], ["staff testing", "TEST", 115, 128]]], ["Staff with a negative SARS-CoV-2 test were able to return to work if they felt well enough to do so.", [["CoV-2 test", "TEST", 27, 37]]], ["The policy was authorised by hospital management on 17 March.Establishing a programme for staff testing at Sheffield Teaching Hospitals NHS Foundation TrustWe present the data from the first fortnight of staff testing.", [["staff testing", "TEST", 90, 103], ["staff testing", "TEST", 204, 217]]], ["Where available, details of staff roles and their work patterns since the onset of symptoms were obtained through their electronic clinical record.", [["symptoms", "PROBLEM", 83, 91]]], ["Following application of the NHS Health Research Authority algorithm (available at http://www.hra-decisiontools.org.uk/research/), it was decided that no formal ethical approval from the Institutional Review Board was required to produce this report.Roll-out of staff testing at Sheffield Teaching Hospitals NHS Foundation TrustIn the week commencing 16 March, 451 staff members were tested for SARS-CoV-2 with 58 (13%) positive.", [["SARS", "DISEASE", 395, 399], ["SARS-CoV", "SPECIES", 395, 403], ["SARS-CoV", "TEST", 395, 403]]], ["In the following week, 1,082 additional staff were tested, and 20 staff were retested because of worsening symptoms, with 224 (20%) positive.", [["worsening symptoms", "PROBLEM", 97, 115]]], ["Of the 20 staff retested, three were positive and 17 remained negative for SARS-CoV-2.", [["SARS", "DISEASE", 75, 79], ["SARS", "PROBLEM", 75, 79], ["CoV", "TEST", 80, 83]]], ["Overall 282 of 1,533 (18%) staff tested positive, 1,246 of 1,533 (81%) tested negative and five of 1,533 (< 1%) had an indeterminate result.", [["indeterminate", "OBSERVATION_MODIFIER", 119, 132]]], ["All samples contained sufficient human cellular material.", [["samples", "ANATOMY", 4, 11], ["cellular", "ANATOMY", 39, 47], ["human", "ORGANISM", 33, 38], ["cellular material", "TISSUE", 39, 56], ["human", "SPECIES", 33, 38], ["human", "SPECIES", 33, 38], ["All samples", "TEST", 0, 11], ["sufficient human cellular material", "OBSERVATION", 22, 56]]], ["Figure 1 details the daily breakdown of SARS-CoV-2 staff testing.Analysis of the first week of staff testing (16 to 22 March 2020)Among staff positive for SARS-CoV-2 for whom data were recorded (n = 52), 25 were nursing staff, eight were doctors, nine were other patient-facing clinical staff, nine were laboratory or secretarial staff and one worked in cleaning services.", [["SARS", "DISEASE", 40, 44], ["SARS", "DISEASE", 155, 159], ["patient", "ORGANISM", 263, 270], ["patient", "SPECIES", 263, 270], ["staff testing", "TEST", 51, 64], ["staff testing", "TEST", 95, 108], ["SARS", "PROBLEM", 155, 159], ["CoV", "TEST", 160, 163]]], ["Regarding symptoms, where data were recorded (n = 48), 23 had not worked with any symptoms, seven had been at work when symptoms developed and had left work on the same day, and 18 had worked at least one full shift with symptoms which were subsequently attributed to COVID-19 disease.", [["symptoms", "PROBLEM", 10, 18], ["any symptoms", "PROBLEM", 78, 90], ["symptoms", "PROBLEM", 120, 128], ["symptoms", "PROBLEM", 221, 229], ["COVID-19 disease", "PROBLEM", 268, 284], ["left", "ANATOMY_MODIFIER", 147, 151]]], ["None of the staff who tested positive for SARS-CoV-2 required hospital admission at the time of their positive result.", [["SARS", "DISEASE", 42, 46], ["SARS-CoV", "ORGANISM", 42, 50], ["SARS-CoV", "SPECIES", 42, 50], ["SARS", "PROBLEM", 42, 46], ["CoV", "TEST", 47, 50]]], ["In the week when staff testing was started, between 16 and 20 March 2020, the Occupational Health department received 4,337 phone calls, compared with 998 calls between 9 and 13 March 2020.Contextualisation of staff testing at Sheffield Teaching Hospitals NHS foundation trust within UK policy and PHE guidanceFrom 12 March 2020, in the UK, community testing was discontinued and any person with a fever or a new persistent cough was advised to self-isolate for 7 days, in order to enable UK laboratories to deliver priority testing for increasing numbers of hospitalised patients [3].", [["PHE", "CHEMICAL", 298, 301], ["fever", "DISEASE", 398, 403], ["cough", "DISEASE", 424, 429], ["patients", "ORGANISM", 572, 580], ["person", "SPECIES", 384, 390], ["patients", "SPECIES", 572, 580], ["staff testing", "TEST", 17, 30], ["community testing", "TEST", 341, 358], ["a fever", "PROBLEM", 396, 403], ["a new persistent cough", "PROBLEM", 407, 429], ["priority testing", "TEST", 516, 532], ["cough", "OBSERVATION", 424, 429]]], ["From 16 March, asymptomatic household members of any person with a fever or new cough were advised to self-isolate for 14 days [4].", [["fever", "DISEASE", 67, 72], ["cough", "DISEASE", 80, 85], ["person", "SPECIES", 53, 59], ["a fever", "PROBLEM", 65, 72], ["new cough", "PROBLEM", 76, 85]]], ["The combined impact has meant that healthcare workers (HCW) with symptoms or with a symptomatic household member have been unable to work, exacerbating pre-existing staff shortages in frontline services in the National Health Service (NHS).", [["symptoms", "PROBLEM", 65, 73]]], ["In a survey of 5,194 doctors across the UK conducted over 24 h on 17 March, 12.8% were unable to work because they were symptomatic, and a further 15.1% were unable to work because of a symptomatic household contact (Michael Marks, personal communication, 26 March 2020).", [["symptomatic", "PROBLEM", 120, 131]]], ["At that time, PHE guidance stated that frontline staff who had been exposed to patients with confirmed SARS-CoV-2 infection without wearing personal protective equipment should continue to work so long as they remain asymptomatic [5].", [["PHE", "CHEMICAL", 14, 17], ["SARS-CoV-2 infection", "DISEASE", 103, 123], ["PHE", "CHEMICAL", 14, 17], ["patients", "ORGANISM", 79, 87], ["SARS-CoV-2", "ORGANISM", 103, 113], ["patients", "SPECIES", 79, 87], ["CoV-", "SPECIES", 108, 112], ["SARS", "PROBLEM", 103, 107], ["CoV-2 infection", "PROBLEM", 108, 123], ["personal protective equipment", "TREATMENT", 140, 169]]], ["This scenario has led to anxiety among exposed staff.", [["anxiety", "DISEASE", 25, 32], ["anxiety", "PROBLEM", 25, 32]]], ["Furthermore, in these conditions, staff members with only mild symptoms may feel pressured to continue working.", [["mild symptoms", "PROBLEM", 58, 71]]], ["Figure 2 describes the timeline of key guidance impacting HCW in relation to the COVID-19 outbreak in the UK.DiscussionOur data demonstrate that the majority of staff who reported symptoms during the first fortnight of staff testing were negative for SARS-CoV-2.", [["SARS", "DISEASE", 251, 255], ["UK", "GENE_OR_GENE_PRODUCT", 106, 108], ["SARS-CoV", "SPECIES", 251, 259], ["the COVID", "TEST", 77, 86], ["symptoms", "PROBLEM", 180, 188], ["staff testing", "TEST", 219, 232], ["SARS", "PROBLEM", 251, 255], ["CoV", "TEST", 256, 259]]], ["Facilitating testing may substantially decrease absence in staff when SARS-CoV-2 can be excluded.", [["SARS", "DISEASE", 70, 74], ["Facilitating testing", "TEST", 0, 20], ["SARS", "PROBLEM", 70, 74], ["CoV", "TEST", 75, 78]]], ["The sensitivity, and therefore the false-negative rate, of the two-gene target RT-PCR assay has not been formally described in the early stages of illness.", [["illness", "DISEASE", 147, 154], ["The sensitivity", "TEST", 0, 15], ["the false", "TEST", 31, 40], ["RT-PCR assay", "TEST", 79, 91], ["illness", "PROBLEM", 147, 154]]], ["However, SARS-2-CoV viral load in upper respiratory secretions is highest between 1 and 5 days from symptom onset, which is the optimal time to test symptomatic HCW [6].", [["upper respiratory secretions", "ANATOMY", 34, 62], ["SARS-2-CoV", "ORGANISM", 9, 19], ["upper respiratory", "ORGANISM_SUBDIVISION", 34, 51], ["secretions", "ORGAN", 52, 62], ["SARS", "TEST", 9, 13], ["CoV viral load", "TEST", 16, 30], ["upper respiratory secretions", "PROBLEM", 34, 62], ["upper", "ANATOMY_MODIFIER", 34, 39], ["respiratory", "ANATOMY", 40, 51], ["secretions", "OBSERVATION", 52, 62]]], ["If this test is negative, provided HCW are well and their symptoms have resolved (except for cough which is known to persist following any respiratory viral illness), it is reasonable that they return to work.", [["cough", "DISEASE", 93, 98], ["respiratory viral illness", "DISEASE", 139, 164], ["this test", "TEST", 3, 12], ["their symptoms", "PROBLEM", 52, 66], ["cough", "PROBLEM", 93, 98], ["any respiratory viral illness", "PROBLEM", 135, 164]]], ["Another major issue for healthcare staffing in the UK is that asymptomatic HCW must self-isolate for 14 days when they have a symptomatic family member.", [["UK", "GENE_OR_GENE_PRODUCT", 51, 53], ["asymptomatic HCW", "PROBLEM", 62, 78]]], ["An additional boost to the workforce could be provided by access to testing for symptomatic household members of HCW.DiscussionThe nature of work performed by healthcare professionals means that they may be at increased risk of COVID-19 infection and can also transmit infection to vulnerable patients [7].", [["infection", "DISEASE", 237, 246], ["infection", "DISEASE", 269, 278], ["patients", "ORGANISM", 293, 301], ["patients", "SPECIES", 293, 301], ["COVID-19", "SPECIES", 228, 236], ["COVID-19 infection", "PROBLEM", 228, 246], ["infection", "OBSERVATION", 237, 246]]], ["More than a third of staff had completed at least one shift while symptomatic.", [["symptomatic", "PROBLEM", 66, 77]]], ["A limitation of this report is that exact symptoms have not been recorded.", [["exact symptoms", "PROBLEM", 36, 50]]], ["Therefore, precise assessment of proportion of staff meeting PHE criteria for self-isolation is not possible.", [["PHE", "CHEMICAL", 61, 64], ["precise assessment", "TEST", 11, 29], ["self-isolation", "TREATMENT", 78, 92], ["not possible", "UNCERTAINTY", 96, 108]]], ["However, during contact of staff members testing positive for SARS-CoV-2, we ascertained that most staff who had continued to work had only mild or non-specific symptoms at the time of clinical work.", [["SARS", "DISEASE", 62, 66], ["SARS-CoV", "SPECIES", 62, 70], ["SARS", "PROBLEM", 62, 66], ["mild or non-specific symptoms", "PROBLEM", 140, 169]]], ["Early non-specific symptoms are challenging as HCWs may inadvertently expose other staff and patients before overt clinical symptoms manifest.", [["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 93, 101], ["Early non-specific symptoms", "PROBLEM", 0, 27], ["overt clinical symptoms", "PROBLEM", 109, 132], ["non-specific", "OBSERVATION_MODIFIER", 6, 18], ["symptoms", "OBSERVATION", 19, 27]]], ["Subclinical and asymptomatic infection has been reported, but its role in transmission is not clear [8-11].", [["infection", "DISEASE", 29, 38], ["Subclinical and asymptomatic infection", "PROBLEM", 0, 38], ["asymptomatic", "OBSERVATION_MODIFIER", 16, 28], ["infection", "OBSERVATION", 29, 38]]], ["Testing asymptomatic staff would have significant practical limitations and is not feasible with testing capacity in the UK.", [["testing capacity", "TEST", 97, 113]]], ["However, testing staff with mild or non-specific symptoms should be considered for infection control purposes, taking into account the practical implications of last-minute staff cover, optimal timing for swabbing to reduce false-negative results and laboratory capacity for testing [12].", [["infection", "DISEASE", 83, 92], ["mild or non-specific symptoms", "PROBLEM", 28, 57], ["infection control purposes", "PROBLEM", 83, 109], ["swabbing", "TREATMENT", 205, 213], ["laboratory capacity", "TEST", 251, 270], ["testing", "TEST", 275, 282]]], ["Another limitation of this report is the lack of data on the roles of every staff member tested, in order to be able to provide a detailed breakdown of infection rate among different staff groups.DiscussionTesting of staff at our institution may also have provided a limited snapshot of SARS-CoV-2 prevalence in the community (i.e. those not requiring hospital admission) with mild influenza-like illness or persistent cough.", [["infection", "DISEASE", 152, 161], ["SARS", "DISEASE", 287, 291], ["influenza-like illness", "DISEASE", 382, 404], ["cough", "DISEASE", 419, 424], ["infection rate", "PROBLEM", 152, 166], ["mild influenza", "PROBLEM", 377, 391], ["persistent cough", "PROBLEM", 408, 424], ["infection", "OBSERVATION", 152, 161], ["mild", "OBSERVATION_MODIFIER", 377, 381], ["influenza", "OBSERVATION", 382, 391], ["persistent", "OBSERVATION_MODIFIER", 408, 418], ["cough", "OBSERVATION", 419, 424]]], ["While it is important that the provision of testing is carefully balanced with consideration of laboratory capacity, increasing laboratory capacity to allow widespread testing of NHS staff could be a vital tool in achieving adequate staffing during the COVID-19 outbreak, and reducing the risk of transmission to vulnerable patients.", [["patients", "ORGANISM", 324, 332], ["patients", "SPECIES", 324, 332], ["testing", "TEST", 44, 51], ["laboratory capacity", "TEST", 96, 115], ["increasing laboratory capacity", "PROBLEM", 117, 147], ["a vital tool", "TEST", 198, 210], ["the COVID", "TEST", 249, 258]]]], "PMC7121872": [["IntroductionGenome-wide association studies (GWAS) of IBD have been a major success story for genome-level studies of complex human disease.", [["IBD", "DISEASE", 54, 57], ["human disease", "DISEASE", 126, 139], ["human", "ORGANISM", 126, 131], ["human", "SPECIES", 126, 131], ["human", "SPECIES", 126, 131], ["IBD", "PROBLEM", 54, 57], ["genome-level studies", "TEST", 94, 114], ["complex human disease", "PROBLEM", 118, 139], ["IBD", "ANATOMY", 54, 57], ["complex human disease", "OBSERVATION", 118, 139]]], ["One of the particularly exciting results from these studies was the identification of autophagy as an unanticipated player in determining risk of IBD.", [["IBD", "DISEASE", 146, 149], ["these studies", "TEST", 46, 59], ["autophagy", "PROBLEM", 86, 95], ["IBD", "PROBLEM", 146, 149], ["IBD", "OBSERVATION", 146, 149]]], ["This pathway, long considered to be a relatively nonselective process of bulk cytoplasmic degradation by the lysosome, is thought to have evolutionary roots as a mechanism to maintain metabolic homeostasis in response to decreased nutrient levels [1].", [["cytoplasmic", "ANATOMY", 78, 89], ["lysosome", "ANATOMY", 109, 117], ["roots", "ANATOMY", 151, 156], ["cytoplasmic", "ORGANISM_SUBSTANCE", 78, 89], ["lysosome", "CELLULAR_COMPONENT", 109, 117], ["bulk cytoplasmic degradation", "PROBLEM", 73, 101], ["evolutionary roots", "PROBLEM", 138, 156], ["decreased nutrient levels", "PROBLEM", 221, 246], ["bulk cytoplasmic degradation", "OBSERVATION", 73, 101]]], ["However, studies over the last 10 years have expanded the functions of autophagy to include roles in organelle clearance, antigen presentation, cell death, development, and the degradation of intracellular pathogens, among others.", [["organelle", "ANATOMY", 101, 110], ["cell", "ANATOMY", 144, 148], ["intracellular", "ANATOMY", 192, 205], ["death", "DISEASE", 149, 154], ["organelle", "CELLULAR_COMPONENT", 101, 110], ["cell", "CELL", 144, 148], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 192, 205], ["studies", "TEST", 9, 16], ["autophagy", "PROBLEM", 71, 80], ["organelle clearance", "TEST", 101, 120], ["cell death", "PROBLEM", 144, 154], ["intracellular pathogens", "PROBLEM", 192, 215], ["cell death", "OBSERVATION", 144, 154], ["intracellular pathogens", "OBSERVATION", 192, 215]]], ["The role of autophagy in immune-related processes [2\u20134] was particularly unexpected and has served as a guide in many studies seeking to connect human genetics to mechanisms of IBD pathogenesis [5\u20137].IntroductionThese genetic studies have identified multiple genes within the autophagy network as playing a role in CD, including ATG16L1, IRGM, NOD2, and LRRK2 [8\u201311].", [["IBD", "DISEASE", 177, 180], ["human", "ORGANISM", 145, 150], ["CD", "GENE_OR_GENE_PRODUCT", 315, 317], ["ATG16L1", "GENE_OR_GENE_PRODUCT", 329, 336], ["IRGM", "GENE_OR_GENE_PRODUCT", 338, 342], ["NOD2", "GENE_OR_GENE_PRODUCT", 344, 348], ["LRRK2", "GENE_OR_GENE_PRODUCT", 354, 359], ["ATG16L1", "PROTEIN", 329, 336], ["IRGM", "PROTEIN", 338, 342], ["NOD2", "PROTEIN", 344, 348], ["LRRK2", "DNA", 354, 359], ["human", "SPECIES", 145, 150], ["human", "SPECIES", 145, 150], ["IBD pathogenesis", "PROBLEM", 177, 193], ["These genetic studies", "TEST", 212, 233], ["IBD", "OBSERVATION", 177, 180]]], ["In the case of UC, the autophagy-related genes DAP1 and SMURF1 have also been identified as determinants of risk [12, 13].", [["UC", "PATHOLOGICAL_FORMATION", 15, 17], ["DAP1", "GENE_OR_GENE_PRODUCT", 47, 51], ["SMURF1", "GENE_OR_GENE_PRODUCT", 56, 62], ["autophagy-related genes", "DNA", 23, 46], ["DAP1", "DNA", 47, 51], ["SMURF1", "DNA", 56, 62], ["UC", "PROBLEM", 15, 17], ["the autophagy", "TEST", 19, 32], ["SMURF1", "PROBLEM", 56, 62], ["UC", "OBSERVATION", 15, 17]]], ["Further studies subsequently identified polymorphisms in ULK1, ATG2A, and GABARAPL1 as harboring significant associations with CD [14, 15].", [["CD", "DISEASE", 127, 129], ["ULK1", "GENE_OR_GENE_PRODUCT", 57, 61], ["ATG2A", "GENE_OR_GENE_PRODUCT", 63, 68], ["GABARAPL1", "GENE_OR_GENE_PRODUCT", 74, 83], ["ULK1", "DNA", 57, 61], ["ATG2A", "DNA", 63, 68], ["GABARAPL1", "DNA", 74, 83], ["Further studies", "TEST", 0, 15], ["polymorphisms in ULK1", "PROBLEM", 40, 61], ["ATG2A", "TEST", 63, 68], ["GABARAPL1", "TREATMENT", 74, 83]]], ["Although autophagy has been implicated in the disease process in a range of other disorders, including neurodegenerative disease [16, 17], atherosclerosis, and cancer, to date no compelling genetic association has been found between autophagy and many immune-related diseases, including multiple sclerosis, celiac disease, rheumatoid arthritis, and psoriasis.", [["cancer", "ANATOMY", 160, 166], ["celiac", "ANATOMY", 307, 313], ["neurodegenerative disease", "DISEASE", 103, 128], ["atherosclerosis", "DISEASE", 139, 154], ["cancer", "DISEASE", 160, 166], ["multiple sclerosis", "DISEASE", 287, 305], ["celiac disease", "DISEASE", 307, 321], ["rheumatoid arthritis", "DISEASE", 323, 343], ["psoriasis", "DISEASE", 349, 358], ["cancer", "CANCER", 160, 166], ["autophagy", "PROBLEM", 9, 18], ["the disease process", "PROBLEM", 42, 61], ["other disorders", "PROBLEM", 76, 91], ["neurodegenerative disease", "PROBLEM", 103, 128], ["atherosclerosis", "PROBLEM", 139, 154], ["cancer", "PROBLEM", 160, 166], ["autophagy", "PROBLEM", 233, 242], ["many immune-related diseases", "PROBLEM", 247, 275], ["multiple sclerosis", "PROBLEM", 287, 305], ["celiac disease", "PROBLEM", 307, 321], ["rheumatoid arthritis", "PROBLEM", 323, 343], ["psoriasis", "PROBLEM", 349, 358], ["disease", "OBSERVATION", 46, 53], ["neurodegenerative disease", "OBSERVATION", 103, 128], ["atherosclerosis", "OBSERVATION", 139, 154], ["cancer", "OBSERVATION", 160, 166], ["multiple", "OBSERVATION_MODIFIER", 287, 295], ["sclerosis", "OBSERVATION", 296, 305], ["celiac", "ANATOMY", 307, 313], ["disease", "OBSERVATION", 314, 321], ["rheumatoid arthritis", "OBSERVATION", 323, 343], ["psoriasis", "OBSERVATION", 349, 358]]], ["However, targeting sequencing studies have also begun to identify coding mutations in essential autophagy genes as playing roles in disease, raising the possibility that more disease-associated autophagy-related polymorphisms have yet to be uncovered [18, 19].IntroductionIn this chapter, we review studies that have employed human genetics to understand the link between autophagy and IBD.", [["IBD", "DISEASE", 386, 389], ["human", "ORGANISM", 326, 331], ["autophagy genes", "DNA", 96, 111], ["human", "SPECIES", 326, 331], ["human", "SPECIES", 326, 331], ["targeting sequencing studies", "TEST", 9, 37], ["coding mutations", "PROBLEM", 66, 82], ["disease", "PROBLEM", 132, 139], ["more disease-associated autophagy", "PROBLEM", 170, 203], ["related polymorphisms", "PROBLEM", 204, 225], ["review studies", "TEST", 292, 306], ["IBD", "PROBLEM", 386, 389], ["autophagy genes", "OBSERVATION", 96, 111], ["IBD", "OBSERVATION", 386, 389]]], ["We begin by examining the idea of the intestinal mucosa as a physiological system wherein homeostasis is particularly vulnerable to disruptions in autophagy.", [["intestinal mucosa", "ANATOMY", 38, 55], ["intestinal mucosa", "MULTI-TISSUE_STRUCTURE", 38, 55], ["disruptions in autophagy", "PROBLEM", 132, 156], ["intestinal mucosa", "ANATOMY", 38, 55]]], ["These roles include (1) degradation of intracellular pathogens (xenophagy), (2) mitophagy, (3) antigen presentation, (4) secretion, and (5) inflammasome regulation.", [["intracellular", "ANATOMY", 39, 52], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 39, 52], ["intracellular pathogens (xenophagy)", "PROBLEM", 39, 74], ["mitophagy", "PROBLEM", 80, 89], ["secretion, and (5) inflammasome regulation", "PROBLEM", 121, 163]]], ["In the cases of xenophagy, mitophagy, and antigen presentation, we present detailed evidence of how autophagy functions in these pathways.", [["xenophagy", "GENE_OR_GENE_PRODUCT", 16, 25], ["xenophagy", "PROBLEM", 16, 25], ["mitophagy", "PROBLEM", 27, 36]]], ["Next, we review results from studies of two particularly well-examined CD risk single-nucleotide polymorphisms (SNPs), rs2241880 (ATG16L1, coding variant T300A) and rs13361189 (IRGM).", [["ATG16L1", "GENE_OR_GENE_PRODUCT", 130, 137], ["rs2241880", "DNA", 119, 128], ["ATG16L1", "DNA", 130, 137], ["IRGM", "DNA", 177, 181], ["studies", "TEST", 29, 36], ["nucleotide polymorphisms (SNPs)", "PROBLEM", 86, 117]]], ["Finally, we discuss approaches from the field of chemical biology that may be used to identify autophagy regulatory pathways with possible implications for therapeutics development.Autophagy in the Intestinal MucosaAs mentioned above, autophagy has been implicated in several immune-related processes that influence IBD pathogenesis, including xenophagy, mitophagy, antigen presentation, secretion and vesicular trafficking, and cytokine-based regulation of inflammasome activity.", [["Intestinal MucosaAs", "ANATOMY", 198, 217], ["vesicular", "ANATOMY", 402, 411], ["IBD", "DISEASE", 316, 319], ["Intestinal MucosaAs", "CANCER", 198, 217], ["xenophagy", "GENE_OR_GENE_PRODUCT", 344, 353], ["antigen", "GENE_OR_GENE_PRODUCT", 366, 373], ["vesicular", "MULTI-TISSUE_STRUCTURE", 402, 411], ["cytokine", "PROTEIN", 429, 437], ["therapeutics development", "TREATMENT", 156, 180], ["Autophagy", "TREATMENT", 181, 190], ["autophagy", "PROBLEM", 235, 244], ["IBD pathogenesis", "PROBLEM", 316, 332], ["xenophagy", "PROBLEM", 344, 353], ["mitophagy", "PROBLEM", 355, 364], ["antigen presentation", "PROBLEM", 366, 386], ["secretion", "PROBLEM", 388, 397], ["vesicular trafficking", "PROBLEM", 402, 423], ["inflammasome activity", "PROBLEM", 458, 479], ["Intestinal MucosaAs", "ANATOMY", 198, 217], ["vesicular trafficking", "OBSERVATION", 402, 423], ["inflammasome activity", "OBSERVATION", 458, 479]]], ["One major point of intersection between these processes is their critical importance in the intestinal mucosa.", [["intestinal mucosa", "ANATOMY", 92, 109], ["intestinal mucosa", "MULTI-TISSUE_STRUCTURE", 92, 109], ["intersection", "OBSERVATION", 19, 31], ["critical", "OBSERVATION_MODIFIER", 65, 73], ["importance", "OBSERVATION", 74, 84], ["intestinal mucosa", "ANATOMY", 92, 109]]], ["This complex environment must maintain a delicate balance of immune responses, which are continuously stimulated by metabolic stresses and antigens from food.", [["antigens", "PROTEIN", 139, 147], ["metabolic stresses", "OBSERVATION", 116, 134]]], ["Microbes also play a major role in this milieu, which carries the highest bacterial load in the body.", [["body", "ANATOMY", 96, 100], ["body", "ORGANISM_SUBDIVISION", 96, 100], ["the highest bacterial load in the body", "PROBLEM", 62, 100], ["highest", "OBSERVATION_MODIFIER", 66, 73], ["bacterial load", "OBSERVATION", 74, 88], ["body", "ANATOMY", 96, 100]]], ["This tissue, therefore, may be especially susceptible to disruption in autophagy, with consequent alteration of homeostatic processes.", [["tissue", "ANATOMY", 5, 11], ["tissue", "TISSUE", 5, 11], ["disruption in autophagy", "PROBLEM", 57, 80], ["homeostatic processes", "PROBLEM", 112, 133], ["may be especially", "UNCERTAINTY", 24, 41], ["disruption", "OBSERVATION", 57, 67], ["homeostatic processes", "OBSERVATION", 112, 133]]], ["For example, mice with conditional knockout of Atg7 in intestinal epithelial cells show increased severity of colitis when exposed to the infectious pathogen Citrobacter rodentium, while mice with deficiency in the core autophagy gene Atg16l1 in hematopoietic cells show increased susceptibility to chemically induced models of colitis [20, 21].Autophagy in the Intestinal MucosaStudies in human genetics have provided evidence that microbial stimulation may exist as a node of functional interaction between CD susceptibility genes, including ATG16L1 and NOD2.", [["intestinal epithelial cells", "ANATOMY", 55, 82], ["hematopoietic cells", "ANATOMY", 246, 265], ["Intestinal", "ANATOMY", 362, 372], ["node", "ANATOMY", 470, 474], ["colitis", "DISEASE", 110, 117], ["colitis", "DISEASE", 328, 335], ["mice", "ORGANISM", 13, 17], ["Atg7", "GENE_OR_GENE_PRODUCT", 47, 51], ["intestinal epithelial cells", "CELL", 55, 82], ["colitis", "PATHOLOGICAL_FORMATION", 110, 117], ["Citrobacter rodentium", "ORGANISM", 158, 179], ["mice", "ORGANISM", 187, 191], ["Atg16l1", "GENE_OR_GENE_PRODUCT", 235, 242], ["hematopoietic cells", "CELL", 246, 265], ["colitis", "PATHOLOGICAL_FORMATION", 328, 335], ["human", "ORGANISM", 390, 395], ["CD", "GENE_OR_GENE_PRODUCT", 509, 511], ["ATG16L1", "GENE_OR_GENE_PRODUCT", 544, 551], ["NOD2", "GENE_OR_GENE_PRODUCT", 556, 560], ["Atg7", "PROTEIN", 47, 51], ["intestinal epithelial cells", "CELL_TYPE", 55, 82], ["core autophagy gene Atg16l1", "DNA", 215, 242], ["hematopoietic cells", "CELL_TYPE", 246, 265], ["CD susceptibility genes", "DNA", 509, 532], ["ATG16L1", "DNA", 544, 551], ["NOD2", "DNA", 556, 560], ["mice", "SPECIES", 13, 17], ["Citrobacter rodentium", "SPECIES", 158, 179], ["mice", "SPECIES", 187, 191], ["human", "SPECIES", 390, 395], ["mice", "SPECIES", 13, 17], ["Citrobacter rodentium", "SPECIES", 158, 179], ["mice", "SPECIES", 187, 191], ["human", "SPECIES", 390, 395], ["Atg7 in intestinal epithelial cells", "PROBLEM", 47, 82], ["increased severity of colitis", "PROBLEM", 88, 117], ["the infectious pathogen Citrobacter rodentium", "PROBLEM", 134, 179], ["deficiency in the core autophagy", "PROBLEM", 197, 229], ["Atg", "TREATMENT", 235, 238], ["hematopoietic cells", "TEST", 246, 265], ["increased susceptibility", "PROBLEM", 271, 295], ["colitis", "PROBLEM", 328, 335], ["Autophagy", "TREATMENT", 345, 354], ["microbial stimulation", "TREATMENT", 433, 454], ["CD susceptibility genes", "PROBLEM", 509, 532], ["ATG16L1 and NOD2", "TREATMENT", 544, 560], ["intestinal epithelial", "ANATOMY", 55, 76], ["increased", "OBSERVATION_MODIFIER", 88, 97], ["severity", "OBSERVATION_MODIFIER", 98, 106], ["colitis", "OBSERVATION", 110, 117], ["infectious", "OBSERVATION_MODIFIER", 138, 148], ["hematopoietic cells", "OBSERVATION", 246, 265], ["increased", "OBSERVATION_MODIFIER", 271, 280], ["susceptibility to chemically induced", "OBSERVATION_MODIFIER", 281, 317], ["colitis", "OBSERVATION", 328, 335], ["Intestinal", "ANATOMY", 362, 372], ["node", "OBSERVATION", 470, 474]]], ["For example, expression of the ATG16L1 CD-associated risk allele (ATG16L1 T300A) results in impairment of autophagy and antigen presentation, both of which are enhanced by muramyl dipeptide (MDP), the bacterial ligand for the receptor NOD2 [22, 23].", [["muramyl dipeptide", "CHEMICAL", 172, 189], ["MDP", "CHEMICAL", 191, 194], ["muramyl dipeptide", "CHEMICAL", 172, 189], ["MDP", "CHEMICAL", 191, 194], ["ATG16L1", "GENE_OR_GENE_PRODUCT", 31, 38], ["ATG16L1 T300A", "GENE_OR_GENE_PRODUCT", 66, 79], ["muramyl dipeptide", "SIMPLE_CHEMICAL", 172, 189], ["MDP", "SIMPLE_CHEMICAL", 191, 194], ["NOD2", "GENE_OR_GENE_PRODUCT", 235, 239], ["ATG16L1 CD-associated risk allele", "DNA", 31, 64], ["ATG16L1 T300A", "DNA", 66, 79], ["NOD2", "PROTEIN", 235, 239], ["the ATG", "TREATMENT", 27, 34], ["impairment of autophagy", "PROBLEM", 92, 115], ["antigen presentation", "TEST", 120, 140], ["the bacterial ligand", "TEST", 197, 217], ["the receptor NOD2", "TEST", 222, 239]]], ["Although no evidence has been found for an epistatic interaction between these two genes, this type of functional interaction suggests that autophagy may operate as a key point of intersection among multiple susceptibility genes.Basic Molecular Events in AutophagyThe process of autophagy begins with an appearance of a flat membrane sheet termed the isolation membrane (also known as the phagophore assembly site in yeast), the origin of which remains unknown.", [["membrane sheet", "ANATOMY", 325, 339], ["membrane", "ANATOMY", 361, 369], ["membrane sheet", "CELLULAR_COMPONENT", 325, 339], ["membrane", "CELLULAR_COMPONENT", 361, 369], ["susceptibility genes", "DNA", 208, 228], ["phagophore assembly site", "PROTEIN", 389, 413], ["yeast", "SPECIES", 417, 422], ["yeast", "SPECIES", 417, 422], ["an epistatic interaction", "PROBLEM", 40, 64], ["multiple susceptibility genes", "PROBLEM", 199, 228], ["autophagy", "PROBLEM", 279, 288], ["a flat membrane sheet", "PROBLEM", 318, 339], ["the isolation membrane", "TREATMENT", 347, 369], ["no evidence", "UNCERTAINTY", 9, 20], ["epistatic", "OBSERVATION_MODIFIER", 43, 52], ["interaction", "OBSERVATION", 53, 64], ["multiple", "OBSERVATION_MODIFIER", 199, 207], ["susceptibility genes", "OBSERVATION", 208, 228], ["Autophagy", "OBSERVATION", 255, 264], ["autophagy", "OBSERVATION", 279, 288], ["flat membrane", "OBSERVATION", 320, 333], ["isolation membrane", "OBSERVATION", 351, 369], ["origin", "ANATOMY_MODIFIER", 429, 435]]], ["The membrane elongates and expands to encompass its cargo, eventually fusing to form a double-membrane structure known as an autophagosome.", [["membrane", "ANATOMY", 4, 12], ["membrane", "ANATOMY", 94, 102], ["autophagosome", "ANATOMY", 125, 138], ["membrane", "CELLULAR_COMPONENT", 4, 12], ["autophagosome", "CELLULAR_COMPONENT", 125, 138], ["double-membrane structure", "PROTEIN", 87, 112], ["The membrane elongates", "PROBLEM", 0, 22], ["a double-membrane structure", "TREATMENT", 85, 112], ["membrane", "OBSERVATION_MODIFIER", 4, 12], ["elongates", "OBSERVATION_MODIFIER", 13, 22], ["autophagosome", "OBSERVATION", 125, 138]]], ["The outer autophagosomal membrane then fuses with the lysosomal membrane, forming a degradative autolysosome.", [["autophagosomal membrane", "ANATOMY", 10, 33], ["lysosomal membrane", "ANATOMY", 54, 72], ["outer autophagosomal membrane", "CELLULAR_COMPONENT", 4, 33], ["lysosomal membrane", "CELLULAR_COMPONENT", 54, 72], ["autolysosome", "CELLULAR_COMPONENT", 96, 108], ["degradative autolysosome", "PROTEIN", 84, 108], ["the lysosomal membrane", "TREATMENT", 50, 72], ["outer", "ANATOMY_MODIFIER", 4, 9], ["autophagosomal membrane", "OBSERVATION", 10, 33], ["lysosomal membrane", "OBSERVATION", 54, 72]]], ["It should be noted that the source of the autophagosomal membrane is still a highly debated topic and the existence of multiple sources cannot be excluded.", [["autophagosomal membrane", "ANATOMY", 42, 65], ["autophagosomal membrane", "CELLULAR_COMPONENT", 42, 65], ["the autophagosomal membrane", "PROBLEM", 38, 65], ["autophagosomal membrane", "OBSERVATION", 42, 65], ["cannot be excluded", "UNCERTAINTY", 136, 154]]], ["In the case of the ER, a novel \u03a9 (omega)-shaped vesicle called the omegasome has been identified, which resides on the ER and might precede the appearance of the isolation membrane [24].Basic Molecular Events in AutophagyMany of the molecular events underlying the assembly and elongation of autophagy membranes were initially identified by genetic screens in Saccharomyces cerevisiae [25, 26].", [["vesicle", "ANATOMY", 48, 55], ["omegasome", "ANATOMY", 67, 76], ["ER", "ANATOMY", 119, 121], ["membrane", "ANATOMY", 172, 180], ["autophagy membranes", "ANATOMY", 292, 311], ["ER", "GENE_OR_GENE_PRODUCT", 19, 21], ["vesicle", "CELLULAR_COMPONENT", 48, 55], ["omegasome", "CANCER", 67, 76], ["ER", "GENE_OR_GENE_PRODUCT", 119, 121], ["membrane", "CELLULAR_COMPONENT", 172, 180], ["membranes", "CELLULAR_COMPONENT", 302, 311], ["Saccharomyces cerevisiae", "ORGANISM", 360, 384], ["ER", "PROTEIN", 19, 21], ["omegasome", "PROTEIN", 67, 76], ["ER", "PROTEIN", 119, 121], ["Saccharomyces cerevisiae", "SPECIES", 360, 384], ["Saccharomyces cerevisiae", "SPECIES", 360, 384], ["a novel \u03a9 (omega)", "TREATMENT", 23, 40], ["the molecular events", "PROBLEM", 229, 249], ["elongation of autophagy membranes", "PROBLEM", 278, 311], ["Autophagy", "OBSERVATION", 212, 221], ["elongation", "OBSERVATION_MODIFIER", 278, 288], ["autophagy membranes", "OBSERVATION", 292, 311]]], ["These screens have identified approximately 35 core autophagy proteins, about half of which have clear homologues in mammals.", [["autophagy proteins", "PROTEIN", 52, 70], ["These screens", "TEST", 0, 13]]], ["For the purposes of this chapter, we divide these genes into five functional categories: (1) the ULK complex (ATG1 complex in yeast); (2) ATG9; (3) Vps34 complexes; and (4, 5) two ubiquitin-like conjugation systems anchored by ATG12 and ATG8, respectively.Basic Molecular Events in AutophagyThe ULK complex (composed of ATG13, FIP200, and either ULK1 or ULK2) plays a central role in starvation-induced autophagy and is thought to be involved in the initiation of the autophagic cascade.", [["autophagic", "ANATOMY", 468, 478], ["ULK", "GENE_OR_GENE_PRODUCT", 97, 100], ["ATG1", "GENE_OR_GENE_PRODUCT", 110, 114], ["Vps34", "GENE_OR_GENE_PRODUCT", 148, 153], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 180, 189], ["ATG12", "GENE_OR_GENE_PRODUCT", 227, 232], ["ATG8", "GENE_OR_GENE_PRODUCT", 237, 241], ["ULK", "GENE_OR_GENE_PRODUCT", 295, 298], ["ATG13", "GENE_OR_GENE_PRODUCT", 320, 325], ["FIP200", "GENE_OR_GENE_PRODUCT", 327, 333], ["ULK1", "GENE_OR_GENE_PRODUCT", 346, 350], ["ULK2", "GENE_OR_GENE_PRODUCT", 354, 358], ["ULK complex", "PROTEIN", 97, 108], ["ATG1 complex", "PROTEIN", 110, 122], ["ATG9", "PROTEIN", 138, 142], ["Vps34 complexes", "PROTEIN", 148, 163], ["ubiquitin", "PROTEIN", 180, 189], ["ATG12", "PROTEIN", 227, 232], ["ATG8", "PROTEIN", 237, 241], ["ULK complex", "PROTEIN", 295, 306], ["ATG13", "PROTEIN", 320, 325], ["FIP200", "PROTEIN", 327, 333], ["ULK1", "PROTEIN", 346, 350], ["ULK2", "PROTEIN", 354, 358], ["yeast", "SPECIES", 126, 131], ["yeast", "SPECIES", 126, 131], ["the ULK complex (ATG1 complex in yeast", "PROBLEM", 93, 131], ["Vps34 complexes", "TEST", 148, 163], ["two ubiquitin-like conjugation systems", "PROBLEM", 176, 214], ["ATG13", "TEST", 320, 325], ["FIP200", "TREATMENT", 327, 333], ["the autophagic cascade", "TREATMENT", 464, 486], ["Molecular Events", "OBSERVATION", 262, 278], ["autophagic cascade", "OBSERVATION", 468, 486]]], ["The complex is recruited to sites of autophagosome formation, where it likely acts to recruit and disassemble other ATG protein complexes [27\u201330].", [["sites", "ANATOMY", 28, 33], ["autophagosome", "ANATOMY", 37, 50], ["autophagosome", "CELLULAR_COMPONENT", 37, 50], ["ATG protein complexes", "PROTEIN", 116, 137], ["autophagosome formation", "PROBLEM", 37, 60], ["complex", "OBSERVATION_MODIFIER", 4, 11], ["autophagosome formation", "OBSERVATION", 37, 60]]], ["ATG9, a transmembrane protein, shuttles between autophagosomes, the trans-Golgi network, and late endosomes in a cycling process that may involve the ULK complex.", [["transmembrane", "ANATOMY", 8, 21], ["autophagosomes", "ANATOMY", 48, 62], ["trans-Golgi network", "ANATOMY", 68, 87], ["late endosomes", "ANATOMY", 93, 107], ["ATG9", "GENE_OR_GENE_PRODUCT", 0, 4], ["transmembrane", "CELLULAR_COMPONENT", 8, 21], ["autophagosomes", "CELLULAR_COMPONENT", 48, 62], ["Golgi network", "CELLULAR_COMPONENT", 74, 87], ["late endosomes", "CELLULAR_COMPONENT", 93, 107], ["ULK", "GENE_OR_GENE_PRODUCT", 150, 153], ["ATG9", "PROTEIN", 0, 4], ["transmembrane protein", "PROTEIN", 8, 29], ["trans-Golgi network", "PROTEIN", 68, 87], ["ULK complex", "PROTEIN", 150, 161], ["a transmembrane protein", "TEST", 6, 29]]], ["ATG9 is of special interest to studies of xenophagy, since a recent report suggested that ATG9 is essential for the formation of the isolation membrane in anti-Salmonella autophagy in mouse embryonic fibroblasts (MEFs) [31].", [["membrane", "ANATOMY", 143, 151], ["embryonic fibroblasts", "ANATOMY", 190, 211], ["MEFs", "ANATOMY", 213, 217], ["ATG9", "GENE_OR_GENE_PRODUCT", 0, 4], ["xenophagy", "GENE_OR_GENE_PRODUCT", 42, 51], ["ATG9", "GENE_OR_GENE_PRODUCT", 90, 94], ["membrane", "CELLULAR_COMPONENT", 143, 151], ["mouse", "ORGANISM", 184, 189], ["embryonic fibroblasts", "CELL", 190, 211], ["MEFs", "CELL", 213, 217], ["ATG9", "PROTEIN", 0, 4], ["ATG9", "PROTEIN", 90, 94], ["mouse embryonic fibroblasts", "CELL_TYPE", 184, 211], ["MEFs", "CELL_TYPE", 213, 217], ["mouse", "SPECIES", 184, 189], ["mouse", "SPECIES", 184, 189], ["the isolation membrane", "TREATMENT", 129, 151], ["embryonic fibroblasts", "OBSERVATION", 190, 211]]], ["In mammals, the Vps34 complex is likely required for the recruitment of several autophagy proteins to sites of autophagosome formation.", [["sites", "ANATOMY", 102, 107], ["autophagosome", "ANATOMY", 111, 124], ["Vps34", "GENE_OR_GENE_PRODUCT", 16, 21], ["autophagosome", "CELLULAR_COMPONENT", 111, 124], ["Vps34 complex", "PROTEIN", 16, 29], ["autophagy proteins", "PROTEIN", 80, 98], ["several autophagy proteins", "TREATMENT", 72, 98], ["autophagosome formation", "PROBLEM", 111, 134], ["Vps34 complex", "OBSERVATION", 16, 29], ["autophagosome formation", "OBSERVATION", 111, 134]]], ["This complex plays a critical role in supplying phosphatidylinositol 3-phosphate (PI3P) to the growing autophagosome, where it acts as an essential driving force in autophagosome assembly [32\u201336].", [["autophagosome", "ANATOMY", 103, 116], ["autophagosome", "ANATOMY", 165, 178], ["phosphatidylinositol 3-phosphate", "CHEMICAL", 48, 80], ["phosphatidylinositol 3-phosphate", "CHEMICAL", 48, 80], ["PI3P", "CHEMICAL", 82, 86], ["phosphatidylinositol 3-phosphate", "GENE_OR_GENE_PRODUCT", 48, 80], ["PI3P", "GENE_OR_GENE_PRODUCT", 82, 86], ["autophagosome", "CELLULAR_COMPONENT", 103, 116], ["autophagosome", "CELLULAR_COMPONENT", 165, 178], ["phosphatidylinositol 3-phosphate (PI3P)", "TREATMENT", 48, 87]]], ["Furthermore, depending on the identity of its protein components, some alternative versions of the Vps34 complex may serve regulatory roles in autophagosome maturation and autophagosome-lysosome fusion [32\u201334, 37\u201339].Basic Molecular Events in AutophagyTwo ubiquitin-like conjugation systems play important roles in autophagosome formation and maturation.", [["autophagosome", "ANATOMY", 143, 156], ["autophagosome", "ANATOMY", 172, 185], ["lysosome", "ANATOMY", 186, 194], ["autophagosome", "ANATOMY", 315, 328], ["Vps34", "GENE_OR_GENE_PRODUCT", 99, 104], ["autophagosome", "CELLULAR_COMPONENT", 143, 156], ["autophagosome", "CELLULAR_COMPONENT", 172, 185], ["lysosome", "CELLULAR_COMPONENT", 186, 194], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 256, 265], ["autophagosome", "CELLULAR_COMPONENT", 315, 328], ["Vps34 complex", "PROTEIN", 99, 112], ["ubiquitin", "PROTEIN", 256, 265], ["the Vps34 complex", "TREATMENT", 95, 112], ["Two ubiquitin-like conjugation systems", "TREATMENT", 252, 290], ["autophagosome maturation", "OBSERVATION", 143, 167], ["lysosome fusion", "OBSERVATION", 186, 201], ["Autophagy", "OBSERVATION", 243, 252], ["autophagosome formation", "OBSERVATION", 315, 338]]], ["The ATG12-based conjugation system is initiated by the E1-like ATG7, which activates and transfers ATG12 to the E2-like ATG10.", [["E2", "CHEMICAL", 112, 114], ["ATG12", "GENE_OR_GENE_PRODUCT", 4, 9], ["E1", "GENE_OR_GENE_PRODUCT", 55, 57], ["ATG7", "GENE_OR_GENE_PRODUCT", 63, 67], ["ATG12", "GENE_OR_GENE_PRODUCT", 99, 104], ["E2", "GENE_OR_GENE_PRODUCT", 112, 114], ["ATG10", "GENE_OR_GENE_PRODUCT", 120, 125], ["ATG12", "PROTEIN", 4, 9], ["E1", "PROTEIN", 55, 57], ["ATG7", "PROTEIN", 63, 67], ["ATG12", "PROTEIN", 99, 104], ["E2", "PROTEIN", 112, 114], ["ATG10", "DNA", 120, 125], ["The ATG12", "TEST", 0, 9]]], ["ATG12 is then subsequently conjugated to ATG5 [40, 41].", [["ATG12", "GENE_OR_GENE_PRODUCT", 0, 5], ["ATG5", "GENE_OR_GENE_PRODUCT", 41, 45], ["ATG12", "PROTEIN", 0, 5], ["ATG5", "PROTEIN", 41, 45]]], ["ATG5 and ATG12 then bind with ATG16L1, forming a complex that is essential for autophagosome formation [42].", [["autophagosome", "ANATOMY", 79, 92], ["ATG5", "GENE_OR_GENE_PRODUCT", 0, 4], ["ATG12", "GENE_OR_GENE_PRODUCT", 9, 14], ["ATG16L1", "GENE_OR_GENE_PRODUCT", 30, 37], ["autophagosome", "CELLULAR_COMPONENT", 79, 92], ["ATG5", "PROTEIN", 0, 4], ["ATG12", "PROTEIN", 9, 14], ["ATG16L1", "DNA", 30, 37], ["ATG5", "PROBLEM", 0, 4], ["ATG", "TREATMENT", 30, 33]]], ["In addition to a key role in autophagosome formation, the second ubiquitin-like conjugation system may play additional roles in cargo recognition [43].", [["autophagosome", "ANATOMY", 29, 42], ["autophagosome", "CELLULAR_COMPONENT", 29, 42], ["ubiquitin", "PROTEIN", 65, 74], ["the second ubiquitin-like conjugation system", "TREATMENT", 54, 98], ["autophagosome formation", "OBSERVATION", 29, 52]]], ["In this system, ATG8 is activated by the E1-like ATG7, is transferred to the E2-like ATG3, and is conjugated to phosphatidylethanolamine through the E3-like action of the ATG5-ATG12 complex.", [["E2", "CHEMICAL", 77, 79], ["phosphatidylethanolamine", "CHEMICAL", 112, 136], ["phosphatidylethanolamine", "CHEMICAL", 112, 136], ["ATG8", "GENE_OR_GENE_PRODUCT", 16, 20], ["E1", "GENE_OR_GENE_PRODUCT", 41, 43], ["ATG7", "GENE_OR_GENE_PRODUCT", 49, 53], ["E2", "GENE_OR_GENE_PRODUCT", 77, 79], ["ATG3", "GENE_OR_GENE_PRODUCT", 85, 89], ["phosphatidylethanolamine", "SIMPLE_CHEMICAL", 112, 136], ["E3", "GENE_OR_GENE_PRODUCT", 149, 151], ["ATG5", "GENE_OR_GENE_PRODUCT", 171, 175], ["ATG12", "GENE_OR_GENE_PRODUCT", 176, 181], ["ATG8", "PROTEIN", 16, 20], ["E1", "PROTEIN", 41, 43], ["ATG7", "PROTEIN", 49, 53], ["E2", "PROTEIN", 77, 79], ["ATG3", "PROTEIN", 85, 89], ["E3", "PROTEIN", 149, 151], ["ATG5", "PROTEIN", 171, 175], ["ATG12 complex", "PROTEIN", 176, 189], ["phosphatidylethanolamine", "TREATMENT", 112, 136]]], ["The conjugation of phosphatidylethanolamine to ATG8 allows subsequent incorporation of ATG8 into the inner and outer membranes of autophagosomes [44\u201346].", [["inner", "ANATOMY", 101, 106], ["outer membranes", "ANATOMY", 111, 126], ["autophagosomes", "ANATOMY", 130, 144], ["phosphatidylethanolamine", "CHEMICAL", 19, 43], ["ATG8", "CHEMICAL", 47, 51], ["phosphatidylethanolamine", "CHEMICAL", 19, 43], ["phosphatidylethanolamine", "SIMPLE_CHEMICAL", 19, 43], ["ATG8", "SIMPLE_CHEMICAL", 47, 51], ["ATG8", "GENE_OR_GENE_PRODUCT", 87, 91], ["inner", "CELLULAR_COMPONENT", 101, 106], ["outer membranes", "CELLULAR_COMPONENT", 111, 126], ["autophagosomes", "CELLULAR_COMPONENT", 130, 144], ["ATG8", "PROTEIN", 47, 51], ["ATG8", "PROTEIN", 87, 91], ["The conjugation of phosphatidylethanolamine", "TREATMENT", 0, 43], ["ATG8", "TREATMENT", 87, 91], ["inner", "ANATOMY_MODIFIER", 101, 106], ["outer membranes", "ANATOMY", 111, 126]]], ["Mammals appear to have two families of ATG8 homologues, known as LC3s and GABARAPs.", [["ATG8", "GENE_OR_GENE_PRODUCT", 39, 43], ["LC3s", "GENE_OR_GENE_PRODUCT", 65, 69], ["GABARAPs", "GENE_OR_GENE_PRODUCT", 74, 82], ["ATG8 homologues", "PROTEIN", 39, 54], ["LC3s", "PROTEIN", 65, 69], ["GABARAPs", "PROTEIN", 74, 82]]], ["While all ATG8 homologues can be incorporated into the autophagosomal membrane, the incorporation of LC3s and GABARAPs might occur at different stages, with LC3s acting at the stage of biogenesis and GABARAPs playing a more important role in autophagosome maturation [47].", [["autophagosomal membrane", "ANATOMY", 55, 78], ["autophagosome", "ANATOMY", 242, 255], ["ATG8", "GENE_OR_GENE_PRODUCT", 10, 14], ["autophagosomal membrane", "CELLULAR_COMPONENT", 55, 78], ["LC3s", "GENE_OR_GENE_PRODUCT", 101, 105], ["GABARAPs", "GENE_OR_GENE_PRODUCT", 110, 118], ["LC3s", "GENE_OR_GENE_PRODUCT", 157, 161], ["GABARAPs", "GENE_OR_GENE_PRODUCT", 200, 208], ["autophagosome", "CELLULAR_COMPONENT", 242, 255], ["ATG8 homologues", "PROTEIN", 10, 25], ["LC3s", "PROTEIN", 101, 105], ["GABARAPs", "PROTEIN", 110, 118], ["LC3s", "PROTEIN", 157, 161], ["GABARAPs", "PROTEIN", 200, 208], ["the incorporation of LC3s", "PROBLEM", 80, 105], ["GABARAPs", "TREATMENT", 110, 118], ["LC3s", "TREATMENT", 157, 161], ["GABARAPs", "TREATMENT", 200, 208], ["autophagosomal membrane", "OBSERVATION", 55, 78]]], ["Given that ATG8 remains associated with autophagosomes even after their fusion with lysosomes, tracking ATG8 and its homologues allows for localization of autophagosomes.", [["autophagosomes", "ANATOMY", 40, 54], ["lysosomes", "ANATOMY", 84, 93], ["autophagosomes", "ANATOMY", 155, 169], ["ATG8", "GENE_OR_GENE_PRODUCT", 11, 15], ["autophagosomes", "CELLULAR_COMPONENT", 40, 54], ["lysosomes", "CELLULAR_COMPONENT", 84, 93], ["ATG8", "GENE_OR_GENE_PRODUCT", 104, 108], ["autophagosomes", "CELLULAR_COMPONENT", 155, 169], ["ATG8", "PROTEIN", 11, 15], ["ATG8", "PROTEIN", 104, 108], ["ATG8", "PROBLEM", 11, 15], ["autophagosomes", "PROBLEM", 40, 54], ["their fusion", "TREATMENT", 66, 78], ["lysosomes", "TREATMENT", 84, 93], ["tracking ATG8", "TREATMENT", 95, 108], ["autophagosomes", "PROBLEM", 155, 169]]], ["Furthermore, since the inner membranes of autophagosomes are degraded upon formation of autolysosomes, tracking ATG8 enables the measurement of autophagic flux as reflected by ATG8 degradation [44, 45].Basic Molecular Events in AutophagySeveral layers of regulation exist in the initiation and progression through the steps of autophagic degradation.", [["inner membranes", "ANATOMY", 23, 38], ["autophagosomes", "ANATOMY", 42, 56], ["autophagic", "ANATOMY", 327, 337], ["inner membranes", "CELLULAR_COMPONENT", 23, 38], ["autophagosomes", "CELLULAR_COMPONENT", 42, 56], ["ATG8", "GENE_OR_GENE_PRODUCT", 112, 116], ["ATG8", "GENE_OR_GENE_PRODUCT", 176, 180], ["autophagosomes", "CELL_TYPE", 42, 56], ["ATG8", "PROTEIN", 112, 116], ["ATG8", "PROTEIN", 176, 180], ["autolysosomes", "PROBLEM", 88, 101], ["autophagic flux", "PROBLEM", 144, 159], ["Basic Molecular Events", "PROBLEM", 202, 224], ["autophagic degradation", "PROBLEM", 327, 349], ["autophagosomes", "OBSERVATION", 42, 56], ["autophagic flux", "OBSERVATION", 144, 159], ["Molecular Events", "OBSERVATION", 208, 224], ["AutophagySeveral layers", "OBSERVATION_MODIFIER", 228, 251], ["progression", "OBSERVATION_MODIFIER", 294, 305], ["autophagic degradation", "OBSERVATION", 327, 349]]], ["One important regulatory influence is the cytoskeleton.", [["cytoskeleton", "ANATOMY", 42, 54], ["cytoskeleton", "CELLULAR_COMPONENT", 42, 54], ["regulatory influence", "OBSERVATION", 14, 34], ["cytoskeleton", "OBSERVATION_MODIFIER", 42, 54]]], ["Autophagosome trafficking involves movement along microtubules, which facilitates fusion with lysosomes [48, 49].", [["Autophagosome", "ANATOMY", 0, 13], ["microtubules", "ANATOMY", 50, 62], ["lysosomes", "ANATOMY", 94, 103], ["Autophagosome", "GENE_OR_GENE_PRODUCT", 0, 13], ["microtubules", "CELLULAR_COMPONENT", 50, 62], ["lysosomes", "CELLULAR_COMPONENT", 94, 103]]], ["Changes in lysosome positioning regulate mTORC1 signaling, since peripheral localization of lysosomes and mTORC1 increases mTORC1 activity, while perinuclear lysosomal clustering decreases activity [49].", [["lysosome", "ANATOMY", 11, 19], ["lysosomes", "ANATOMY", 92, 101], ["perinuclear lysosomal", "ANATOMY", 146, 167], ["lysosome", "CELLULAR_COMPONENT", 11, 19], ["mTORC1", "GENE_OR_GENE_PRODUCT", 41, 47], ["lysosomes", "CELLULAR_COMPONENT", 92, 101], ["mTORC1", "GENE_OR_GENE_PRODUCT", 106, 112], ["mTORC1", "GENE_OR_GENE_PRODUCT", 123, 129], ["perinuclear", "CELLULAR_COMPONENT", 146, 157], ["lysosomal", "CELLULAR_COMPONENT", 158, 167], ["mTORC1", "PROTEIN", 41, 47], ["mTORC1", "PROTEIN", 106, 112], ["mTORC1", "PROTEIN", 123, 129], ["perinuclear lysosomal clustering decreases activity", "PROBLEM", 146, 197], ["lysosome positioning", "OBSERVATION", 11, 31], ["mTORC1 signaling", "OBSERVATION", 41, 57], ["lysosomes", "OBSERVATION", 92, 101], ["mTORC1", "OBSERVATION_MODIFIER", 106, 112], ["increases", "OBSERVATION_MODIFIER", 113, 122], ["mTORC1 activity", "OBSERVATION", 123, 138], ["perinuclear", "OBSERVATION_MODIFIER", 146, 157], ["lysosomal", "OBSERVATION_MODIFIER", 158, 167], ["clustering", "OBSERVATION_MODIFIER", 168, 178], ["decreases", "OBSERVATION_MODIFIER", 179, 188], ["activity", "OBSERVATION_MODIFIER", 189, 197]]], ["Heat shock protein beta-1 (HSPB1), a protein that interacts with and mediates reorganization of the actin cytoskeleton, is also linked to mitophagy [50].", [["cytoskeleton", "ANATOMY", 106, 118], ["Heat shock protein beta-1", "GENE_OR_GENE_PRODUCT", 0, 25], ["HSPB1", "GENE_OR_GENE_PRODUCT", 27, 32], ["actin", "GENE_OR_GENE_PRODUCT", 100, 105], ["cytoskeleton", "CELLULAR_COMPONENT", 106, 118], ["Heat shock protein beta-1", "PROTEIN", 0, 25], ["HSPB1", "PROTEIN", 27, 32], ["actin", "PROTEIN", 100, 105], ["Heat shock protein beta", "TEST", 0, 23], ["HSPB1", "TEST", 27, 32], ["actin cytoskeleton", "OBSERVATION", 100, 118]]], ["Disruption of HSPB1 signaling can lead to accumulation of dysfunctional mitochondria, mitochondrial fragmentation, and effects in mitochondrial respiration in MEFs [51].Basic Molecular Events in AutophagyTranscription also serves as a regulatory influence in the autophagic process.", [["mitochondria", "ANATOMY", 72, 84], ["mitochondrial", "ANATOMY", 86, 99], ["mitochondrial", "ANATOMY", 130, 143], ["MEFs", "ANATOMY", 159, 163], ["HSPB1", "GENE_OR_GENE_PRODUCT", 14, 19], ["mitochondria", "CELLULAR_COMPONENT", 72, 84], ["mitochondrial", "CELLULAR_COMPONENT", 86, 99], ["mitochondrial", "CELLULAR_COMPONENT", 130, 143], ["MEFs", "CELL", 159, 163], ["HSPB1", "PROTEIN", 14, 19], ["HSPB1 signaling", "PROBLEM", 14, 29], ["dysfunctional mitochondria", "PROBLEM", 58, 84], ["mitochondrial fragmentation", "PROBLEM", 86, 113], ["mitochondrial respiration", "TEST", 130, 155], ["Transcription", "TREATMENT", 204, 217], ["dysfunctional mitochondria", "OBSERVATION", 58, 84], ["mitochondrial fragmentation", "OBSERVATION", 86, 113], ["mitochondrial respiration", "OBSERVATION", 130, 155], ["Autophagy", "OBSERVATION", 195, 204], ["autophagic process", "OBSERVATION", 263, 281]]], ["Autophagosome and lysosome biogenesis appear to be transcriptionally coregulated by the transcription factor EB (TFEB) [52].", [["Autophagosome", "ANATOMY", 0, 13], ["lysosome", "ANATOMY", 18, 26], ["Autophagosome", "GENE_OR_GENE_PRODUCT", 0, 13], ["lysosome", "CELLULAR_COMPONENT", 18, 26], ["EB (TFEB) [52]", "GENE_OR_GENE_PRODUCT", 109, 123], ["transcription factor", "PROTEIN", 88, 108], ["TFEB", "PROTEIN", 113, 117], ["lysosome biogenesis", "OBSERVATION", 18, 37]]], ["Overexpression of TFEB induces autophagy, while a block of TFEB expression by RNAi decreases autophagy.", [["TFEB", "GENE_OR_GENE_PRODUCT", 18, 22], ["TFEB", "GENE_OR_GENE_PRODUCT", 59, 63], ["TFEB", "PROTEIN", 18, 22], ["TFEB", "PROTEIN", 59, 63], ["autophagy", "PROBLEM", 31, 40], ["a block of TFEB expression", "TREATMENT", 48, 74], ["RNAi decreases autophagy", "PROBLEM", 78, 102]]], ["Interestingly, TFEB action is implicated in basal as well as starvation-induced autophagy, and therefore TFEB might represent a transcriptional master regulator of the autophagy pathway.", [["TFEB", "GENE_OR_GENE_PRODUCT", 15, 19], ["TFEB", "GENE_OR_GENE_PRODUCT", 105, 109], ["TFEB", "PROTEIN", 15, 19], ["TFEB", "PROTEIN", 105, 109]]], ["Furthermore, translocation of TFEB from the cytosol to the nucleus is strongly enhanced upon removal of nutrients, suggesting that TFEB function is sensitive to nutrients and growth factors.", [["cytosol", "ANATOMY", 44, 51], ["nucleus", "ANATOMY", 59, 66], ["TFEB", "GENE_OR_GENE_PRODUCT", 30, 34], ["cytosol", "CELLULAR_COMPONENT", 44, 51], ["nucleus", "CELLULAR_COMPONENT", 59, 66], ["TFEB", "GENE_OR_GENE_PRODUCT", 131, 135], ["TFEB", "PROTEIN", 30, 34], ["TFEB", "PROTEIN", 131, 135], ["growth factors", "PROTEIN", 175, 189], ["translocation of TFEB", "PROBLEM", 13, 34], ["removal of nutrients", "TREATMENT", 93, 113], ["TFEB function", "TEST", 131, 144], ["TFEB", "OBSERVATION", 30, 34], ["nucleus", "ANATOMY", 59, 66], ["enhanced", "OBSERVATION", 79, 87]]], ["Under fed conditions, phosphorylation on serine 142 of TFEB can be mediated by the extracellular signal-regulated kinase 2 (ERK2) and might be sufficient to retain TFEB in the cytosol.", [["cytosol", "ANATOMY", 176, 183], ["serine", "CHEMICAL", 41, 47], ["serine 142", "AMINO_ACID", 41, 51], ["TFEB", "GENE_OR_GENE_PRODUCT", 55, 59], ["extracellular signal-regulated kinase 2", "GENE_OR_GENE_PRODUCT", 83, 122], ["ERK2", "GENE_OR_GENE_PRODUCT", 124, 128], ["TFEB", "GENE_OR_GENE_PRODUCT", 164, 168], ["cytosol", "CELLULAR_COMPONENT", 176, 183], ["TFEB", "PROTEIN", 55, 59], ["extracellular signal-regulated kinase 2", "PROTEIN", 83, 122], ["ERK2", "PROTEIN", 124, 128], ["TFEB", "PROTEIN", 164, 168], ["phosphorylation", "TREATMENT", 22, 37], ["TFEB", "TREATMENT", 55, 59], ["the extracellular signal", "TEST", 79, 103]]], ["A comprehensive analysis of 51 genes with known functions in the autophagy pathway sheds some light on transcriptional regulation of autophagy in the context of starvation and TFEB function.", [["TFEB", "GENE_OR_GENE_PRODUCT", 176, 180], ["51 genes", "DNA", 28, 36], ["TFEB", "PROTEIN", 176, 180], ["A comprehensive analysis", "TEST", 0, 24], ["known functions in the autophagy pathway", "PROBLEM", 42, 82]]], ["Strikingly, TFEB-dependent transcription patterns generally correlate with starvation effects, further emphasizing the role of TFEB as an autophagy regulator that can directly or indirectly sense nutritional status [52].", [["TFEB", "GENE_OR_GENE_PRODUCT", 12, 16], ["TFEB", "GENE_OR_GENE_PRODUCT", 127, 131], ["TFEB", "PROTEIN", 12, 16], ["TFEB", "PROTEIN", 127, 131], ["starvation effects", "PROBLEM", 75, 93], ["TFEB", "TREATMENT", 127, 131], ["an autophagy regulator", "TREATMENT", 135, 157]]], ["However, the transcription of the majority of genes is not significantly affected by starvation or TFEB expression levels [52], suggesting that transcription factors other than TFEB control the expression of most autophagy and autophagy-related genes, possibly in a nutrient-insensitive fashion.Molecular Basis of Xenophagy ::: XenophagyThe molecular events surrounding the process of xenophagy follow the same basic pattern as those involved in autophagic degradation of other cellular contents, such as organelles or aggregated protein deposits.", [["autophagic", "ANATOMY", 446, 456], ["cellular", "ANATOMY", 478, 486], ["organelles", "ANATOMY", 505, 515], ["Xenophagy", "CHEMICAL", 328, 337], ["TFEB", "GENE_OR_GENE_PRODUCT", 99, 103], ["TFEB", "GENE_OR_GENE_PRODUCT", 177, 181], ["xenophagy", "GENE_OR_GENE_PRODUCT", 385, 394], ["cellular", "CELL", 478, 486], ["organelles", "CELLULAR_COMPONENT", 505, 515], ["TFEB", "PROTEIN", 99, 103], ["transcription factors", "PROTEIN", 144, 165], ["TFEB", "PROTEIN", 177, 181], ["autophagy and autophagy-related genes", "DNA", 213, 250], ["TFEB expression levels", "TEST", 99, 121], ["transcription factors", "PROBLEM", 144, 165], ["TFEB", "TREATMENT", 177, 181], ["most autophagy", "PROBLEM", 208, 222], ["Xenophagy", "TREATMENT", 328, 337], ["The molecular events", "PROBLEM", 337, 357], ["xenophagy", "PROBLEM", 385, 394], ["autophagic degradation of other cellular contents", "PROBLEM", 446, 495], ["aggregated protein deposits", "PROBLEM", 519, 546], ["autophagic degradation", "OBSERVATION", 446, 468], ["cellular contents", "OBSERVATION", 478, 495], ["aggregated protein deposits", "OBSERVATION", 519, 546]]], ["However, the mechanisms underlying the selection of cargo for degradation by xenophagy remain largely unknown.", [["xenophagy", "GENE_OR_GENE_PRODUCT", 77, 86], ["xenophagy", "PROBLEM", 77, 86]]], ["Components of the innate immune response can interact with autophagy proteins to target bacteria for autophagic degradation.", [["autophagic", "ANATOMY", 101, 111], ["autophagy proteins", "PROTEIN", 59, 77], ["autophagy proteins", "TEST", 59, 77], ["target bacteria", "PROBLEM", 81, 96], ["autophagic degradation", "PROBLEM", 101, 123]]], ["Mechanisms involved in xenophagy of other species of bacteria may share some components with anti-Salmonella xenophagy, but to date, detailed molecular mechanisms have been best explored for Salmonella.Molecular Basis of Xenophagy ::: XenophagyUpon infection of epithelial cells, Salmonella enterica serotype Typhimurium (S. Typhimurium) resides in Salmonella-containing vacuoles (SCVs).", [["epithelial cells", "ANATOMY", 262, 278], ["vacuoles", "ANATOMY", 371, 379], ["SCVs", "ANATOMY", 381, 385], ["infection", "DISEASE", 249, 258], ["XenophagyUpon", "GENE_OR_GENE_PRODUCT", 235, 248], ["epithelial cells", "CELL", 262, 278], ["Salmonella enterica serotype Typhimurium", "ORGANISM", 280, 320], ["S. Typhimurium", "ORGANISM", 322, 336], ["vacuoles", "CELLULAR_COMPONENT", 371, 379], ["SCVs", "CELL", 381, 385], ["epithelial cells", "CELL_TYPE", 262, 278], ["Salmonella enterica", "SPECIES", 280, 299], ["serotype Typhimurium", "SPECIES", 300, 320], ["S. Typhimurium", "SPECIES", 322, 336], ["Salmonella", "SPECIES", 191, 201], ["Salmonella enterica serotype Typhimurium", "SPECIES", 280, 320], ["S. Typhimurium", "SPECIES", 322, 336], ["bacteria", "PROBLEM", 53, 61], ["anti-Salmonella xenophagy", "PROBLEM", 93, 118], ["Salmonella", "PROBLEM", 191, 201], ["XenophagyUpon infection", "PROBLEM", 235, 258], ["epithelial cells", "PROBLEM", 262, 278], ["Salmonella enterica serotype Typhimurium", "PROBLEM", 280, 320], ["bacteria", "OBSERVATION", 53, 61], ["infection", "OBSERVATION", 249, 258], ["epithelial cells", "OBSERVATION", 262, 278], ["enterica", "OBSERVATION_MODIFIER", 291, 299], ["serotype Typhimurium", "OBSERVATION", 300, 320]]], ["The environment of the SCV promotes bacterial survival and replication.", [["the SCV promotes bacterial survival", "TREATMENT", 19, 54], ["SCV", "ANATOMY", 23, 26], ["bacterial survival", "OBSERVATION", 36, 54]]], ["The SCV protective niche is established by effectors of two type III secretion systems (T3SSs) encoded by Salmonella pathogenicity islands 1 and 2 (SP-1 and SP-2).", [["type III secretion systems", "GENE_OR_GENE_PRODUCT", 60, 86], ["Salmonella pathogenicity islands 1", "GENE_OR_GENE_PRODUCT", 106, 140], ["SP-1", "GENE_OR_GENE_PRODUCT", 148, 152], ["SP-2", "GENE_OR_GENE_PRODUCT", 157, 161], ["type III secretion systems", "PROTEIN", 60, 86], ["SP", "DNA", 148, 150], ["SP", "DNA", 157, 159], ["The SCV protective niche", "TREATMENT", 0, 24], ["Salmonella pathogenicity islands", "TEST", 106, 138], ["SP", "TEST", 148, 150], ["SCV", "ANATOMY", 4, 7], ["protective niche", "OBSERVATION", 8, 24]]], ["The secretion and activity of T3SS components is highly regulated both temporally and spatially.", [["T3SS", "GENE_OR_GENE_PRODUCT", 30, 34], ["T3SS components", "PROTEIN", 30, 45], ["The secretion and activity of T3SS components", "PROBLEM", 0, 45], ["activity", "OBSERVATION_MODIFIER", 18, 26]]], ["For example, pH sensing regulates the transition from translocon protein secretion and pore formation to effector secretion [53].", [["translocon", "ANATOMY", 54, 64], ["pore", "ANATOMY", 87, 91], ["pore", "CELLULAR_COMPONENT", 87, 91], ["translocon protein", "PROTEIN", 54, 72], ["pH sensing regulates", "PROBLEM", 13, 33], ["translocon protein secretion", "PROBLEM", 54, 82]]], ["Once secreted into the host cell, the activity of effectors can be modulated.", [["cell", "ANATOMY", 28, 32], ["host cell", "CELL", 23, 32], ["host cell", "OBSERVATION", 23, 32]]], ["For example, the T3SS SP-1 effectors SopA, SopE, SptP, and SopB are all ubiquitinated shortly after infection by the host cell machinery [54].", [["cell", "ANATOMY", 122, 126], ["infection", "DISEASE", 100, 109], ["SP-1", "GENE_OR_GENE_PRODUCT", 22, 26], ["SopA", "GENE_OR_GENE_PRODUCT", 37, 41], ["SopE", "GENE_OR_GENE_PRODUCT", 43, 47], ["SptP", "GENE_OR_GENE_PRODUCT", 49, 53], ["SopB", "GENE_OR_GENE_PRODUCT", 59, 63], ["host cell", "CELL", 117, 126], ["T3SS SP-1 effectors", "PROTEIN", 17, 36], ["SopA", "PROTEIN", 37, 41], ["SopE", "PROTEIN", 43, 47], ["SptP", "PROTEIN", 49, 53], ["SopB", "PROTEIN", 59, 63], ["the T3SS SP", "TEST", 13, 24], ["infection", "PROBLEM", 100, 109], ["ubiquitinated", "OBSERVATION_MODIFIER", 72, 85]]], ["The phosphoinositide phosphatase activity of SopB regulates several processes that promote internalization and survival of S. Typhimurium, including cytoskeletal rearrangements that promote invasion, SCV biogenesis and maturation, and prosurvival Akt activation [54].", [["cytoskeletal", "ANATOMY", 149, 161], ["phosphoinositide", "CHEMICAL", 4, 20], ["phosphoinositide", "SIMPLE_CHEMICAL", 4, 20], ["SopB", "GENE_OR_GENE_PRODUCT", 45, 49], ["S. Typhimurium", "ORGANISM", 123, 137], ["SCV", "CELLULAR_COMPONENT", 200, 203], ["Akt", "GENE_OR_GENE_PRODUCT", 247, 250], ["phosphoinositide phosphatase", "PROTEIN", 4, 32], ["SopB", "PROTEIN", 45, 49], ["Akt", "PROTEIN", 247, 250], ["S. Typhimurium", "SPECIES", 123, 137], ["S. Typhimurium", "SPECIES", 123, 137], ["The phosphoinositide phosphatase activity", "TEST", 0, 41], ["SopB regulates", "PROBLEM", 45, 59], ["S. Typhimurium", "PROBLEM", 123, 137], ["cytoskeletal rearrangements", "PROBLEM", 149, 176], ["phosphoinositide phosphatase", "OBSERVATION", 4, 32], ["cytoskeletal rearrangements", "OBSERVATION", 149, 176], ["invasion", "OBSERVATION_MODIFIER", 190, 198], ["SCV biogenesis", "OBSERVATION", 200, 214]]], ["The ability of SopB to regulate these functions is dependent upon its ubiquitination status [54, 55].", [["SopB", "GENE_OR_GENE_PRODUCT", 15, 19], ["SopB", "PROTEIN", 15, 19], ["SopB", "TREATMENT", 15, 19]]], ["A SopB mutant that cannot be ubiquitinated has a number of defects, including a failure to relocalize from the plasma membrane to SCVs, disrupted recruitment of Rab5 to SCVs, and perturbed S. Typhimurium replication [54].", [["plasma membrane", "ANATOMY", 111, 126], ["SCVs", "ANATOMY", 130, 134], ["SCVs", "ANATOMY", 169, 173], ["SopB", "GENE_OR_GENE_PRODUCT", 2, 6], ["plasma membrane", "CELLULAR_COMPONENT", 111, 126], ["SCVs", "GENE_OR_GENE_PRODUCT", 130, 134], ["Rab5", "GENE_OR_GENE_PRODUCT", 161, 165], ["SCVs", "GENE_OR_GENE_PRODUCT", 169, 173], ["S. Typhimurium", "ORGANISM", 189, 203], ["SopB", "PROTEIN", 2, 6], ["Rab5", "PROTEIN", 161, 165], ["S. Typhimurium", "SPECIES", 189, 203], ["S. Typhimurium", "SPECIES", 189, 203], ["A SopB mutant", "TREATMENT", 0, 13], ["defects", "PROBLEM", 59, 66], ["a failure", "PROBLEM", 78, 87], ["the plasma membrane to SCVs", "PROBLEM", 107, 134], ["defects", "OBSERVATION", 59, 66]]], ["Thus, ubiquitination-dependent relocalization of SopB to SCVs promotes the establishment of SCVs as a niche environment for replication.", [["SCVs", "ANATOMY", 57, 61], ["SCVs", "ANATOMY", 92, 96], ["SopB", "GENE_OR_GENE_PRODUCT", 49, 53], ["SCVs", "GENE_OR_GENE_PRODUCT", 57, 61], ["SCVs", "CELL", 92, 96], ["SopB", "PROTEIN", 49, 53], ["SopB to SCVs", "TREATMENT", 49, 61], ["dependent", "OBSERVATION_MODIFIER", 21, 30], ["relocalization", "OBSERVATION_MODIFIER", 31, 45]]], ["This is due in part to the ability of SopB to reduce the net negative charge of PI(4,5)P2 and phosphatidylserine lipids on SCV membranes, thereby disrupting maturation and fusion with lysosomes [55].Molecular Basis of Xenophagy ::: XenophagyAlthough most S. Typhimurium resides in SCVs, a small but significant fraction is released into the cytosol from damaged SCVs.", [["SCV membranes", "ANATOMY", 123, 136], ["lysosomes", "ANATOMY", 184, 193], ["SCVs", "ANATOMY", 281, 285], ["cytosol", "ANATOMY", 341, 348], ["SCVs", "ANATOMY", 362, 366], ["phosphatidylserine", "CHEMICAL", 94, 112], ["PI(4,5)P2", "CHEMICAL", 80, 89], ["phosphatidylserine", "CHEMICAL", 94, 112], ["SopB", "GENE_OR_GENE_PRODUCT", 38, 42], ["PI(4,5)P2", "SIMPLE_CHEMICAL", 80, 89], ["phosphatidylserine lipids", "SIMPLE_CHEMICAL", 94, 119], ["SCV membranes", "CELLULAR_COMPONENT", 123, 136], ["lysosomes", "CELLULAR_COMPONENT", 184, 193], ["S. Typhimurium", "ORGANISM", 255, 269], ["SCVs", "CELL", 281, 285], ["cytosol", "CELLULAR_COMPONENT", 341, 348], ["SCVs", "CELL", 362, 366], ["SopB", "PROTEIN", 38, 42], ["S. Typhimurium", "SPECIES", 255, 269], ["S. Typhimurium", "SPECIES", 255, 269], ["SopB", "TREATMENT", 38, 42], ["the net negative charge of PI", "TREATMENT", 53, 82], ["phosphatidylserine lipids", "TREATMENT", 94, 119], ["SCV membranes", "TREATMENT", 123, 136], ["significant fraction", "PROBLEM", 299, 319], ["SCV membranes", "ANATOMY", 123, 136], ["Typhimurium", "OBSERVATION", 258, 269], ["SCVs", "OBSERVATION", 281, 285], ["small", "OBSERVATION_MODIFIER", 289, 294], ["significant", "OBSERVATION_MODIFIER", 299, 310], ["fraction", "OBSERVATION", 311, 319], ["cytosol", "ANATOMY", 341, 348], ["damaged SCVs", "OBSERVATION", 354, 366]]], ["This cytosolic S. Typhimurium rapidly becomes ubiquitinated.", [["cytosolic", "ANATOMY", 5, 14], ["cytosolic", "CELLULAR_COMPONENT", 5, 14], ["S. Typhimurium", "ORGANISM", 15, 29], ["S. Typhimurium", "SPECIES", 15, 29], ["S. Typhimurium", "SPECIES", 15, 29], ["This cytosolic S. Typhimurium", "PROBLEM", 0, 29], ["ubiquitinated", "PROBLEM", 46, 59], ["Typhimurium", "OBSERVATION_MODIFIER", 18, 29], ["rapidly", "OBSERVATION_MODIFIER", 30, 37]]], ["Ubiquitinated bacteria may be recognized by selective cargo receptors, including p62 and NBR1, which act as bridging factors that bind to both ubiquitin and the autophagosome. p62 and NBR1 share a similar protein structure and domain composition and may show some level of redundancy, particularly in degradation of protein aggregates (aggrephagy) and mitochondria (mitophagy).", [["autophagosome", "ANATOMY", 161, 174], ["mitochondria", "ANATOMY", 352, 364], ["p62", "GENE_OR_GENE_PRODUCT", 81, 84], ["NBR1", "GENE_OR_GENE_PRODUCT", 89, 93], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 143, 152], ["autophagosome", "CELLULAR_COMPONENT", 161, 174], ["p62", "GENE_OR_GENE_PRODUCT", 176, 179], ["NBR1", "GENE_OR_GENE_PRODUCT", 184, 188], ["aggrephagy", "GENE_OR_GENE_PRODUCT", 336, 346], ["mitochondria", "CELLULAR_COMPONENT", 352, 364], ["mitophagy", "CELLULAR_COMPONENT", 366, 375], ["selective cargo receptors", "PROTEIN", 44, 69], ["p62", "PROTEIN", 81, 84], ["NBR1", "PROTEIN", 89, 93], ["bridging factors", "PROTEIN", 108, 124], ["ubiquitin", "PROTEIN", 143, 152], ["p62", "PROTEIN", 176, 179], ["NBR1", "PROTEIN", 184, 188], ["Ubiquitinated bacteria", "PROBLEM", 0, 22], ["p62", "TREATMENT", 81, 84], ["NBR1", "TREATMENT", 89, 93], ["bridging factors", "PROBLEM", 108, 124], ["p62", "TEST", 176, 179], ["a similar protein structure", "PROBLEM", 195, 222], ["domain composition", "TEST", 227, 245], ["some level of redundancy", "PROBLEM", 259, 283], ["protein aggregates", "PROBLEM", 316, 334], ["bacteria", "OBSERVATION", 14, 22], ["protein structure", "OBSERVATION", 205, 222], ["redundancy", "OBSERVATION", 273, 283]]], ["However, while p62 is important for the autophagic clearance of Salmonella, NBR1 is not [56].", [["autophagic", "ANATOMY", 40, 50], ["p62", "GENE_OR_GENE_PRODUCT", 15, 18], ["NBR1", "GENE_OR_GENE_PRODUCT", 76, 80], ["p62", "PROTEIN", 15, 18], ["NBR1", "PROTEIN", 76, 80], ["Salmonella", "SPECIES", 64, 74], ["the autophagic clearance", "TEST", 36, 60], ["Salmonella", "PROBLEM", 64, 74]]], ["Therefore, the mechanism of xenophagy, which relies on ubiquitination events on or around intracellular bacteria, might differ from other ubiquitin-dependent selective autophagy events.", [["intracellular", "ANATOMY", 90, 103], ["xenophagy", "GENE_OR_GENE_PRODUCT", 28, 37], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 90, 103], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 138, 147], ["ubiquitin", "PROTEIN", 138, 147], ["xenophagy", "PROBLEM", 28, 37], ["ubiquitination events", "PROBLEM", 55, 76], ["intracellular bacteria", "PROBLEM", 90, 112], ["other ubiquitin-dependent selective autophagy events", "PROBLEM", 132, 184], ["selective", "OBSERVATION_MODIFIER", 158, 167], ["autophagy events", "OBSERVATION", 168, 184]]], ["Interestingly, nuclear dot protein 52 (NDP52), in addition to p62, has been implicated in the recognition of ubiquitin-coated invasive bacteria, but not in other forms of selective autophagy [57].", [["nuclear dot protein 52", "GENE_OR_GENE_PRODUCT", 15, 37], ["NDP52", "GENE_OR_GENE_PRODUCT", 39, 44], ["p62", "GENE_OR_GENE_PRODUCT", 62, 65], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 109, 118], ["nuclear dot protein 52", "PROTEIN", 15, 37], ["NDP52", "PROTEIN", 39, 44], ["p62", "PROTEIN", 62, 65], ["ubiquitin", "PROTEIN", 109, 118], ["nuclear dot protein", "TEST", 15, 34], ["ubiquitin-coated invasive bacteria", "PROBLEM", 109, 143], ["selective autophagy", "PROBLEM", 171, 190]]], ["NDP52 contains a putative LIR motif at its N terminus, can directly bind ubiquitin through a C-terminal ubiquitin-binding zinc finger, and can form homo-oligomers via its coiled-coil domain [57\u201359]. p62 and NDP52 appear to act cooperatively in the recognition and killing of S. Typhimurium, Listeria monocytogenes, and Shigella flexneri [60, 61].", [["N", "CHEMICAL", 43, 44], ["C", "CHEMICAL", 93, 94], ["zinc", "CHEMICAL", 122, 126], ["NDP52", "GENE_OR_GENE_PRODUCT", 0, 5], ["LIR", "GENE_OR_GENE_PRODUCT", 26, 29], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 73, 82], ["p62", "GENE_OR_GENE_PRODUCT", 199, 202], ["NDP52", "GENE_OR_GENE_PRODUCT", 207, 212], ["S. Typhimurium", "ORGANISM", 275, 289], ["Listeria monocytogenes", "ORGANISM", 291, 313], ["Shigella flexneri", "ORGANISM", 319, 336], ["NDP52", "PROTEIN", 0, 5], ["LIR motif", "PROTEIN", 26, 35], ["N terminus", "PROTEIN", 43, 53], ["ubiquitin", "PROTEIN", 73, 82], ["C-terminal ubiquitin-binding zinc finger", "PROTEIN", 93, 133], ["coiled-coil domain", "PROTEIN", 171, 189], ["p62", "PROTEIN", 199, 202], ["NDP52", "PROTEIN", 207, 212], ["S. Typhimurium", "SPECIES", 275, 289], ["Listeria monocytogenes", "SPECIES", 291, 313], ["Shigella flexneri", "SPECIES", 319, 336], ["S. Typhimurium", "SPECIES", 275, 289], ["Listeria monocytogenes", "SPECIES", 291, 313], ["Shigella flexneri", "SPECIES", 319, 336], ["a putative LIR motif", "TREATMENT", 15, 35], ["a C-terminal ubiquitin-binding zinc finger", "TREATMENT", 91, 133], ["its coiled-coil domain", "TREATMENT", 167, 189], ["p62", "TEST", 199, 202], ["S. Typhimurium", "TEST", 275, 289], ["Listeria monocytogenes", "PROBLEM", 291, 313], ["Shigella flexneri", "PROBLEM", 319, 336], ["Listeria monocytogenes", "OBSERVATION", 291, 313]]], ["However, p62 and NDP52 are recruited to distinct microdomains of invading Salmonella, suggesting that ubiquitin coats on Salmonella might be heterogeneous [60].Molecular Basis of Xenophagy ::: XenophagyInterestingly, in macrophages but not in epithelial cells, proteasomes localize to ubiquitin-coated Salmonella with potential effects on efficient rupture of damaged SCVs and major histocompatibility complex (MHC) class I antigen presentation [62, 63].", [["microdomains", "ANATOMY", 49, 61], ["macrophages", "ANATOMY", 220, 231], ["epithelial cells", "ANATOMY", 243, 259], ["proteasomes", "ANATOMY", 261, 272], ["SCVs", "ANATOMY", 368, 372], ["Xenophagy", "CHEMICAL", 193, 202], ["p62", "GENE_OR_GENE_PRODUCT", 9, 12], ["NDP52", "GENE_OR_GENE_PRODUCT", 17, 22], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 102, 111], ["macrophages", "CELL", 220, 231], ["epithelial cells", "CELL", 243, 259], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 285, 294], ["SCVs", "CELL", 368, 372], ["p62", "PROTEIN", 9, 12], ["NDP52", "PROTEIN", 17, 22], ["macrophages", "CELL_TYPE", 220, 231], ["epithelial cells", "CELL_TYPE", 243, 259], ["proteasomes", "PROTEIN", 261, 272], ["ubiquitin", "PROTEIN", 285, 294], ["major histocompatibility complex (MHC) class I antigen", "PROTEIN", 377, 431], ["p62", "TEST", 9, 12], ["NDP52", "TEST", 17, 22], ["invading Salmonella", "PROBLEM", 65, 84], ["ubiquitin coats", "PROBLEM", 102, 117], ["Salmonella", "PROBLEM", 121, 131], ["Xenophagy", "TREATMENT", 193, 202], ["epithelial cells", "PROBLEM", 243, 259], ["ubiquitin-coated Salmonella", "TREATMENT", 285, 312], ["efficient rupture of damaged SCVs", "PROBLEM", 339, 372], ["distinct", "OBSERVATION_MODIFIER", 40, 48], ["microdomains", "OBSERVATION_MODIFIER", 49, 61], ["invading Salmonella", "OBSERVATION", 65, 84], ["ubiquitin coats", "OBSERVATION", 102, 117], ["heterogeneous", "OBSERVATION_MODIFIER", 141, 154], ["macrophages", "OBSERVATION", 220, 231], ["not in", "UNCERTAINTY", 236, 242], ["epithelial cells", "OBSERVATION", 243, 259], ["efficient", "OBSERVATION_MODIFIER", 339, 348], ["rupture", "OBSERVATION", 349, 356], ["damaged SCVs", "OBSERVATION", 360, 372]]], ["Taken together, ubiquitin-dependent autophagic targeting of intracellular pathogens and by-products has implications for pathogen growth and the regulation of inflammatory responses.", [["autophagic", "ANATOMY", 36, 46], ["intracellular", "ANATOMY", 60, 73], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 16, 25], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 60, 73], ["ubiquitin", "PROTEIN", 16, 25], ["intracellular pathogens", "PROBLEM", 60, 83], ["pathogen growth", "PROBLEM", 121, 136], ["inflammatory responses", "PROBLEM", 159, 181], ["intracellular pathogens", "OBSERVATION", 60, 83], ["inflammatory", "OBSERVATION_MODIFIER", 159, 171]]], ["However, in most cases, the E3 ubiquitin ligases, the nature of ubiquitin modifications, and the substrates involved in ubiquitin-dependent xenophagy are not known and may be pathogen- as well as cell type-specific.", [["cell", "ANATOMY", 196, 200], ["E3", "GENE_OR_GENE_PRODUCT", 28, 30], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 64, 73], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 120, 129], ["xenophagy", "GENE_OR_GENE_PRODUCT", 140, 149], ["cell", "CELL", 196, 200], ["E3 ubiquitin ligases", "PROTEIN", 28, 48], ["ubiquitin modifications", "PROTEIN", 64, 87], ["ubiquitin-dependent xenophagy", "PROTEIN", 120, 149], ["the E3 ubiquitin ligases", "PROBLEM", 24, 48], ["ubiquitin modifications", "TREATMENT", 64, 87], ["ubiquitin-dependent xenophagy", "PROBLEM", 120, 149], ["pathogen", "PROBLEM", 175, 183], ["ubiquitin ligases", "OBSERVATION", 31, 48], ["ubiquitin modifications", "OBSERVATION", 64, 87], ["may be", "UNCERTAINTY", 168, 174], ["pathogen", "OBSERVATION", 175, 183]]], ["One important exception is LRSAM1, an LRR- and RING-domain protein that was recently identified as an E3 ubiquitin ligase crucial for ubiquitin-dependent autophagy of S. Typhimurium [64].", [["LRSAM1", "GENE_OR_GENE_PRODUCT", 27, 33], ["LRR", "GENE_OR_GENE_PRODUCT", 38, 41], ["E3", "GENE_OR_GENE_PRODUCT", 102, 104], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 134, 143], ["S. Typhimurium", "ORGANISM", 167, 181], ["LRSAM1", "PROTEIN", 27, 33], ["LRR", "PROTEIN", 38, 41], ["RING-domain protein", "PROTEIN", 47, 66], ["E3 ubiquitin ligase", "PROTEIN", 102, 121], ["ubiquitin", "PROTEIN", 134, 143], ["S. Typhimurium", "SPECIES", 167, 181], ["S. Typhimurium", "SPECIES", 167, 181], ["an LRR", "TEST", 35, 41], ["RING-domain protein", "PROBLEM", 47, 66], ["an E3 ubiquitin ligase", "TREATMENT", 99, 121]]], ["Interestingly, LRSAM1 was required for ubiquitination of intracellular bacteria but dispensable for ubiquitination of aggregated proteins, confirming that LRSAM1 serves as a selective and novel antibacterial sensor that mediates target selection for the xenophagy pathway.", [["intracellular", "ANATOMY", 57, 70], ["LRSAM1", "CHEMICAL", 155, 161], ["LRSAM1", "GENE_OR_GENE_PRODUCT", 15, 21], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 57, 70], ["LRSAM1", "GENE_OR_GENE_PRODUCT", 155, 161], ["xenophagy", "GENE_OR_GENE_PRODUCT", 254, 263], ["LRSAM1", "PROTEIN", 15, 21], ["aggregated proteins", "PROTEIN", 118, 137], ["LRSAM1", "PROTEIN", 155, 161], ["ubiquitination of intracellular bacteria", "PROBLEM", 39, 79], ["ubiquitination of aggregated proteins", "PROBLEM", 100, 137], ["a selective and novel antibacterial sensor", "TREATMENT", 172, 214], ["the xenophagy pathway", "TREATMENT", 250, 271], ["intracellular bacteria", "OBSERVATION", 57, 79]]], ["To date, however, LRSAM1 remains the only known ubiquitin ligase associated with antibacterial autophagy, and a detailed biochemical characterization of the aforementioned factors will yield critical insights into host\u2013pathogen interactions and may boost the development of novel pharmaceuticals aimed to combat infectious diseases.Xenophagy and IBD Risk Genes ::: XenophagyAs mentioned above, intestinal tissues are in constant interaction with both commensal and pathogenic bacteria.", [["intestinal tissues", "ANATOMY", 394, 412], ["infectious diseases", "DISEASE", 312, 331], ["LRSAM1", "GENE_OR_GENE_PRODUCT", 18, 24], ["XenophagyAs", "SIMPLE_CHEMICAL", 365, 376], ["intestinal tissues", "TISSUE", 394, 412], ["LRSAM1", "PROTEIN", 18, 24], ["ubiquitin ligase", "PROTEIN", 48, 64], ["known ubiquitin ligase", "PROBLEM", 42, 64], ["antibacterial autophagy", "PROBLEM", 81, 104], ["novel pharmaceuticals", "TREATMENT", 274, 295], ["infectious diseases", "PROBLEM", 312, 331], ["XenophagyAs", "TREATMENT", 365, 376], ["intestinal tissues", "PROBLEM", 394, 412], ["pathogenic bacteria", "PROBLEM", 465, 484], ["ubiquitin ligase", "OBSERVATION", 48, 64], ["antibacterial autophagy", "OBSERVATION", 81, 104], ["IBD", "OBSERVATION", 346, 349], ["intestinal tissues", "ANATOMY", 394, 412], ["pathogenic bacteria", "OBSERVATION", 465, 484]]], ["To prevent inappropriate responses to commensal bacteria, the cells of the intestinal mucosa must be educated to tolerate these microbes and their products [65].", [["cells", "ANATOMY", 62, 67], ["intestinal mucosa", "ANATOMY", 75, 92], ["cells", "CELL", 62, 67], ["intestinal mucosa", "MULTI-TISSUE_STRUCTURE", 75, 92], ["inappropriate responses", "PROBLEM", 11, 34], ["commensal bacteria", "PROBLEM", 38, 56], ["these microbes", "TREATMENT", 122, 136], ["commensal bacteria", "OBSERVATION_MODIFIER", 38, 56], ["intestinal mucosa", "ANATOMY", 75, 92]]], ["Breakdown of this tolerance, with consequent inappropriate inflammation, has been proposed to play a major role in the pathogenesis of IBD.", [["inflammation", "DISEASE", 59, 71], ["IBD", "DISEASE", 135, 138], ["consequent inappropriate inflammation", "PROBLEM", 34, 71], ["IBD", "PROBLEM", 135, 138], ["inappropriate", "OBSERVATION_MODIFIER", 45, 58], ["inflammation", "OBSERVATION", 59, 71], ["IBD", "OBSERVATION", 135, 138]]], ["This model is supported by the finding that the IBD-associated genes ATG16L1, IRGM, and ULK1 all play roles in the process of xenophagy.", [["ATG16L1", "GENE_OR_GENE_PRODUCT", 69, 76], ["IRGM", "GENE_OR_GENE_PRODUCT", 78, 82], ["ULK1", "GENE_OR_GENE_PRODUCT", 88, 92], ["xenophagy", "GENE_OR_GENE_PRODUCT", 126, 135], ["IBD-associated genes", "DNA", 48, 68], ["ATG16L1", "DNA", 69, 76], ["IRGM", "DNA", 78, 82], ["ULK1", "DNA", 88, 92], ["the IBD", "PROBLEM", 44, 51], ["associated genes ATG16L1", "PROBLEM", 52, 76], ["IRGM", "TEST", 78, 82], ["xenophagy", "TREATMENT", 126, 135], ["IBD", "OBSERVATION", 48, 51]]], ["ATG16L1, IRGM, and ULK1 each function in the degradation of S. Typhimurium, while ATG16L1 and IRGM also play a role in antibacterial autophagy of a CD-relevant strain of Escherichia coli (adherent-invasive E. coli, or AIEC) [10, 66\u201369].", [["ATG16L1", "GENE_OR_GENE_PRODUCT", 0, 7], ["IRGM", "GENE_OR_GENE_PRODUCT", 9, 13], ["ULK1", "GENE_OR_GENE_PRODUCT", 19, 23], ["S. Typhimurium", "ORGANISM", 60, 74], ["ATG16L1", "GENE_OR_GENE_PRODUCT", 82, 89], ["IRGM", "GENE_OR_GENE_PRODUCT", 94, 98], ["Escherichia coli", "ORGANISM", 170, 186], ["E. coli", "ORGANISM", 206, 213], ["ATG16L1", "PROTEIN", 0, 7], ["IRGM", "PROTEIN", 9, 13], ["ULK1", "PROTEIN", 19, 23], ["ATG16L1", "PROTEIN", 82, 89], ["IRGM", "PROTEIN", 94, 98], ["S. Typhimurium", "SPECIES", 60, 74], ["Escherichia coli", "SPECIES", 170, 186], ["E. coli", "SPECIES", 206, 213], ["S. Typhimurium", "SPECIES", 60, 74], ["Escherichia coli", "SPECIES", 170, 186], ["E. coli", "SPECIES", 206, 213], ["ATG16L1", "TEST", 0, 7], ["IRGM", "TEST", 9, 13], ["S. Typhimurium", "PROBLEM", 60, 74], ["antibacterial autophagy", "TREATMENT", 119, 142], ["a CD", "PROBLEM", 146, 150], ["Escherichia coli", "PROBLEM", 170, 186], ["adherent-invasive E. coli", "PROBLEM", 188, 213], ["Escherichia coli", "OBSERVATION", 170, 186]]], ["ULK1 may also function in the degradation of L. monocytogenes.", [["ULK1", "GENE_OR_GENE_PRODUCT", 0, 4], ["L. monocytogenes", "ORGANISM", 45, 61], ["ULK1", "PROTEIN", 0, 4], ["L. monocytogenes", "SPECIES", 45, 61], ["L. monocytogenes", "SPECIES", 45, 61], ["ULK1", "PROBLEM", 0, 4], ["L. monocytogenes", "OBSERVATION", 45, 61]]], ["Furthermore, the function of LRRK2 in reactive oxygen species (ROS)-driven bacterial killing, as well as its role in autophagy, raises the possibility that this protein may also be involved in xenophagy of gut bacteria [70\u201372].", [["gut", "ANATOMY", 206, 209], ["oxygen", "CHEMICAL", 47, 53], ["ROS", "CHEMICAL", 63, 66], ["oxygen", "CHEMICAL", 47, 53], ["LRRK2", "GENE_OR_GENE_PRODUCT", 29, 34], ["reactive oxygen species", "SIMPLE_CHEMICAL", 38, 61], ["ROS", "SIMPLE_CHEMICAL", 63, 66], ["gut", "ORGANISM_SUBDIVISION", 206, 209], ["LRRK2", "PROTEIN", 29, 34], ["LRRK2", "PROBLEM", 29, 34], ["reactive oxygen species", "PROBLEM", 38, 61], ["bacterial killing", "PROBLEM", 75, 92], ["this protein", "PROBLEM", 156, 168], ["gut bacteria", "PROBLEM", 206, 218], ["reactive", "OBSERVATION_MODIFIER", 38, 46], ["oxygen species", "OBSERVATION", 47, 61], ["bacterial killing", "OBSERVATION", 75, 92], ["raises the possibility", "UNCERTAINTY", 128, 150]]], ["Defects in these gene products might lead to impaired bacterial handling, promoting an environment of chronic inflammation and inappropriate host responses to commensal bacteria.Xenophagy and IBD Risk Genes ::: XenophagySome intracellular pathogens have also been highlighted as potential contributors to risk of CD, including mycobacteria.", [["intracellular", "ANATOMY", 225, 238], ["inflammation", "DISEASE", 110, 122], ["CD", "DISEASE", 313, 315], ["XenophagySome", "GENE_OR_GENE_PRODUCT", 211, 224], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 225, 238], ["Defects in these gene products", "PROBLEM", 0, 30], ["impaired bacterial handling", "PROBLEM", 45, 72], ["chronic inflammation", "PROBLEM", 102, 122], ["inappropriate host responses", "PROBLEM", 127, 155], ["commensal bacteria", "PROBLEM", 159, 177], ["XenophagySome intracellular pathogens", "PROBLEM", 211, 248], ["CD", "PROBLEM", 313, 315], ["mycobacteria", "PROBLEM", 327, 339], ["might lead to", "UNCERTAINTY", 31, 44], ["impaired", "OBSERVATION_MODIFIER", 45, 53], ["bacterial handling", "OBSERVATION", 54, 72], ["chronic", "OBSERVATION_MODIFIER", 102, 109], ["inflammation", "OBSERVATION", 110, 122], ["IBD", "OBSERVATION", 192, 195], ["pathogens", "OBSERVATION", 239, 248], ["mycobacteria", "OBSERVATION", 327, 339]]], ["Genetic loci that include IRGM, LRRK2, and NOD2 have been associated with increased susceptibility to leprosy and tuberculosis, suggesting an interesting point of interaction between autophagy genes, CD, and mycobacteria.", [["leprosy", "DISEASE", 102, 109], ["tuberculosis", "DISEASE", 114, 126], ["IRGM", "GENE_OR_GENE_PRODUCT", 26, 30], ["LRRK2", "GENE_OR_GENE_PRODUCT", 32, 37], ["NOD2", "GENE_OR_GENE_PRODUCT", 43, 47], ["CD", "GENE_OR_GENE_PRODUCT", 200, 202], ["IRGM", "PROTEIN", 26, 30], ["LRRK2", "PROTEIN", 32, 37], ["NOD2", "PROTEIN", 43, 47], ["autophagy genes", "DNA", 183, 198], ["Genetic loci", "TEST", 0, 12], ["IRGM", "TEST", 26, 30], ["LRRK2", "TEST", 32, 37], ["NOD2", "PROBLEM", 43, 47], ["increased susceptibility to leprosy", "PROBLEM", 74, 109], ["tuberculosis", "PROBLEM", 114, 126], ["autophagy genes", "PROBLEM", 183, 198], ["CD", "PROBLEM", 200, 202], ["mycobacteria", "PROBLEM", 208, 220], ["increased", "OBSERVATION_MODIFIER", 74, 83], ["susceptibility", "OBSERVATION_MODIFIER", 84, 98], ["leprosy", "OBSERVATION", 102, 109], ["tuberculosis", "OBSERVATION", 114, 126], ["autophagy genes", "OBSERVATION", 183, 198], ["mycobacteria", "OBSERVATION", 208, 220]]], ["These studies, combined with reports that autophagy may play a key role in control of Mycobacterium tuberculosis, have led to the suggestion that control of mycobacteria might be altered in CD [73, 74].", [["Mycobacterium tuberculosis", "DISEASE", 86, 112], ["CD", "DISEASE", 190, 192], ["Mycobacterium tuberculosis", "ORGANISM", 86, 112], ["Mycobacterium tuberculosis", "SPECIES", 86, 112], ["Mycobacterium tuberculosis", "SPECIES", 86, 112], ["These studies", "TEST", 0, 13], ["autophagy", "TREATMENT", 42, 51], ["Mycobacterium tuberculosis", "PROBLEM", 86, 112], ["mycobacteria", "PROBLEM", 157, 169], ["Mycobacterium", "OBSERVATION", 86, 99], ["mycobacteria", "OBSERVATION", 157, 169]]], ["Genetic studies appear to support this idea, especially in the context of granulomas, a histological hallmark of both CD and tuberculosis: polymorphisms in loci containing the autophagy genes ATG2A and GABARAPL1 have been linked to granulomas in CD patients.", [["granulomas", "ANATOMY", 74, 84], ["granulomas", "ANATOMY", 232, 242], ["granulomas", "DISEASE", 74, 84], ["CD", "DISEASE", 118, 120], ["tuberculosis", "DISEASE", 125, 137], ["granulomas", "DISEASE", 232, 242], ["CD", "DISEASE", 246, 248], ["granulomas", "PATHOLOGICAL_FORMATION", 74, 84], ["ATG2A", "GENE_OR_GENE_PRODUCT", 192, 197], ["GABARAPL1", "GENE_OR_GENE_PRODUCT", 202, 211], ["granulomas", "PATHOLOGICAL_FORMATION", 232, 242], ["patients", "ORGANISM", 249, 257], ["autophagy genes", "DNA", 176, 191], ["ATG2A", "DNA", 192, 197], ["GABARAPL1", "DNA", 202, 211], ["patients", "SPECIES", 249, 257], ["Genetic studies", "TEST", 0, 15], ["granulomas", "PROBLEM", 74, 84], ["tuberculosis", "PROBLEM", 125, 137], ["polymorphisms in loci", "PROBLEM", 139, 160], ["GABARAPL1", "TREATMENT", 202, 211], ["granulomas", "OBSERVATION", 74, 84], ["both CD", "OBSERVATION_MODIFIER", 113, 120], ["tuberculosis", "OBSERVATION", 125, 137], ["granulomas", "OBSERVATION", 232, 242]]], ["To date, however, connections between CD and the mycobacterioses remain largely speculative, to be answered perhaps by future well-powered GWAS for tuberculosis [75].Xenophagy and IBD Risk Genes ::: XenophagyThe recent wealth of data from the human microbiome project has also highlighted how little we understand of the complex relationship between IBD and microbial stimulation.", [["mycobacterioses", "DISEASE", 49, 64], ["tuberculosis", "DISEASE", 148, 160], ["Xenophagy", "CHEMICAL", 199, 208], ["IBD", "DISEASE", 350, 353], ["CD", "GENE_OR_GENE_PRODUCT", 38, 40], ["human", "ORGANISM", 243, 248], ["human", "SPECIES", 243, 248], ["human", "SPECIES", 243, 248], ["the mycobacterioses", "PROBLEM", 45, 64], ["tuberculosis", "PROBLEM", 148, 160], ["Xenophagy", "TREATMENT", 199, 208], ["microbial stimulation", "TREATMENT", 358, 379], ["IBD", "OBSERVATION", 180, 183], ["microbial stimulation", "OBSERVATION", 358, 379]]], ["Certainly the diversity and composition of the gut microbiota are major factors influencing gut homeostasis, and particular dietary nutrients and metabolites are likely to interact with host genetics to influence host-microbiome interactions.", [["gut microbiota", "ANATOMY", 47, 61], ["gut", "ANATOMY", 92, 95], ["gut microbiota", "MULTI-TISSUE_STRUCTURE", 47, 61], ["gut", "ORGANISM_SUBDIVISION", 92, 95], ["diversity", "OBSERVATION", 14, 23]]], ["An imbalance in the composition of the gut microbiome, termed dysbiosis, has been associated with IBD, including shifts in relative abundances of bacterial taxa, decreases in the diversity of the bacterial community, and alterations in the functional composition of the microbiome.Molecular Basis of Mitophagy ::: MitophagyIn contrast to other substrates for selective autophagy, for example, surplus peroxisomes or ribosomes, mitophagy is well studied and underlying biochemical mechanisms for this process are emerging.", [["gut microbiome", "ANATOMY", 39, 53], ["community", "ANATOMY", 206, 215], ["peroxisomes", "ANATOMY", 401, 412], ["ribosomes", "ANATOMY", 416, 425], ["dysbiosis", "DISEASE", 62, 71], ["IBD", "DISEASE", 98, 101], ["gut", "ORGANISM_SUBDIVISION", 39, 42], ["peroxisomes", "CELLULAR_COMPONENT", 401, 412], ["ribosomes", "CELLULAR_COMPONENT", 416, 425], ["An imbalance", "PROBLEM", 0, 12], ["termed dysbiosis", "PROBLEM", 55, 71], ["IBD", "PROBLEM", 98, 101], ["bacterial taxa", "PROBLEM", 146, 160], ["Mitophagy", "TREATMENT", 314, 323], ["mitophagy", "PROBLEM", 427, 436], ["imbalance", "OBSERVATION", 3, 12], ["gut", "ANATOMY", 39, 42], ["dysbiosis", "OBSERVATION", 62, 71], ["IBD", "OBSERVATION", 98, 101], ["abundances", "OBSERVATION_MODIFIER", 132, 142], ["bacterial taxa", "OBSERVATION", 146, 160], ["decreases", "OBSERVATION_MODIFIER", 162, 171], ["bacterial community", "OBSERVATION_MODIFIER", 196, 215], ["Mitophagy", "OBSERVATION", 300, 309]]], ["Upon loss of mitochondrial membrane potential, PTEN-induced putative kinase 1 (PINK1) accumulates on the outer mitochondrial membrane [77, 78].", [["mitochondrial membrane", "ANATOMY", 13, 35], ["outer mitochondrial membrane", "ANATOMY", 105, 133], ["mitochondrial membrane", "CELLULAR_COMPONENT", 13, 35], ["PTEN-induced putative kinase 1", "GENE_OR_GENE_PRODUCT", 47, 77], ["PINK1", "GENE_OR_GENE_PRODUCT", 79, 84], ["outer", "CELLULAR_COMPONENT", 105, 110], ["mitochondrial membrane", "CELLULAR_COMPONENT", 111, 133], ["PTEN", "PROTEIN", 47, 51], ["putative kinase 1", "PROTEIN", 60, 77], ["PINK1", "PROTEIN", 79, 84], ["mitochondrial membrane potential", "TEST", 13, 45], ["PTEN", "TEST", 47, 51], ["putative kinase", "TEST", 60, 75], ["mitochondrial membrane", "OBSERVATION", 13, 35], ["outer", "ANATOMY_MODIFIER", 105, 110], ["mitochondrial membrane", "ANATOMY", 111, 133]]], ["This step is accompanied by stabilization of PINK1 protein and may involve a membrane potential-dependent block of PINK1 proteolysis by the mitochondrial inner membrane protease presenilin-associated rhomboid-like protein (PARL).", [["membrane", "ANATOMY", 77, 85], ["mitochondrial inner membrane", "ANATOMY", 140, 168], ["PINK1", "GENE_OR_GENE_PRODUCT", 45, 50], ["membrane", "CELLULAR_COMPONENT", 77, 85], ["PINK1", "GENE_OR_GENE_PRODUCT", 115, 120], ["mitochondrial", "CELLULAR_COMPONENT", 140, 153], ["inner membrane", "CELLULAR_COMPONENT", 154, 168], ["presenilin-associated rhomboid-like protein", "GENE_OR_GENE_PRODUCT", 178, 221], ["PARL", "GENE_OR_GENE_PRODUCT", 223, 227], ["PINK1 protein", "PROTEIN", 45, 58], ["PINK1", "PROTEIN", 115, 120], ["mitochondrial inner membrane protease presenilin-associated rhomboid-like protein", "PROTEIN", 140, 221], ["PARL", "PROTEIN", 223, 227], ["PINK1 protein", "PROBLEM", 45, 58], ["PINK1 proteolysis", "PROBLEM", 115, 132], ["the mitochondrial inner membrane protease presenilin", "TEST", 136, 188], ["stabilization", "OBSERVATION", 28, 41], ["PINK1 protein", "OBSERVATION", 45, 58], ["dependent block", "OBSERVATION_MODIFIER", 96, 111], ["PINK1 proteolysis", "OBSERVATION", 115, 132]]], ["This protease is effective in healthy mitochondria but impaired in damaged mitochondria [77, 79].", [["mitochondria", "ANATOMY", 38, 50], ["mitochondria", "ANATOMY", 75, 87], ["mitochondria", "CELLULAR_COMPONENT", 38, 50], ["mitochondria", "CELLULAR_COMPONENT", 75, 87], ["protease", "PROTEIN", 5, 13], ["This protease", "TREATMENT", 0, 13]]], ["PINK1 then recruits Parkin1 to damaged mitochondria, which results in Parkin1-dependent ubiquitination of some mitochondrial proteins such as voltage-dependent anion channel 1 (VDAC1) and mitofusins [80\u201383]. p62 accumulates around ubiquitin-decorated damaged mitochondria and PB1-domain-mediated oligomerization of p62 results in mitochondrial clustering, eventually leading to autophagic degradation of mitochondria [80].", [["mitochondria", "ANATOMY", 39, 51], ["mitochondrial", "ANATOMY", 111, 124], ["mitochondria", "ANATOMY", 259, 271], ["mitochondrial", "ANATOMY", 330, 343], ["autophagic", "ANATOMY", 378, 388], ["mitochondria", "ANATOMY", 404, 416], ["PINK1", "GENE_OR_GENE_PRODUCT", 0, 5], ["Parkin1", "GENE_OR_GENE_PRODUCT", 20, 27], ["mitochondria", "CELLULAR_COMPONENT", 39, 51], ["Parkin1", "GENE_OR_GENE_PRODUCT", 70, 77], ["mitochondrial", "CELLULAR_COMPONENT", 111, 124], ["voltage-dependent anion channel 1", "GENE_OR_GENE_PRODUCT", 142, 175], ["VDAC1", "GENE_OR_GENE_PRODUCT", 177, 182], ["mitofusins", "GENE_OR_GENE_PRODUCT", 188, 198], ["p62", "GENE_OR_GENE_PRODUCT", 208, 211], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 231, 240], ["mitochondria", "CELLULAR_COMPONENT", 259, 271], ["p62", "GENE_OR_GENE_PRODUCT", 315, 318], ["mitochondrial", "CELLULAR_COMPONENT", 330, 343], ["mitochondria", "CELLULAR_COMPONENT", 404, 416], ["PINK1", "PROTEIN", 0, 5], ["Parkin1", "PROTEIN", 20, 27], ["Parkin1", "PROTEIN", 70, 77], ["mitochondrial proteins", "PROTEIN", 111, 133], ["voltage-dependent anion channel 1", "PROTEIN", 142, 175], ["VDAC1", "PROTEIN", 177, 182], ["mitofusins", "PROTEIN", 188, 198], ["p62", "PROTEIN", 208, 211], ["ubiquitin", "PROTEIN", 231, 240], ["PB1", "PROTEIN", 276, 279], ["p62", "PROTEIN", 315, 318], ["damaged mitochondria", "PROBLEM", 31, 51], ["some mitochondrial proteins", "PROBLEM", 106, 133], ["voltage-dependent anion channel", "TREATMENT", 142, 173], ["mitofusins", "TEST", 188, 198], ["decorated damaged mitochondria", "PROBLEM", 241, 271], ["mitochondrial clustering", "PROBLEM", 330, 354], ["autophagic degradation of mitochondria", "PROBLEM", 378, 416], ["mitochondrial proteins", "OBSERVATION", 111, 133], ["mitochondrial clustering", "OBSERVATION", 330, 354]]], ["It should be noted that the mitochondrial ubiquitination event required for mitophagy may involve multiple substrates and/or may be cell type-specific, as p62 recruitment to damaged mitochondria and mitophagy is not impaired in VDAC1-deficient MEFs [78].", [["mitochondrial", "ANATOMY", 28, 41], ["cell", "ANATOMY", 132, 136], ["mitochondria", "ANATOMY", 182, 194], ["MEFs", "ANATOMY", 244, 248], ["mitochondrial", "CELLULAR_COMPONENT", 28, 41], ["cell", "CELL", 132, 136], ["p62", "GENE_OR_GENE_PRODUCT", 155, 158], ["mitochondria", "CELLULAR_COMPONENT", 182, 194], ["VDAC1", "GENE_OR_GENE_PRODUCT", 228, 233], ["p62", "PROTEIN", 155, 158], ["VDAC1", "PROTEIN", 228, 233], ["the mitochondrial ubiquitination event", "PROBLEM", 24, 62], ["mitophagy", "PROBLEM", 76, 85]]], ["In addition, activating molecule in beclin 1-regulated autophagy (Ambra1), an autophagy-regulating protein initially identified in neuronal cells [84], is recruited to damaged mitochondria in a Parkin1-dependent fashion [85] and knockdown of Ambra1 expression results in impairment of mitophagy.", [["neuronal cells", "ANATOMY", 131, 145], ["mitochondria", "ANATOMY", 176, 188], ["beclin 1", "GENE_OR_GENE_PRODUCT", 36, 44], ["Ambra1", "GENE_OR_GENE_PRODUCT", 66, 72], ["neuronal cells", "CELL", 131, 145], ["mitochondria", "CELLULAR_COMPONENT", 176, 188], ["Parkin1", "GENE_OR_GENE_PRODUCT", 194, 201], ["Ambra1", "GENE_OR_GENE_PRODUCT", 242, 248], ["beclin 1", "PROTEIN", 36, 44], ["Ambra1", "PROTEIN", 66, 72], ["autophagy-regulating protein", "PROTEIN", 78, 106], ["neuronal cells", "CELL_TYPE", 131, 145], ["Parkin1", "PROTEIN", 194, 201], ["Ambra1", "PROTEIN", 242, 248], ["activating molecule in beclin", "PROBLEM", 13, 42], ["an autophagy", "TEST", 75, 87], ["a Parkin1-dependent fashion", "TREATMENT", 192, 219], ["Ambra1 expression", "PROBLEM", 242, 259], ["mitophagy", "PROBLEM", 285, 294], ["neuronal cells", "OBSERVATION", 131, 145]]], ["Interestingly, Ambra1 recruitment most likely involves direct binding to Parkin1, but Ambra1 is not a substrate for Parkin1-mediated ubiquitination [85].", [["Ambra1", "GENE_OR_GENE_PRODUCT", 15, 21], ["Parkin1", "GENE_OR_GENE_PRODUCT", 73, 80], ["Ambra1", "GENE_OR_GENE_PRODUCT", 86, 92], ["Parkin1", "GENE_OR_GENE_PRODUCT", 116, 123], ["Ambra1", "PROTEIN", 15, 21], ["Parkin1", "PROTEIN", 73, 80], ["Ambra1", "PROTEIN", 86, 92], ["Parkin1", "PROTEIN", 116, 123]]], ["Thus, Parkin1-mediated mitophagy relies at least in part on effects other than ubiquitination.Mitophagy and IBD Risk Genes ::: MitophagyAs mentioned above, the best evidence linking mitophagy to IBD comes from the identification of SMURF1 as a gene associated with susceptibility to UC.", [["IBD", "DISEASE", 195, 198], ["UC", "DISEASE", 283, 285], ["Parkin1", "GENE_OR_GENE_PRODUCT", 6, 13], ["SMURF1", "GENE_OR_GENE_PRODUCT", 232, 238], ["UC", "PATHOLOGICAL_FORMATION", 283, 285], ["Parkin1", "PROTEIN", 6, 13], ["SMURF1", "DNA", 232, 238], ["Mitophagy", "TREATMENT", 127, 136], ["IBD", "PROBLEM", 195, 198], ["SMURF1", "PROBLEM", 232, 238], ["IBD", "OBSERVATION", 108, 111], ["mitophagy", "OBSERVATION", 182, 191], ["IBD", "OBSERVATION", 195, 198], ["SMURF1", "OBSERVATION", 232, 238]]], ["SMURF1 is a HECT domain-containing E3 ubiquitin ligase that interacts with the selective autophagy factor p62 [76].", [["SMURF1", "GENE_OR_GENE_PRODUCT", 0, 6], ["HECT", "GENE_OR_GENE_PRODUCT", 12, 16], ["E3", "GENE_OR_GENE_PRODUCT", 35, 37], ["p62", "GENE_OR_GENE_PRODUCT", 106, 109], ["SMURF1", "PROTEIN", 0, 6], ["HECT domain-containing E3 ubiquitin ligase", "PROTEIN", 12, 54], ["selective autophagy factor", "PROTEIN", 79, 105], ["p62", "PROTEIN", 106, 109], ["a HECT domain", "TREATMENT", 10, 23], ["E3 ubiquitin ligase", "TREATMENT", 35, 54], ["ubiquitin ligase", "OBSERVATION", 38, 54]]], ["Smurf1\u2212/\u2212 MEFs show defects in the degradation of Sindbis and herpes simplex virus as well as impaired clearance of damaged mitochondria.", [["Smurf1\u2212/\u2212 MEFs", "ANATOMY", 0, 14], ["mitochondria", "ANATOMY", 124, 136], ["herpes simplex virus", "DISEASE", 62, 82], ["Smurf1", "GENE_OR_GENE_PRODUCT", 0, 6], ["Sindbis", "ORGANISM", 50, 57], ["herpes simplex virus", "ORGANISM", 62, 82], ["mitochondria", "CELLULAR_COMPONENT", 124, 136], ["Smurf1\u2212/\u2212 MEFs", "CELL_LINE", 0, 14], ["herpes simplex virus", "SPECIES", 62, 82], ["herpes simplex virus", "SPECIES", 62, 82], ["Smurf1\u2212/\u2212 MEFs", "TREATMENT", 0, 14], ["defects", "PROBLEM", 20, 27], ["the degradation of Sindbis", "PROBLEM", 31, 57], ["herpes simplex virus", "PROBLEM", 62, 82], ["damaged mitochondria", "PROBLEM", 116, 136], ["defects", "OBSERVATION", 20, 27], ["Sindbis", "ANATOMY", 50, 57], ["herpes simplex virus", "OBSERVATION", 62, 82], ["damaged mitochondria", "OBSERVATION", 116, 136]]], ["Supporting this observation, Smurf1-deficient mice display an accumulation of damaged mitochondria in the heart, brain, and liver.", [["mitochondria", "ANATOMY", 86, 98], ["heart", "ANATOMY", 106, 111], ["brain", "ANATOMY", 113, 118], ["liver", "ANATOMY", 124, 129], ["Smurf1", "GENE_OR_GENE_PRODUCT", 29, 35], ["mice", "ORGANISM", 46, 50], ["mitochondria", "CELLULAR_COMPONENT", 86, 98], ["heart", "ORGAN", 106, 111], ["brain", "ORGAN", 113, 118], ["liver", "ORGAN", 124, 129], ["Smurf1", "PROTEIN", 29, 35], ["mice", "SPECIES", 46, 50], ["mice", "SPECIES", 46, 50], ["this observation", "TEST", 11, 27], ["damaged mitochondria in the heart, brain, and liver", "PROBLEM", 78, 129], ["accumulation", "OBSERVATION_MODIFIER", 62, 74], ["damaged mitochondria", "OBSERVATION", 78, 98], ["heart", "ANATOMY", 106, 111], ["brain", "ANATOMY", 113, 118], ["liver", "ANATOMY", 124, 129]]], ["Interestingly, Smurf1\u2212/\u2212 MEFs are competent for starvation-induced bulk autophagy, indicating that Smurf1 is a specific mediator of selective autophagy.", [["Smurf1\u2212/\u2212 MEFs", "ANATOMY", 15, 29], ["Smurf1", "GENE_OR_GENE_PRODUCT", 15, 21], ["Smurf1", "GENE_OR_GENE_PRODUCT", 99, 105], ["Smurf1", "PROTEIN", 15, 21], ["Smurf1", "PROTEIN", 99, 105], ["Smurf1\u2212/\u2212 MEFs", "TREATMENT", 15, 29], ["induced bulk autophagy", "PROBLEM", 59, 81], ["bulk autophagy", "OBSERVATION", 67, 81]]], ["However, a mechanistic link between SMURF1 polymorphisms and IBD pathogenesis remains to be examined.Molecular Basis of Autophagy in Antigen Presentation ::: Antigen PresentationMHC molecules on the cell surface present peptide antigens to T cells.", [["cell surface", "ANATOMY", 199, 211], ["T cells", "ANATOMY", 240, 247], ["IBD", "DISEASE", 61, 64], ["SMURF1", "GENE_OR_GENE_PRODUCT", 36, 42], ["cell surface", "CELLULAR_COMPONENT", 199, 211], ["T cells", "CELL", 240, 247], ["SMURF1", "PROTEIN", 36, 42], ["Antigen PresentationMHC molecules", "PROTEIN", 158, 191], ["T cells", "CELL_TYPE", 240, 247], ["a mechanistic link between SMURF1 polymorphisms", "PROBLEM", 9, 56], ["IBD pathogenesis", "PROBLEM", 61, 77], ["Antigen PresentationMHC molecules", "PROBLEM", 158, 191], ["IBD", "OBSERVATION", 61, 64], ["Autophagy", "OBSERVATION", 120, 129]]], ["MHC class I molecules interact with the T cell receptor (TCR) of CD8+ cytotoxic T cells, while MHC class II molecules interact with the TCR of CD4+ helper T cells.", [["T cell", "ANATOMY", 40, 46], ["CD8+ cytotoxic T cells", "ANATOMY", 65, 87], ["CD4+ helper T cells", "ANATOMY", 143, 162], ["MHC class I", "GENE_OR_GENE_PRODUCT", 0, 11], ["T cell receptor", "GENE_OR_GENE_PRODUCT", 40, 55], ["TCR", "GENE_OR_GENE_PRODUCT", 57, 60], ["CD8", "GENE_OR_GENE_PRODUCT", 65, 68], ["TCR", "GENE_OR_GENE_PRODUCT", 136, 139], ["CD4", "GENE_OR_GENE_PRODUCT", 143, 146], ["MHC class I molecules", "PROTEIN", 0, 21], ["T cell receptor", "PROTEIN", 40, 55], ["TCR", "PROTEIN", 57, 60], ["CD8", "PROTEIN", 65, 68], ["cytotoxic T cells", "CELL_TYPE", 70, 87], ["MHC class II molecules", "PROTEIN", 95, 117], ["TCR", "PROTEIN", 136, 139], ["CD4", "PROTEIN", 143, 146], ["helper T cells", "CELL_TYPE", 148, 162], ["the T cell receptor", "TEST", 36, 55], ["CD8", "PROBLEM", 65, 68], ["cytotoxic T cells", "PROBLEM", 70, 87], ["cytotoxic T cells", "OBSERVATION", 70, 87]]], ["MHC class I antigens are derived from proteasomal degradation of cytosolic proteins.", [["proteasomal", "ANATOMY", 38, 49], ["cytosolic", "ANATOMY", 65, 74], ["MHC class I antigens", "GENE_OR_GENE_PRODUCT", 0, 20], ["MHC class I antigens", "PROTEIN", 0, 20], ["cytosolic proteins", "PROTEIN", 65, 83], ["proteasomal degradation of cytosolic proteins", "PROBLEM", 38, 83], ["cytosolic proteins", "OBSERVATION", 65, 83]]], ["In contrast, MHC class II antigens are delivered to the lysosome before transfer to the MHC class II loading compartment and transport to the cell surface.", [["lysosome", "ANATOMY", 56, 64], ["cell surface", "ANATOMY", 142, 154], ["MHC class II antigens", "GENE_OR_GENE_PRODUCT", 13, 34], ["lysosome", "CELLULAR_COMPONENT", 56, 64], ["cell surface", "CELLULAR_COMPONENT", 142, 154], ["MHC class II antigens", "PROTEIN", 13, 34], ["MHC class II", "PROTEIN", 88, 100]]], ["Delivery of these antigens to the lysosome can occur either via endocytosis of protein antigens from the extracellular space or by autophagy of cytoplasmic material [86\u201388].", [["lysosome", "ANATOMY", 34, 42], ["extracellular space", "ANATOMY", 105, 124], ["cytoplasmic", "ANATOMY", 144, 155], ["lysosome", "CELLULAR_COMPONENT", 34, 42], ["protein antigens", "GENE_OR_GENE_PRODUCT", 79, 95], ["extracellular space", "CELLULAR_COMPONENT", 105, 124], ["cytoplasmic", "ORGANISM_SUBSTANCE", 144, 155], ["protein antigens", "PROTEIN", 79, 95]]], ["Autophagy also plays an important role in the presentation of pathogen antigens by dendritic cells (DCs).", [["dendritic cells", "ANATOMY", 83, 98], ["DCs", "ANATOMY", 100, 103], ["dendritic cells", "CELL", 83, 98], ["DCs", "CELL", 100, 103], ["pathogen antigens", "PROTEIN", 62, 79], ["dendritic cells", "CELL_TYPE", 83, 98], ["DCs", "CELL_TYPE", 100, 103], ["dendritic cells", "OBSERVATION", 83, 98]]], ["Mice lacking Atg5 specifically in DCs show impaired CD4+ T cell priming following infection with herpes simplex virus, an impairment that is due to a decreased ability of Atg5-deficient DCs to process and present antigens for presentation on MHC class II molecules [89].", [["DCs", "ANATOMY", 34, 37], ["CD4+", "ANATOMY", 52, 56], ["T cell", "ANATOMY", 57, 63], ["DCs", "ANATOMY", 186, 189], ["infection", "DISEASE", 82, 91], ["herpes simplex virus", "DISEASE", 97, 117], ["Mice", "ORGANISM", 0, 4], ["Atg5", "GENE_OR_GENE_PRODUCT", 13, 17], ["DCs", "CELL", 34, 37], ["CD4", "GENE_OR_GENE_PRODUCT", 52, 55], ["T cell", "CELL", 57, 63], ["herpes simplex virus", "ORGANISM", 97, 117], ["Atg5", "GENE_OR_GENE_PRODUCT", 171, 175], ["DCs", "CELL", 186, 189], ["Atg5", "PROTEIN", 13, 17], ["DCs", "CELL_TYPE", 34, 37], ["CD4", "PROTEIN", 52, 55], ["Atg5", "PROTEIN", 171, 175], ["DCs", "CELL_TYPE", 186, 189], ["MHC class II molecules", "PROTEIN", 242, 264], ["Mice", "SPECIES", 0, 4], ["herpes simplex virus", "SPECIES", 97, 117], ["herpes simplex virus", "SPECIES", 97, 117], ["T cell priming", "PROBLEM", 57, 71], ["infection", "PROBLEM", 82, 91], ["herpes simplex virus", "PROBLEM", 97, 117], ["an impairment", "PROBLEM", 119, 132], ["Atg5-deficient DCs", "TREATMENT", 171, 189], ["impaired", "OBSERVATION_MODIFIER", 43, 51], ["CD4", "OBSERVATION", 52, 55], ["infection", "OBSERVATION", 82, 91], ["herpes simplex virus", "OBSERVATION", 97, 117]]], ["Furthermore, these cells show delayed fusion of phagosomes to lysosomes.", [["cells", "ANATOMY", 19, 24], ["phagosomes", "ANATOMY", 48, 58], ["lysosomes", "ANATOMY", 62, 71], ["cells", "CELL", 19, 24], ["phagosomes", "CELLULAR_COMPONENT", 48, 58], ["lysosomes", "CELLULAR_COMPONENT", 62, 71], ["these cells", "TEST", 13, 24], ["delayed fusion of phagosomes", "PROBLEM", 30, 58], ["delayed fusion", "OBSERVATION", 30, 44]]], ["Autophagic degradation may also combine with vesicular trafficking to facilitate presentation of citrullinated self-peptides by DCs to CD4+ T cells.", [["vesicular", "ANATOMY", 45, 54], ["DCs", "ANATOMY", 128, 131], ["CD4+ T cells", "ANATOMY", 135, 147], ["vesicular", "MULTI-TISSUE_STRUCTURE", 45, 54], ["DCs", "CELL", 128, 131], ["CD4", "GENE_OR_GENE_PRODUCT", 135, 138], ["DCs", "CELL_TYPE", 128, 131], ["CD4", "PROTEIN", 135, 138], ["T cells", "CELL_TYPE", 140, 147], ["Autophagic degradation", "PROBLEM", 0, 22], ["citrullinated self-peptides", "TREATMENT", 97, 124]]], ["This finding is particularly relevant to IBD, since immune responses against citrullinated self-proteins are associated with autoimmunity [90, 91].Antigen Presentation and IBD Risk Genes ::: Antigen PresentationInterestingly, DCs from patients with CD-associated risk variants of ATG16L1 or NOD2 show defects in autophagy induction, bacterial trafficking, and MHC class II antigen presentation to CD4+ T cells [23].", [["DCs", "ANATOMY", 226, 229], ["CD4+ T cells", "ANATOMY", 397, 409], ["IBD", "DISEASE", 41, 44], ["autoimmunity", "DISEASE", 125, 137], ["CD", "DISEASE", 249, 251], ["DCs", "CELL", 226, 229], ["patients", "ORGANISM", 235, 243], ["ATG16L1", "GENE_OR_GENE_PRODUCT", 280, 287], ["NOD2", "GENE_OR_GENE_PRODUCT", 291, 295], ["MHC class II antigen", "GENE_OR_GENE_PRODUCT", 360, 380], ["CD4", "GENE_OR_GENE_PRODUCT", 397, 400], ["citrullinated self-proteins", "PROTEIN", 77, 104], ["DCs", "CELL_TYPE", 226, 229], ["ATG16L1", "PROTEIN", 280, 287], ["NOD2", "PROTEIN", 291, 295], ["MHC class II antigen", "PROTEIN", 360, 380], ["CD4", "PROTEIN", 397, 400], ["T cells", "CELL_TYPE", 402, 409], ["patients", "SPECIES", 235, 243], ["IBD", "PROBLEM", 41, 44], ["immune responses", "PROBLEM", 52, 68], ["citrullinated self-proteins", "PROBLEM", 77, 104], ["autoimmunity", "PROBLEM", 125, 137], ["CD", "PROBLEM", 249, 251], ["ATG16L1", "PROBLEM", 280, 287], ["NOD2", "PROBLEM", 291, 295], ["defects in autophagy induction", "PROBLEM", 301, 331], ["bacterial trafficking", "PROBLEM", 333, 354], ["CD4", "TEST", 397, 400], ["IBD", "OBSERVATION", 41, 44], ["defects", "OBSERVATION", 301, 308], ["bacterial trafficking", "OBSERVATION", 333, 354]]], ["Furthermore, autophagy was recently reported to destabilize the immune synapse between DCs and T cells; in this report, decreased expression of ATG16L1 or IRGM resulted in hyperstable interactions between DCs and T cells as well as increased activation of T cells, suggesting a mechanism by which adaptive immunity might be increased in patients with CD who carry ATG16L1 risk alleles [92].Vesicular Trafficking and SecretionThe suggestion that the secretory pathway might be modulated by autophagy in the context of CD arose from the GWAS-based identification of ATG16L1 as a common CD-associated risk gene.", [["immune synapse", "ANATOMY", 64, 78], ["DCs", "ANATOMY", 87, 90], ["T cells", "ANATOMY", 95, 102], ["DCs", "ANATOMY", 205, 208], ["T cells", "ANATOMY", 213, 220], ["T cells", "ANATOMY", 256, 263], ["Vesicular", "ANATOMY", 390, 399], ["CD", "DISEASE", 351, 353], ["CD", "DISEASE", 517, 519], ["DCs", "CELL", 87, 90], ["T cells", "CELL", 95, 102], ["ATG16L1", "GENE_OR_GENE_PRODUCT", 144, 151], ["IRGM", "GENE_OR_GENE_PRODUCT", 155, 159], ["DCs", "CELL", 205, 208], ["T cells", "CELL", 213, 220], ["T cells", "CELL", 256, 263], ["patients", "ORGANISM", 337, 345], ["ATG16L1", "GENE_OR_GENE_PRODUCT", 364, 371], ["Vesicular", "MULTI-TISSUE_STRUCTURE", 390, 399], ["ATG16L1", "GENE_OR_GENE_PRODUCT", 564, 571], ["DCs", "CELL_TYPE", 87, 90], ["T cells", "CELL_TYPE", 95, 102], ["ATG16L1", "PROTEIN", 144, 151], ["IRGM", "PROTEIN", 155, 159], ["DCs", "CELL_TYPE", 205, 208], ["T cells", "CELL_TYPE", 213, 220], ["T cells", "CELL_TYPE", 256, 263], ["ATG16L1 risk alleles", "DNA", 364, 384], ["ATG16L1", "DNA", 564, 571], ["common CD-associated risk gene", "DNA", 577, 607], ["patients", "SPECIES", 337, 345], ["autophagy", "PROBLEM", 13, 22], ["ATG16L1", "PROBLEM", 144, 151], ["hyperstable interactions between DCs and T cells", "PROBLEM", 172, 220], ["increased activation of T cells", "PROBLEM", 232, 263], ["the secretory pathway", "PROBLEM", 445, 466], ["CD", "PROBLEM", 517, 519], ["the GWAS", "TEST", 531, 539], ["ATG16L1", "PROBLEM", 564, 571], ["Secretion", "OBSERVATION", 416, 425]]], ["Patients carrying the CD-associated variant of this gene (ATG16L1 T300A), as well as Atg16l1 hypomorphic (Atg16l1HM) mice, were found to show abnormalities in specialized epithelial cells called Paneth cells.", [["epithelial cells", "ANATOMY", 171, 187], ["Paneth cells", "ANATOMY", 195, 207], ["Patients", "ORGANISM", 0, 8], ["CD", "GENE_OR_GENE_PRODUCT", 22, 24], ["ATG16L1 T300A", "GENE_OR_GENE_PRODUCT", 58, 71], ["Atg16l1", "GENE_OR_GENE_PRODUCT", 85, 92], ["epithelial cells", "CELL", 171, 187], ["Paneth cells", "CELL", 195, 207], ["ATG16L1 T300A", "DNA", 58, 71], ["Atg16l1 hypomorphic", "DNA", 85, 104], ["epithelial cells", "CELL_TYPE", 171, 187], ["Paneth cells", "CELL_TYPE", 195, 207], ["Patients", "SPECIES", 0, 8], ["mice", "SPECIES", 117, 121], ["Atg", "TEST", 85, 88], ["hypomorphic", "PROBLEM", 93, 104], ["abnormalities in specialized epithelial cells", "PROBLEM", 142, 187], ["Paneth cells", "PROBLEM", 195, 207], ["abnormalities", "OBSERVATION", 142, 155], ["epithelial cells", "OBSERVATION", 171, 187], ["Paneth cells", "OBSERVATION", 195, 207]]], ["These cells play a central role in innate immunity and are an important source of antimicrobial peptides in the small intestine, serving to prevent microbial invasion and control the composition of the gut microflora [93].", [["cells", "ANATOMY", 6, 11], ["small intestine", "ANATOMY", 112, 127], ["gut microflora", "ANATOMY", 202, 216], ["cells", "CELL", 6, 11], ["small intestine", "ORGAN", 112, 127], ["gut", "ORGANISM_SUBDIVISION", 202, 205], ["antimicrobial peptides", "TREATMENT", 82, 104], ["microbial invasion", "PROBLEM", 148, 166], ["central", "OBSERVATION_MODIFIER", 19, 26], ["antimicrobial peptides", "OBSERVATION", 82, 104], ["small intestine", "ANATOMY", 112, 127], ["microbial", "OBSERVATION_MODIFIER", 148, 157], ["invasion", "OBSERVATION", 158, 166]]], ["ATG16L1 T300A patients and Atg16l1HM mice exhibit decreased numbers of granules and diffuse staining for lysozyme in their Paneth cells, raising the possibility that autophagy plays a key role in secretion in these cells [94, 95].", [["granules", "ANATOMY", 71, 79], ["Paneth cells", "ANATOMY", 123, 135], ["cells", "ANATOMY", 215, 220], ["ATG16L1", "GENE_OR_GENE_PRODUCT", 0, 7], ["patients", "ORGANISM", 14, 22], ["Atg16l1HM mice", "ORGANISM", 27, 41], ["granules", "ORGANISM_SUBSTANCE", 71, 79], ["lysozyme", "GENE_OR_GENE_PRODUCT", 105, 113], ["Paneth cells", "CELL", 123, 135], ["cells", "CELL", 215, 220], ["lysozyme", "PROTEIN", 105, 113], ["Paneth cells", "CELL_TYPE", 123, 135], ["patients", "SPECIES", 14, 22], ["mice", "SPECIES", 37, 41], ["Atg", "TREATMENT", 27, 30], ["decreased numbers of granules", "PROBLEM", 50, 79], ["diffuse staining for lysozyme in their Paneth cells", "PROBLEM", 84, 135], ["autophagy", "PROBLEM", 166, 175], ["decreased", "OBSERVATION_MODIFIER", 50, 59], ["numbers", "OBSERVATION_MODIFIER", 60, 67], ["granules", "OBSERVATION", 71, 79], ["diffuse", "OBSERVATION_MODIFIER", 84, 91], ["Paneth cells", "OBSERVATION", 123, 135], ["raising the possibility", "UNCERTAINTY", 137, 160]]], ["Supporting this hypothesis, mice lacking Atg5 or Atg7 in intestinal epithelial cells also show Paneth cell defects [96].", [["intestinal epithelial cells", "ANATOMY", 57, 84], ["Paneth cell", "ANATOMY", 95, 106], ["mice", "ORGANISM", 28, 32], ["Atg5", "GENE_OR_GENE_PRODUCT", 41, 45], ["Atg7", "GENE_OR_GENE_PRODUCT", 49, 53], ["intestinal epithelial cells", "CELL", 57, 84], ["Paneth cell", "CELL", 95, 106], ["Atg5", "PROTEIN", 41, 45], ["Atg7", "PROTEIN", 49, 53], ["intestinal epithelial cells", "CELL_TYPE", 57, 84], ["mice", "SPECIES", 28, 32], ["mice", "SPECIES", 28, 32], ["this hypothesis", "PROBLEM", 11, 26], ["mice lacking Atg5", "TREATMENT", 28, 45], ["Atg7 in intestinal epithelial cells", "TEST", 49, 84], ["Paneth cell defects", "PROBLEM", 95, 114], ["intestinal epithelial", "ANATOMY", 57, 78], ["Paneth cell defects", "OBSERVATION", 95, 114]]], ["Interestingly, the Paneth cell phenotype in Atg16l1HM mice can be influenced by exposure to a pathogen, since the cellular defects can be eliminated by maintaining mice in a virus-free environment [94].", [["Paneth cell", "ANATOMY", 19, 30], ["cellular", "ANATOMY", 114, 122], ["Paneth cell", "CELL", 19, 30], ["Atg16l1HM mice", "ORGANISM", 44, 58], ["cellular", "CELL", 114, 122], ["mice", "ORGANISM", 164, 168], ["mice", "SPECIES", 54, 58], ["mice", "SPECIES", 164, 168], ["mice", "SPECIES", 164, 168], ["Atg", "TREATMENT", 44, 47], ["a pathogen", "PROBLEM", 92, 102], ["the cellular defects", "PROBLEM", 110, 130], ["Paneth cell phenotype", "OBSERVATION", 19, 40], ["cellular defects", "OBSERVATION", 114, 130]]], ["Paneth cell defects have also been observed in mice lacking other CD-associated genes, including Nod2 and Xbp1 [97, 98].", [["Paneth cell", "ANATOMY", 0, 11], ["Paneth cell", "CELL", 0, 11], ["mice", "ORGANISM", 47, 51], ["CD", "GENE_OR_GENE_PRODUCT", 66, 68], ["Nod2", "GENE_OR_GENE_PRODUCT", 97, 101], ["Xbp1", "GENE_OR_GENE_PRODUCT", 106, 110], ["CD-associated genes", "DNA", 66, 85], ["Nod2", "PROTEIN", 97, 101], ["Xbp1", "DNA", 106, 110], ["mice", "SPECIES", 47, 51], ["mice", "SPECIES", 47, 51], ["Paneth cell defects", "PROBLEM", 0, 19], ["Nod2", "TEST", 97, 101], ["Xbp1", "TEST", 106, 110], ["cell defects", "OBSERVATION", 7, 19]]], ["More recently, a role was reported for Paneth cells in sensing nutrient availability, demonstrating that caloric restriction reduces Paneth cell-specific signaling by mTORC1, a regulator of autophagy [99].", [["Paneth cells", "ANATOMY", 39, 51], ["Paneth cell", "ANATOMY", 133, 144], ["Paneth cells", "CELL", 39, 51], ["Paneth cell", "CELL", 133, 144], ["mTORC1", "GENE_OR_GENE_PRODUCT", 167, 173], ["Paneth cells", "CELL_TYPE", 39, 51], ["Paneth cell", "CELL_TYPE", 133, 144], ["mTORC1", "PROTEIN", 167, 173], ["Paneth cells", "PROBLEM", 39, 51], ["caloric restriction", "TREATMENT", 105, 124], ["Paneth cell", "PROBLEM", 133, 144]]], ["Taken together, these reports suggest that Paneth cell homeostasis and function are intimately linked to autophagy.", [["Paneth cell", "ANATOMY", 43, 54], ["Paneth cell", "CELL", 43, 54], ["Paneth cell homeostasis", "PROBLEM", 43, 66], ["Paneth cell homeostasis", "OBSERVATION", 43, 66]]], ["However, whether autophagy directly regulates vesicular trafficking and secretion remains unknown, since the molecular mechanisms by which ATG16L1 might regulate these cellular functions are poorly understood.Inflammasome Hyperactivation and Cytokine SecretionInflammasomes are molecular scaffolds that activate caspase 1 and maturation of the proinflammatory cytokines interleukin (IL)-1\u03b2 and IL-18.", [["vesicular", "ANATOMY", 46, 55], ["cellular", "ANATOMY", 168, 176], ["vesicular", "MULTI-TISSUE_STRUCTURE", 46, 55], ["ATG16L1", "GENE_OR_GENE_PRODUCT", 139, 146], ["cellular", "CELL", 168, 176], ["Cytokine SecretionInflammasomes", "GENE_OR_GENE_PRODUCT", 242, 273], ["caspase 1", "GENE_OR_GENE_PRODUCT", 312, 321], ["interleukin (IL)-1\u03b2", "GENE_OR_GENE_PRODUCT", 370, 389], ["IL-18", "GENE_OR_GENE_PRODUCT", 394, 399], ["ATG16L1", "PROTEIN", 139, 146], ["Cytokine", "PROTEIN", 242, 250], ["caspase 1", "PROTEIN", 312, 321], ["proinflammatory cytokines", "PROTEIN", 344, 369], ["interleukin (IL)-1\u03b2 and IL-18", "PROTEIN", 370, 399], ["autophagy", "PROBLEM", 17, 26], ["ATG", "TREATMENT", 139, 142], ["Inflammasome Hyperactivation", "PROBLEM", 209, 237], ["Cytokine SecretionInflammasomes", "TREATMENT", 242, 273], ["molecular scaffolds", "TREATMENT", 278, 297], ["caspase", "TEST", 312, 319], ["the proinflammatory cytokines interleukin (IL)", "TREATMENT", 340, 386], ["IL", "TEST", 394, 396], ["vesicular trafficking", "OBSERVATION", 46, 67], ["Cytokine SecretionInflammasomes", "OBSERVATION", 242, 273], ["proinflammatory", "OBSERVATION_MODIFIER", 344, 359]]], ["Several types of inflammasomes have been described, which are activated by a number of endogenous and exogenous signals.Inflammasome Hyperactivation and Cytokine SecretionRecent studies have shown that autophagy defects can lead to inflammasome hyperactivation.", [["inflammasomes", "PROTEIN", 17, 30], ["Cytokine", "PROTEIN", 153, 161], ["inflammasomes", "PROBLEM", 17, 30], ["Inflammasome Hyperactivation", "PROBLEM", 120, 148], ["Cytokine SecretionRecent studies", "TEST", 153, 185], ["autophagy defects", "PROBLEM", 202, 219], ["inflammasome hyperactivation", "PROBLEM", 232, 260], ["inflammasomes", "OBSERVATION", 17, 30], ["endogenous", "OBSERVATION_MODIFIER", 87, 97], ["exogenous signals", "OBSERVATION", 102, 119], ["autophagy defects", "OBSERVATION", 202, 219], ["inflammasome hyperactivation", "OBSERVATION", 232, 260]]], ["For example, stimulation of Atg16l1\u2212/\u2212 fetal macrophages with lipopolysaccharide (LPS) induces elevated levels of activate caspase 1 and enhanced secretion of IL-1\u03b2 and IL-18 [21].", [["Atg16l1\u2212/\u2212 fetal macrophages", "ANATOMY", 28, 56], ["lipopolysaccharide", "CHEMICAL", 62, 80], ["LPS", "CHEMICAL", 82, 85], ["Atg16l1", "GENE_OR_GENE_PRODUCT", 28, 35], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 62, 80], ["LPS", "SIMPLE_CHEMICAL", 82, 85], ["caspase 1", "GENE_OR_GENE_PRODUCT", 123, 132], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 159, 164], ["IL-18", "GENE_OR_GENE_PRODUCT", 169, 174], ["Atg16l1\u2212/\u2212 fetal macrophages", "CELL_LINE", 28, 56], ["caspase 1", "PROTEIN", 123, 132], ["IL-1\u03b2", "PROTEIN", 159, 164], ["Atg", "TEST", 28, 31], ["fetal macrophages", "PROBLEM", 39, 56], ["lipopolysaccharide (LPS", "TREATMENT", 62, 85], ["elevated levels of activate caspase", "PROBLEM", 95, 130], ["enhanced secretion", "TEST", 137, 155], ["IL", "TEST", 159, 161], ["IL", "TEST", 169, 171], ["macrophages", "ANATOMY", 45, 56]]], ["Mice with specific deletion of Atg16l1 in hematopoietic cells also show higher serum levels of IL-1\u03b2 and IL-18 in response to dextran sulfate sodium (DSS), accompanied by increased inflammation and mortality.Inflammasome Hyperactivation and Cytokine SecretionThe underlying mechanism linking autophagy to regulation of the inflammasome remains unknown.", [["hematopoietic cells", "ANATOMY", 42, 61], ["serum", "ANATOMY", 79, 84], ["dextran sulfate sodium", "CHEMICAL", 126, 148], ["DSS", "CHEMICAL", 150, 153], ["inflammation", "DISEASE", 181, 193], ["sodium", "CHEMICAL", 142, 148], ["Mice", "ORGANISM", 0, 4], ["Atg16l1", "GENE_OR_GENE_PRODUCT", 31, 38], ["hematopoietic cells", "CELL", 42, 61], ["serum", "ORGANISM_SUBSTANCE", 79, 84], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 95, 100], ["IL-18", "GENE_OR_GENE_PRODUCT", 105, 110], ["dextran sulfate sodium", "SIMPLE_CHEMICAL", 126, 148], ["DSS", "SIMPLE_CHEMICAL", 150, 153], ["Atg16l1", "PROTEIN", 31, 38], ["hematopoietic cells", "CELL_TYPE", 42, 61], ["IL-1\u03b2", "PROTEIN", 95, 100], ["IL-18", "PROTEIN", 105, 110], ["Cytokine", "PROTEIN", 241, 249], ["Mice", "SPECIES", 0, 4], ["Atg", "TREATMENT", 31, 34], ["hematopoietic cells", "TEST", 42, 61], ["serum levels", "TEST", 79, 91], ["IL", "TEST", 95, 97], ["IL", "TEST", 105, 107], ["dextran sulfate sodium", "TREATMENT", 126, 148], ["increased inflammation", "PROBLEM", 171, 193], ["Inflammasome Hyperactivation", "PROBLEM", 208, 236], ["Cytokine Secretion", "PROBLEM", 241, 259], ["the inflammasome", "PROBLEM", 319, 335], ["hematopoietic cells", "OBSERVATION", 42, 61], ["increased", "OBSERVATION_MODIFIER", 171, 180], ["inflammation", "OBSERVATION", 181, 193], ["Cytokine Secretion", "OBSERVATION", 241, 259], ["inflammasome", "OBSERVATION", 323, 335]]], ["One possibility is that defects specifically in mitophagy result in increased levels of ROS, which are known to cause hyperactivation of inflammatory activity [100\u2013102].", [["ROS", "CHEMICAL", 88, 91], ["ROS", "SIMPLE_CHEMICAL", 88, 91], ["defects", "PROBLEM", 24, 31], ["mitophagy", "PROBLEM", 48, 57], ["increased levels of ROS", "PROBLEM", 68, 91], ["hyperactivation of inflammatory activity", "PROBLEM", 118, 158], ["defects", "OBSERVATION", 24, 31], ["increased", "OBSERVATION_MODIFIER", 68, 77], ["inflammatory", "OBSERVATION_MODIFIER", 137, 149]]], ["Supporting this idea, Atg16l1\u2212/\u2212 macrophages treated with a ROS scavenger did not show the increased IL-1\u03b2 secretion described above [21].Inflammasome Hyperactivation and Cytokine SecretionSamples from patients have also shown ATG16L1 coding variant-dependent alterations in IL-1\u03b2 secretion.", [["Atg16l1\u2212/\u2212 macrophages", "ANATOMY", 22, 44], ["ROS", "CHEMICAL", 60, 63], ["Atg16l1", "CELL", 22, 29], ["ROS", "SIMPLE_CHEMICAL", 60, 63], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 101, 106], ["Cytokine", "GENE_OR_GENE_PRODUCT", 171, 179], ["patients", "ORGANISM", 202, 210], ["ATG16L1", "GENE_OR_GENE_PRODUCT", 227, 234], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 275, 280], ["Atg16l1\u2212/\u2212 macrophages", "CELL_LINE", 22, 44], ["IL-1\u03b2", "PROTEIN", 101, 106], ["Cytokine SecretionSamples", "PROTEIN", 171, 196], ["ATG16L1", "DNA", 227, 234], ["IL-1\u03b2", "PROTEIN", 275, 280], ["patients", "SPECIES", 202, 210], ["Atg", "TREATMENT", 22, 25], ["a ROS scavenger", "TEST", 58, 73], ["the increased IL", "PROBLEM", 87, 103], ["Inflammasome Hyperactivation", "PROBLEM", 138, 166], ["Cytokine SecretionSamples", "TEST", 171, 196], ["ATG", "TREATMENT", 227, 230], ["dependent alterations in IL", "PROBLEM", 250, 277], ["dependent", "OBSERVATION_MODIFIER", 250, 259]]], ["In these studies, stimulation of peripheral blood mononuclear cells with MDP, but not LPS, resulted in a relative increase of IL-1\u03b2 secretion from ATG16L1 T300A-expressing cells.", [["peripheral blood mononuclear cells", "ANATOMY", 33, 67], ["ATG16L1 T300A-expressing cells", "ANATOMY", 147, 177], ["MDP", "CHEMICAL", 73, 76], ["LPS", "CHEMICAL", 86, 89], ["MDP", "CHEMICAL", 73, 76], ["peripheral blood mononuclear cells", "CELL", 33, 67], ["MDP", "SIMPLE_CHEMICAL", 73, 76], ["LPS", "SIMPLE_CHEMICAL", 86, 89], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 126, 131], ["ATG16L1 T300A", "SIMPLE_CHEMICAL", 147, 160], ["cells", "CELL", 172, 177], ["peripheral blood mononuclear cells", "CELL_TYPE", 33, 67], ["IL-1\u03b2", "PROTEIN", 126, 131], ["ATG16L1 T300A-expressing cells", "CELL_LINE", 147, 177], ["these studies", "TEST", 3, 16], ["peripheral blood mononuclear cells", "TEST", 33, 67], ["MDP", "TEST", 73, 76], ["LPS", "TEST", 86, 89], ["a relative increase of IL", "PROBLEM", 103, 128], ["ATG", "TEST", 147, 150], ["peripheral", "ANATOMY_MODIFIER", 33, 43], ["blood", "ANATOMY", 44, 49], ["mononuclear cells", "OBSERVATION", 50, 67], ["increase", "OBSERVATION_MODIFIER", 114, 122]]], ["Although no difference was found in levels of activated caspase 1, protein levels of pro-IL-1\u03b2 and mRNA levels of IL-1\u03b2 were increased in the context of the ATG16L1 risk allele [103].Inflammasome Hyperactivation and Cytokine SecretionThe autophagy adapter p62 may also provide a connection between IL-1\u03b2 signaling and ATG16L1 [104].", [["caspase 1", "GENE_OR_GENE_PRODUCT", 56, 65], ["pro-IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 85, 94], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 114, 119], ["ATG16L1", "GENE_OR_GENE_PRODUCT", 157, 164], ["p62", "GENE_OR_GENE_PRODUCT", 256, 259], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 298, 303], ["ATG16L1", "GENE_OR_GENE_PRODUCT", 318, 325], ["caspase 1", "PROTEIN", 56, 65], ["IL-1\u03b2", "PROTEIN", 114, 119], ["ATG16L1 risk allele", "DNA", 157, 176], ["Cytokine", "PROTEIN", 216, 224], ["autophagy adapter", "PROTEIN", 238, 255], ["p62", "PROTEIN", 256, 259], ["IL-1\u03b2", "PROTEIN", 298, 303], ["activated caspase", "TEST", 46, 63], ["protein levels", "TEST", 67, 81], ["pro-IL", "TEST", 85, 91], ["mRNA levels", "TEST", 99, 110], ["IL", "TEST", 114, 116], ["the ATG", "TREATMENT", 153, 160], ["Inflammasome Hyperactivation", "PROBLEM", 183, 211], ["Cytokine Secretion", "PROBLEM", 216, 234], ["The autophagy adapter p62", "TREATMENT", 234, 259], ["a connection between IL", "TREATMENT", 277, 300], ["no", "UNCERTAINTY", 9, 11], ["increased", "OBSERVATION_MODIFIER", 125, 134], ["Cytokine Secretion", "OBSERVATION", 216, 234]]], ["In a recent study, we showed that levels of p62 are normally regulated by ATG16L1-based activation of the ubiquitin ligase Cullin-3, which promotes proteasomal degradation of p62.", [["proteasomal", "ANATOMY", 148, 159], ["p62", "GENE_OR_GENE_PRODUCT", 44, 47], ["ATG16L1", "GENE_OR_GENE_PRODUCT", 74, 81], ["Cullin-3", "GENE_OR_GENE_PRODUCT", 123, 131], ["p62", "GENE_OR_GENE_PRODUCT", 175, 178], ["p62", "PROTEIN", 44, 47], ["ATG16L1", "PROTEIN", 74, 81], ["ubiquitin ligase", "PROTEIN", 106, 122], ["Cullin-3", "PROTEIN", 123, 131], ["p62", "PROTEIN", 175, 178], ["a recent study", "TEST", 3, 17], ["levels of p62", "PROBLEM", 34, 47], ["ATG", "TEST", 74, 77], ["the ubiquitin ligase Cullin", "TREATMENT", 102, 129], ["proteasomal degradation of p62", "PROBLEM", 148, 178], ["proteasomal degradation", "OBSERVATION", 148, 171]]], ["Loss of ATG16L1, however, can result in decreased levels of Cullin-3 and decreased degradation of p62.", [["ATG16L1", "GENE_OR_GENE_PRODUCT", 8, 15], ["Cullin-3", "GENE_OR_GENE_PRODUCT", 60, 68], ["p62", "GENE_OR_GENE_PRODUCT", 98, 101], ["ATG16L1", "PROTEIN", 8, 15], ["Cullin-3", "PROTEIN", 60, 68], ["p62", "PROTEIN", 98, 101], ["Loss of ATG16L1", "PROBLEM", 0, 15], ["Cullin", "TEST", 60, 66], ["decreased degradation of p62", "PROBLEM", 73, 101], ["ATG16L1", "OBSERVATION", 8, 15]]], ["As p62 can act as a scaffold in the IL-1\u03b2 signaling pathway, elevated levels of p62 may result in amplified IL-1\u03b2 signaling [104].ATG16L1 T300AOne of the best-studied CD-associated risk alleles is the T300A coding polymorphism in ATG16L1.", [["p62", "GENE_OR_GENE_PRODUCT", 3, 6], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 36, 41], ["p62", "GENE_OR_GENE_PRODUCT", 80, 83], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 108, 113], ["ATG16L1", "GENE_OR_GENE_PRODUCT", 230, 237], ["p62", "PROTEIN", 3, 6], ["IL-1\u03b2", "PROTEIN", 36, 41], ["p62", "PROTEIN", 80, 83], ["IL", "PROTEIN", 108, 110], ["ATG16L1 T300", "DNA", 130, 142], ["CD-associated risk alleles", "DNA", 167, 193], ["T300A coding polymorphism", "DNA", 201, 226], ["ATG16L1", "DNA", 230, 237], ["a scaffold in the IL", "TREATMENT", 18, 38], ["elevated levels of p62", "PROBLEM", 61, 83], ["amplified IL", "TEST", 98, 110], ["ATG", "TEST", 130, 133], ["risk alleles", "PROBLEM", 181, 193], ["ATG", "TREATMENT", 230, 233]]], ["Atg16l1\u2212/\u2212 mice are not viable [21], but an alternative hypomorphic model (Atg16l1HM) has yielded important clues to how the T300A coding polymorphism may result in altered autophagy and increased inflammation [94, 95].", [["inflammation", "DISEASE", 197, 209], ["Atg", "GENE_OR_GENE_PRODUCT", 0, 3], ["16l1", "GENE_OR_GENE_PRODUCT", 3, 7], ["Atg16l1HM", "GENE_OR_GENE_PRODUCT", 75, 84], ["T300A", "GENE_OR_GENE_PRODUCT", 125, 130], ["16l1", "PROTEIN", 3, 7], ["Atg16l1HM", "PROTEIN", 75, 84], ["T300A coding polymorphism", "DNA", 125, 150], ["mice", "SPECIES", 11, 15], ["mice", "SPECIES", 11, 15], ["Atg", "TREATMENT", 0, 3], ["an alternative hypomorphic model", "PROBLEM", 41, 73], ["altered autophagy", "PROBLEM", 165, 182], ["increased inflammation", "PROBLEM", 187, 209], ["increased", "OBSERVATION_MODIFIER", 187, 196], ["inflammation", "OBSERVATION", 197, 209]]], ["The site of the T300A polymorphism is near a WD-repeat domain, which is present in mammalian ATG16L1 but absent in yeast Atg16.", [["T300A", "GENE_OR_GENE_PRODUCT", 16, 21], ["ATG16L1", "GENE_OR_GENE_PRODUCT", 93, 100], ["T300A", "DNA", 16, 21], ["WD-repeat domain", "DNA", 45, 61], ["mammalian ATG16L1", "DNA", 83, 100], ["yeast Atg16", "DNA", 115, 126], ["yeast", "SPECIES", 115, 120], ["yeast", "SPECIES", 115, 120], ["a WD-repeat domain", "TEST", 43, 61], ["mammalian ATG", "TREATMENT", 83, 96], ["yeast Atg", "TREATMENT", 115, 124], ["mammalian ATG", "OBSERVATION", 83, 96], ["yeast Atg", "OBSERVATION", 115, 124]]], ["This domain is not required for autophagy, consistent with the finding that the T300A polymorphism does not affect classical autophagy [42, 67].ATG16L1 T300AAs a core autophagy protein, ATG16L1 has been shown to play multiple roles in IBD-relevant processes, including xenophagy, antigen presentation, IL-1\u03b2 production, and secretion (see Fig. 12.1).", [["T300A", "GENE_OR_GENE_PRODUCT", 80, 85], ["ATG16L1 T300AAs", "GENE_OR_GENE_PRODUCT", 144, 159], ["ATG16L1", "GENE_OR_GENE_PRODUCT", 186, 193], ["xenophagy", "GENE_OR_GENE_PRODUCT", 269, 278], ["antigen", "GENE_OR_GENE_PRODUCT", 280, 287], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 302, 307], ["T300A", "PROTEIN", 80, 85], ["ATG16L1 T300AAs", "PROTEIN", 144, 159], ["autophagy protein", "PROTEIN", 167, 184], ["ATG16L1", "PROTEIN", 186, 193], ["autophagy", "PROBLEM", 32, 41], ["ATG", "TEST", 144, 147], ["ATG16L1", "PROBLEM", 186, 193], ["IBD", "PROBLEM", 235, 238], ["xenophagy", "PROBLEM", 269, 278], ["IL", "TEST", 302, 304], ["IBD", "OBSERVATION", 235, 238]]], ["Interestingly, the CD-associated risk allele appears to have different effects on these functions depending on the cell type examined [42, 67].", [["cell", "ANATOMY", 115, 119], ["cell", "CELL", 115, 119], ["CD-associated risk allele", "DNA", 19, 44], ["these functions", "TEST", 82, 97], ["the cell type", "TEST", 111, 124]]], ["It is perhaps not surprising, then, that T300A has also been associated with defects in antigen presentation increases in IL-1\u03b2 production and abnormalities in Paneth cell secretion in patient samples [23, 95, 103].", [["Paneth cell", "ANATOMY", 160, 171], ["samples", "ANATOMY", 193, 200], ["T300A", "GENE_OR_GENE_PRODUCT", 41, 46], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 122, 127], ["Paneth cell", "CELL", 160, 171], ["patient", "ORGANISM", 185, 192], ["T300A", "PROTEIN", 41, 46], ["IL-1\u03b2", "PROTEIN", 122, 127], ["patient", "SPECIES", 185, 192], ["defects in antigen presentation", "PROBLEM", 77, 108], ["IL", "TEST", 122, 124], ["abnormalities in Paneth cell secretion", "PROBLEM", 143, 181], ["patient samples", "TEST", 185, 200], ["perhaps not", "UNCERTAINTY", 6, 17], ["associated with", "UNCERTAINTY", 61, 76], ["defects", "OBSERVATION", 77, 84], ["increases", "OBSERVATION_MODIFIER", 109, 118], ["Paneth cell secretion", "OBSERVATION", 160, 181]]], ["In addition, antibacterial autophagy of Salmonella is affected by the presence of the ATG16L1 CD risk allele [67], and patients with the T300A allele show increased susceptibility to infection by Helicobacter pylori [105].", [["infection", "DISEASE", 183, 192], ["ATG16L1 CD", "GENE_OR_GENE_PRODUCT", 86, 96], ["patients", "ORGANISM", 119, 127], ["T300A", "GENE_OR_GENE_PRODUCT", 137, 142], ["Helicobacter pylori", "ORGANISM", 196, 215], ["ATG16L1 CD risk allele", "DNA", 86, 108], ["T300A allele", "DNA", 137, 149], ["patients", "SPECIES", 119, 127], ["Helicobacter pylori", "SPECIES", 196, 215], ["Helicobacter pylori", "SPECIES", 196, 215], ["antibacterial autophagy", "TEST", 13, 36], ["Salmonella", "PROBLEM", 40, 50], ["the ATG", "TREATMENT", 82, 89], ["increased susceptibility to infection", "PROBLEM", 155, 192], ["Helicobacter pylori", "PROBLEM", 196, 215], ["increased", "OBSERVATION_MODIFIER", 155, 164], ["infection", "OBSERVATION", 183, 192]]], ["These findings illustrate that disease genes are likely to have specific functions in specific cell types, and researchers must consider the cell type- and stimulation-specific contexts used to examine disease-associated phenotypes.", [["cell", "ANATOMY", 95, 99], ["cell", "ANATOMY", 141, 145], ["cell", "CELL", 95, 99], ["cell", "CELL", 141, 145], ["disease genes", "DNA", 31, 44], ["disease genes", "PROBLEM", 31, 44], ["the cell type", "TEST", 137, 150], ["stimulation", "TREATMENT", 156, 167], ["disease", "PROBLEM", 202, 209], ["associated phenotypes", "PROBLEM", 210, 231], ["specific cell types", "OBSERVATION", 86, 105]]]], "734be7d6e7aae297e20519965e591c9f129f9695": [["IntroductionIn the early February, 2020, we called up an experts' committee to formulate the first edition of consensus statement on diagnosis, treatment and prevention of coronavirus disease 2019 in children, which has been published in World Journal of Pediatrics [1] .", [["coronavirus disease", "DISEASE", 172, 191], ["coronavirus", "ORGANISM", 172, 183], ["children", "ORGANISM", 200, 208], ["children", "SPECIES", 200, 208], ["treatment", "TREATMENT", 144, 153], ["coronavirus disease", "PROBLEM", 172, 191], ["coronavirus disease", "OBSERVATION", 172, 191]]], ["With accumulated experiences in diagnosis and treatment of COVID-19 in children, we have updated the consensus statement and released the second edition recently.", [["children", "ORGANISM", 71, 79], ["children", "SPECIES", 71, 79], ["treatment", "TREATMENT", 46, 55]]], ["The current version in English is a condensed version of the second edition of consensus statement on diagnosis, treatment and prevention of COVID-19 in children.IntroductionCompared with the adult patients, the number of pediatric patients was lower with milder symptoms and better prognosis.", [["children", "ORGANISM", 153, 161], ["patients", "ORGANISM", 198, 206], ["patients", "ORGANISM", 232, 240], ["children", "SPECIES", 153, 161], ["patients", "SPECIES", 198, 206], ["patients", "SPECIES", 232, 240], ["treatment", "TREATMENT", 113, 122], ["milder symptoms", "PROBLEM", 256, 271]]], ["There was a death reported as of March 8, 2020 [3] .", [["death", "DISEASE", 12, 17], ["a death", "PROBLEM", 10, 17]]], ["Up to now, COVID-19 pandemic affects more than 185 countries around the world.", [["COVID-19", "ORGANISM", 11, 19]]], ["China is under the risk of transmission of imported cases, which brings a new challenge in containing the epidemic in children.", [["children", "ORGANISM", 118, 126], ["children", "SPECIES", 118, 126]]], ["The statement will help pediatricians throughout the world in better diagnosis and treatment of COVID-19 in children.EtiologyThe description of severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) can be referred to the first edition of statement [1] .Route of transmissionRespiratory droplets and close contact are the main transmission routes of infection.", [["acute respiratory syndrome", "DISEASE", 151, 177], ["infection", "DISEASE", 364, 373], ["children", "ORGANISM", 108, 116], ["children", "SPECIES", 108, 116], ["severe acute respiratory syndrome", "PROBLEM", 144, 177], ["related coronavirus", "PROBLEM", 178, 197], ["infection", "PROBLEM", 364, 373], ["severe", "OBSERVATION_MODIFIER", 144, 150], ["acute", "OBSERVATION_MODIFIER", 151, 156], ["respiratory syndrome", "OBSERVATION", 157, 177], ["Respiratory droplets", "OBSERVATION", 289, 309], ["infection", "OBSERVATION", 364, 373]]], ["When exposed to high concentration of aerosol for a long time in a relatively enclosed environment, aerosol transmission may occur.", [["aerosol", "TREATMENT", 38, 45], ["aerosol transmission", "TREATMENT", 100, 120]]], ["Live SARS-COV-2 can be isolated from the feces and urine in infected patients; the viral nucleic acid clearance in the feces was later than nasopharyngeal swabs.", [["feces", "ANATOMY", 41, 46], ["urine", "ANATOMY", 51, 56], ["feces", "ANATOMY", 119, 124], ["nasopharyngeal swabs", "ANATOMY", 140, 160], ["nucleic acid", "CHEMICAL", 89, 101], ["COV-2", "CELL", 10, 15], ["feces", "ORGANISM_SUBSTANCE", 41, 46], ["urine", "ORGANISM_SUBSTANCE", 51, 56], ["patients", "ORGANISM", 69, 77], ["feces", "ORGANISM_SUBSTANCE", 119, 124], ["nasopharyngeal swabs", "ORGANISM_SUBSTANCE", 140, 160], ["patients", "SPECIES", 69, 77], ["Live SARS", "TEST", 0, 9], ["the feces and urine in infected patients", "PROBLEM", 37, 77], ["the viral nucleic acid clearance", "TEST", 79, 111], ["nasopharyngeal swabs", "TEST", 140, 160], ["feces", "ANATOMY", 119, 124]]], ["So attention should be paid to the aerosol or contact transmission caused by environmental pollution of feces and urine.Route of transmissionClose contact with infected patients with or without symptoms is the main transmission route of SARS-CoV-2 infection in children.", [["feces", "ANATOMY", 104, 109], ["urine", "ANATOMY", 114, 119], ["SARS-CoV-2 infection", "DISEASE", 237, 257], ["feces", "ORGANISM_SUBSTANCE", 104, 109], ["urine", "ORGANISM_SUBSTANCE", 114, 119], ["patients", "ORGANISM", 169, 177], ["SARS-CoV-2", "ORGANISM", 237, 247], ["children", "ORGANISM", 261, 269], ["patients", "SPECIES", 169, 177], ["children", "SPECIES", 261, 269], ["SARS-CoV-2", "SPECIES", 237, 247], ["environmental pollution of feces and urine", "PROBLEM", 77, 119], ["symptoms", "PROBLEM", 194, 202], ["SARS", "PROBLEM", 237, 241], ["2 infection", "PROBLEM", 246, 257], ["infection", "OBSERVATION", 248, 257]]], ["Pediatric patients are mostly clustered cases.", [["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18]]], ["There is no direct evidence of vertical mother-to-child transmission, but newborns can be infected through close contact [1, 4] .Susceptible populationChildren of all ages are susceptible to SARS-CoV-2 infection.", [["SARS-CoV-2 infection", "DISEASE", 191, 211], ["newborns", "ORGANISM", 74, 82], ["Children", "ORGANISM", 151, 159], ["SARS-CoV-2", "ORGANISM", 191, 201], ["Children", "SPECIES", 151, 159], ["SARS-CoV-2", "SPECIES", 191, 201], ["SARS", "PROBLEM", 191, 195], ["CoV-2 infection", "PROBLEM", 196, 211], ["no direct evidence of", "UNCERTAINTY", 9, 30], ["infection", "OBSERVATION", 202, 211]]], ["Children with underlying diseases (such as congenital heart, lung and airway disease, chronic heart and kidney disease, malnutrition, hereditary metabolic diseases, immunodeficiency disease, tumor, etc.) are likely to become severe cases [1, 4] .Pathological changesAccording to the current available pathological findings of adult patients, lung and immune system are mainly damaged.", [["heart", "ANATOMY", 54, 59], ["lung", "ANATOMY", 61, 65], ["airway", "ANATOMY", 70, 76], ["heart", "ANATOMY", 94, 99], ["kidney", "ANATOMY", 104, 110], ["tumor", "ANATOMY", 191, 196], ["lung", "ANATOMY", 342, 346], ["immune system", "ANATOMY", 351, 364], ["congenital heart, lung and airway disease", "DISEASE", 43, 84], ["chronic heart and kidney disease", "DISEASE", 86, 118], ["malnutrition", "DISEASE", 120, 132], ["hereditary metabolic diseases", "DISEASE", 134, 163], ["immunodeficiency disease", "DISEASE", 165, 189], ["tumor", "DISEASE", 191, 196], ["Children", "ORGANISM", 0, 8], ["heart", "ORGAN", 54, 59], ["lung", "ORGAN", 61, 65], ["airway", "MULTI-TISSUE_STRUCTURE", 70, 76], ["heart", "ORGAN", 94, 99], ["kidney", "ORGAN", 104, 110], ["tumor", "CANCER", 191, 196], ["patients", "ORGANISM", 332, 340], ["lung", "ORGAN", 342, 346], ["immune system", "ANATOMICAL_SYSTEM", 351, 364], ["Children", "SPECIES", 0, 8], ["patients", "SPECIES", 332, 340], ["underlying diseases", "PROBLEM", 14, 33], ["congenital heart, lung and airway disease", "PROBLEM", 43, 84], ["chronic heart and kidney disease", "PROBLEM", 86, 118], ["malnutrition", "PROBLEM", 120, 132], ["hereditary metabolic diseases", "PROBLEM", 134, 163], ["immunodeficiency disease", "PROBLEM", 165, 189], ["tumor", "PROBLEM", 191, 196], ["Pathological changesAccording", "PROBLEM", 246, 275], ["lung and immune system", "PROBLEM", 342, 364], ["diseases", "OBSERVATION", 25, 33], ["heart", "ANATOMY", 54, 59], ["lung", "ANATOMY", 61, 65], ["airway", "ANATOMY", 70, 76], ["disease", "OBSERVATION", 77, 84], ["chronic", "OBSERVATION_MODIFIER", 86, 93], ["heart", "ANATOMY", 94, 99], ["kidney", "ANATOMY", 104, 110], ["disease", "OBSERVATION", 111, 118], ["malnutrition", "OBSERVATION", 120, 132], ["hereditary", "OBSERVATION_MODIFIER", 134, 144], ["metabolic diseases", "OBSERVATION", 145, 163], ["tumor", "OBSERVATION", 191, 196], ["lung", "ANATOMY", 342, 346], ["immune system", "OBSERVATION", 351, 364]]], ["Among them, the lungs appear with varying degrees of consolidation.", [["lungs", "ANATOMY", 16, 21], ["lungs", "ORGAN", 16, 21], ["consolidation", "PROBLEM", 53, 66], ["lungs", "ANATOMY", 16, 21], ["varying", "OBSERVATION_MODIFIER", 34, 41], ["degrees", "OBSERVATION_MODIFIER", 42, 49], ["consolidation", "OBSERVATION", 53, 66]]], ["Serous fluid, fibrin exudate and hyaline membrane formation were found in alveolar cavity.", [["Serous fluid", "ANATOMY", 0, 12], ["fibrin exudate", "ANATOMY", 14, 28], ["hyaline membrane", "ANATOMY", 33, 49], ["alveolar cavity", "ANATOMY", 74, 89], ["Serous fluid", "ORGANISM_SUBSTANCE", 0, 12], ["fibrin", "GENE_OR_GENE_PRODUCT", 14, 20], ["hyaline membrane", "CELLULAR_COMPONENT", 33, 49], ["alveolar cavity", "MULTI-TISSUE_STRUCTURE", 74, 89], ["Serous fluid", "PROBLEM", 0, 12], ["fibrin exudate", "PROBLEM", 14, 28], ["hyaline membrane formation", "PROBLEM", 33, 59], ["fluid", "OBSERVATION", 7, 12], ["fibrin exudate", "OBSERVATION", 14, 28], ["hyaline membrane formation", "OBSERVATION", 33, 59], ["alveolar cavity", "ANATOMY", 74, 89]]], ["Alveolar septum is hyperemia and edema, mononuclear cell and lymphocyte infiltration and intravascular transparent thrombosis can be seen.", [["Alveolar septum", "ANATOMY", 0, 15], ["edema", "ANATOMY", 33, 38], ["mononuclear cell", "ANATOMY", 40, 56], ["lymphocyte", "ANATOMY", 61, 71], ["intravascular", "ANATOMY", 89, 102], ["hyperemia", "DISEASE", 19, 28], ["edema", "DISEASE", 33, 38], ["thrombosis", "DISEASE", 115, 125], ["Alveolar septum", "MULTI-TISSUE_STRUCTURE", 0, 15], ["edema", "PATHOLOGICAL_FORMATION", 33, 38], ["mononuclear cell", "CELL", 40, 56], ["lymphocyte", "CELL", 61, 71], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 89, 102], ["mononuclear cell", "CELL_TYPE", 40, 56], ["hyperemia", "PROBLEM", 19, 28], ["edema", "PROBLEM", 33, 38], ["mononuclear cell", "PROBLEM", 40, 56], ["lymphocyte infiltration", "PROBLEM", 61, 84], ["intravascular transparent thrombosis", "PROBLEM", 89, 125], ["septum", "ANATOMY_MODIFIER", 9, 15], ["hyperemia", "OBSERVATION", 19, 28], ["edema", "OBSERVATION", 33, 38], ["mononuclear cell", "OBSERVATION", 40, 56], ["lymphocyte infiltration", "OBSERVATION", 61, 84], ["intravascular", "OBSERVATION_MODIFIER", 89, 102], ["transparent", "OBSERVATION_MODIFIER", 103, 114], ["thrombosis", "OBSERVATION", 115, 125]]], ["Mucous and mucus plug formation can be seen in bronchial lumen of the lung [4] [5] [6] .Clinical manifestationsThe incubation period of SARS-CoV-2 infection ranges from 1 to 14 days, mostly ranging from 3 to 7 days.Clinical manifestationsFever, dry cough, and fatigue are the main clinical manifestations.", [["Mucous", "ANATOMY", 0, 6], ["mucus plug", "ANATOMY", 11, 21], ["bronchial lumen", "ANATOMY", 47, 62], ["lung", "ANATOMY", 70, 74], ["SARS", "DISEASE", 136, 140], ["infection", "DISEASE", 147, 156], ["Fever", "DISEASE", 238, 243], ["dry cough", "DISEASE", 245, 254], ["fatigue", "DISEASE", 260, 267], ["mucus plug", "TISSUE", 11, 21], ["bronchial lumen", "MULTI-TISSUE_STRUCTURE", 47, 62], ["lung", "ORGAN", 70, 74], ["SARS-CoV-2", "ORGANISM", 136, 146], ["SARS-CoV-2", "SPECIES", 136, 146], ["Mucous and mucus plug formation", "PROBLEM", 0, 31], ["Clinical manifestations", "PROBLEM", 88, 111], ["SARS", "PROBLEM", 136, 140], ["CoV", "TEST", 141, 144], ["2 infection", "PROBLEM", 145, 156], ["Clinical manifestations", "PROBLEM", 215, 238], ["Fever", "PROBLEM", 238, 243], ["dry cough", "PROBLEM", 245, 254], ["fatigue", "PROBLEM", 260, 267], ["mucus plug", "OBSERVATION", 11, 21], ["can be seen", "UNCERTAINTY", 32, 43], ["bronchial", "ANATOMY", 47, 56], ["lumen", "ANATOMY_MODIFIER", 57, 62], ["lung", "ANATOMY", 70, 74], ["SARS", "OBSERVATION", 136, 140], ["infection", "OBSERVATION", 147, 156], ["dry", "OBSERVATION_MODIFIER", 245, 248], ["cough", "OBSERVATION", 249, 254]]], ["A few children have upper respiratory symptoms such as nasal congestion, runny nose, and sore throat.", [["respiratory", "ANATOMY", 26, 37], ["nasal", "ANATOMY", 55, 60], ["nasal congestion", "DISEASE", 55, 71], ["runny nose", "DISEASE", 73, 83], ["sore throat", "DISEASE", 89, 100], ["children", "ORGANISM", 6, 14], ["nasal", "ORGANISM_SUBDIVISION", 55, 60], ["nose", "ORGANISM_SUBDIVISION", 79, 83], ["throat", "ORGANISM_SUBDIVISION", 94, 100], ["children", "SPECIES", 6, 14], ["upper respiratory symptoms", "PROBLEM", 20, 46], ["nasal congestion", "PROBLEM", 55, 71], ["runny nose", "PROBLEM", 73, 83], ["sore throat", "PROBLEM", 89, 100], ["few", "OBSERVATION_MODIFIER", 2, 5], ["upper", "ANATOMY_MODIFIER", 20, 25], ["respiratory", "ANATOMY", 26, 37], ["nasal", "ANATOMY", 55, 60], ["congestion", "OBSERVATION", 61, 71], ["runny nose", "ANATOMY", 73, 83], ["sore throat", "ANATOMY", 89, 100]]], ["Some infected newborns and children may have atypical symptoms, presenting as gastrointestinal symptoms such as vomiting, diarrhea or only poor spirit and shortness of breath.Clinical manifestationsMost children have relatively mild clinical symptoms without fever or pneumonia.", [["gastrointestinal", "ANATOMY", 78, 94], ["vomiting", "DISEASE", 112, 120], ["diarrhea", "DISEASE", 122, 130], ["shortness of breath", "DISEASE", 155, 174], ["fever", "DISEASE", 259, 264], ["pneumonia", "DISEASE", 268, 277], ["newborns", "ORGANISM", 14, 22], ["children", "ORGANISM", 27, 35], ["gastrointestinal", "ORGAN", 78, 94], ["children", "ORGANISM", 203, 211], ["children", "SPECIES", 27, 35], ["children", "SPECIES", 203, 211], ["atypical symptoms", "PROBLEM", 45, 62], ["gastrointestinal symptoms", "PROBLEM", 78, 103], ["vomiting", "PROBLEM", 112, 120], ["diarrhea", "PROBLEM", 122, 130], ["poor spirit", "PROBLEM", 139, 150], ["shortness of breath", "PROBLEM", 155, 174], ["Clinical manifestations", "PROBLEM", 175, 198], ["relatively mild clinical symptoms", "PROBLEM", 217, 250], ["fever", "PROBLEM", 259, 264], ["pneumonia", "PROBLEM", 268, 277], ["infected", "OBSERVATION", 5, 13], ["pneumonia", "OBSERVATION", 268, 277]]], ["Severe pediatric cases show obvious dyspnea, and may rapidly progress to acute respiratory distress syndrome, septic shock, refractory metabolic acidosis, coagulation dysfunction and multiple-organ failure.", [["respiratory", "ANATOMY", 79, 90], ["organ", "ANATOMY", 192, 197], ["dyspnea", "DISEASE", 36, 43], ["acute respiratory distress syndrome", "DISEASE", 73, 108], ["septic shock", "DISEASE", 110, 122], ["metabolic acidosis", "DISEASE", 135, 153], ["coagulation dysfunction", "DISEASE", 155, 178], ["multiple-organ failure", "DISEASE", 183, 205], ["organ", "ORGAN", 192, 197], ["Severe pediatric cases", "PROBLEM", 0, 22], ["obvious dyspnea", "PROBLEM", 28, 43], ["acute respiratory distress syndrome", "PROBLEM", 73, 108], ["septic shock", "PROBLEM", 110, 122], ["refractory metabolic acidosis", "PROBLEM", 124, 153], ["coagulation dysfunction", "PROBLEM", 155, 178], ["multiple-organ failure", "PROBLEM", 183, 205], ["obvious", "OBSERVATION_MODIFIER", 28, 35], ["dyspnea", "OBSERVATION", 36, 43], ["acute", "OBSERVATION_MODIFIER", 73, 78], ["respiratory distress", "OBSERVATION", 79, 99], ["septic shock", "OBSERVATION", 110, 122], ["refractory", "OBSERVATION_MODIFIER", 124, 134], ["metabolic acidosis", "OBSERVATION", 135, 153], ["coagulation dysfunction", "OBSERVATION", 155, 178], ["multiple", "OBSERVATION_MODIFIER", 183, 191], ["organ", "ANATOMY", 192, 197], ["failure", "OBSERVATION", 198, 205]]], ["Those who progress into severely and critically ill diseases may have low to moderate fever even without obvious fever during the disease.SARS-CoV-2 nuclear acid testSARS-CoV-2 can be detected in blood, feces, anal swabs and other specimens.", [["blood", "ANATOMY", 196, 201], ["feces", "ANATOMY", 203, 208], ["anal swabs", "ANATOMY", 210, 220], ["specimens", "ANATOMY", 231, 240], ["critically ill diseases", "DISEASE", 37, 60], ["fever", "DISEASE", 86, 91], ["fever", "DISEASE", 113, 118], ["testSARS-CoV-2", "GENE_OR_GENE_PRODUCT", 162, 176], ["blood", "ORGANISM_SUBSTANCE", 196, 201], ["feces", "ORGANISM_SUBSTANCE", 203, 208], ["anal swabs", "ORGANISM_SUBSTANCE", 210, 220], ["SARS-CoV-2 nuclear acid testSARS-CoV-2", "DNA", 138, 176], ["critically ill diseases", "PROBLEM", 37, 60], ["low to moderate fever", "PROBLEM", 70, 91], ["obvious fever", "PROBLEM", 105, 118], ["the disease", "PROBLEM", 126, 137], ["SARS", "TEST", 138, 142], ["CoV", "TEST", 143, 146], ["nuclear acid testSARS", "TEST", 149, 170], ["CoV", "TEST", 171, 174], ["blood, feces", "TEST", 196, 208], ["anal swabs and other specimens", "TEST", 210, 240], ["low to moderate", "OBSERVATION_MODIFIER", 70, 85], ["fever", "OBSERVATION", 86, 91], ["anal", "ANATOMY", 210, 214]]], ["For improving the positive test rate, collect sputum sample, and collect lower respiratory tract secretion samples in patients under tracheal intubation.", [["sputum sample", "ANATOMY", 46, 59], ["lower respiratory tract", "ANATOMY", 73, 96], ["samples", "ANATOMY", 107, 114], ["tracheal", "ANATOMY", 133, 141], ["tract", "ORGANISM_SUBDIVISION", 91, 96], ["patients", "ORGANISM", 118, 126], ["tracheal", "ORGAN", 133, 141], ["patients", "SPECIES", 118, 126], ["the positive test rate", "TEST", 14, 36], ["sputum sample", "TEST", 46, 59], ["lower respiratory tract secretion samples", "PROBLEM", 73, 114], ["tracheal intubation", "TREATMENT", 133, 152], ["respiratory tract", "ANATOMY", 79, 96], ["tracheal", "ANATOMY", 133, 141], ["intubation", "OBSERVATION", 142, 152]]], ["Samples should be sent for test as soon as possible.Blood SARS-CoV-2 antibody detectionSerum SARS-CoV-2 specific antibodies IgM and IgG test positive for two consecutive times is helpful for diagnosis.", [["Blood", "ANATOMY", 52, 57], ["Blood", "ORGANISM_SUBSTANCE", 52, 57], ["CoV-2", "GENE_OR_GENE_PRODUCT", 63, 68], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 93, 103], ["IgM", "GENE_OR_GENE_PRODUCT", 124, 127], ["IgG", "GENE_OR_GENE_PRODUCT", 132, 135], ["Blood SARS-CoV-2 antibody detectionSerum SARS-CoV-2 specific antibodies", "PROTEIN", 52, 123], ["IgM", "PROTEIN", 124, 127], ["IgG", "PROTEIN", 132, 135], ["Samples", "TEST", 0, 7], ["test", "TEST", 27, 31], ["Blood SARS", "TEST", 52, 62], ["CoV", "TEST", 63, 66], ["antibody detectionSerum", "TEST", 69, 92], ["SARS", "TEST", 93, 97], ["CoV", "TEST", 98, 101], ["specific antibodies IgM", "TEST", 104, 127], ["IgG test", "TEST", 132, 140]]], ["However, negative antibody tests cannot exclude infection at the early stage of disease onset.", [["infection", "DISEASE", 48, 57], ["antibody tests", "TEST", 18, 32], ["infection", "PROBLEM", 48, 57], ["disease onset", "PROBLEM", 80, 93], ["disease", "OBSERVATION", 80, 87]]], ["Non-specific reactions must be ruled out for positive IgM antibody detection.", [["IgM antibody", "PROTEIN", 54, 66], ["Non-specific reactions", "PROBLEM", 0, 22], ["positive IgM antibody detection", "PROBLEM", 45, 76], ["IgM antibody", "OBSERVATION", 54, 66]]], ["The diagnostic value of IgM and IgG detection needs further evaluation, because it takes a certain period for the body to produce serum-specific antibodies and reach the detection threshold after virus infection and the kinetic features of serum-specific antibody production after the virus infection are still unclear.", [["body", "ANATOMY", 114, 118], ["serum", "ANATOMY", 130, 135], ["serum", "ANATOMY", 240, 245], ["infection", "DISEASE", 202, 211], ["infection", "DISEASE", 291, 300], ["IgM", "GENE_OR_GENE_PRODUCT", 24, 27], ["IgG", "GENE_OR_GENE_PRODUCT", 32, 35], ["body", "ORGANISM_SUBDIVISION", 114, 118], ["serum", "ORGANISM_SUBSTANCE", 130, 135], ["serum", "ORGANISM_SUBSTANCE", 240, 245], ["IgM", "PROTEIN", 24, 27], ["IgG", "PROTEIN", 32, 35], ["serum-specific antibodies", "PROTEIN", 130, 155], ["IgM", "TEST", 24, 27], ["IgG detection", "TEST", 32, 45], ["further evaluation", "TEST", 52, 70], ["serum-specific antibodies", "PROBLEM", 130, 155], ["virus infection", "PROBLEM", 196, 211], ["the kinetic features", "TEST", 216, 236], ["serum", "TEST", 240, 245], ["specific antibody production", "PROBLEM", 246, 274], ["the virus infection", "PROBLEM", 281, 300]]], ["Antibody test can be used for retrospective auxiliary diagnosis and seroepidemiological surveys.Chest imaging examinationDigital X-ray photography X-ray photography is not recommended as the first choice, because it is easy to missed diagnosis.", [["Antibody test", "TEST", 0, 13], ["seroepidemiological surveys", "TEST", 68, 95], ["Chest imaging examination", "TEST", 96, 121], ["Digital X-ray photography X-ray photography", "TEST", 121, 164]]], ["Infected pediatric patients commonly have no abnormal X-ray imaging results at the early stage of disease onset.", [["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27], ["abnormal X-ray imaging", "PROBLEM", 45, 67], ["disease onset", "PROBLEM", 98, 111], ["disease", "OBSERVATION", 98, 105]]], ["Only those severe cases or those at the progression stage show \"white-lung\" pattern.", [["lung", "ANATOMY", 70, 74], ["lung", "ORGAN", 70, 74], ["those severe cases", "PROBLEM", 5, 23], ["white-lung\" pattern", "PROBLEM", 64, 83], ["severe", "OBSERVATION_MODIFIER", 11, 17], ["lung", "ANATOMY", 70, 74]]], ["X-ray photography can be used for reviewing and comparison [9, 10] .CT scanningTo enhance the imaging features of CT examination in each stage, to observe pulmonary imaging changes in children more clearly, were commend using a spiral CT volume scan of 16 rows or more to reconstruct a thin layer of 1.0-1.5 mm, with standard algorithms and bone algorithms being the best [9, 10].CT scanning1.", [["pulmonary", "ANATOMY", 155, 164], ["bone", "ANATOMY", 341, 345], ["pulmonary", "ORGAN", 155, 164], ["children", "ORGANISM", 184, 192], ["bone", "TISSUE", 341, 345], ["children", "SPECIES", 184, 192], ["X-ray photography", "TEST", 0, 17], [".CT scanning", "TEST", 67, 79], ["the imaging features", "TEST", 90, 110], ["CT examination", "TEST", 114, 128], ["pulmonary imaging", "TEST", 155, 172], ["a spiral CT volume scan", "TEST", 226, 249], ["standard algorithms and bone algorithms", "TEST", 317, 356], ["CT scanning1", "TEST", 380, 392], ["pulmonary", "ANATOMY", 155, 164], ["bone", "ANATOMY", 341, 345]]], ["Early stage: Mostly appearing with single or multiple localized ground-glass opacities in the form of light cloud or fine mesh, with thickened blood vessels shadows inside the lesions.", [["blood vessels", "ANATOMY", 143, 156], ["lesions", "ANATOMY", 176, 183], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 143, 156], ["lesions", "PATHOLOGICAL_FORMATION", 176, 183], ["multiple localized ground-glass opacities", "PROBLEM", 45, 86], ["light cloud or fine mesh", "PROBLEM", 102, 126], ["thickened blood vessels shadows", "PROBLEM", 133, 164], ["the lesions", "PROBLEM", 172, 183], ["multiple", "OBSERVATION_MODIFIER", 45, 53], ["localized", "OBSERVATION_MODIFIER", 54, 63], ["ground-glass opacities", "OBSERVATION", 64, 86], ["light", "OBSERVATION_MODIFIER", 102, 107], ["cloud", "OBSERVATION_MODIFIER", 108, 113], ["fine mesh", "OBSERVATION", 117, 126], ["thickened", "OBSERVATION_MODIFIER", 133, 142], ["blood vessels", "OBSERVATION", 143, 156], ["shadows", "OBSERVATION_MODIFIER", 157, 164], ["lesions", "OBSERVATION", 176, 183]]], ["A few presenting with localized consolidation, located under the pleura or near the bron-chial blood vessel bundles; among them, the periphery of the subpleural lung is the most commonly affected, and most are located in the bilateral lower lobes.", [["pleura", "ANATOMY", 65, 71], ["bron-chial blood vessel bundles", "ANATOMY", 84, 115], ["subpleural lung", "ANATOMY", 150, 165], ["lower lobes", "ANATOMY", 235, 246], ["pleura", "ORGAN", 65, 71], ["blood vessel bundles", "MULTI-TISSUE_STRUCTURE", 95, 115], ["subpleural", "MULTI-TISSUE_STRUCTURE", 150, 160], ["lung", "ORGAN", 161, 165], ["lower lobes", "MULTI-TISSUE_STRUCTURE", 235, 246], ["localized consolidation", "PROBLEM", 22, 45], ["few", "OBSERVATION_MODIFIER", 2, 5], ["localized", "OBSERVATION_MODIFIER", 22, 31], ["consolidation", "OBSERVATION", 32, 45], ["pleura", "ANATOMY", 65, 71], ["bron-chial", "ANATOMY_MODIFIER", 84, 94], ["blood vessel", "ANATOMY", 95, 107], ["bundles", "ANATOMY_MODIFIER", 108, 115], ["periphery", "ANATOMY_MODIFIER", 133, 142], ["subpleural", "ANATOMY_MODIFIER", 150, 160], ["lung", "ANATOMY", 161, 165], ["most commonly", "OBSERVATION_MODIFIER", 173, 186], ["bilateral", "ANATOMY_MODIFIER", 225, 234], ["lower lobes", "ANATOMY", 235, 246]]], ["Progressive stage: Few patients have increased groundglass shadows, or the affected area enlarged tending to merge, thus presenting with large-scale consolidation (rarely seen in patients).", [["area", "ANATOMY", 84, 88], ["patients", "ORGANISM", 23, 31], ["patients", "ORGANISM", 179, 187], ["patients", "SPECIES", 23, 31], ["patients", "SPECIES", 179, 187], ["increased groundglass shadows", "PROBLEM", 37, 66], ["the affected area", "PROBLEM", 71, 88], ["large-scale consolidation", "PROBLEM", 137, 162], ["Few", "OBSERVATION_MODIFIER", 19, 22], ["increased", "OBSERVATION_MODIFIER", 37, 46], ["groundglass shadows", "OBSERVATION", 47, 66], ["affected", "OBSERVATION_MODIFIER", 75, 83], ["area", "OBSERVATION_MODIFIER", 84, 88], ["enlarged", "OBSERVATION", 89, 97], ["large", "OBSERVATION_MODIFIER", 137, 142], ["-scale", "OBSERVATION_MODIFIER", 142, 148], ["consolidation", "OBSERVATION", 149, 162]]], ["Severe or critical stage: Very rarely seen in patients who have diffused consolidation of unilateral or bilateral lungs and accompanied with ground-glass opacities, bronchial inflation signs; pleural effusions are rarely seen.", [["lungs", "ANATOMY", 114, 119], ["bronchial", "ANATOMY", 165, 174], ["pleural effusions", "ANATOMY", 192, 209], ["pleural effusions", "DISEASE", 192, 209], ["patients", "ORGANISM", 46, 54], ["lungs", "ORGAN", 114, 119], ["pleural effusions", "CANCER", 192, 209], ["patients", "SPECIES", 46, 54], ["diffused consolidation of unilateral or bilateral lungs", "PROBLEM", 64, 119], ["ground-glass opacities", "PROBLEM", 141, 163], ["bronchial inflation signs", "PROBLEM", 165, 190], ["pleural effusions", "PROBLEM", 192, 209], ["diffused", "OBSERVATION_MODIFIER", 64, 72], ["consolidation", "OBSERVATION", 73, 86], ["unilateral", "ANATOMY_MODIFIER", 90, 100], ["bilateral", "ANATOMY_MODIFIER", 104, 113], ["lungs", "ANATOMY", 114, 119], ["glass opacities", "OBSERVATION", 148, 163], ["bronchial", "ANATOMY", 165, 174], ["inflation", "OBSERVATION_MODIFIER", 175, 184], ["signs", "OBSERVATION_MODIFIER", 185, 190], ["pleural", "ANATOMY", 192, 199], ["effusions", "OBSERVATION", 200, 209]]], ["Absorption stage: the original lesions completely absorbed and improved, the interstitial fibrosis is rarely seen.Suspected cases [1, 4, 8]According to the global trend of disease outbreaks, we update the epidemiological history that requires close attention in clinical practice as follows.", [["lesions", "ANATOMY", 31, 38], ["interstitial", "ANATOMY", 77, 89], ["fibrosis", "DISEASE", 90, 98], ["lesions", "PATHOLOGICAL_FORMATION", 31, 38], ["interstitial", "MULTI-TISSUE_STRUCTURE", 77, 89], ["the original lesions", "PROBLEM", 18, 38], ["the interstitial fibrosis", "PROBLEM", 73, 98], ["lesions", "OBSERVATION", 31, 38], ["completely", "OBSERVATION_MODIFIER", 39, 49], ["absorbed", "OBSERVATION_MODIFIER", 50, 58], ["improved", "OBSERVATION_MODIFIER", 63, 71], ["interstitial", "ANATOMY_MODIFIER", 77, 89], ["fibrosis", "OBSERVATION", 90, 98], ["disease", "OBSERVATION", 172, 179]]], ["COVID-19 should be suspected in patients who meet any one of the criteria in the epidemiological history and any two of the criteria in clinical manifestations.Epidemiological history1.", [["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40], ["COVID", "TEST", 0, 5], ["clinical manifestations", "PROBLEM", 136, 159]]], ["Children with a travel or residence history in a community with infected cases reported in China or a country or region with a serious epidemic within 14 days prior to disease onset (With the global pandemic of COVID-19, imported cases deserve attention).", [["Children", "ORGANISM", 0, 8], ["Children", "SPECIES", 0, 8], ["disease onset", "PROBLEM", 168, 181]]], ["Children with a history of contacting patients infected with SARS-Cov-2 within 14 days prior to disease onset.", [["SARS", "DISEASE", 61, 65], ["Children", "ORGANISM", 0, 8], ["patients", "ORGANISM", 38, 46], ["Children", "SPECIES", 0, 8], ["patients", "SPECIES", 38, 46], ["SARS", "PROBLEM", 61, 65], ["disease onset", "PROBLEM", 96, 109]]], ["Children with a history of contacting patients with fever or respiratory symptoms from communities with reported cases in China or countries or regions with serious epidemic within 14 days prior to disease onset; 4.", [["respiratory", "ANATOMY", 61, 72], ["fever", "DISEASE", 52, 57], ["respiratory symptoms", "DISEASE", 61, 81], ["Children", "ORGANISM", 0, 8], ["patients", "ORGANISM", 38, 46], ["Children", "SPECIES", 0, 8], ["patients", "SPECIES", 38, 46], ["fever", "PROBLEM", 52, 57], ["respiratory symptoms", "PROBLEM", 61, 81], ["disease onset", "PROBLEM", 198, 211]]], ["Clustered cases: two or more cases with fever and/or respiratory symptoms within 14 days in small groups (such as family members, school classmates, etc.); 5.", [["respiratory", "ANATOMY", 53, 64], ["fever", "DISEASE", 40, 45], ["respiratory symptoms", "DISEASE", 53, 73], ["fever", "PROBLEM", 40, 45], ["respiratory symptoms", "PROBLEM", 53, 73], ["respiratory", "ANATOMY", 53, 64]]], ["Newborns delivered by mothers with confirmed infection.Clinical manifestations1.", [["infection", "DISEASE", 45, 54], ["Newborns", "ORGANISM", 0, 8], ["mothers", "ORGANISM", 22, 29], ["Newborns", "SPECIES", 0, 8], ["infection", "PROBLEM", 45, 54], ["infection", "OBSERVATION", 45, 54]]], ["Fever, fatigue, dry cough, and/or other respiratory symptoms; some pediatric patients may have low-grade fever or no fever.Confirmed cases [1, 4, 8]Suspected cases who meet any one of the following criteria:Confirmed cases [1, 4, 8]1.", [["respiratory", "ANATOMY", 40, 51], ["Fever", "DISEASE", 0, 5], ["fatigue", "DISEASE", 7, 14], ["dry cough", "DISEASE", 16, 25], ["respiratory symptoms", "DISEASE", 40, 60], ["fever", "DISEASE", 105, 110], ["fever", "DISEASE", 117, 122], ["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85], ["Fever", "PROBLEM", 0, 5], ["fatigue", "PROBLEM", 7, 14], ["dry cough", "PROBLEM", 16, 25], ["other respiratory symptoms", "PROBLEM", 34, 60], ["low-grade fever", "PROBLEM", 95, 110], ["fever", "PROBLEM", 117, 122], ["dry", "OBSERVATION_MODIFIER", 16, 19], ["cough", "OBSERVATION", 20, 25], ["respiratory", "ANATOMY", 40, 51], ["low-grade", "OBSERVATION_MODIFIER", 95, 104], ["fever", "OBSERVATION", 105, 110], ["no", "UNCERTAINTY", 114, 116], ["fever", "OBSERVATION", 117, 122]]], ["Testing positive for SARS-CoV-2 by real-time PCR.Confirmed cases [1, 4, 8]2.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 21, 31], ["SARS-CoV", "SPECIES", 21, 29], ["Testing", "TEST", 0, 7], ["SARS", "PROBLEM", 21, 25], ["CoV", "TEST", 26, 29]]], ["Genetic sequencing of respiratory tract or blood samples is highly homologous with the known SARS-CoV-2.", [["respiratory tract", "ANATOMY", 22, 39], ["blood samples", "ANATOMY", 43, 56], ["respiratory tract", "ORGAN", 22, 39], ["blood samples", "ORGANISM_SUBSTANCE", 43, 56], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 93, 103], ["SARS-CoV-2", "DNA", 93, 103], ["SARS-CoV", "SPECIES", 93, 101], ["Genetic sequencing of respiratory tract", "PROBLEM", 0, 39], ["blood samples", "TEST", 43, 56], ["respiratory tract", "ANATOMY", 22, 39]]], ["Both serum-specific antibodies IgM and IgG are positive.", [["serum", "ANATOMY", 5, 10], ["serum", "ORGANISM_SUBSTANCE", 5, 10], ["IgM", "GENE_OR_GENE_PRODUCT", 31, 34], ["IgG", "GENE_OR_GENE_PRODUCT", 39, 42], ["serum-specific antibodies", "PROTEIN", 5, 30], ["IgM", "PROTEIN", 31, 34], ["IgG", "PROTEIN", 39, 42], ["Both serum", "TEST", 0, 10], ["specific antibodies IgM", "TEST", 11, 34], ["IgG", "TEST", 39, 42]]], ["Serum-specific antibody IgG changed from negative to positive or increased fourfolds or higher than that in the acute phase during the recovery period.Asymptomatic infection (silent infection)Testing positive for SARS-CoV-2, but without clinical symptoms or abnormal chest imaging findings.Acute upper respiratory tract infectionWith only fever, cough, pharyngeal pain, nasal congestion, fatigue, headache, myalgia or discomfort, etc., and without signs of pneumonia by chest imaging or sepsis.Mild pneumoniaWith or without fever, with respiratory symptoms such as cough; and chest imaging indicating changes of viral pneumonia, but not reaching the criteria of severe pneumonia.", [["chest", "ANATOMY", 267, 272], ["upper respiratory tract", "ANATOMY", 296, 319], ["pharyngeal", "ANATOMY", 353, 363], ["nasal", "ANATOMY", 370, 375], ["chest", "ANATOMY", 470, 475], ["respiratory", "ANATOMY", 536, 547], ["infection", "DISEASE", 164, 173], ["silent infection", "DISEASE", 175, 191], ["upper respiratory tract infectionWith", "DISEASE", 296, 333], ["fever", "DISEASE", 339, 344], ["cough", "DISEASE", 346, 351], ["pharyngeal pain", "DISEASE", 353, 368], ["nasal congestion", "DISEASE", 370, 386], ["fatigue", "DISEASE", 388, 395], ["headache", "DISEASE", 397, 405], ["myalgia", "DISEASE", 407, 414], ["pneumonia", "DISEASE", 457, 466], ["sepsis", "DISEASE", 487, 493], ["pneumoniaWith", "DISEASE", 499, 512], ["fever", "DISEASE", 524, 529], ["respiratory symptoms", "DISEASE", 536, 556], ["cough", "DISEASE", 565, 570], ["viral pneumonia", "DISEASE", 612, 627], ["pneumonia", "DISEASE", 669, 678], ["IgG", "GENE_OR_GENE_PRODUCT", 24, 27], ["chest", "ORGANISM_SUBDIVISION", 267, 272], ["upper", "ORGANISM_SUBDIVISION", 296, 301], ["respiratory tract", "ORGANISM_SUBDIVISION", 302, 319], ["pharyngeal", "ORGANISM_SUBDIVISION", 353, 363], ["nasal", "ORGANISM_SUBDIVISION", 370, 375], ["chest", "ORGANISM_SUBDIVISION", 470, 475], ["Serum-specific antibody IgG", "PROTEIN", 0, 27], ["SARS-CoV", "SPECIES", 213, 221], ["Serum-specific antibody IgG", "TEST", 0, 27], ["increased fourfolds", "PROBLEM", 65, 84], ["Asymptomatic infection", "PROBLEM", 151, 173], ["silent infection", "PROBLEM", 175, 191], ["SARS", "PROBLEM", 213, 217], ["CoV", "TEST", 218, 221], ["clinical symptoms", "PROBLEM", 237, 254], ["abnormal chest imaging findings", "PROBLEM", 258, 289], ["Acute upper respiratory tract infectionWith", "PROBLEM", 290, 333], ["fever", "PROBLEM", 339, 344], ["cough", "PROBLEM", 346, 351], ["pharyngeal pain", "PROBLEM", 353, 368], ["nasal congestion", "PROBLEM", 370, 386], ["fatigue", "PROBLEM", 388, 395], ["headache", "PROBLEM", 397, 405], ["myalgia", "PROBLEM", 407, 414], ["discomfort", "PROBLEM", 418, 428], ["pneumonia", "PROBLEM", 457, 466], ["chest imaging", "TEST", 470, 483], ["sepsis", "PROBLEM", 487, 493], ["Mild pneumoniaWith", "PROBLEM", 494, 512], ["fever", "PROBLEM", 524, 529], ["respiratory symptoms", "PROBLEM", 536, 556], ["cough", "PROBLEM", 565, 570], ["chest imaging", "TEST", 576, 589], ["viral pneumonia", "PROBLEM", 612, 627], ["severe pneumonia", "PROBLEM", 662, 678], ["increased", "OBSERVATION_MODIFIER", 65, 74], ["fourfolds", "OBSERVATION", 75, 84], ["higher", "OBSERVATION_MODIFIER", 88, 94], ["infection", "OBSERVATION", 164, 173], ["infection", "OBSERVATION", 182, 191], ["without", "UNCERTAINTY", 229, 236], ["chest", "ANATOMY", 267, 272], ["upper", "ANATOMY_MODIFIER", 296, 301], ["respiratory tract", "ANATOMY", 302, 319], ["fever", "OBSERVATION", 339, 344], ["pharyngeal", "ANATOMY", 353, 363], ["pain", "OBSERVATION", 364, 368], ["nasal", "ANATOMY", 370, 375], ["congestion", "OBSERVATION", 376, 386], ["pneumonia", "OBSERVATION", 457, 466], ["chest", "ANATOMY", 470, 475], ["sepsis", "OBSERVATION", 487, 493], ["without", "UNCERTAINTY", 516, 523], ["fever", "OBSERVATION", 524, 529], ["chest", "ANATOMY", 576, 581], ["viral", "OBSERVATION_MODIFIER", 612, 617], ["pneumonia", "OBSERVATION", 618, 627], ["severe", "OBSERVATION_MODIFIER", 662, 668], ["pneumonia", "OBSERVATION", 669, 678]]], ["Disturbance of consciousness: somnolence, coma, or convulsion.", [["Disturbance of consciousness", "DISEASE", 0, 28], ["somnolence", "DISEASE", 30, 40], ["coma", "DISEASE", 42, 46], ["convulsion", "DISEASE", 51, 61], ["Disturbance of consciousness", "PROBLEM", 0, 28], ["somnolence", "PROBLEM", 30, 40], ["coma", "PROBLEM", 42, 46], ["convulsion", "PROBLEM", 51, 61]]], ["Food refusal or feeding difficulty, with signs of dehydration.Pulmonary high-resolution CT (HRCT) examinationshowing bilateral or multi-lobe infiltrates, rapid progression of disease in a short period or with pleural effusion.Critical casesThose who meet any of the following criteria and require ICU care:Early identification of severe and critical casesHigh-risk children and early warning indicators are highlighted in this edition.High-risk children [1, 4, 8, 11]According to the current accumulated experiences in managing confirmed COVID-19 pediatric patients and experiences from diagnosis and treatment of community-acquired pneumonia in children, children who meet any of the following criteria are at high-risk to become severe or critical cases:Early warning indicatorsEarly warning indicators for severe or critical diseases are as followings:Early warning indicators1.", [["Pulmonary", "ANATOMY", 62, 71], ["multi-lobe infiltrates", "ANATOMY", 130, 152], ["pleural effusion", "ANATOMY", 209, 225], ["dehydration", "DISEASE", 50, 61], ["pleural effusion", "DISEASE", 209, 225], ["pneumonia", "DISEASE", 633, 642], ["pleural effusion", "CANCER", 209, 225], ["children", "ORGANISM", 365, 373], ["children", "ORGANISM", 445, 453], ["patients", "ORGANISM", 557, 565], ["children", "ORGANISM", 646, 654], ["children", "ORGANISM", 656, 664], ["children", "SPECIES", 365, 373], ["children", "SPECIES", 445, 453], ["patients", "SPECIES", 557, 565], ["children", "SPECIES", 646, 654], ["children", "SPECIES", 656, 664], ["feeding difficulty", "PROBLEM", 16, 34], ["dehydration", "PROBLEM", 50, 61], ["Pulmonary high-resolution CT (HRCT)", "TEST", 62, 97], ["bilateral or multi-lobe infiltrates", "PROBLEM", 117, 152], ["disease", "PROBLEM", 175, 182], ["pleural effusion", "PROBLEM", 209, 225], ["severe and critical cases", "PROBLEM", 330, 355], ["treatment", "TREATMENT", 601, 610], ["community-acquired pneumonia", "PROBLEM", 614, 642], ["Early warning indicators", "PROBLEM", 756, 780], ["severe or critical diseases", "PROBLEM", 809, 836], ["Early warning indicators", "PROBLEM", 855, 879], ["dehydration", "OBSERVATION", 50, 61], ["bilateral", "ANATOMY_MODIFIER", 117, 126], ["lobe", "ANATOMY_MODIFIER", 136, 140], ["infiltrates", "OBSERVATION", 141, 152], ["rapid", "OBSERVATION_MODIFIER", 154, 159], ["progression", "OBSERVATION_MODIFIER", 160, 171], ["disease", "OBSERVATION", 175, 182], ["short", "OBSERVATION_MODIFIER", 188, 193], ["pleural", "ANATOMY", 209, 216], ["effusion", "OBSERVATION", 217, 225], ["risk children", "OBSERVATION_MODIFIER", 360, 373], ["pneumonia", "OBSERVATION", 633, 642], ["diseases", "OBSERVATION", 828, 836]]], ["Increased respiratory rate (RR): > 50 times/min (2-12 months), > 40 times/min (1-5 years), > 30 times/ min (> 5 years) (after ruling out the effects of fever and crying).", [["respiratory", "ANATOMY", 10, 21], ["fever", "DISEASE", 152, 157], ["Increased respiratory rate", "PROBLEM", 0, 26], ["fever", "PROBLEM", 152, 157], ["crying", "PROBLEM", 162, 168], ["respiratory rate", "OBSERVATION", 10, 26]]], ["Persistent high fever for 3-5 days, a disease course longer than 1 week, and no improvements in symptoms or signs or progressive exacerbation.", [["fever", "DISEASE", 16, 21], ["Persistent high fever", "PROBLEM", 0, 21], ["symptoms", "PROBLEM", 96, 104], ["signs", "PROBLEM", 108, 113], ["progressive exacerbation", "PROBLEM", 117, 141], ["high", "OBSERVATION_MODIFIER", 11, 15], ["fever", "OBSERVATION", 16, 21], ["no", "UNCERTAINTY", 77, 79], ["progressive", "OBSERVATION_MODIFIER", 117, 128], ["exacerbation", "OBSERVATION", 129, 141]]], ["With poor mental response, lethargy, etc. 4.", [["lethargy", "DISEASE", 27, 35], ["poor mental response", "PROBLEM", 5, 25], ["lethargy", "PROBLEM", 27, 35], ["poor", "OBSERVATION_MODIFIER", 5, 9], ["mental response", "OBSERVATION", 10, 25]]], ["Significantly reduced and/or progressively decreased peripheral blood lymphocytes.", [["peripheral blood lymphocytes", "ANATOMY", 53, 81], ["peripheral blood lymphocytes", "CELL", 53, 81], ["peripheral blood lymphocytes", "CELL_TYPE", 53, 81], ["progressively decreased peripheral blood lymphocytes", "PROBLEM", 29, 81], ["reduced", "OBSERVATION_MODIFIER", 14, 21], ["progressively", "OBSERVATION_MODIFIER", 29, 42], ["decreased", "OBSERVATION_MODIFIER", 43, 52], ["peripheral", "ANATOMY_MODIFIER", 53, 63], ["blood lymphocytes", "OBSERVATION", 64, 81]]], ["Progressively increased enzymatic indexes, such as myocardial enzymes, liver enzymes, lactate dehydrogenase.", [["myocardial", "ANATOMY", 51, 61], ["liver", "ANATOMY", 71, 76], ["lactate", "CHEMICAL", 86, 93], ["lactate", "CHEMICAL", 86, 93], ["myocardial", "MULTI-TISSUE_STRUCTURE", 51, 61], ["liver", "ORGAN", 71, 76], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 86, 107], ["myocardial enzymes", "PROTEIN", 51, 69], ["liver enzymes", "PROTEIN", 71, 84], ["lactate dehydrogenase", "PROTEIN", 86, 107], ["Progressively increased enzymatic indexes", "PROBLEM", 0, 41], ["myocardial enzymes", "TEST", 51, 69], ["liver enzymes", "TEST", 71, 84], ["lactate dehydrogenase", "PROBLEM", 86, 107], ["increased", "OBSERVATION_MODIFIER", 14, 23], ["enzymatic indexes", "OBSERVATION", 24, 41], ["liver", "ANATOMY", 71, 76]]], ["Unexplainable metabolic acidosis.", [["metabolic acidosis", "DISEASE", 14, 32], ["Unexplainable metabolic acidosis", "PROBLEM", 0, 32], ["metabolic acidosis", "OBSERVATION", 14, 32]]], ["Significantly increased D-dimer, IL-6, IL-10, and ferritin levels.", [["D-dimer", "GENE_OR_GENE_PRODUCT", 24, 31], ["IL-6", "GENE_OR_GENE_PRODUCT", 33, 37], ["IL-10", "GENE_OR_GENE_PRODUCT", 39, 44], ["ferritin", "GENE_OR_GENE_PRODUCT", 50, 58], ["IL", "PROTEIN", 39, 41], ["ferritin", "PROTEIN", 50, 58], ["Significantly increased D-dimer", "PROBLEM", 0, 31], ["IL", "TEST", 33, 35], ["IL", "TEST", 39, 41], ["ferritin levels", "TEST", 50, 65], ["increased", "OBSERVATION_MODIFIER", 14, 23], ["D-dimer", "OBSERVATION_MODIFIER", 24, 31]]], ["SpO 2 \u2264 95% under the resting state.", [["SpO", "TEST", 0, 3]]], ["Extrapulmonary complications.", [["Extrapulmonary", "ANATOMY", 0, 14], ["Extrapulmonary complications", "PROBLEM", 0, 28], ["complications", "OBSERVATION", 15, 28]]], ["Co-infected with other viruses and/or bacteria.Differential diagnosis [1]Differential diagnosis should be made to distinguish from influenza virus, parainfluenza virus, adenovirus, respiratory syncytial virus, rhinovirus, human metapneumovirus, SARS coronavirus, and other known viral infections, as well as mycoplasma pneumoniae and chlamydia pneumonia and bacterial pneumonia.", [["influenza virus", "DISEASE", 131, 146], ["parainfluenza virus", "DISEASE", 148, 167], ["respiratory syncytial virus", "DISEASE", 181, 208], ["rhinovirus", "DISEASE", 210, 220], ["human metapneumovirus", "DISEASE", 222, 243], ["SARS coronavirus", "DISEASE", 245, 261], ["viral infections", "DISEASE", 279, 295], ["mycoplasma pneumoniae", "DISEASE", 308, 329], ["chlamydia pneumonia", "DISEASE", 334, 353], ["bacterial pneumonia", "DISEASE", 358, 377], ["influenza virus", "ORGANISM", 131, 146], ["parainfluenza virus", "ORGANISM", 148, 167], ["adenovirus", "ORGANISM", 169, 179], ["respiratory syncytial virus", "ORGANISM", 181, 208], ["rhinovirus", "ORGANISM", 210, 220], ["human", "ORGANISM", 222, 227], ["metapneumovirus", "ORGANISM", 228, 243], ["SARS coronavirus", "ORGANISM", 245, 261], ["mycoplasma pneumoniae", "ORGANISM", 308, 329], ["influenza virus", "SPECIES", 131, 146], ["parainfluenza virus", "SPECIES", 148, 167], ["respiratory syncytial virus", "SPECIES", 181, 208], ["rhinovirus", "SPECIES", 210, 220], ["human", "SPECIES", 222, 227], ["metapneumovirus", "SPECIES", 228, 243], ["SARS coronavirus", "SPECIES", 245, 261], ["mycoplasma pneumoniae", "SPECIES", 308, 329], ["influenza virus", "SPECIES", 131, 146], ["parainfluenza virus", "SPECIES", 148, 167], ["respiratory syncytial virus", "SPECIES", 181, 208], ["human metapneumovirus", "SPECIES", 222, 243], ["SARS coronavirus", "SPECIES", 245, 261], ["mycoplasma pneumoniae", "SPECIES", 308, 329], ["other viruses", "PROBLEM", 17, 30], ["bacteria", "PROBLEM", 38, 46], ["influenza virus", "PROBLEM", 131, 146], ["parainfluenza virus", "PROBLEM", 148, 167], ["adenovirus", "PROBLEM", 169, 179], ["respiratory syncytial virus", "PROBLEM", 181, 208], ["rhinovirus", "PROBLEM", 210, 220], ["human metapneumovirus", "PROBLEM", 222, 243], ["SARS coronavirus", "PROBLEM", 245, 261], ["known viral infections", "PROBLEM", 273, 295], ["mycoplasma pneumoniae", "PROBLEM", 308, 329], ["chlamydia pneumonia", "PROBLEM", 334, 353], ["bacterial pneumonia", "PROBLEM", 358, 377], ["viruses", "OBSERVATION", 23, 30], ["respiratory syncytial", "ANATOMY", 181, 202], ["viral infections", "OBSERVATION", 279, 295], ["chlamydia", "OBSERVATION_MODIFIER", 334, 343], ["pneumonia", "OBSERVATION", 344, 353], ["bacterial", "OBSERVATION_MODIFIER", 358, 367], ["pneumonia", "OBSERVATION", 368, 377]]], ["The coinfection with other viruses and/ or bacteria should be considered in diagnosis.General treatment and monitoring [1, 4, 8]Detailed information can be referred to the first edition [1] .", [["coinfection", "DISEASE", 4, 15], ["The coinfection with other viruses", "PROBLEM", 0, 34], ["bacteria", "PROBLEM", 43, 51], ["General treatment", "TREATMENT", 86, 103], ["monitoring", "TEST", 108, 118], ["coinfection", "OBSERVATION", 4, 15]]], ["Meanwhile, based on the pathological changes obtained from adults and referring to the special physiological structural characteristics of children, attention should be paid to appropriate humidity of airways.Symptomatic treatment [1, 4, 8, 12, 13]The patients with high fever should be actively controlled.", [["airways", "ANATOMY", 201, 208], ["fever", "DISEASE", 271, 276], ["children", "ORGANISM", 139, 147], ["airways", "MULTI-TISSUE_STRUCTURE", 201, 208], ["patients", "ORGANISM", 252, 260], ["children", "SPECIES", 139, 147], ["patients", "SPECIES", 252, 260], ["Symptomatic treatment", "TREATMENT", 209, 230], ["high fever", "PROBLEM", 266, 276], ["airways", "ANATOMY", 201, 208]]], ["If patients' body temperature exceeds 38.5 \u00b0C with obvious discomfort, physical cooling (warm water bath, use of antipyretic patch, etc.) or antipyretic drug treatment should be given.", [["body", "ANATOMY", 13, 17], ["patients", "ORGANISM", 3, 11], ["body", "ORGANISM_SUBDIVISION", 13, 17], ["patients", "SPECIES", 3, 11], ["patients' body temperature", "TEST", 3, 29], ["obvious discomfort", "PROBLEM", 51, 69], ["physical cooling (warm water bath", "TREATMENT", 71, 104], ["antipyretic patch", "TREATMENT", 113, 130], ["antipyretic drug treatment", "TREATMENT", 141, 167]]], ["Common drugs include: ibuprofen orally, 5-10 mg/kg every time; acetaminophen orally, 10-15 mg/kg every time.", [["ibuprofen", "CHEMICAL", 22, 31], ["acetaminophen", "CHEMICAL", 63, 76], ["ibuprofen", "CHEMICAL", 22, 31], ["acetaminophen", "CHEMICAL", 63, 76], ["ibuprofen", "SIMPLE_CHEMICAL", 22, 31], ["acetaminophen", "SIMPLE_CHEMICAL", 63, 76], ["Common drugs", "TREATMENT", 0, 12], ["ibuprofen orally", "TREATMENT", 22, 38], ["acetaminophen", "TREATMENT", 63, 76]]], ["Keep children quiet and administrate sedatives immediately when convulsions or seizure occur.", [["convulsions", "DISEASE", 64, 75], ["seizure", "DISEASE", 79, 86], ["children", "ORGANISM", 5, 13], ["children", "SPECIES", 5, 13], ["sedatives", "TREATMENT", 37, 46], ["convulsions", "PROBLEM", 64, 75], ["seizure", "PROBLEM", 79, 86]]], ["Dispels phlegm when with increased respiratory secretions.", [["respiratory secretions", "ANATOMY", 35, 57], ["Dispels phlegm", "DISEASE", 0, 14], ["Dispels phlegm", "PROBLEM", 0, 14], ["increased respiratory secretions", "PROBLEM", 25, 57], ["increased", "OBSERVATION_MODIFIER", 25, 34], ["respiratory secretions", "OBSERVATION", 35, 57]]], ["Since mucus and mucus plug may occur in the lungs of patients revealed by pathological analysis in adults, use of expectorant drugs can reduce or avoid respiratory tract obstruction.", [["mucus", "ANATOMY", 6, 11], ["mucus plug", "ANATOMY", 16, 26], ["lungs", "ANATOMY", 44, 49], ["respiratory tract", "ANATOMY", 152, 169], ["respiratory tract obstruction", "DISEASE", 152, 181], ["mucus", "MULTI-TISSUE_STRUCTURE", 6, 11], ["mucus plug", "TISSUE", 16, 26], ["lungs", "ORGAN", 44, 49], ["patients", "ORGANISM", 53, 61], ["respiratory tract", "ORGANISM_SUBDIVISION", 152, 169], ["patients", "SPECIES", 53, 61], ["mucus", "PROBLEM", 6, 11], ["mucus plug", "PROBLEM", 16, 26], ["pathological analysis", "TEST", 74, 95], ["expectorant drugs", "TREATMENT", 114, 131], ["respiratory tract obstruction", "PROBLEM", 152, 181], ["mucus plug", "OBSERVATION", 16, 26], ["lungs", "ANATOMY", 44, 49], ["respiratory tract", "ANATOMY", 152, 169], ["obstruction", "OBSERVATION", 170, 181]]], ["Commonly used drugs include: inhalation of acetylcysteine solution by nebulization, each 3 mL (0.3 g), 1-2 times/day for 5-7 days; Inhalation of ambroxol hydrochloride solution by atomization (ambroxol hydrochloride solution mixed with normal saline according to a ratio of 1:1, at 1 mL (< 2 years), 2 mL (2-12 years), 3 mL (> 12 years), 1-2 times/ day for 5-7 days.", [["acetylcysteine", "CHEMICAL", 43, 57], ["ambroxol hydrochloride", "CHEMICAL", 145, 167], ["ambroxol hydrochloride", "CHEMICAL", 193, 215], ["acetylcysteine", "CHEMICAL", 43, 57], ["ambroxol hydrochloride", "CHEMICAL", 145, 167], ["ambroxol hydrochloride", "CHEMICAL", 193, 215], ["acetylcysteine", "SIMPLE_CHEMICAL", 43, 57], ["ambroxol", "SIMPLE_CHEMICAL", 145, 153], ["ambroxol", "SIMPLE_CHEMICAL", 193, 201], ["acetylcysteine solution", "TREATMENT", 43, 66], ["ambroxol hydrochloride solution", "TREATMENT", 145, 176], ["atomization (ambroxol hydrochloride solution", "TREATMENT", 180, 224], ["normal saline", "TREATMENT", 236, 249]]], ["According to the airway secretion, closed tracheal suction can be used if necessary after nebulization.Oxygen therapyWhen hypoxia occurs, effective oxygen therapy should be given immediately including nasal catheter, mask oxygen.", [["airway", "ANATOMY", 17, 23], ["tracheal", "ANATOMY", 42, 50], ["nasal", "ANATOMY", 201, 206], ["Oxygen", "CHEMICAL", 103, 109], ["hypoxia", "DISEASE", 122, 129], ["oxygen", "CHEMICAL", 148, 154], ["oxygen", "CHEMICAL", 222, 228], ["Oxygen", "CHEMICAL", 103, 109], ["oxygen", "CHEMICAL", 148, 154], ["oxygen", "CHEMICAL", 222, 228], ["airway", "MULTI-TISSUE_STRUCTURE", 17, 23], ["tracheal", "ORGAN", 42, 50], ["Oxygen", "SIMPLE_CHEMICAL", 103, 109], ["oxygen", "SIMPLE_CHEMICAL", 148, 154], ["oxygen", "SIMPLE_CHEMICAL", 222, 228], ["closed tracheal suction", "TREATMENT", 35, 58], ["nebulization", "TREATMENT", 90, 102], ["Oxygen therapy", "TREATMENT", 103, 117], ["hypoxia", "PROBLEM", 122, 129], ["effective oxygen therapy", "TREATMENT", 138, 162], ["nasal catheter", "TREATMENT", 201, 215], ["mask oxygen", "TREATMENT", 217, 228], ["airway", "ANATOMY", 17, 23], ["secretion", "OBSERVATION", 24, 33], ["tracheal", "ANATOMY", 42, 50], ["suction", "OBSERVATION", 51, 58], ["oxygen therapy", "OBSERVATION", 148, 162], ["nasal", "ANATOMY", 201, 206], ["catheter", "OBSERVATION", 207, 215]]], ["Nasal high-flow oxygen therapy, and non-invasive or invasive mechanical ventilation should be undertaken when necessary [1] .Antiviral therapy [1, 14-23]Children are a special group and the clinical manifestations of pediatric cases are relatively mild.", [["Nasal", "ANATOMY", 0, 5], ["oxygen", "CHEMICAL", 16, 22], ["oxygen", "CHEMICAL", 16, 22], ["oxygen", "SIMPLE_CHEMICAL", 16, 22], ["Children", "ORGANISM", 153, 161], ["Children", "SPECIES", 153, 161], ["Nasal high-flow oxygen therapy", "TREATMENT", 0, 30], ["non-invasive or invasive mechanical ventilation", "TREATMENT", 36, 83], ["Antiviral therapy", "TREATMENT", 125, 142], ["flow oxygen therapy", "OBSERVATION", 11, 30], ["mild", "OBSERVATION_MODIFIER", 248, 252]]], ["Though some antiviral drugs are under clinical trial in infected adults, antiviral drugs without clear evidences of safety and efficiency are not recommended to be used in pediatric patients.", [["patients", "ORGANISM", 182, 190], ["patients", "SPECIES", 182, 190], ["some antiviral drugs", "TREATMENT", 7, 27], ["infected adults", "TREATMENT", 56, 71], ["antiviral drugs", "TREATMENT", 73, 88], ["antiviral drugs", "OBSERVATION", 12, 27]]], ["The revised antiviral drug therapy remains to be interferon-\u03b1 (IFN-\u03b1) sprays and aerosol inhalation.", [["interferon-\u03b1 (IFN-\u03b1", "CHEMICAL", 49, 68], ["interferon-\u03b1", "SIMPLE_CHEMICAL", 49, 61], ["IFN-\u03b1", "SIMPLE_CHEMICAL", 63, 68], ["interferon", "PROTEIN", 49, 59], ["IFN", "PROTEIN", 63, 66], ["The revised antiviral drug therapy", "TREATMENT", 0, 34], ["interferon-\u03b1 (IFN-\u03b1) sprays", "TREATMENT", 49, 76], ["aerosol inhalation", "TREATMENT", 81, 99], ["antiviral drug", "OBSERVATION", 12, 26]]], ["We do not recommend using lopinavir/ritonavir, ribavirin or chloroquine phosphate in pediatric patients.Antiviral therapy [1, 14-23]IFN-\u03b1 can reduce viral load, and early use can help to reduce symptoms and shorten the disease course.", [["lopinavir/ritonavir", "CHEMICAL", 26, 45], ["ribavirin", "CHEMICAL", 47, 56], ["chloroquine phosphate", "CHEMICAL", 60, 81], ["1, 14-23]IFN-\u03b1", "CHEMICAL", 123, 137], ["lopinavir", "CHEMICAL", 26, 35], ["ritonavir", "CHEMICAL", 36, 45], ["ribavirin", "CHEMICAL", 47, 56], ["chloroquine phosphate", "CHEMICAL", 60, 81], ["lopinavir", "SIMPLE_CHEMICAL", 26, 35], ["ritonavir", "SIMPLE_CHEMICAL", 36, 45], ["ribavirin", "SIMPLE_CHEMICAL", 47, 56], ["chloroquine phosphate", "SIMPLE_CHEMICAL", 60, 81], ["patients", "ORGANISM", 95, 103], ["14-23]IFN-\u03b1", "SIMPLE_CHEMICAL", 126, 137], ["IFN", "PROTEIN", 132, 135], ["patients", "SPECIES", 95, 103], ["lopinavir", "TREATMENT", 26, 35], ["ritonavir", "TREATMENT", 36, 45], ["ribavirin", "TREATMENT", 47, 56], ["chloroquine phosphate", "TREATMENT", 60, 81], ["Antiviral therapy", "TREATMENT", 104, 121], ["IFN", "TREATMENT", 132, 135], ["viral load", "PROBLEM", 149, 159], ["symptoms", "PROBLEM", 194, 202], ["the disease course", "PROBLEM", 215, 233], ["viral load", "OBSERVATION", 149, 159]]], ["The recommended usage is as follows:Antiviral therapy [1, 14-23]1.", [["14-23]1", "SIMPLE_CHEMICAL", 58, 65], ["Antiviral therapy", "TREATMENT", 36, 53]]], ["IFN-\u03b1 spray: 1-2 sprays on each side of the nasal cavity, 8-10 sprays to the oropharynx for 8-10 times/day, with a treatment course of 5-7 days.", [["nasal cavity", "ANATOMY", 44, 56], ["oropharynx", "ANATOMY", 77, 87], ["IFN-\u03b1", "CHEMICAL", 0, 5], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 0, 5], ["nasal cavity", "MULTI-TISSUE_STRUCTURE", 44, 56], ["oropharynx", "ORGAN", 77, 87], ["IFN", "PROTEIN", 0, 3], ["IFN-\u03b1 spray", "TREATMENT", 0, 11], ["nasal cavity", "ANATOMY", 44, 56], ["oropharynx", "ANATOMY", 77, 87]]], ["According to previous evidences, interferon-\u03b1 sprays can be used to high-risk children who had close contact with suspected patients or those with upper respiratory tract symptoms in the early stage of virus infection; and the daily dosage should not be less than 800,000 International Units (IU).", [["upper respiratory tract", "ANATOMY", 147, 170], ["interferon-\u03b1", "CHEMICAL", 33, 45], ["respiratory tract symptoms", "DISEASE", 153, 179], ["infection", "DISEASE", 208, 217], ["interferon-\u03b1", "GENE_OR_GENE_PRODUCT", 33, 45], ["children", "ORGANISM", 78, 86], ["patients", "ORGANISM", 124, 132], ["upper", "ORGANISM_SUBDIVISION", 147, 152], ["respiratory tract", "ORGANISM_SUBDIVISION", 153, 170], ["interferon", "PROTEIN", 33, 43], ["children", "SPECIES", 78, 86], ["patients", "SPECIES", 124, 132], ["interferon-\u03b1 sprays", "TREATMENT", 33, 52], ["upper respiratory tract symptoms", "PROBLEM", 147, 179], ["virus infection", "PROBLEM", 202, 217], ["respiratory tract", "ANATOMY", 153, 170], ["early stage", "OBSERVATION_MODIFIER", 187, 198]]], ["IFN-\u03b1 nebulization: IFN-\u03b1 200,000-400,000 IU/kg or 2-4 \u03bcg/kg, 2 mL of normal saline, atomization inhalation, 2 times/day, at a treatment course of 5-7 days.Use of other antiviral drugs [1, 4, 14-23]In the retrospective studies in abidol, no effects have been found in improving symptoms and shortening clearance time of viral nucleic acid in respiratory specimens have been found.", [["respiratory specimens", "ANATOMY", 342, 363], ["IFN-\u03b1", "CHEMICAL", 20, 25], ["abidol", "CHEMICAL", 230, 236], ["nucleic acid", "CHEMICAL", 326, 338], ["abidol", "CHEMICAL", 230, 236], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 0, 5], ["IFN-\u03b1", "SIMPLE_CHEMICAL", 20, 25], ["saline", "SIMPLE_CHEMICAL", 77, 83], ["abidol", "SIMPLE_CHEMICAL", 230, 236], ["IFN", "PROTEIN", 0, 3], ["IFN", "PROTEIN", 20, 23], ["IFN", "TREATMENT", 20, 23], ["normal saline", "TREATMENT", 70, 83], ["atomization inhalation", "TREATMENT", 85, 107], ["other antiviral drugs", "TREATMENT", 163, 184], ["improving symptoms", "PROBLEM", 268, 286], ["shortening clearance", "PROBLEM", 291, 311], ["viral nucleic acid in respiratory specimens", "PROBLEM", 320, 363]]], ["Arbidol has been administrated for confirmed cases; however, the efficacy still needs to be confirmed.", [["Arbidol", "CHEMICAL", 0, 7], ["Arbidol", "CHEMICAL", 0, 7], ["Arbidol", "SIMPLE_CHEMICAL", 0, 7], ["Arbidol", "TREATMENT", 0, 7]]], ["Attention should be paid to its adverse effects such as nausea, diarrhea, elevated liver enzymes, bradycardia.", [["liver", "ANATOMY", 83, 88], ["nausea", "DISEASE", 56, 62], ["diarrhea", "DISEASE", 64, 72], ["elevated liver enzymes", "DISEASE", 74, 96], ["bradycardia", "DISEASE", 98, 109], ["liver", "ORGAN", 83, 88], ["liver enzymes", "PROTEIN", 83, 96], ["nausea", "PROBLEM", 56, 62], ["diarrhea", "PROBLEM", 64, 72], ["elevated liver enzymes", "PROBLEM", 74, 96], ["bradycardia", "PROBLEM", 98, 109], ["liver", "ANATOMY", 83, 88]]], ["Oseltamivir and other anti-influenza agents can be added for COVID-19 patients coinfected with other influenza virus.Traditional Chinese medicine treatmentPlease refer to the detailed information in the first edition [1] .Treatment of severe and critical cases [1, 4, 24-27]On the basis of symptomatic treatment, we should actively prevent and treat complications, underlying diseases, secondary infection, and provide organ function support as indicated.Respiratory supportChildren who undergo non-invasive mechanical ventilation for two hours without improvements in conditions, or cannot tolerate non-invasive ventilation, with increased airway secretions, severe cough, or hemodynamic instability, should be subjected to invasive mechanical ventilation promptly.", [["organ", "ANATOMY", 419, 424], ["airway", "ANATOMY", 641, 647], ["Oseltamivir", "CHEMICAL", 0, 11], ["influenza virus", "DISEASE", 101, 116], ["infection", "DISEASE", 396, 405], ["cough", "DISEASE", 667, 672], ["hemodynamic instability", "DISEASE", 677, 700], ["Oseltamivir", "CHEMICAL", 0, 11], ["Oseltamivir", "SIMPLE_CHEMICAL", 0, 11], ["patients", "ORGANISM", 70, 78], ["influenza virus", "ORGANISM", 101, 116], ["organ", "ORGAN", 419, 424], ["airway", "MULTI-TISSUE_STRUCTURE", 641, 647], ["patients", "SPECIES", 70, 78], ["influenza virus", "SPECIES", 101, 116], ["Oseltamivir", "TREATMENT", 0, 11], ["other anti-influenza agents", "TREATMENT", 16, 43], ["COVID", "TREATMENT", 61, 66], ["other influenza virus", "PROBLEM", 95, 116], ["Traditional Chinese medicine treatment", "TREATMENT", 117, 155], ["severe and critical cases", "PROBLEM", 235, 260], ["symptomatic treatment", "TREATMENT", 290, 311], ["complications", "PROBLEM", 350, 363], ["underlying diseases", "PROBLEM", 365, 384], ["secondary infection", "PROBLEM", 386, 405], ["organ function support", "TREATMENT", 419, 441], ["non-invasive mechanical ventilation", "TREATMENT", 495, 530], ["non-invasive ventilation", "TREATMENT", 600, 624], ["increased airway secretions", "PROBLEM", 631, 658], ["severe cough", "PROBLEM", 660, 672], ["hemodynamic instability", "PROBLEM", 677, 700], ["invasive mechanical ventilation", "TREATMENT", 725, 756], ["severe", "OBSERVATION_MODIFIER", 235, 241], ["symptomatic", "OBSERVATION_MODIFIER", 290, 301], ["treatment", "OBSERVATION", 302, 311], ["secondary", "OBSERVATION_MODIFIER", 386, 395], ["infection", "OBSERVATION", 396, 405], ["mechanical ventilation", "OBSERVATION", 508, 530], ["increased", "OBSERVATION_MODIFIER", 631, 640], ["airway", "ANATOMY", 641, 647], ["secretions", "OBSERVATION", 648, 658], ["severe", "OBSERVATION_MODIFIER", 660, 666], ["cough", "OBSERVATION", 667, 672], ["hemodynamic instability", "OBSERVATION", 677, 700], ["mechanical ventilation", "OBSERVATION", 734, 756]]], ["The invasive mechanical ventilation should adopt low tidal volume \"lung protective ventilation strategy\" to reduce ventilator related lung injury.", [["lung", "ANATOMY", 67, 71], ["lung", "ANATOMY", 134, 138], ["lung injury", "DISEASE", 134, 145], ["lung", "ORGAN", 67, 71], ["lung", "ORGAN", 134, 138], ["The invasive mechanical ventilation", "TREATMENT", 0, 35], ["low tidal volume \"lung protective ventilation strategy", "TREATMENT", 49, 103], ["ventilator related lung injury", "PROBLEM", 115, 145], ["invasive", "OBSERVATION_MODIFIER", 4, 12], ["mechanical ventilation", "OBSERVATION", 13, 35], ["low", "OBSERVATION_MODIFIER", 49, 52], ["tidal volume", "OBSERVATION", 53, 65], ["lung", "ANATOMY", 67, 71], ["protective ventilation", "OBSERVATION", 72, 94], ["lung", "ANATOMY", 134, 138], ["injury", "OBSERVATION", 139, 145]]], ["If necessary, prone position ventilation, lung recruitment, or extracorporeal membrane oxygenation (ECMO) can be applied.Circulation supportOn the basis of full fluid resuscitation, improve microcirculation, use vasoactive drugs, and monitor hemodynamics if necessary.GlucocorticoidsAccording to the degree of systemic inflammation, dyspnea, combination with ARDS and chest imaging exacerbation, glucocorticoids can be used in severe cases for a short period of time (3-5 days) ; and the recommended dose should not exceed 1-2 mg/kg/day equivalent to methylprednisolone.Blood purification therapyThe blood purification system includes plasma exchange, adsorption, perfusion, blood/plasma filtration, etc. It can remove inflammatory factors and block \"cytokine storm\", thus reducing the damage of inflammatory reaction to the body, and can be used for treating severe and critical patients in the early and middle stages of cytokine storm.ImmunoglobulinImmunoglobulin can be used in severe cases when indicated, but its efficacy needs further evaluation.BronchoscopyWhen severe and critical cases have obvious airway obstruction, bronchoscopy and lavage can be performed under the three-level protective measures.Anticoagulation therapyChildren with significantly increased D-dimer and at high risk of thrombosis can be treated with low molecular weight heparin calcium at an early stage; and anticoagulant therapy can be given if necessary.Convalescent plasma therapyConvalescent plasma therapy can be used in children with a very fast exacerbation of conditions, and those with severe and critical diseases.PreventionDetailed information on prevention of infection in children can be referred to the first edition [1] .", [["lung", "ANATOMY", 42, 46], ["extracorporeal membrane", "ANATOMY", 63, 86], ["chest", "ANATOMY", 368, 373], ["Blood", "ANATOMY", 570, 575], ["blood", "ANATOMY", 600, 605], ["plasma", "ANATOMY", 635, 641], ["blood", "ANATOMY", 675, 680], ["plasma", "ANATOMY", 681, 687], ["body", "ANATOMY", 825, 829], ["airway", "ANATOMY", 1109, 1115], ["plasma", "ANATOMY", 1453, 1459], ["plasma", "ANATOMY", 1480, 1486], ["systemic inflammation", "DISEASE", 310, 331], ["dyspnea", "DISEASE", 333, 340], ["ARDS", "DISEASE", 359, 363], ["glucocorticoids", "CHEMICAL", 396, 411], ["methylprednisolone", "CHEMICAL", 551, 569], ["ImmunoglobulinImmunoglobulin", "CHEMICAL", 938, 966], ["airway obstruction", "DISEASE", 1109, 1127], ["thrombosis", "DISEASE", 1301, 1311], ["heparin", "CHEMICAL", 1353, 1360], ["calcium", "CHEMICAL", 1361, 1368], ["infection", "DISEASE", 1656, 1665], ["methylprednisolone", "CHEMICAL", 551, 569], ["ImmunoglobulinImmunoglobulin", "CHEMICAL", 938, 966], ["calcium", "CHEMICAL", 1361, 1368], ["lung", "ORGAN", 42, 46], ["glucocorticoids", "SIMPLE_CHEMICAL", 396, 411], ["methylprednisolone", "SIMPLE_CHEMICAL", 551, 569], ["Blood", "ORGANISM_SUBSTANCE", 570, 575], ["blood", "ORGANISM_SUBSTANCE", 600, 605], ["plasma", "ORGANISM_SUBSTANCE", 635, 641], ["blood", "ORGANISM_SUBSTANCE", 675, 680], ["plasma", "ORGANISM_SUBSTANCE", 681, 687], ["body", "ORGANISM_SUBDIVISION", 825, 829], ["patients", "ORGANISM", 880, 888], ["ImmunoglobulinImmunoglobulin", "SIMPLE_CHEMICAL", 938, 966], ["airway obstruction", "PATHOLOGICAL_FORMATION", 1109, 1127], ["Children", "ORGANISM", 1235, 1243], ["D-dimer", "GENE_OR_GENE_PRODUCT", 1273, 1280], ["weight heparin", "SIMPLE_CHEMICAL", 1346, 1360], ["calcium", "SIMPLE_CHEMICAL", 1361, 1368], ["plasma", "ORGANISM_SUBSTANCE", 1453, 1459], ["plasma", "ORGANISM_SUBSTANCE", 1480, 1486], ["children", "ORGANISM", 1510, 1518], ["children", "ORGANISM", 1669, 1677], ["inflammatory factors", "PROTEIN", 719, 739], ["cytokine", "PROTEIN", 751, 759], ["cytokine", "PROTEIN", 923, 931], ["D-dimer", "PROTEIN", 1273, 1280], ["patients", "SPECIES", 880, 888], ["Children", "SPECIES", 1235, 1243], ["children", "SPECIES", 1510, 1518], ["children", "SPECIES", 1669, 1677], ["prone position ventilation", "TREATMENT", 14, 40], ["lung recruitment", "TREATMENT", 42, 58], ["extracorporeal membrane oxygenation", "TREATMENT", 63, 98], ["ECMO", "TREATMENT", 100, 104], ["full fluid resuscitation", "TREATMENT", 156, 180], ["vasoactive drugs", "TREATMENT", 212, 228], ["Glucocorticoids", "TREATMENT", 268, 283], ["systemic inflammation", "PROBLEM", 310, 331], ["dyspnea", "PROBLEM", 333, 340], ["ARDS", "PROBLEM", 359, 363], ["chest imaging exacerbation", "PROBLEM", 368, 394], ["glucocorticoids", "TREATMENT", 396, 411], ["methylprednisolone", "TREATMENT", 551, 569], ["Blood purification therapy", "TREATMENT", 570, 596], ["The blood purification system", "TEST", 596, 625], ["plasma exchange", "TEST", 635, 650], ["perfusion", "TEST", 664, 673], ["blood/plasma filtration", "TEST", 675, 698], ["inflammatory factors", "PROBLEM", 719, 739], ["block \"cytokine storm", "PROBLEM", 744, 765], ["inflammatory reaction", "PROBLEM", 796, 817], ["cytokine storm", "PROBLEM", 923, 937], ["ImmunoglobulinImmunoglobulin", "TREATMENT", 938, 966], ["further evaluation", "TEST", 1034, 1052], ["airway obstruction", "PROBLEM", 1109, 1127], ["bronchoscopy", "TEST", 1129, 1141], ["lavage", "TREATMENT", 1146, 1152], ["the three-level protective measures", "TREATMENT", 1176, 1211], ["Anticoagulation therapy", "TREATMENT", 1212, 1235], ["significantly increased D-dimer", "PROBLEM", 1249, 1280], ["thrombosis", "PROBLEM", 1301, 1311], ["low molecular weight heparin calcium", "TREATMENT", 1332, 1368], ["anticoagulant therapy", "TREATMENT", 1392, 1413], ["Convalescent plasma therapy", "TREATMENT", 1440, 1467], ["Convalescent plasma therapy", "TREATMENT", 1467, 1494], ["a very fast exacerbation of conditions", "PROBLEM", 1524, 1562], ["severe and critical diseases", "PROBLEM", 1579, 1607], ["infection", "PROBLEM", 1656, 1665], ["lung", "ANATOMY", 42, 46], ["recruitment", "OBSERVATION", 47, 58], ["fluid resuscitation", "OBSERVATION", 161, 180], ["systemic", "OBSERVATION_MODIFIER", 310, 318], ["inflammation", "OBSERVATION", 319, 331], ["dyspnea", "OBSERVATION", 333, 340], ["ARDS", "OBSERVATION", 359, 363], ["chest", "ANATOMY", 368, 373], ["purification therapy", "OBSERVATION", 576, 596], ["plasma filtration", "OBSERVATION", 681, 698], ["inflammatory", "OBSERVATION_MODIFIER", 719, 731], ["inflammatory", "OBSERVATION", 796, 808], ["middle stages", "OBSERVATION_MODIFIER", 906, 919], ["cytokine storm", "OBSERVATION", 923, 937], ["severe", "OBSERVATION_MODIFIER", 1070, 1076], ["airway", "ANATOMY", 1109, 1115], ["obstruction", "OBSERVATION", 1116, 1127], ["lavage", "OBSERVATION", 1146, 1152], ["thrombosis", "OBSERVATION", 1301, 1311], ["plasma therapy", "OBSERVATION", 1453, 1467], ["critical", "OBSERVATION_MODIFIER", 1590, 1598], ["diseases", "OBSERVATION", 1599, 1607], ["infection", "OBSERVATION", 1656, 1665]]], ["We highlight the following visiting and accompanying policy in ward for pediatric patients.Strict visiting and family members accompanyingpolicy.", [["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90]]], ["However, hospitals should fully evaluate the age span of children admitted, differences in care needs, children's compliance with treatment, allocation of nursing human resources, possible secondary risks and hazards, etc. 2.", [["children", "ORGANISM", 57, 65], ["children", "ORGANISM", 103, 111], ["human", "ORGANISM", 163, 168], ["children", "SPECIES", 57, 65], ["children", "SPECIES", 103, 111], ["human", "SPECIES", 163, 168], ["human", "SPECIES", 163, 168], ["treatment", "TREATMENT", 130, 139], ["nursing human resources", "TREATMENT", 155, 178], ["secondary risks and hazards", "PROBLEM", 189, 216]]], ["Children are not allowed to leave the isolation ward on their own.", [["Children", "ORGANISM", 0, 8], ["Children", "SPECIES", 0, 8]]], ["If visiting children in critical condition is needed, visitors must take the protective measures the same with healthcare workers.", [["children", "ORGANISM", 12, 20], ["children", "SPECIES", 12, 20]]], ["Patients should wear protective clothing to go into the ward along with the specified route during the specified time; and hand hygiene must be strictly implemented at the same time.", [["hand", "ANATOMY", 123, 127], ["Patients", "ORGANISM", 0, 8], ["hand", "ORGANISM_SUBDIVISION", 123, 127], ["Patients", "SPECIES", 0, 8], ["protective clothing", "TREATMENT", 21, 40], ["hand hygiene", "TREATMENT", 123, 135]]], ["The quarantine measures for visitors are the same with those for patients.", [["patients", "ORGANISM", 65, 73], ["patients", "SPECIES", 65, 73], ["The quarantine measures", "TREATMENT", 0, 23]]], ["During this period, they should undertake health monitoring, wear masks, reduce close contact with their families, eat and drink separately, mantain hand hygiene, avoid going out and receive follow-up tests.Strict visiting and family members accompanyingAuthor contributions All authors contributed equally to this paper.Strict visiting and family members accompanyingFunding None.Compliance with ethical standardsEthical approval Not required for this consensus statement.", [["hand", "ANATOMY", 149, 153], ["hand", "ORGANISM_SUBDIVISION", 149, 153], ["health monitoring", "TEST", 42, 59], ["masks", "TREATMENT", 66, 71], ["follow-up tests", "TEST", 191, 206], ["ethical standards", "TREATMENT", 397, 414], ["Ethical approval", "TREATMENT", 414, 430]]]], "32340aab9caf3eaea5fc9775667d501671cacbe7": [["Others might be interested in the extent to which guidelines are followed in their unit or hospital, or on a broader scale.", [["a broader scale", "TREATMENT", 107, 122]]]], "5237c45681cad45eb4e6c51317e32c0e9b638c08": [["IntroductionThe fast-occurring changes and challenges of the Anthropocene include megatrends in human population growth, socio-economical transformation, climate change, habitat reduction and fragmentation and land use modification.", [["human", "ORGANISM", 96, 101], ["human", "SPECIES", 96, 101], ["human", "SPECIES", 96, 101], ["the Anthropocene include megatrends", "TREATMENT", 57, 92], ["economical transformation", "PROBLEM", 127, 152], ["habitat reduction", "TREATMENT", 170, 187], ["fragmentation", "PROBLEM", 192, 205], ["land use modification", "TREATMENT", 210, 231]]], ["These factors alter the living organism assemblages and interactions, both at the macroscopical and at the microscopical scale (Gillings and Paulsen, 2014) , including host-parasite interaction and global emergence of wildlife zoonotic diseases (Dantas-Torres, 2015; Cunningham et al., 2017; Aguirre, 2017; Allen et al., 2017) .IntroductionHuman impact on the ecosystems has exponentially increased during the last decades so that many of the observed changes are unprecedented in terms of effect size, and rate of change.", [["zoonotic diseases", "DISEASE", 227, 244], ["Human", "ORGANISM", 340, 345], ["Human", "SPECIES", 340, 345], ["These factors", "PROBLEM", 0, 13], ["exponentially", "OBSERVATION_MODIFIER", 375, 388], ["increased", "OBSERVATION_MODIFIER", 389, 398], ["size", "OBSERVATION_MODIFIER", 497, 501]]], ["The atmosphere and oceans have warmed, the amounts of snow and ice have diminished, and sea level has risen.", [["diminished", "PROBLEM", 72, 82], ["sea level", "TEST", 88, 97], ["oceans", "OBSERVATION_MODIFIER", 19, 25], ["amounts", "OBSERVATION_MODIFIER", 43, 50], ["diminished", "OBSERVATION_MODIFIER", 72, 82]]], ["Human influence on the climate system is incontrovertible, and recent anthropogenic emissions of greenhouse gases are the highest in history.", [["Human", "ORGANISM", 0, 5], ["Human", "SPECIES", 0, 5], ["recent anthropogenic emissions of greenhouse gases", "PROBLEM", 63, 113], ["anthropogenic emissions", "OBSERVATION", 70, 93], ["greenhouse gases", "OBSERVATION", 97, 113]]], ["Despite this, carbon dioxide emissions continue to rise and the last four years have been the warmest on record.", [["carbon dioxide", "CHEMICAL", 14, 28], ["carbon dioxide", "CHEMICAL", 14, 28], ["carbon dioxide", "SIMPLE_CHEMICAL", 14, 28], ["carbon dioxide emissions", "TREATMENT", 14, 38]]], ["In particular, 2018 surface temperatures were more than 0.4\u00b0C higher than the long-term average recorded over the period (ECMWF Copernicus Climate change service report https://bit.ly/ 2FbJvhq, accessed May 27, 2019).", [["surface", "ANATOMY", 20, 27], ["surface temperatures", "TEST", 20, 40], ["higher", "OBSERVATION_MODIFIER", 62, 68], ["long-term", "OBSERVATION_MODIFIER", 78, 87]]], ["Recent climate changes have had widespread impacts on human and natural systems, including the emergence of wildlife zoonotic diseases (https://www.ipcc.ch/, accessed May 27, 2019).IntroductionAlong with climate change, land use change is often ranked among the most important factors affecting the emergence of wildlife zoonosis (Loh et al., 2015; Allen et al., 2017; Guo et al., 2018) .", [["zoonotic diseases", "DISEASE", 117, 134], ["zoonosis", "DISEASE", 321, 329], ["human", "ORGANISM", 54, 59], ["human", "SPECIES", 54, 59], ["human", "SPECIES", 54, 59], ["Recent climate changes", "PROBLEM", 0, 22], ["widespread impacts on human and natural systems", "PROBLEM", 32, 79], ["wildlife zoonotic diseases", "PROBLEM", 108, 134], ["climate", "OBSERVATION", 7, 14], ["widespread", "OBSERVATION_MODIFIER", 32, 42], ["impacts", "OBSERVATION_MODIFIER", 43, 50]]], ["Recent studies indicate that human-dominated ecosystems now cover more of Earth's land surface than \"wild\" ecosystems.", [["human", "ORGANISM", 29, 34], ["human", "SPECIES", 29, 34], ["human", "SPECIES", 29, 34], ["Recent studies", "TEST", 0, 14]]], ["Ellis and Ramankutty (2008) proposed an empirical analysis of global patterns of human population distribution, land use and other activities, and produced a global map of eighteen \"anthropogenic biomes\".", [["human", "ORGANISM", 81, 86], ["human", "SPECIES", 81, 86], ["human", "SPECIES", 81, 86], ["an empirical analysis", "TEST", 37, 58], ["global", "OBSERVATION_MODIFIER", 62, 68], ["human population", "OBSERVATION", 81, 97]]], ["According to this classification, more than 75% of Earth's ice-free land show evidence of alteration, from the relatively light impacts of mobile bands of hunter-gatherers to the complete replacement of pre-existing ecosystems with infrastructures, as a result of human residence and land use.", [["human", "ORGANISM", 264, 269], ["human", "SPECIES", 264, 269], ["human", "SPECIES", 264, 269], ["Earth's ice", "TEST", 51, 62], ["evidence of", "UNCERTAINTY", 78, 89], ["alteration", "OBSERVATION", 90, 100], ["ecosystems", "OBSERVATION", 216, 226]]], ["Nowadays, the majority of all people live in densely populated urbanized biomes, supporting only 11% of the terrestrial net primary production, and new forms of human-ecosystem interaction arise, from low-density ex-urban developments to vast conurbations that combine high-density cities, low-density suburbs, agriculture, and even new forested areas (Ellis and Ramankutty, 2008) .IntroductionLand use change, other than being considered an important driver of climate change, is also directly associated to biodiversity loss along with other socio-economic determinants of wildlife exploitation.", [["people", "ORGANISM", 30, 36], ["human", "ORGANISM", 161, 166], ["people", "SPECIES", 30, 36], ["human", "SPECIES", 161, 166], ["human", "SPECIES", 161, 166], ["high-density cities", "PROBLEM", 269, 288], ["biodiversity loss", "PROBLEM", 509, 526], ["primary production", "OBSERVATION", 124, 142], ["low-density", "OBSERVATION_MODIFIER", 201, 212], ["high-density", "OBSERVATION_MODIFIER", 269, 281], ["low-density", "OBSERVATION_MODIFIER", 290, 301], ["new", "OBSERVATION_MODIFIER", 333, 336], ["forested", "OBSERVATION_MODIFIER", 337, 345], ["biodiversity loss", "OBSERVATION", 509, 526]]], ["As a consequence, we are now facing a sixth mass extinction event that is strongly correlated to anthropogenic factors (Ceballos et al., 2015) .", [["a sixth mass extinction event", "PROBLEM", 36, 65], ["mass", "OBSERVATION", 44, 48]]], ["The loss of biodiversity is a critical problem for humans in the first place, threatening valuable ecosystem services and wellbeing.", [["loss of biodiversity", "DISEASE", 4, 24], ["humans", "ORGANISM", 51, 57], ["humans", "SPECIES", 51, 57], ["humans", "SPECIES", 51, 57], ["loss", "OBSERVATION_MODIFIER", 4, 8], ["biodiversity", "OBSERVATION", 12, 24]]], ["A growing body of evidence indicates that current anthropogenic extinction rates are the highest and the rapidest ever observed on earth.", [["current anthropogenic extinction rates", "PROBLEM", 42, 80], ["anthropogenic extinction", "OBSERVATION", 50, 74]]], ["Humans have in fact triggered declines and extinctions of animals in the past 500 years comparable to the 5 previous mass extinctions together.", [["Humans", "ORGANISM", 0, 6], ["declines", "OBSERVATION_MODIFIER", 30, 38], ["extinctions", "OBSERVATION_MODIFIER", 43, 54], ["mass", "OBSERVATION", 117, 121]]], ["As an example, 322 vertebrate species disappeared since 1500, 28% of vertebrate declined in the last 40 years, 35% of lepidoptera declined in the last 40 years, 33% of all insects with IUCN-documented population trends are declining although with strong variation among orders (Dirzo et al., 2014) .IntroductionEvidences suggest that biodiversity loss is a driver for wildlife disease emergence (Dantas-Torres, 2015; Civitello et al., 2015; Keesing and Ostfeld, 2015; Levi et al., 2016a) , although the level and quality of data available is diversified or even totally lacking for many disease systems in different biomes so limiting the possibility to validate model assumptions through empirical observations.IntroductionThe relationship between biodiversity loss and disease emergence was originally based on the dilution effect hypothesis.", [["lepidoptera", "DISEASE", 118, 129], ["biodiversity loss", "DISEASE", 334, 351], ["biodiversity loss", "DISEASE", 749, 766], ["lepidoptera", "PROBLEM", 118, 129], ["IUCN", "TEST", 185, 189], ["biodiversity loss", "PROBLEM", 334, 351], ["many disease systems", "PROBLEM", 582, 602], ["biodiversity loss", "PROBLEM", 749, 766], ["disease emergence", "PROBLEM", 771, 788], ["the dilution effect hypothesis", "PROBLEM", 813, 843], ["biodiversity loss", "OBSERVATION", 334, 351], ["biodiversity loss", "OBSERVATION", 749, 766]]], ["Vector-borne diseases such as Lyme disease and West Nile Virus illness in North America represent some of the best examples validating this theory (Ostfeld, 2009; Levine et al., 2017) .", [["Vector-borne diseases", "DISEASE", 0, 21], ["Lyme disease", "DISEASE", 30, 42], ["Nile Virus illness", "DISEASE", 52, 70], ["West Nile Virus", "ORGANISM", 47, 62], ["Nile Virus", "SPECIES", 52, 62], ["West Nile Virus", "SPECIES", 47, 62], ["Vector-borne diseases", "PROBLEM", 0, 21], ["Lyme disease", "PROBLEM", 30, 42], ["West Nile Virus illness", "PROBLEM", 47, 70], ["borne diseases", "OBSERVATION", 7, 21]]], ["The dilution effect hypothesis predicts that diverse ecological communities limit disease spread via several mechanisms.", [["The dilution effect hypothesis", "PROBLEM", 0, 30], ["disease spread", "PROBLEM", 82, 96], ["dilution effect", "OBSERVATION", 4, 19], ["diverse", "OBSERVATION_MODIFIER", 45, 52], ["ecological", "OBSERVATION_MODIFIER", 53, 63], ["communities", "OBSERVATION_MODIFIER", 64, 75]]], ["Therefore, diversity loss could worsen epidemics that harm humans and wildlife.", [["humans", "ORGANISM", 59, 65], ["humans", "SPECIES", 59, 65], ["humans", "SPECIES", 59, 65], ["diversity loss", "PROBLEM", 11, 25], ["diversity loss", "OBSERVATION", 11, 25]]], ["However, there is contentious debate over whether this hypothesis applies broadly, especially for parasites that infect humans (Civitello et al., 2015; Ruyts et al., 2018) .IntroductionTo fully understand the ecology and emergence of vector-borne diseases, it is critical to focus on vectorial capacity, and it is important to elucidate the factors in this complex interplay to find novel approaches to control (Kramer, 2016) .", [["vector-borne diseases", "DISEASE", 234, 255], ["humans", "ORGANISM", 120, 126], ["humans", "SPECIES", 120, 126], ["humans", "SPECIES", 120, 126], ["parasites", "PROBLEM", 98, 107], ["vector-borne diseases", "PROBLEM", 234, 255]]], ["A paramount component of this parameter is the vector to host ratio, which in turn is dependent on changes in vector-host abundance and behaviour, as well as changes in vector-host choice.", [["paramount", "OBSERVATION_MODIFIER", 2, 11], ["component", "OBSERVATION_MODIFIER", 12, 21], ["dependent", "OBSERVATION_MODIFIER", 86, 95]]], ["In this paper, we will summarize some of the most recent findings on the consequences of such changes mostly considering research work carried out during the last decade within the European context over the ecology and transmission dynamics of two flaviviruses, namely Tick-borne encephalitis virus (TBEV) and West Nile Virus (WNV).Vector-borne infections are on the riseAmong emerging zoonotic wildlife diseases, vector-borne infections pose a major challenge to public health both in terms of vector and pathogen abundance and diversity and of human and animal morbidity and mortality.", [["flaviviruses", "DISEASE", 248, 260], ["Tick-borne encephalitis virus (TBEV) and West Nile Virus", "DISEASE", 269, 325], ["infections", "DISEASE", 345, 355], ["zoonotic wildlife diseases", "DISEASE", 386, 412], ["vector-borne infections", "DISEASE", 414, 437], ["Tick-borne encephalitis virus", "ORGANISM", 269, 298], ["TBEV", "ORGANISM", 300, 304], ["West Nile Virus", "ORGANISM", 310, 325], ["WNV", "ORGANISM", 327, 330], ["human", "ORGANISM", 546, 551], ["Tick-borne encephalitis virus", "SPECIES", 269, 298], ["West Nile Virus", "SPECIES", 310, 325], ["human", "SPECIES", 546, 551], ["Tick-borne encephalitis virus", "SPECIES", 269, 298], ["TBEV", "SPECIES", 300, 304], ["West Nile Virus", "SPECIES", 310, 325], ["WNV", "SPECIES", 327, 330], ["human", "SPECIES", 546, 551], ["such changes", "PROBLEM", 89, 101], ["two flaviviruses", "PROBLEM", 244, 260], ["Tick-borne encephalitis virus", "PROBLEM", 269, 298], ["borne infections", "PROBLEM", 339, 355], ["borne infections", "PROBLEM", 421, 437], ["borne", "OBSERVATION_MODIFIER", 339, 344], ["infections", "OBSERVATION", 345, 355], ["zoonotic", "OBSERVATION_MODIFIER", 386, 394]]], ["Furthermore, the continuous discovery of new pathogens and the emergence of new epidemiological cycles, due for example to the invasion of new habitat by vector species, claim the need for a constant and intensified surveillance.Vector-borne infections are on the riseIn general, vector-borne pathogens account for more than 17% of all infectious diseases, causing more than 700 000 deaths annually (https://www.who.int/news-room/fact-sheets/detail/vector-bornediseases, accessed May 27, 2019).", [["Vector-borne infections", "DISEASE", 229, 252], ["infectious diseases", "DISEASE", 336, 355], ["deaths", "DISEASE", 383, 389], ["new pathogens", "PROBLEM", 41, 54], ["new epidemiological cycles", "TREATMENT", 76, 102], ["a constant and intensified surveillance", "TEST", 189, 228], ["borne infections", "PROBLEM", 236, 252], ["vector-borne pathogens", "PROBLEM", 280, 302], ["all infectious diseases", "PROBLEM", 332, 355], ["new", "OBSERVATION_MODIFIER", 41, 44], ["pathogens", "OBSERVATION", 45, 54], ["borne", "OBSERVATION_MODIFIER", 236, 241], ["infections", "OBSERVATION", 242, 252], ["infectious", "OBSERVATION", 336, 346]]], ["The burden of these diseases is highest in tropical and subtropical areas where especially mosquitoborne diseases disproportionately affect the poorest populations.", [["mosquitoborne diseases", "DISEASE", 91, 113], ["these diseases", "PROBLEM", 14, 28], ["mosquitoborne diseases", "PROBLEM", 91, 113], ["burden", "OBSERVATION_MODIFIER", 4, 10], ["diseases", "OBSERVATION", 20, 28], ["highest", "OBSERVATION_MODIFIER", 32, 39], ["tropical", "OBSERVATION_MODIFIER", 43, 51], ["subtropical", "OBSERVATION_MODIFIER", 56, 67], ["areas", "OBSERVATION_MODIFIER", 68, 73], ["poorest", "OBSERVATION_MODIFIER", 144, 151], ["populations", "OBSERVATION_MODIFIER", 152, 163]]], ["In such areas, major outbreaks of dengue, malaria, chikungunya, yellow fever and more recently Zika have been afflicting populations, claimed lives and overwhelmed health systems.", [["dengue", "DISEASE", 34, 40], ["malaria", "DISEASE", 42, 49], ["chikungunya", "DISEASE", 51, 62], ["yellow fever", "DISEASE", 64, 76], ["dengue", "SPECIES", 34, 40], ["dengue", "PROBLEM", 34, 40], ["malaria", "PROBLEM", 42, 49], ["chikungunya", "PROBLEM", 51, 62], ["yellow fever", "PROBLEM", 64, 76], ["major", "OBSERVATION_MODIFIER", 15, 20], ["outbreaks", "OBSERVATION_MODIFIER", 21, 30], ["dengue", "OBSERVATION", 34, 40], ["malaria", "OBSERVATION_MODIFIER", 42, 49], ["chikungunya", "OBSERVATION_MODIFIER", 51, 62]]], ["Other diseases such as Chagas disease and leishmaniosis affect hundreds of millions of people worldwide (https://www.who.int/news-room/fact-sheets/detail/ vector-borne-diseases, accessed May 27, 2019).Vector-borne infections are on the riseWithin the temperate areas of the northern hemisphere wildlife zoonoses carried by ticks pose the greatest challenge when compared to mosquito-borne infection.", [["Chagas disease", "DISEASE", 23, 37], ["leishmaniosis", "DISEASE", 42, 55], ["infections", "DISEASE", 214, 224], ["zoonoses", "DISEASE", 303, 311], ["infection", "DISEASE", 389, 398], ["people", "ORGANISM", 87, 93], ["people", "SPECIES", 87, 93], ["Other diseases", "PROBLEM", 0, 14], ["Chagas disease", "PROBLEM", 23, 37], ["leishmaniosis affect", "PROBLEM", 42, 62], ["borne infections", "PROBLEM", 208, 224], ["mosquito-borne infection", "PROBLEM", 374, 398], ["diseases", "OBSERVATION", 6, 14], ["Chagas disease", "OBSERVATION", 23, 37], ["leishmaniosis", "OBSERVATION", 42, 55], ["borne", "OBSERVATION_MODIFIER", 208, 213], ["infections", "OBSERVATION", 214, 224], ["infection", "OBSERVATION", 389, 398]]], ["In general, reported cases of vector-borne infections have increased during the last 30 years in the northern hemisphere (Semenza and Suk, 2018) .", [["vector-borne infections", "DISEASE", 30, 53], ["vector-borne infections", "PROBLEM", 30, 53], ["increased", "OBSERVATION_MODIFIER", 59, 68], ["northern hemisphere", "ANATOMY", 101, 120]]], ["In Europe, the most challenging infections include Ixodes ricinus transmitted diseases such as Lyme borreliosis (LB) and Tick-borne encephalitis (TBE) with an average number of 85.000 and 16.000 cases reported annually respectively.", [["infections", "DISEASE", 32, 42], ["Ixodes ricinus transmitted diseases", "DISEASE", 51, 86], ["Lyme borreliosis", "DISEASE", 95, 111], ["LB", "DISEASE", 113, 115], ["Tick-borne encephalitis", "DISEASE", 121, 144], ["TBE", "DISEASE", 146, 149], ["Ixodes ricinus", "ORGANISM", 51, 65], ["Tick-borne encephalitis", "ORGANISM", 121, 144], ["Ixodes ricinus", "SPECIES", 51, 65], ["Tick-borne encephalitis", "SPECIES", 121, 144], ["Ixodes ricinus", "SPECIES", 51, 65], ["Tick-borne encephalitis (TBE", "SPECIES", 121, 149], ["Ixodes ricinus transmitted diseases", "PROBLEM", 51, 86], ["Lyme borreliosis (LB)", "PROBLEM", 95, 116], ["Tick-borne encephalitis", "PROBLEM", 121, 144], ["most challenging", "OBSERVATION_MODIFIER", 15, 31], ["infections", "OBSERVATION", 32, 42], ["Lyme", "OBSERVATION_MODIFIER", 95, 99], ["encephalitis", "OBSERVATION", 132, 144]]], ["Other tick-borne diseases with rising public health concern include rickettsiosis and Crimean-Congo Hemorrhagic Fever.", [["tick-borne diseases", "DISEASE", 6, 25], ["rickettsiosis", "DISEASE", 68, 81], ["Fever", "DISEASE", 112, 117], ["Other tick-borne diseases", "PROBLEM", 0, 25], ["rickettsiosis", "PROBLEM", 68, 81], ["Crimean", "TEST", 86, 93], ["Congo Hemorrhagic Fever", "PROBLEM", 94, 117], ["rickettsiosis", "OBSERVATION", 68, 81], ["Hemorrhagic", "OBSERVATION_MODIFIER", 100, 111], ["Fever", "OBSERVATION", 112, 117]]], ["Mosquito borne diseases of concern include viral infection induced by WNV, Usutu virus (USUV) and Chikungunya virus (CHIKV), while others (i.e. dengue virus, Plasmodium spp.) still represent a potential threat with few sporadic autochthonous episodes of local circulation, especially within the countries of the Mediterranean basin.Vector-borne infections are on the riseA similar trend has been reported for the USA where cases of mosquito-borne and tick-borne diseases have more than tripled since 2004, characterized by steadily increasing incidence of tick-borne diseases and sporadic outbreaks of domestic and invasive mosquito-borne diseases (Petersen et al., 2019) .Vector-borne infections are on the riseTransmission of vector-borne pathogens is particularly sensitive to anthropogenic changes as they imply the interaction of three principal players: the pathogen, the vector (represented in many cases by an invertebrate) and a vertebrate host which can acquire and transmit the infection, if competent.", [["Mosquito borne diseases", "DISEASE", 0, 23], ["viral infection", "DISEASE", 43, 58], ["Chikungunya virus (CHIKV)", "DISEASE", 98, 123], ["dengue", "DISEASE", 144, 150], ["Plasmodium spp.", "DISEASE", 158, 173], ["Vector-borne infections", "DISEASE", 332, 355], ["mosquito-borne", "DISEASE", 432, 446], ["tick-borne diseases", "DISEASE", 451, 470], ["tick-borne diseases", "DISEASE", 556, 575], ["mosquito-borne diseases", "DISEASE", 624, 647], ["infections", "DISEASE", 686, 696], ["infection", "DISEASE", 989, 998], ["WNV", "ORGANISM", 70, 73], ["Usutu virus", "ORGANISM", 75, 86], ["USUV", "GENE_OR_GENE_PRODUCT", 88, 92], ["Chikungunya virus", "ORGANISM", 98, 115], ["CHIKV", "ORGANISM", 117, 122], ["dengue virus", "ORGANISM", 144, 156], ["Plasmodium spp.", "ORGANISM", 158, 173], ["Usutu virus", "SPECIES", 75, 86], ["Chikungunya virus", "SPECIES", 98, 115], ["dengue virus", "SPECIES", 144, 156], ["Plasmodium spp.", "SPECIES", 158, 173], ["WNV", "SPECIES", 70, 73], ["Usutu virus", "SPECIES", 75, 86], ["USUV", "SPECIES", 88, 92], ["Chikungunya virus", "SPECIES", 98, 115], ["CHIKV", "SPECIES", 117, 122], ["dengue virus", "SPECIES", 144, 156], ["Plasmodium spp.", "SPECIES", 158, 173], ["Mosquito borne diseases", "PROBLEM", 0, 23], ["viral infection", "PROBLEM", 43, 58], ["WNV", "PROBLEM", 70, 73], ["Usutu virus (USUV)", "PROBLEM", 75, 93], ["Chikungunya virus", "PROBLEM", 98, 115], ["CHIKV", "PROBLEM", 117, 122], ["dengue virus", "PROBLEM", 144, 156], ["Plasmodium spp.", "PROBLEM", 158, 173], ["local circulation", "PROBLEM", 254, 271], ["borne infections", "PROBLEM", 339, 355], ["tick-borne diseases", "PROBLEM", 451, 470], ["tick-borne diseases", "PROBLEM", 556, 575], ["sporadic outbreaks of domestic and invasive mosquito-borne diseases", "PROBLEM", 580, 647], ["borne infections", "PROBLEM", 680, 696], ["borne pathogens", "PROBLEM", 735, 750], ["the infection", "PROBLEM", 985, 998], ["viral", "OBSERVATION_MODIFIER", 43, 48], ["infection", "OBSERVATION", 49, 58], ["few", "OBSERVATION_MODIFIER", 215, 218], ["sporadic", "OBSERVATION_MODIFIER", 219, 227], ["autochthonous", "OBSERVATION", 228, 241], ["local circulation", "OBSERVATION", 254, 271], ["borne", "OBSERVATION_MODIFIER", 339, 344], ["infections", "OBSERVATION", 345, 355], ["invasive", "OBSERVATION_MODIFIER", 615, 623], ["borne", "OBSERVATION_MODIFIER", 680, 685], ["infections", "OBSERVATION", 686, 696], ["infection", "OBSERVATION", 989, 998]]], ["Changes in vector-host interaction and in the vectorial capacity can determine a rise in infection hazard and disease incidence.Vectorial capacity is key to vector-borne disease hazard and emergenceVectorial capacity (VC) is crucial at predicting changes in disease hazard and the emergence of vector-borne infections.", [["infection", "DISEASE", 89, 98], ["infections", "DISEASE", 307, 317], ["infection hazard", "PROBLEM", 89, 105], ["disease incidence", "PROBLEM", 110, 127], ["Vectorial capacity", "PROBLEM", 128, 146], ["borne disease hazard", "PROBLEM", 164, 184], ["Vectorial capacity", "PROBLEM", 198, 216], ["disease hazard", "PROBLEM", 258, 272], ["vector-borne infections", "PROBLEM", 294, 317], ["infection", "OBSERVATION", 89, 98], ["capacity", "OBSERVATION_MODIFIER", 208, 216], ["disease", "OBSERVATION", 258, 265], ["infections", "OBSERVATION", 307, 317]]], ["Firstly developed as an index for exploration of control methods for malaria and other mosquito-borne diseases of humans (MacDonald, 1955) , its adaptation to mosquito and tick borne zoonoses, which usually imply more than one reservoir host species, requires particular attention.", [["malaria", "DISEASE", 69, 76], ["mosquito-borne diseases", "DISEASE", 87, 110], ["zoonoses", "DISEASE", 183, 191], ["humans", "ORGANISM", 114, 120], ["humans", "SPECIES", 114, 120], ["humans", "SPECIES", 114, 120], ["an index", "TEST", 21, 29], ["exploration of control methods", "TREATMENT", 34, 64], ["malaria", "PROBLEM", 69, 76], ["other mosquito-borne diseases of humans", "PROBLEM", 81, 120], ["mosquito and tick borne zoonoses", "PROBLEM", 159, 191]]], ["In general, vectorial capacity describes the dynamic relationship between vectors of infectious disease agents and the vertebrate hosts.", [["infectious disease", "DISEASE", 85, 103], ["vectorial capacity", "PROBLEM", 12, 30], ["infectious disease agents", "TREATMENT", 85, 110], ["vectorial capacity", "OBSERVATION", 12, 30], ["infectious", "OBSERVATION", 85, 95]]], ["It combines the physiological and genetic attributes of vectors that determine their susceptibility to infection and their ability to transmit pathogens with relevant ecological and behavioural traits of vectors such as longevity, host preference and host abundance (Eldridge and Edman, 2004) .", [["infection", "DISEASE", 103, 112], ["their susceptibility to infection", "PROBLEM", 79, 112], ["infection", "OBSERVATION", 103, 112]]], ["In the case of mosquito borne diseases, the concept of VC is the measure of a mosquito population's capacity to transmit an infectious agent to a new susceptible population.", [["mosquito borne diseases", "DISEASE", 15, 38], ["mosquito borne diseases", "PROBLEM", 15, 38], ["a mosquito population's capacity", "PROBLEM", 76, 108], ["an infectious agent", "TREATMENT", 121, 140], ["a new susceptible population", "PROBLEM", 144, 172]]], ["Vectorial capacity is the expected number of hosts infected per infected host assuming perfect vector efficiency, and can be expressed, in the case of mosquitoes, as follows (Smith and McKenzie, 2004; McMillan et al., 2019) :Vectorial capacity is key to vector-borne disease hazard and emergencewhere m is the vector to host ratio (i.e. the number of female mosquitoes per host), a is the mosquito biting rate (i.e. number of bites on a host, per vector, per unit of time), 1/g is the average vector life-span and n is the length of the extrinsic incubation period.Vectorial capacity is key to vector-borne disease hazard and emergenceConsequently, R 0 , which is the expected number of infected hosts generated by one infected host in a susceptible population, or conversely the number of infected mosquitoes generated by one infected mosquito, can be derived as: Where b and c are the transmission efficiency from infected vector to host and infected host to vector respectively and 1/r is the length of the host infectious period (Smith and McKenzie, 2004) .Vectorial capacity is key to vector-borne disease hazard and emergenceThe concept of R 0 can be applied to ticks, indicating in this case the number of infective ticks yielded for one infected tick bite on a susceptible host (Randolph et al., 1996) .", [["infected mosquitoes", "DISEASE", 790, 809], ["tick bite", "DISEASE", 1254, 1263], ["R 0", "GENE_OR_GENE_PRODUCT", 649, 652], ["mosquito", "ORGANISM", 836, 844], ["c", "GENE_OR_GENE_PRODUCT", 877, 878], ["R 0", "GENE_OR_GENE_PRODUCT", 1146, 1149], ["Vectorial capacity", "PROBLEM", 0, 18], ["Vectorial capacity", "PROBLEM", 225, 243], ["Vectorial capacity", "PROBLEM", 565, 583], ["borne disease hazard", "PROBLEM", 601, 621], ["infected hosts", "PROBLEM", 687, 701], ["infected mosquitoes", "PROBLEM", 790, 809], ["the transmission efficiency", "PROBLEM", 883, 910], ["infected vector", "TREATMENT", 916, 931], ["Vectorial capacity", "PROBLEM", 1061, 1079], ["borne disease hazard", "PROBLEM", 1097, 1117], ["infective ticks", "PROBLEM", 1213, 1228], ["one infected tick bite", "PROBLEM", 1241, 1263], ["hosts", "OBSERVATION_MODIFIER", 45, 50], ["infected", "OBSERVATION", 51, 59], ["vector efficiency", "OBSERVATION", 95, 112], ["infected", "OBSERVATION", 687, 695], ["infected", "OBSERVATION", 790, 798], ["infected", "OBSERVATION", 916, 924], ["host", "OBSERVATION_MODIFIER", 1010, 1014], ["infectious", "OBSERVATION", 1015, 1025], ["infective", "OBSERVATION", 1213, 1222]]], ["In this case an indication of the size of R 0,T can be given by:Vectorial capacity is key to vector-borne disease hazard and emergencewhere m is the tick to host ratio, h and t are the host mortality rate and host incubation period respectively, \u03b2 is transmission efficiency, \u03bc is the tick survival, 1/\u03b1 is the duration of host infectivity in the unit of time (Randolph et al., 1996) .", [["Vectorial capacity", "PROBLEM", 64, 82]]], ["Analyzing the relationship between R 0 and VC as carried out above for mosquitoes, we can derive a measure for tick-borne infection vectorial capacity (VC T ) as follows:Vectorial capacity is key to vector-borne disease hazard and emergenceHowever, these measures of R 0,T and VC T are a simplification as tick-borne infections involve more complex biological processes and transmission dynamics (three life stages: larvae, nymphs, adults) with respect to mosquito-borne pathogens, so that modelling is not so straightforward (Hartemink et al., 2008; Ros\u00e0 et al., 2003) .", [["infection", "DISEASE", 122, 131], ["infections", "DISEASE", 317, 327], ["R 0", "GENE_OR_GENE_PRODUCT", 35, 38], ["R 0", "GENE_OR_GENE_PRODUCT", 267, 270], ["T", "CELL", 271, 272], ["VC T", "GENE_OR_GENE_PRODUCT", 277, 281], ["mosquitoes", "PROBLEM", 71, 81], ["tick-borne infection vectorial capacity", "PROBLEM", 111, 150], ["Vectorial capacity", "PROBLEM", 170, 188], ["borne disease hazard", "PROBLEM", 206, 226], ["a simplification as tick-borne infections", "PROBLEM", 286, 327], ["mosquito-borne pathogens", "PROBLEM", 456, 480]]], ["In addition, pathogen transmission may follow several routes: transovarial (from an infected female tick to her eggs), transstadial (from a tick stage to the next), systemic (from an infectious vertebrate host to an uninfected tick) and non-systemic transmission (i.e. infected and uninfected ticks simultaneously feed on susceptible or immune vertebrate hosts, resulting in all ticks in the co-feeding group potentially becoming infected).", [["eggs", "ANATOMY", 112, 116], ["transovarial", "PROBLEM", 62, 74], ["a tick stage", "PROBLEM", 138, 150], ["non-systemic transmission", "PROBLEM", 237, 262], ["immune vertebrate hosts", "TREATMENT", 337, 360], ["all ticks", "PROBLEM", 375, 384], ["infectious", "OBSERVATION", 183, 193], ["infected", "OBSERVATION", 430, 438]]], ["In particular, co-feeding transmission is recognized to be the most efficient transmission route for some pathogens like TBEV (Labuda et al., 1997; Nonaka et al., 2010; Randolph, 2011) .Vectorial capacity is key to vector-borne disease hazard and emergenceA broad range of factors and events can affect VC at various level of complexity and scale.", [["TBEV", "DISEASE", 121, 125], ["TBEV", "ORGANISM", 121, 125], ["TBEV", "SPECIES", 121, 125], ["some pathogens", "PROBLEM", 101, 115], ["Vectorial capacity", "PROBLEM", 186, 204], ["borne disease hazard", "PROBLEM", 222, 242]]], ["For instance, global phenomena such as climate and land use changes can affect the occurrence of the vectors and thus the possibility for a vector borne pathogen to circulate (Weaver and Reisen, 2010; Mills et al., 2010) .", [["global phenomena", "PROBLEM", 14, 30], ["a vector borne pathogen", "PROBLEM", 138, 161], ["global", "OBSERVATION_MODIFIER", 14, 20], ["phenomena", "OBSERVATION", 21, 30]]], ["At a local scale, variation in climatic conditions might affect parameters such as vector longevity and feeding behaviour or changes in vector and reservoir host abundance and competence that can modulate pathogen infection rate in the vectors.", [["infection", "DISEASE", 214, 223], ["a local scale", "TREATMENT", 3, 16], ["variation in climatic conditions", "PROBLEM", 18, 50], ["vector longevity", "TREATMENT", 83, 99], ["feeding behaviour", "PROBLEM", 104, 121], ["changes in vector and reservoir host abundance", "PROBLEM", 125, 171], ["pathogen infection rate in the vectors", "PROBLEM", 205, 243], ["climatic conditions", "OBSERVATION", 31, 50], ["pathogen", "OBSERVATION_MODIFIER", 205, 213], ["infection", "OBSERVATION", 214, 223]]], ["In fact, as vector-borne diseases usually arise from the interaction among a vector and a reservoir host, changes in host abundance and host community composition, due for example to intensive land use or wildlife management practices, including artificial feeding, can exert a dramatic effect in terms of changes in hazard, since host can affect both vector abundance and infection prevalence.", [["community", "ANATOMY", 141, 150], ["infection", "DISEASE", 373, 382], ["vector-borne diseases", "PROBLEM", 12, 33], ["a reservoir host", "TREATMENT", 88, 104], ["wildlife management practices", "TREATMENT", 205, 234], ["artificial feeding", "TREATMENT", 246, 264], ["infection prevalence", "PROBLEM", 373, 393], ["infection", "OBSERVATION", 373, 382]]], ["Therefore, the contributions of specific wildlife species to vector and pathogen maintenance, and the role of a host species in determining risk to a target host may depend on the community composition of hosts and vectors (Ostfeld et al., 2018; Levi et al., 2016b; Levine et al., 2017) .", [["community", "ANATOMY", 180, 189], ["pathogen maintenance", "TREATMENT", 72, 92], ["a host species", "TREATMENT", 110, 124]]], ["Actually, the assessment of the meta-community structure Esser et al., 2016) is an approach that public health scientists can use to better evaluate the factors that affect times and places for the origin and emergence of infectious diseases.Vectorial capacity is key to vector-borne disease hazard and emergenceAt individual scale, genetic determinants can affect traits such as vector feeding preferences and vector competence (Emami et al., 2017) .", [["infectious diseases", "DISEASE", 222, 241], ["the assessment", "TEST", 10, 24], ["infectious diseases", "PROBLEM", 222, 241], ["Vectorial capacity", "PROBLEM", 242, 260], ["borne disease hazard", "PROBLEM", 278, 298], ["emergenceAt individual scale", "TREATMENT", 303, 331], ["infectious", "OBSERVATION", 222, 232]]], ["Other effects, such as the consequences of changes in vector microbiome composition on pathogen survival and transmission have just begun to be analyzed (Minard et al., 2018) .Emerging flaviviruses in EuropeFlaviviruses are among the best examples of the consequences of the anthropogenic impacts on host-parasite interaction and on how their modifications affect infection hazard.", [["infection", "DISEASE", 364, 373], ["pathogen survival", "TREATMENT", 87, 104], ["Emerging flaviviruses in EuropeFlaviviruses", "PROBLEM", 176, 219], ["infection hazard", "PROBLEM", 364, 380], ["flaviviruses", "OBSERVATION", 185, 197], ["anthropogenic", "OBSERVATION", 275, 288]]], ["Amongst the more than 70 described Flaviviruses, at least 40 are pathogenic for humans.", [["Flaviviruses", "DISEASE", 35, 47], ["Flaviviruses", "CANCER", 35, 47], ["humans", "ORGANISM", 80, 86], ["humans", "SPECIES", 80, 86], ["humans", "SPECIES", 80, 86], ["Flaviviruses", "OBSERVATION", 35, 47], ["pathogenic", "OBSERVATION", 65, 75]]], ["They include, other than tick-borne encephalitis virus (TBEV) and WNV, also other emerging viruses such as Powassan virus (POWV) Usutu virus (USUV), and Zika virus (ZIKV).", [["encephalitis", "DISEASE", 36, 48], ["TBEV", "DISEASE", 56, 60], ["tick-borne encephalitis virus", "ORGANISM", 25, 54], ["TBEV", "ORGANISM", 56, 60], ["Powassan virus", "ORGANISM", 107, 121], ["POWV) Usutu virus", "ORGANISM", 123, 140], ["USUV", "ORGANISM", 142, 146], ["Zika virus", "ORGANISM", 153, 163], ["tick-borne encephalitis virus", "SPECIES", 25, 54], ["Powassan virus", "SPECIES", 107, 121], ["Usutu virus", "SPECIES", 129, 140], ["Zika virus", "SPECIES", 153, 163], ["tick-borne encephalitis virus", "SPECIES", 25, 54], ["TBEV", "SPECIES", 56, 60], ["WNV", "SPECIES", 66, 69], ["Powassan virus", "SPECIES", 107, 121], ["POWV", "SPECIES", 123, 127], ["Usutu virus", "SPECIES", 129, 140], ["USUV", "SPECIES", 142, 146], ["Zika virus", "SPECIES", 153, 163], ["ZIKV", "SPECIES", 165, 169], ["tick-borne encephalitis virus", "PROBLEM", 25, 54], ["WNV", "PROBLEM", 66, 69], ["other emerging viruses", "PROBLEM", 76, 98], ["Powassan virus", "PROBLEM", 107, 121], ["Usutu virus (USUV)", "PROBLEM", 129, 147], ["Zika virus", "PROBLEM", 153, 163], ["viruses", "OBSERVATION", 91, 98]]], ["Furthermore, well-known flaviviruses of remote regions appear to have increased their distribution (e.g. TBEV, Zika virus, Kyasanur Forest disease virus).", [["Kyasanur Forest disease", "DISEASE", 123, 146], ["Zika virus", "ORGANISM", 111, 121], ["Kyasanur Forest disease virus", "ORGANISM", 123, 152], ["Zika virus", "SPECIES", 111, 121], ["TBEV", "SPECIES", 105, 109], ["Zika virus", "SPECIES", 111, 121], ["Kyasanur Forest disease virus", "SPECIES", 123, 152], ["TBEV", "PROBLEM", 105, 109], ["Zika virus", "PROBLEM", 111, 121], ["Kyasanur Forest disease virus", "PROBLEM", 123, 152], ["flaviviruses", "OBSERVATION", 24, 36], ["increased", "OBSERVATION_MODIFIER", 70, 79], ["distribution", "OBSERVATION_MODIFIER", 86, 98]]], ["In other cases, they increased their human pathogenicity so that they might have been overlooked and/or misdiagnosed and thus only now apparently emerging (e.g. USUV) (Cadar et al., 2017; Grottola et al., 2017) .Emerging flaviviruses in EuropeA broad number of review and research articles have been already produced over the consequences of the anthropogenic changes on the various parameters included in the vectorial capacity computation for a number of viral infections, especially those transmitted by mosquitoes.", [["viral infections", "DISEASE", 457, 473], ["human", "ORGANISM", 37, 42], ["human", "SPECIES", 37, 42], ["human", "SPECIES", 37, 42], ["Emerging flaviviruses", "PROBLEM", 212, 233], ["the anthropogenic changes", "PROBLEM", 342, 367], ["the vectorial capacity computation", "TEST", 406, 440], ["viral infections", "PROBLEM", 457, 473], ["flaviviruses", "OBSERVATION", 221, 233], ["anthropogenic", "OBSERVATION", 346, 359], ["vectorial capacity", "OBSERVATION", 410, 428], ["viral infections", "OBSERVATION", 457, 473]]], ["We will consider here as examples two flaviviruses, namely TBEV and WNV.Tick-borne encephalitis virus (TBEV)Over the past four decades, TBE has become a growing public health challenge in Europe and parts of Asia.", [["TBEV and WNV", "DISEASE", 59, 71], ["Tick-borne encephalitis", "DISEASE", 72, 95], ["TBEV", "DISEASE", 103, 107], ["TBE", "DISEASE", 136, 139], ["TBEV", "ORGANISM", 59, 63], ["WNV", "ORGANISM", 68, 71], ["Tick-borne encephalitis virus", "ORGANISM", 72, 101], ["Tick-borne encephalitis virus", "SPECIES", 72, 101], ["TBEV", "SPECIES", 59, 63], ["WNV", "SPECIES", 68, 71], ["Tick-borne encephalitis virus", "SPECIES", 72, 101], ["TBEV", "SPECIES", 103, 107], ["TBE", "SPECIES", 136, 139], ["WNV", "PROBLEM", 68, 71], ["Tick-borne encephalitis virus", "PROBLEM", 72, 101], ["TBE", "PROBLEM", 136, 139], ["growing", "OBSERVATION_MODIFIER", 153, 160]]], ["It is a neurological zoonotic infection with various degree of severity caused by TBEV which includes three subtypes: European (TBEV-Eur), Siberian (TBEV-Sib) and Far-Eastern (TBEV-FE) (Simmonds et al., 2012) .", [["neurological", "ANATOMY", 8, 20], ["zoonotic infection", "DISEASE", 21, 39], ["TBEV", "DISEASE", 82, 86], ["TBEV", "SPECIES", 82, 86], ["TBEV", "SPECIES", 176, 180], ["a neurological zoonotic infection", "PROBLEM", 6, 39], ["TBEV", "PROBLEM", 82, 86], ["Far-Eastern", "TEST", 163, 174], ["neurological", "OBSERVATION_MODIFIER", 8, 20], ["zoonotic", "OBSERVATION_MODIFIER", 21, 29], ["infection", "OBSERVATION", 30, 39], ["TBEV", "OBSERVATION", 82, 86]]], ["Humans are infected sporadically, either by a tick bite or by ingestion of infected raw milk or milk products (Dorko et al., 2018) .", [["milk", "ANATOMY", 88, 92], ["milk", "ANATOMY", 96, 100], ["tick bite", "DISEASE", 46, 55], ["Humans", "ORGANISM", 0, 6], ["milk", "ORGANISM_SUBSTANCE", 88, 92], ["milk", "ORGANISM_SUBSTANCE", 96, 100], ["milk", "SPECIES", 88, 92], ["a tick bite", "PROBLEM", 44, 55], ["infected", "OBSERVATION", 11, 19]]], ["Other mammals (e.g. ruminants, carnivores) can also be infected, but most of the time do not show clinical signs.", [["carnivores", "ORGANISM", 31, 41], ["infected", "OBSERVATION", 55, 63]]], ["The hard ticks Ixodes ricinus, I. persulcatus, Dermacentor reticulatus and Haemaphysalis concinna are known vectors of TBEV in Europe.", [["TBEV", "DISEASE", 119, 123], ["ticks", "ORGANISM", 9, 14], ["Ixodes ricinus", "ORGANISM", 15, 29], ["I. persulcatus", "ORGANISM", 31, 45], ["Dermacentor reticulatus", "ORGANISM", 47, 70], ["Haemaphysalis concinna", "ORGANISM", 75, 97], ["TBEV", "ORGANISM", 119, 123], ["Ixodes ricinus", "SPECIES", 15, 29], ["I. persulcatus", "SPECIES", 31, 45], ["Dermacentor reticulatus", "SPECIES", 47, 70], ["Haemaphysalis concinna", "SPECIES", 75, 97], ["Ixodes ricinus", "SPECIES", 15, 29], ["I. persulcatus", "SPECIES", 31, 45], ["Dermacentor reticulatus", "SPECIES", 47, 70], ["Haemaphysalis concinna", "SPECIES", 75, 97], ["TBEV", "SPECIES", 119, 123], ["The hard ticks Ixodes ricinus", "PROBLEM", 0, 29]]], ["Ixodes ricinus mainly carry the TBEV-Eur variant in central and north-eastern Europe (Dobler et al., 2012) .", [["Ixodes ricinus", "ORGANISM", 0, 14], ["Ixodes ricinus", "SPECIES", 0, 14], ["Ixodes ricinus", "SPECIES", 0, 14], ["TBEV", "OBSERVATION", 32, 36], ["central", "ANATOMY_MODIFIER", 52, 59]]], ["However, in recent years new transmission cycles have been reported as in the case of the isolation of TBEV-Sib subtype in this tick species within a new foci of emergence (J\u00e4\u00e4skel\u00e4inen et al., 2016) .Tick-borne encephalitis virus (TBEV)Ixodes ricinus is an exophilic hard tick belonging to the Ixodes ricinus complex (Acari: Ixodidae).", [["foci", "ANATOMY", 154, 158], ["Tick-borne encephalitis", "DISEASE", 201, 224], ["TBEV-Sib subtype", "ORGANISM", 103, 119], ["Tick-borne encephalitis virus", "ORGANISM", 201, 230], ["TBEV", "ORGANISM", 232, 236], ["Ixodes ricinus", "ORGANISM", 237, 251], ["Ixodes ricinus", "ORGANISM", 295, 309], ["Tick-borne encephalitis virus", "SPECIES", 201, 230], ["Ixodes ricinus", "SPECIES", 237, 251], ["Ixodes ricinus", "SPECIES", 295, 309], ["TBEV", "SPECIES", 103, 107], ["Tick-borne encephalitis virus", "SPECIES", 201, 230], ["TBEV", "SPECIES", 232, 236], ["Ixodes ricinus", "SPECIES", 237, 251], ["Ixodes ricinus", "SPECIES", 295, 309], ["TBEV", "PROBLEM", 103, 107], ["Sib subtype", "PROBLEM", 108, 119], ["this tick species", "PROBLEM", 123, 140], ["Tick-borne encephalitis virus", "PROBLEM", 201, 230], ["an exophilic hard tick", "PROBLEM", 255, 277], ["TBEV", "OBSERVATION", 103, 107], ["new", "OBSERVATION_MODIFIER", 150, 153], ["foci", "OBSERVATION_MODIFIER", 154, 158]]], ["It is a three-host tick having catholic feeding habits, with the adults occurring on medium-sized and large animals such as hedgehogs, hares, deer and domestic livestock, and the immature stages mainly parasitizing lizards, birds and small to mediumsized mammals, in addition to large animals (Gray et al., 2016) .", [["deer", "SPECIES", 142, 146], ["large", "OBSERVATION_MODIFIER", 102, 107], ["immature", "OBSERVATION_MODIFIER", 179, 187], ["stages", "OBSERVATION_MODIFIER", 188, 194], ["mainly", "OBSERVATION_MODIFIER", 195, 201], ["parasitizing lizards", "OBSERVATION", 202, 222], ["small", "OBSERVATION_MODIFIER", 234, 239], ["large", "OBSERVATION_MODIFIER", 279, 284]]], ["Both developing and host-seeking ticks are very vulnerable to desiccation, and therefore require microclimates where the relative humidity remains above 80% for prolonged periods.", [["ticks", "ORGANISM", 33, 38], ["microclimates", "TREATMENT", 97, 110], ["the relative humidity", "TEST", 117, 138], ["host", "OBSERVATION_MODIFIER", 20, 24], ["humidity", "OBSERVATION_MODIFIER", 130, 138]]], ["Questing by individual ticks can persist for several weeks or months in suitable habitat, and is stagedependent with larvae questing for the shortest periods and adults for the longest (Gray et al., 2016) .Tick-borne encephalitis virus (TBEV)TBEV is maintained in wild enzootic cycle by ticks and their hosts.", [["Tick-borne encephalitis", "DISEASE", 206, 229], ["TBEV", "DISEASE", 242, 246], ["Tick-borne encephalitis virus", "ORGANISM", 206, 235], ["TBEV", "ORGANISM", 237, 241], ["TBEV", "ORGANISM", 242, 246], ["Tick-borne encephalitis virus", "SPECIES", 206, 235], ["Tick-borne encephalitis virus", "SPECIES", 206, 235], ["TBEV", "SPECIES", 237, 241], ["TBEV", "SPECIES", 242, 246], ["Tick-borne encephalitis virus", "PROBLEM", 206, 235]]], ["Ticks are both vectors and reservoirs of TBEV as they carry the virus throughout their life.", [["TBEV", "DISEASE", 41, 45], ["TBEV", "ORGANISM", 41, 45], ["TBEV", "SPECIES", 41, 45]]], ["Therefore, the virus can be transmitted by all stages, although nymphs and adult account for most of the virus transmission (Valarcher et al., 2015) .Tick-borne encephalitis virus (TBEV)In mainland Europe, TBEV is highly efficiently transmitted by cofeeding ticks on rodents mainly of the genus Myodes and Apodemus (Labuda et al., 1997; Nonaka et al., 2010; Randolph, 2011; Knap et al., 2012) .", [["Tick-borne encephalitis", "DISEASE", 150, 173], ["TBEV", "DISEASE", 181, 185], ["TBEV", "DISEASE", 206, 210], ["Tick-borne encephalitis virus", "ORGANISM", 150, 179], ["TBEV", "ORGANISM", 206, 210], ["Tick-borne encephalitis virus", "SPECIES", 150, 179], ["Tick-borne encephalitis virus", "SPECIES", 150, 179], ["TBEV", "SPECIES", 181, 185], ["TBEV", "SPECIES", 206, 210], ["the virus", "PROBLEM", 11, 20], ["nymphs", "PROBLEM", 64, 70], ["Tick-borne encephalitis virus", "PROBLEM", 150, 179], ["virus", "OBSERVATION", 15, 20], ["genus Myodes", "ANATOMY", 289, 301]]], ["Leukocytes migrate between tick feeding sites, bearing infective virions and providing a transport route for the virus between co-feeding ticks, independently of a systemic viraemia.", [["Leukocytes", "ANATOMY", 0, 10], ["sites", "ANATOMY", 40, 45], ["virions", "ANATOMY", 65, 72], ["viraemia", "DISEASE", 173, 181], ["Leukocytes", "CELL", 0, 10], ["feeding sites", "MULTI-TISSUE_STRUCTURE", 32, 45], ["Leukocytes", "CELL_TYPE", 0, 10], ["Leukocytes", "PROBLEM", 0, 10], ["tick feeding sites", "TREATMENT", 27, 45], ["bearing infective virions", "PROBLEM", 47, 72], ["a transport route", "TREATMENT", 87, 104], ["the virus between co-feeding ticks", "TREATMENT", 109, 143], ["a systemic viraemia", "PROBLEM", 162, 181], ["infective virions", "OBSERVATION", 55, 72], ["systemic", "ANATOMY", 164, 172], ["viraemia", "OBSERVATION", 173, 181]]], ["Rodents therefore act as transient bridges (Randolph, 2011) .Tick-borne encephalitis virus (TBEV)Insectivores and rodents may also act as TBEV reservoirs since they may maintain the virus latently, but susceptibility to TBEV varies from species to species.", [["Tick-borne encephalitis", "DISEASE", 61, 84], ["TBEV", "DISEASE", 220, 224], ["Tick-borne encephalitis virus", "ORGANISM", 61, 90], ["TBEV", "ORGANISM", 92, 96], ["rodents", "ORGANISM", 114, 121], ["TBEV", "ORGANISM", 138, 142], ["TBEV", "ORGANISM", 220, 224], ["Tick-borne encephalitis virus", "SPECIES", 61, 90], ["Tick-borne encephalitis virus", "SPECIES", 61, 90], ["TBEV", "SPECIES", 92, 96], ["TBEV", "SPECIES", 138, 142], ["TBEV", "SPECIES", 220, 224], ["Tick-borne encephalitis virus", "PROBLEM", 61, 90], ["TBEV reservoirs", "TREATMENT", 138, 153], ["the virus latently", "PROBLEM", 178, 196], ["TBEV", "PROBLEM", 220, 224]]], ["Some develop a high viraemia and thus may play a major role in the transmission of TBEV to ticks.", [["viraemia", "DISEASE", 20, 28], ["TBEV", "DISEASE", 83, 87], ["TBEV", "ORGANISM", 83, 87], ["TBEV", "SPECIES", 83, 87], ["a high viraemia", "PROBLEM", 13, 28], ["high", "OBSERVATION_MODIFIER", 15, 19], ["viraemia", "OBSERVATION", 20, 28]]], ["For example, the northern red-backed vole (Myodes rutilus) or the bank vole (Myodes glareolus), can serve as reservoir hosts by means of a prolonged viraemia and possibly by vertical virus transmission to offspring (Bakhvalova et al., 2006 (Bakhvalova et al., , 2009 Tonteri et al., 2011 Tonteri et al., , 2013 .", [["viraemia", "DISEASE", 149, 157], ["red-backed vole", "ORGANISM", 26, 41], ["Myodes rutilus", "ORGANISM", 43, 57], ["bank vole", "ORGANISM", 66, 75], ["Myodes glareolus", "ORGANISM", 77, 93], ["Myodes rutilus", "SPECIES", 43, 57], ["Myodes glareolus", "SPECIES", 77, 93], ["northern red-backed vole", "SPECIES", 17, 41], ["Myodes rutilus", "SPECIES", 43, 57], ["bank vole", "SPECIES", 66, 75], ["Myodes glareolus", "SPECIES", 77, 93], ["a prolonged viraemia", "PROBLEM", 137, 157], ["bank vole", "ANATOMY", 66, 75]]], ["The extent at which ticks become infected as a consequence of different transmission routes under natural condition needs further investigation (Jaenson et al., 2012) .Tick-borne encephalitis virus (TBEV)Because of the peculiarity of it transmission cycle, vectorial capacity for TBEV can be highly influenced by exogenous anthropogenic drivenchanges which interact in affecting the essential parameters implicated such as the vector to host ratio, the vector survival and the host mortality rate.Tick-borne encephalitis virus (TBEV)At the large scale, changes in climate and land use affected the geographic range of Ixodes ricinus, its survival rate, its seasonal questing activity and finally TBE hazard (Gray et al., 2009 (Gray et al., , 2016 Knap et al., 2009; Tagliapietra et al., 2011; Medlock et al., 2013; Kilpatrick and Randolph, 2012; Daniel et al., 2018) .", [["Tick-borne encephalitis", "DISEASE", 168, 191], ["TBEV", "DISEASE", 199, 203], ["TBEV", "DISEASE", 280, 284], ["Tick-borne encephalitis", "DISEASE", 497, 520], ["Tick-borne encephalitis virus", "ORGANISM", 168, 197], ["TBEV", "ORGANISM", 280, 284], ["Tick-borne encephalitis virus", "ORGANISM", 497, 526], ["Ixodes ricinus", "ORGANISM", 618, 632], ["Tick-borne encephalitis virus", "SPECIES", 168, 197], ["Tick-borne encephalitis virus", "SPECIES", 497, 526], ["Ixodes ricinus", "SPECIES", 618, 632], ["Tick-borne encephalitis virus", "SPECIES", 168, 197], ["TBEV", "SPECIES", 199, 203], ["TBEV", "SPECIES", 280, 284], ["Tick-borne encephalitis virus", "SPECIES", 497, 526], ["TBEV", "SPECIES", 528, 532], ["Ixodes ricinus", "SPECIES", 618, 632], ["TBE", "SPECIES", 696, 699], ["infected", "PROBLEM", 33, 41], ["further investigation", "TEST", 122, 143], ["Tick-borne encephalitis virus", "PROBLEM", 168, 197], ["vectorial capacity", "PROBLEM", 257, 275], ["TBEV", "PROBLEM", 280, 284], ["exogenous anthropogenic drivenchanges", "PROBLEM", 313, 350], ["the vector survival", "TREATMENT", 449, 468], ["the host mortality rate", "TEST", 473, 496], ["Tick-borne encephalitis virus", "PROBLEM", 497, 526], ["extent", "OBSERVATION_MODIFIER", 4, 10], ["infected", "OBSERVATION", 33, 41], ["anthropogenic drivenchanges", "OBSERVATION", 323, 350]]], ["Furthermore in mainland Europe, it has been found that climate played a critical role on the persistence of TBEV transmission cycles via co-feeding mechanism mainly acting on seasonality of ticks and in particular on their synchronicity (Randolph et al., 1999; Ros\u00e0 et al., 2019) .Tick-borne encephalitis virus (TBEV)However, changes in climate and land use are not sufficient to explain changes in Ixodes ricinus temporal and spatial variation as well as in TBE hazard (Randolph, 2010; Medlock et al., 2013) .", [["TBEV", "DISEASE", 108, 112], ["Tick-borne encephalitis", "DISEASE", 281, 304], ["TBEV", "DISEASE", 312, 316], ["TBEV", "ORGANISM", 108, 112], ["Tick-borne encephalitis virus", "ORGANISM", 281, 310], ["TBEV", "ORGANISM", 312, 316], ["Ixodes ricinus", "ORGANISM", 399, 413], ["Tick-borne encephalitis virus", "SPECIES", 281, 310], ["Ixodes ricinus", "SPECIES", 399, 413], ["TBEV", "SPECIES", 108, 112], ["Tick-borne encephalitis virus", "SPECIES", 281, 310], ["TBEV", "SPECIES", 312, 316], ["Ixodes ricinus", "SPECIES", 399, 413], ["TBE", "SPECIES", 459, 462], ["TBEV transmission cycles", "TREATMENT", 108, 132], ["co-feeding mechanism", "PROBLEM", 137, 157], ["Tick-borne encephalitis virus", "PROBLEM", 281, 310], ["changes in Ixodes ricinus temporal and spatial variation", "PROBLEM", 388, 444], ["spatial variation", "OBSERVATION", 427, 444]]], ["In fact, tick distribution, abundance and its infection rate with TBEV are also greatly affected by changes in other exogenous factors such as tick host abundance and distribution.", [["infection", "DISEASE", 46, 55], ["TBEV", "DISEASE", 66, 70], ["exogenous factors", "PROTEIN", 117, 134], ["TBEV", "SPECIES", 66, 70], ["its infection rate", "PROBLEM", 42, 60], ["TBEV", "PROBLEM", 66, 70], ["tick", "OBSERVATION_MODIFIER", 9, 13], ["distribution", "OBSERVATION_MODIFIER", 14, 26], ["abundance", "OBSERVATION_MODIFIER", 28, 37], ["infection", "OBSERVATION", 46, 55], ["exogenous factors", "OBSERVATION", 117, 134], ["distribution", "OBSERVATION_MODIFIER", 167, 179]]], ["Rodents for example are widespread in most ecological systems, have a small home range (max 2-3 ha) and are heavily parasitized by ticks.", [["widespread", "OBSERVATION_MODIFIER", 24, 34], ["small", "OBSERVATION_MODIFIER", 70, 75], ["heavily", "OBSERVATION_MODIFIER", 108, 115], ["parasitized", "OBSERVATION", 116, 127]]], ["The fluctuations of rodent populations are well studied and often dramatic, although anthropogenic pressure can alter them substantially (Hansson and Henttonen, 1988; Rowe and Terry, 2014) .", [["fluctuations", "OBSERVATION_MODIFIER", 4, 16], ["rodent", "OBSERVATION_MODIFIER", 20, 26], ["populations", "OBSERVATION_MODIFIER", 27, 38], ["dramatic", "OBSERVATION_MODIFIER", 66, 74]]], ["The large variation in rodents survival rates and population abundance affects in turn the tick feeding host availability (especially for the immature stage) and thus infection prevalence (Gern et al., 1998) .", [["infection", "DISEASE", 167, 176], ["The large variation in rodents survival rates", "PROBLEM", 0, 45], ["infection prevalence", "PROBLEM", 167, 187], ["large", "OBSERVATION_MODIFIER", 4, 9], ["variation", "OBSERVATION_MODIFIER", 10, 19], ["rodents", "OBSERVATION_MODIFIER", 23, 30], ["survival", "OBSERVATION_MODIFIER", 31, 39], ["infection", "OBSERVATION", 167, 176]]], ["The relationship between tick demography and rodent density is complex.", [["rodent", "OBSERVATION_MODIFIER", 45, 51], ["density", "OBSERVATION", 52, 59], ["complex", "OBSERVATION_MODIFIER", 63, 70]]], ["A negative effect of rodent density on the mean larval intensity per host has been previously observed (Kiffner et al., 2011; Perkins et al., 2003) , but in another study, an increase of the total number of feeding larvae on rodents recorded in a year was positively correlated with rodent density (Ros\u00e0 et al., 2007) .", [["rodent", "ORGANISM", 21, 27], ["rodent density", "PROBLEM", 21, 35], ["another study", "TEST", 157, 170], ["negative effect", "OBSERVATION_MODIFIER", 2, 17], ["rodent", "OBSERVATION_MODIFIER", 21, 27], ["density", "OBSERVATION", 28, 35], ["mean larval intensity", "OBSERVATION_MODIFIER", 43, 64], ["increase", "OBSERVATION_MODIFIER", 175, 183]]], ["Total larval density was higher in the years and trapping grids where rodent density was higher, while for nymphs no such effect was observed.", [["rodent", "ORGANISM", 70, 76], ["Total larval density", "PROBLEM", 0, 20], ["trapping grids", "PROBLEM", 49, 63], ["rodent density", "PROBLEM", 70, 84], ["nymphs", "PROBLEM", 107, 113], ["larval", "OBSERVATION_MODIFIER", 6, 12], ["density", "OBSERVATION", 13, 20], ["higher", "OBSERVATION_MODIFIER", 25, 31], ["rodent", "OBSERVATION_MODIFIER", 70, 76], ["density", "OBSERVATION", 77, 84], ["higher", "OBSERVATION_MODIFIER", 89, 95]]], ["The best explanatory variable for nymph density was the larval density in the previous year, confirming the discrete nature of tick demography (Ros\u00e0 et al., 2007) .", [["nymph density", "PROBLEM", 34, 47], ["larval density", "OBSERVATION_MODIFIER", 56, 70], ["discrete", "OBSERVATION_MODIFIER", 108, 116]]], ["In contrast to rodents, other large-and meso-wild and domestic mammals play an important role as hosts sustaining tick populations, therefore indirectly affecting the spatial and temporal distribution of TBE foci and infection hazard Knap and Av\u0161i\u010d-\u017dupanc, 2013; Jaenson et al., 2012 Jaenson et al., , 2018 .", [["infection", "DISEASE", 217, 226], ["domestic mammals", "ORGANISM", 54, 70], ["tick populations", "CELL", 114, 130], ["tick populations", "PROBLEM", 114, 130], ["TBE foci", "PROBLEM", 204, 212], ["infection", "PROBLEM", 217, 226], ["large", "OBSERVATION_MODIFIER", 30, 35], ["temporal", "OBSERVATION_MODIFIER", 179, 187], ["TBE foci", "OBSERVATION", 204, 212]]], ["The European continent has been characterized by contrasting trends in ungulate distribution and abundance in the last decades.", [["ungulate", "OBSERVATION_MODIFIER", 71, 79], ["distribution", "OBSERVATION_MODIFIER", 80, 92], ["abundance", "OBSERVATION_MODIFIER", 97, 106]]], ["After a generalized decline mostly due to over-harvesting, after the second world war this negative trend has been reversed.", [["a generalized decline", "PROBLEM", 6, 27], ["generalized", "OBSERVATION_MODIFIER", 8, 19], ["decline", "OBSERVATION", 20, 27]]], ["Factors such as socio-economic changes due to traditional agriculture abandonment and climate change drove forest re-expansion (e.g. Lindner et al., 2014 ; see also https://www.eea.europa.eu/data-and-maps/indicators/forest-growth-2/assessment, accessed May 27, 2019).", [["socio-economic changes", "PROBLEM", 16, 38], ["traditional agriculture abandonment", "TREATMENT", 46, 81], ["forest re-expansion", "TREATMENT", 107, 126]]], ["More recently, regulations for habitat conservation and wildlife harvest and management (Kerstin et al., 2008) , laid the seeds for a constant and solid re-growth of ungulate populations, especially deer, in terms of abundance and distribution (Apollonio et al., 2017) .", [["habitat conservation", "TREATMENT", 31, 51], ["wildlife harvest", "TREATMENT", 56, 72], ["management", "TREATMENT", 77, 87], ["a constant and solid re-growth of ungulate populations", "PROBLEM", 132, 186], ["wildlife harvest", "OBSERVATION", 56, 72], ["ungulate populations", "OBSERVATION", 166, 186]]], ["Deer density is known to affect local tick abundance, hence it plays an important role on tick-borne diseases hazard.", [["tick-borne diseases", "DISEASE", 90, 109], ["Deer", "GENE_OR_GENE_PRODUCT", 0, 4], ["density", "OBSERVATION", 5, 12]]], ["A number of studies focused on the evaluation of the effect of deer density on tick populations but the finding can change accordingly to the scale with an observed increase (Gilbert et al., 2012) or a decrease (Perkins et al., 2006) .", [["deer", "ORGANISM", 63, 67], ["deer", "SPECIES", 63, 67], ["the evaluation", "TEST", 31, 45], ["deer density on tick populations", "PROBLEM", 63, 95], ["the scale", "TEST", 138, 147], ["density", "OBSERVATION", 68, 75], ["increase", "OBSERVATION_MODIFIER", 165, 173], ["decrease", "OBSERVATION_MODIFIER", 202, 210]]], ["For TBEV, an empirical study performed in several sites in Europe using a case-control approach , and substantiated by a deterministic framework , showed that TBEV occurrence starts to decrease at a threshold value of deer density, consequently decreasing the tick burden on rodents.", [["TBEV", "DISEASE", 159, 163], ["TBEV", "ORGANISM", 159, 163], ["TBEV", "SPECIES", 4, 8], ["TBEV", "SPECIES", 159, 163], ["deer", "SPECIES", 218, 222], ["TBEV", "PROBLEM", 4, 8], ["an empirical study", "TEST", 10, 28], ["TBEV occurrence", "PROBLEM", 159, 174], ["the tick burden", "PROBLEM", 256, 271], ["TBEV", "OBSERVATION", 159, 163], ["decrease", "OBSERVATION_MODIFIER", 185, 193], ["density", "OBSERVATION", 223, 230], ["decreasing", "OBSERVATION_MODIFIER", 245, 255]]], ["However, an important aspect underlined by those suites of studies was the spatial scale at which hosts range at different densities, which in turn may affect the probability of contact with ticks and between ticks and different hosts .", [["densities", "OBSERVATION", 123, 132]]], ["Today, ungulate populations suffer contrasting conservation and distribution status at the global level, with local overabundance including, in some cases, the use of urbanized systems and city parks, to one extreme, and a discontinuous distribution affected by fragmentation and major barriers, to the other (Apollonio et al., 2017) .", [["ungulate populations", "PROBLEM", 7, 27], ["fragmentation", "OBSERVATION", 262, 275]]], ["This leads to isolated or poorly connected populations, where driving movements such as dispersal and migration are constrained.", [["poorly connected populations", "PROBLEM", 26, 54], ["poorly connected", "OBSERVATION_MODIFIER", 26, 42], ["populations", "OBSERVATION", 43, 54], ["migration", "OBSERVATION_MODIFIER", 102, 111]]], ["Moreover, since movement is an ecological process occurring in heterogeneous landscapes (Nathan et al., 2008) , the intense variation of spatio-temporal distribution of habitats (e.g., fragmentation), resources (e.g., change in vegetation productivity phenology, Pettorelli et al., 2005) , and climatic constraints (e.g., snow cover and snow melting cycles, Ossi et al., 2015) affects animal movement and distribution with profound consequences on disease hazard.Tick-borne encephalitis virus (TBEV)Tick borne pathogens like TBEV are dependent on hosts' movement, on top of their density and distribution, to emerge and persist in new environments.", [["Tick-borne encephalitis", "DISEASE", 463, 486], ["TBEV", "DISEASE", 525, 529], ["Tick-borne encephalitis virus", "ORGANISM", 463, 492], ["TBEV", "ORGANISM", 494, 498], ["Tick borne pathogens", "ORGANISM", 499, 519], ["TBEV", "ORGANISM", 525, 529], ["Tick-borne encephalitis virus", "SPECIES", 463, 492], ["Tick-borne encephalitis virus", "SPECIES", 463, 492], ["TBEV", "SPECIES", 494, 498], ["TBEV", "SPECIES", 525, 529], ["an ecological process", "PROBLEM", 28, 49], ["profound consequences on disease hazard", "PROBLEM", 423, 462], ["Tick-borne encephalitis virus", "PROBLEM", 463, 492], ["Tick borne pathogens", "PROBLEM", 499, 519], ["TBEV", "PROBLEM", 525, 529], ["heterogeneous", "OBSERVATION_MODIFIER", 63, 76], ["intense", "OBSERVATION_MODIFIER", 116, 123], ["temporal", "OBSERVATION_MODIFIER", 144, 152], ["distribution", "OBSERVATION_MODIFIER", 153, 165], ["TBEV", "OBSERVATION", 525, 529], ["density", "OBSERVATION", 580, 587], ["new", "OBSERVATION_MODIFIER", 631, 634]]], ["However, for the tick cycle to be completed, the scales of movement of different hosts shall overlap, so that feeding and questing ticks can be transferred from one host to the other through their presence and movements in their common habitat.", [["the tick cycle", "TEST", 13, 27]]], ["Overabundance of secondary hosts, such as deer, may increase tick availability and thus correlate with TBEV occurrence Knap and Av\u0161i\u010d-\u017dupanc, 2013) , but not necessarily correspond to local TBEV emergence via tick-removal from overlapping competent hosts .", [["TBEV", "ORGANISM", 190, 194], ["deer", "SPECIES", 42, 46], ["TBEV", "SPECIES", 103, 107], ["TBEV", "SPECIES", 190, 194], ["tick-removal", "TREATMENT", 209, 221], ["TBEV", "OBSERVATION", 190, 194]]], ["In fact, changes in infection hazard can be converted in increased infection risk when a co-occurrence of factors, such as changes in deer abundance and favourable climatic conditions or socio economic drivers, increase exposure of people to infected ticks, as seen in Europe during the last decades (Godfrey and Randolph, 2011; Jaenson et al., 2012 Jaenson et al., , 2018 .Tick-borne encephalitis virus (TBEV)Indeed, further research is needed to disentangle the effects of movement and space use of different hosts on tick-borne pathogens transmission, including TBEV, to better understand the scale at which transmission and potential dilution processes interact by producing new knowledge on the tick-host choice and virus transmission in different hosts.West Nile Virus (WNV)WNV is a neurotropic mosquito-borne virus belonging to the Flavivirus genus and Japanese encephalitis virus serogroup which was firstly isolated in Uganda in 1937 and that currently has reached a widespread distribution throughout the world.", [["infection", "DISEASE", 20, 29], ["infection", "DISEASE", 67, 76], ["infected ticks", "DISEASE", 242, 256], ["Tick-borne encephalitis", "DISEASE", 374, 397], ["West Nile Virus (WNV)WNV", "DISEASE", 759, 783], ["Flavivirus genus", "DISEASE", 839, 855], ["Japanese encephalitis", "DISEASE", 860, 881], ["people", "ORGANISM", 232, 238], ["Tick-borne encephalitis virus", "ORGANISM", 374, 403], ["West Nile Virus (WNV)WNV", "ORGANISM", 759, 783], ["neurotropic", "ORGANISM", 789, 800], ["mosquito-borne virus", "ORGANISM", 801, 821], ["Flavivirus genus", "ORGANISM", 839, 855], ["Japanese encephalitis virus", "ORGANISM", 860, 887], ["people", "SPECIES", 232, 238], ["Tick-borne encephalitis virus", "SPECIES", 374, 403], ["West Nile Virus", "SPECIES", 759, 774], ["mosquito-borne virus", "SPECIES", 801, 821], ["Japanese encephalitis virus serogroup", "SPECIES", 860, 897], ["deer", "SPECIES", 134, 138], ["Tick-borne encephalitis virus", "SPECIES", 374, 403], ["TBEV", "SPECIES", 405, 409], ["TBEV", "SPECIES", 565, 569], ["West Nile Virus", "SPECIES", 759, 774], ["WNV", "SPECIES", 776, 779], ["WNV", "SPECIES", 780, 783], ["neurotropic mosquito-borne virus", "SPECIES", 789, 821], ["Japanese encephalitis virus", "SPECIES", 860, 887], ["changes in infection hazard", "PROBLEM", 9, 36], ["increased infection risk", "PROBLEM", 57, 81], ["Tick-borne encephalitis virus", "PROBLEM", 374, 403], ["the tick-host choice", "TREATMENT", 696, 716], ["WNV", "PROBLEM", 780, 783], ["a neurotropic mosquito-borne virus", "PROBLEM", 787, 821], ["the Flavivirus genus", "PROBLEM", 835, 855], ["Japanese encephalitis virus serogroup", "PROBLEM", 860, 897], ["infection", "OBSERVATION", 20, 29], ["increased", "OBSERVATION_MODIFIER", 57, 66], ["infection", "OBSERVATION", 67, 76], ["Flavivirus genus", "ANATOMY", 839, 855], ["widespread", "OBSERVATION_MODIFIER", 976, 986], ["distribution", "OBSERVATION_MODIFIER", 987, 999]]], ["WNV is transmitted by mosquitoes, with a wide variety of bird species acting as natural reservoir hosts, amplifying the virus.", [["WNV", "DISEASE", 0, 3], ["WNV", "ORGANISM", 0, 3], ["WNV", "SPECIES", 0, 3], ["WNV", "PROBLEM", 0, 3], ["bird species", "PROBLEM", 57, 69], ["natural reservoir hosts", "TREATMENT", 80, 103], ["the virus", "PROBLEM", 116, 125], ["bird species", "OBSERVATION", 57, 69]]], ["WNV can also affect a range of vertebrate species, including amphibians, reptiles and mammals.", [["WNV", "DISEASE", 0, 3], ["WNV", "ORGANISM", 0, 3], ["WNV", "SPECIES", 0, 3], ["WNV", "PROBLEM", 0, 3], ["vertebrate species", "PROBLEM", 31, 49], ["vertebrate species", "OBSERVATION", 31, 49]]], ["It is particularly pathogenic in humans and horses, which act as 'dead-end hosts' as they do not develop viraemia levels sufficiently high to efficiently transmit the virus to a new vector (P\u00e9rez-Ram\u00edrez et al., 2017) .West Nile Virus (WNV)Two main genetic variants or lineages can be distinguished, namely lineages 1 and 2 (L1 and L2).", [["viraemia", "DISEASE", 105, 113], ["West Nile Virus", "DISEASE", 219, 234], ["humans", "ORGANISM", 33, 39], ["horses", "ORGANISM_SUBDIVISION", 44, 50], ["West Nile Virus", "ORGANISM", 219, 234], ["WNV", "ORGANISM", 236, 239], ["humans", "SPECIES", 33, 39], ["West Nile Virus", "SPECIES", 219, 234], ["humans", "SPECIES", 33, 39], ["West Nile Virus", "SPECIES", 219, 234], ["WNV", "SPECIES", 236, 239], ["viraemia levels", "TEST", 105, 120], ["West Nile Virus (WNV", "PROBLEM", 219, 239], ["pathogenic", "OBSERVATION_MODIFIER", 19, 29], ["L1", "ANATOMY_MODIFIER", 325, 327], ["L2", "ANATOMY_MODIFIER", 332, 334]]], ["L1 includes most of the strains isolated in Africa, Europe, Asia, Oceania (Kunjin isolates) and North America.", [["L1", "DNA", 0, 2], ["the strains", "PROBLEM", 20, 31], ["strains", "OBSERVATION", 24, 31]]], ["L2 was mainly restricted to Africa, but it has recently been introduced in Central and Eastern Europe and extended further into Southern Europe.", [["mainly", "OBSERVATION_MODIFIER", 7, 13], ["restricted", "OBSERVATION", 14, 24], ["Africa", "OBSERVATION", 28, 34], ["Central", "OBSERVATION_MODIFIER", 75, 82]]], ["Other viral variants have been isolated in different parts of the world and have been proposed as different lineages.", [["Other viral variants", "PROBLEM", 0, 20], ["viral variants", "OBSERVATION", 6, 20]]], ["Differences in pathogenicity among strains do not correlate with phylogenetic lineage or geographic origin, and confirmed that recent European and African WNV strains belonging to L1 and L2 are highly virulent and do not differ in their pathotype profile compared to the prototype NY99 strain (Perez-Ramirez et al., 2017) .West Nile Virus (WNV)WNV is a significant burden for public health in Europe, as it caused hundreds of cases during the last decade, mostly in the Southern part of the continent (https://ecdc.europa.eu/en/west-nile-fever, accessed May 27, 2019).", [["West Nile Virus (WNV)WNV", "DISEASE", 323, 347], ["African WNV strains", "ORGANISM", 147, 166], ["NY99 strain", "ORGANISM", 281, 292], ["West Nile Virus", "ORGANISM", 323, 338], ["WNV", "ORGANISM", 340, 343], ["WNV", "ORGANISM", 344, 347], ["L1", "DNA", 180, 182], ["L2", "DNA", 187, 189], ["West Nile Virus", "SPECIES", 323, 338], ["WNV", "SPECIES", 155, 158], ["West Nile Virus", "SPECIES", 323, 338], ["WNV", "SPECIES", 340, 343], ["WNV", "SPECIES", 344, 347], ["pathogenicity among strains", "PROBLEM", 15, 42], ["recent European and African WNV strains", "PROBLEM", 127, 166], ["highly virulent", "PROBLEM", 194, 209], ["WNV", "PROBLEM", 344, 347], ["L1", "ANATOMY", 180, 182], ["L2", "ANATOMY", 187, 189], ["virulent", "OBSERVATION", 201, 209], ["significant", "OBSERVATION_MODIFIER", 353, 364], ["burden", "OBSERVATION_MODIFIER", 365, 371]]], ["While most human infections are asymptomatic, about 25% of the infections develop symptoms such as fever and headache and less than 1% more severe neurological diseases (Barzon, 2018) .West Nile Virus (WNV)Phylogenetic studies on WNV strains isolated from several European countries indicate that the virus has established in Europe and is likely to having been introduced by migratory birds previously infected in Africa (Paz and Semenza, 2013) .West Nile Virus (WNV)Several mosquito genera are competent for WNV transmission; however, mosquitoes belonging to the Culex pipiens complex and their hybrids play a central role in modulating the virus circulation and the seasonal shifts among birds and humans .West Nile Virus (WNV)We have observed that VC M is substantially driven by the vector to host ratio, which in turn is proportionally affected by both Culex spp mosquito and avian abundances.", [["neurological", "ANATOMY", 147, 159], ["hybrids", "ANATOMY", 597, 604], ["human infections", "DISEASE", 11, 27], ["infections", "DISEASE", 63, 73], ["fever", "DISEASE", 99, 104], ["headache", "DISEASE", 109, 117], ["neurological diseases", "DISEASE", 147, 168], ["West Nile Virus", "DISEASE", 447, 462], ["WNV transmission", "DISEASE", 510, 526], ["human", "ORGANISM", 11, 16], ["West Nile Virus", "ORGANISM", 185, 200], ["WNV", "ORGANISM", 202, 205], ["WNV strains", "ORGANISM", 230, 241], ["birds", "ORGANISM", 386, 391], ["West Nile Virus", "ORGANISM", 447, 462], ["WNV", "ORGANISM", 464, 467], ["WNV", "ORGANISM", 510, 513], ["Culex pipiens", "ORGANISM", 565, 578], ["humans", "ORGANISM", 701, 707], ["West Nile Virus", "ORGANISM", 709, 724], ["WNV", "ORGANISM", 726, 729], ["Culex spp mosquito", "ORGANISM", 859, 877], ["avian", "ORGANISM", 882, 887], ["Culex pipiens complex", "PROTEIN", 565, 586], ["human", "SPECIES", 11, 16], ["West Nile Virus", "SPECIES", 185, 200], ["West Nile Virus", "SPECIES", 447, 462], ["Culex pipiens", "SPECIES", 565, 578], ["humans", "SPECIES", 701, 707], ["West Nile Virus", "SPECIES", 709, 724], ["human", "SPECIES", 11, 16], ["West Nile Virus", "SPECIES", 185, 200], ["WNV", "SPECIES", 202, 205], ["WNV", "SPECIES", 230, 233], ["West Nile Virus", "SPECIES", 447, 462], ["WNV", "SPECIES", 464, 467], ["WNV", "SPECIES", 510, 513], ["Culex pipiens", "SPECIES", 565, 578], ["humans", "SPECIES", 701, 707], ["West Nile Virus", "SPECIES", 709, 724], ["WNV", "SPECIES", 726, 729], ["Culex spp mosquito", "SPECIES", 859, 877], ["asymptomatic", "PROBLEM", 32, 44], ["the infections", "PROBLEM", 59, 73], ["symptoms", "PROBLEM", 82, 90], ["fever", "PROBLEM", 99, 104], ["headache", "PROBLEM", 109, 117], ["less than 1% more severe neurological diseases", "PROBLEM", 122, 168], ["West Nile Virus (WNV", "PROBLEM", 185, 205], ["Phylogenetic studies", "TEST", 206, 226], ["WNV strains", "PROBLEM", 230, 241], ["the virus", "PROBLEM", 297, 306], ["WNV transmission", "PROBLEM", 510, 526], ["the Culex pipiens complex", "PROBLEM", 561, 586], ["the virus circulation", "PROBLEM", 639, 660], ["infections", "OBSERVATION", 17, 27], ["severe", "OBSERVATION_MODIFIER", 140, 146], ["neurological diseases", "OBSERVATION", 147, 168], ["virus", "OBSERVATION", 301, 306], ["likely to", "UNCERTAINTY", 340, 349], ["virus", "OBSERVATION", 643, 648]]], ["Climatic changes might substantially alter mosquito density and dynamics since temperature plays a key role at shaping the biological processes involved in the mosquito life cycle.", [["Climatic changes", "PROBLEM", 0, 16]]], ["In fact, warmer conditions hasten Culex spp immature stages development (Loetti et al., 2011) but can also substantially decrease mosquito longevity (Ciota et al., 2014; Andreadis et al., 2014) .", [["warmer conditions", "TREATMENT", 9, 26]]], ["Modelling studies have been performed to assess the possible impact of temperature change on Culex spp abundance.", [["Culex spp", "ORGANISM", 93, 102], ["Modelling studies", "TEST", 0, 17], ["temperature change", "PROBLEM", 71, 89]]], ["For instance, it has been shown that in Southern Europe higher temperatures throughout the year can decrease Culex spp adult survival during summer but at the same time increase considerably spring population size (Marini et al., 2016) , while at Northern latitudes, changes in temperatures could increase the peak vector abundance (Ewing et al., 2016) .", [["changes in temperatures", "PROBLEM", 267, 290], ["size", "OBSERVATION_MODIFIER", 209, 213]]], ["Urbanization, land use and human activities might influence mosquito dynamics as well.", [["human", "ORGANISM", 27, 32], ["human", "SPECIES", 27, 32], ["human", "SPECIES", 27, 32], ["human activities", "TREATMENT", 27, 43]]], ["It has been observed that Culex spp mosquitoes proliferate well both in agricultural and urban areas (McClure et al., 2018; Ferraguti et al., 2016; Johnson et al., 2012; Zittra et al., 2016; Trawinski and Mackay, 2010; Diuk-Wasser et al., 2006) , and anthropized environments might favor an earlier peak larval density thanks to a urban heat island effect (Townroe and Callaghan, 2014) .West Nile Virus (WNV)Climate change is influencing avian populations as well (Lindstr\u00f6m et al., 2013) .", [["West Nile Virus", "DISEASE", 387, 402], ["Culex spp mosquitoes", "ORGANISM", 26, 46], ["West Nile Virus", "ORGANISM", 387, 402], ["WNV", "ORGANISM", 404, 407], ["avian", "ORGANISM", 438, 443], ["Nile Virus", "SPECIES", 392, 402], ["Culex spp mosquitoes", "SPECIES", 26, 46], ["West Nile Virus", "SPECIES", 387, 402], ["WNV", "SPECIES", 404, 407], ["an earlier peak larval density", "PROBLEM", 288, 318]]], ["For instance, American southern species, originally adapted to warm conditions, are now more present also at northern latitudes (Princ\u00e9 and Zuckerberg, 2015) , while also northern European bird communities would benefit from local climate warming (Jiguet et al., 2010) .", [["local climate warming", "TREATMENT", 225, 246]]], ["In addition, migratory behaviors are influenced by temperatures rise (Potvin et al., 2016) which might lead WNV to be introduced in previously unaffected areas (Bessell et al., 2016) .", [["WNV", "ORGANISM", 108, 111], ["WNV", "SPECIES", 108, 111], ["temperatures rise", "PROBLEM", 51, 68]]], ["Finally, it has been shown that land use changes caused by human activities influence bird species richness and abundance as well (Rittenhouse et al., 2012; Bowler et al., 2018) thus eventually affecting the vector to host ratio.West Nile Virus (WNV)Two other parameters determining the vectorial capacity, namely the extrinsic incubation period and the biting rate, are strongly influenced by temperature.", [["human", "ORGANISM", 59, 64], ["West Nile Virus", "ORGANISM", 229, 244], ["WNV", "ORGANISM", 246, 249], ["human", "SPECIES", 59, 64], ["West Nile Virus", "SPECIES", 229, 244], ["human", "SPECIES", 59, 64], ["West Nile Virus", "SPECIES", 229, 244], ["WNV", "SPECIES", 246, 249], ["the vectorial capacity", "PROBLEM", 283, 305], ["the biting rate", "TEST", 350, 365], ["vectorial capacity", "OBSERVATION", 287, 305]]], ["In fact, the extrinsic incubation period n is shorter and the biting rate a is larger with warmer conditions (Reisen et al., 2006; Ewing et al., 2016) .", [["larger", "OBSERVATION_MODIFIER", 79, 85]]], ["Since some mosquito species are generalist and express opportunistic feeding behaviour, while others are specialists and feed preferentially on selected hosts (Burkett-Cadena et al., 2008; Farajollahi et al., 2011) , we remark that the mosquito biting rate can also be influenced by the avian density and heterogeneity, which are sensitive to environmental changes as we have observed above.", [["mosquito", "ORGANISM", 236, 244], ["the mosquito biting rate", "PROBLEM", 232, 256], ["density", "OBSERVATION", 293, 300]]], ["Studies of mosquito feeding preferences have been essential to understand the ecology of WNV.", [["WNV", "DISEASE", 89, 92], ["WNV", "ORGANISM", 89, 92], ["WNV", "SPECIES", 89, 92]]], ["Combining analysis of host preference, abundance, host behaviour and reservoir competence, Kilpatrick et al. (2006) demonstrated that the American robin (Turdus migratorius) acted as an unexpected 'super-spreader' of the WNV in North America.", [["WNV", "DISEASE", 221, 224], ["Turdus migratorius", "ORGANISM", 154, 172], ["WNV", "ORGANISM", 221, 224], ["Turdus migratorius", "SPECIES", 154, 172], ["American robin", "SPECIES", 138, 152], ["Turdus migratorius", "SPECIES", 154, 172], ["WNV", "SPECIES", 221, 224], ["the American robin (Turdus migratorius)", "TREATMENT", 134, 173]]], ["In Europe, for the first time, Rizzoli et al. (2015) demonstrated a clear feeding preference for the common blackbird (Turdus merula), both for wild collected specimens and in the lab, suggesting a potential important role for this species in the WNV epidemiology in Northern Italy.", [["specimens", "ANATOMY", 159, 168], ["WNV", "DISEASE", 247, 250], ["Turdus merula", "ORGANISM", 119, 132], ["Turdus merula", "SPECIES", 119, 132], ["Turdus merula", "SPECIES", 119, 132], ["WNV", "SPECIES", 247, 250], ["the common blackbird (Turdus merula", "PROBLEM", 97, 132], ["wild collected specimens", "TEST", 144, 168], ["this species", "PROBLEM", 227, 239]]], ["In addition, they found that later in the mosquitoes activity season (from July to October), the abundance of blackbird drops significantly and Cx. pipiens s.l. preferences shift toward the Eurasian magpie (Pica pica), especially in sites closer to human settlements, indicating that this species may contribute to WNV seasonal spill-over events to human and domestic animal species .Conclusions and perspectivesWe are now facing great challenges such as human population growth, climate change, land use and biodiversity loss which all act as drivers for changes in host-parasite interaction and the emergence of a number of wildlife zoonotic diseases as observed during the last decades.", [["zoonotic diseases", "DISEASE", 635, 652], ["human", "ORGANISM", 249, 254], ["WNV", "ORGANISM", 315, 318], ["human", "ORGANISM", 349, 354], ["human", "ORGANISM", 455, 460], ["human", "SPECIES", 249, 254], ["human", "SPECIES", 349, 354], ["human", "SPECIES", 455, 460], ["Cx. pipiens", "SPECIES", 144, 155], ["Eurasian magpie", "SPECIES", 190, 205], ["human", "SPECIES", 249, 254], ["WNV", "SPECIES", 315, 318], ["human", "SPECIES", 349, 354], ["human", "SPECIES", 455, 460], ["blackbird drops", "PROBLEM", 110, 125], ["this species", "PROBLEM", 284, 296], ["WNV seasonal spill", "PROBLEM", 315, 333], ["human population growth", "TREATMENT", 455, 478], ["biodiversity loss", "PROBLEM", 509, 526], ["parasite interaction", "PROBLEM", 572, 592], ["wildlife zoonotic diseases", "PROBLEM", 626, 652]]], ["Zoonotic spillover is a complex phenomenon which requires several factors to align, including the ecological, epidemiological and behavioural determinants of pathogen exposure, and the within-human factors that affect susceptibility to infection so that all zoonotic pathogens must overcome a hierarchical series of barriers to cause spillover infections in humans.", [["infection", "DISEASE", 236, 245], ["zoonotic pathogens", "DISEASE", 258, 276], ["spillover infections", "DISEASE", 334, 354], ["human", "ORGANISM", 192, 197], ["humans", "ORGANISM", 358, 364], ["human", "SPECIES", 192, 197], ["humans", "SPECIES", 358, 364], ["human", "SPECIES", 192, 197], ["humans", "SPECIES", 358, 364], ["a complex phenomenon", "PROBLEM", 22, 42], ["pathogen exposure", "PROBLEM", 158, 175], ["susceptibility to infection", "PROBLEM", 218, 245], ["all zoonotic pathogens", "PROBLEM", 254, 276], ["spillover infections in humans", "PROBLEM", 334, 364], ["complex", "OBSERVATION_MODIFIER", 24, 31], ["phenomenon", "OBSERVATION", 32, 42], ["infection", "OBSERVATION", 236, 245], ["spillover infections", "OBSERVATION", 334, 354]]], ["Understanding how these barriers are functionally and quantitatively linked, and how they interact in space and time, will substantially improve our ability to predict or prevent spillover events (Plowright et al., 2017) .Conclusions and perspectivesVector borne diseases are particularly sensitive to anthropogenic changes and their transmission is a complex non-linear process, which poses several challenges (Hollingsworth et al., 2015) .", [["Vector borne diseases", "DISEASE", 250, 271], ["spillover events", "PROBLEM", 179, 195], ["Vector borne diseases", "PROBLEM", 250, 271], ["anthropogenic changes", "PROBLEM", 302, 323], ["a complex non-linear process", "PROBLEM", 350, 378]]], ["Rarely such information and integration among levels is available.Conclusions and perspectivesThe rapidity of changes in environmental condition should require a similar speed in the way wildlife parasitologists approach the assessment of changes and the rise in vector-borne diseases hazard.", [["changes in environmental condition", "PROBLEM", 110, 144], ["the assessment", "TEST", 221, 235], ["rapidity", "OBSERVATION_MODIFIER", 98, 106]]], ["In turn, big data handling and interpretation necessarily requires an integrated and interdisciplinary approach under a One Health perspective (Vayssier-Taussat et al., 2015; Ezenwa et al., 2015; Kosoy and Kosoy, 2018) .Conclusions and perspectivesThe multi-host ecology of zoonoses leads to complex dynamics, and both empirical and analytical tools are vital to the development of effective control policies and research agendas.", [["zoonoses", "DISEASE", 274, 282], ["effective control policies", "TREATMENT", 382, 408]]], ["Much attention has focused on modelling pathogens with simpler life cycles and immediate global urgency, such as influenza and severe acute respiratory syndrome (SARS).", [["influenza", "DISEASE", 113, 122], ["acute respiratory syndrome", "DISEASE", 134, 160], ["SARS", "DISEASE", 162, 166], ["modelling pathogens", "PROBLEM", 30, 49], ["simpler life cycles", "TREATMENT", 55, 74], ["immediate global urgency", "PROBLEM", 79, 103], ["influenza", "PROBLEM", 113, 122], ["severe acute respiratory syndrome", "PROBLEM", 127, 160], ["global", "OBSERVATION_MODIFIER", 89, 95], ["urgency", "OBSERVATION", 96, 103], ["severe", "OBSERVATION_MODIFIER", 127, 133], ["acute", "OBSERVATION_MODIFIER", 134, 139], ["respiratory syndrome", "OBSERVATION", 140, 160]]], ["Meanwhile, vector-transmitted, chronic, and protozoan infections have been less studied.", [["protozoan infections", "DISEASE", 44, 64], ["protozoan infections", "PROBLEM", 44, 64], ["chronic", "OBSERVATION_MODIFIER", 31, 38], ["protozoan", "OBSERVATION_MODIFIER", 44, 53], ["infections", "OBSERVATION", 54, 64], ["less studied", "OBSERVATION_MODIFIER", 75, 87]]], ["Progress in understanding and fighting zoonoses requires a new generation of models that addresses a broader set of pathogen life histories and integrates across host species and scientific disciplines (Lloyd-Smith et al., 2009 ), especially considering that these infections often rely on cross-species transmission.Conclusions and perspectivesBecause of the high number of factors implicated in the transmission of vector borne pathogens and the complexity of their transmission cycles, the forecasting of vector-borne disease hazards under a global change scenario is particularly challenging and the development of predictive models requires the intensification of the research efforts aimed at better understanding how changes in vector-host interaction in wildlife can alter the vectorial capacity with the establishment of long term studies based on a multidisciplinary approach under a One-Health framework.Conflict of interest declarationThe study described is original and is not under consideration by any other journal.", [["zoonoses", "DISEASE", 39, 47], ["infections", "DISEASE", 265, 275], ["these infections", "PROBLEM", 259, 275], ["vector borne pathogens", "PROBLEM", 417, 439], ["their transmission cycles", "TREATMENT", 462, 487], ["borne disease hazards", "PROBLEM", 515, 536], ["a global change scenario", "PROBLEM", 543, 567], ["long term studies", "TEST", 830, 847], ["The study", "TEST", 947, 956], ["infections", "OBSERVATION", 265, 275], ["high", "OBSERVATION_MODIFIER", 360, 364]]]], "ccb3945ab082e7fa801464934f6124815dca5f2b": [["DISCARDED COVID 19 GEAR: A LOOMING THREATThe current outbreak of Covid19 heralds a public health emergency of global concern.", [["Covid19", "CHEMICAL", 65, 72]]], ["The individuals afflicted with Covid19 have created a black swan event 1 , strangling the economy.DISCARDED COVID 19 GEAR: A LOOMING THREATThe race against the novel coronavirus has gained traction with the government on a knifeedge to crush the curve by implementing social distancing; the only vaccination currently to curb its spread.DISCARDED COVID 19 GEAR: A LOOMING THREATThe virus has rejuvenated Nature, while the human activity was at a standstill due to the global lockdown.", [["Covid19", "CHEMICAL", 31, 38], ["coronavirus", "DISEASE", 166, 177], ["coronavirus", "ORGANISM", 166, 177], ["human", "ORGANISM", 422, 427], ["human", "SPECIES", 422, 427], ["human", "SPECIES", 422, 427], ["Covid19", "TREATMENT", 31, 38], ["a black swan event", "PROBLEM", 52, 70], ["the novel coronavirus", "PROBLEM", 156, 177], ["vaccination", "TREATMENT", 296, 307], ["the global lockdown", "PROBLEM", 464, 483], ["virus", "OBSERVATION", 382, 387]]], ["Epidemiologists are now concerned about the Covid19 protective gear that are in a surplus production but maybe indecorously disposed and may spark an additional epidemic who are yet to be sensitisised of its safe disposal.A triad of vigilant well-informed community on how to rationally use 'safety gear' ,doctors and strict reinforcement of safe handling of the heap of biomedical waste must be undertaken to stem the repercussions of this unprecedented crisis.", [["the heap of biomedical waste", "TREATMENT", 359, 387]]]], "PMC7102703": [["IntroductionCoronaviruses (CoVs) are a family of enveloped viruses containing a positive-sense RNA genome.", [["IntroductionCoronaviruses", "GENE_OR_GENE_PRODUCT", 0, 25], ["CoVs", "GENE_OR_GENE_PRODUCT", 27, 31], ["IntroductionCoronaviruses", "PROTEIN", 0, 25], ["CoVs", "PROTEIN", 27, 31], ["positive-sense RNA genome", "DNA", 80, 105], ["enveloped viruses", "PROBLEM", 49, 66], ["RNA genome", "OBSERVATION", 95, 105]]], ["CoVs belong to the family Coronaviridae within the order Nidovirales.", [["CoVs", "GENE_OR_GENE_PRODUCT", 0, 4], ["CoVs", "PROTEIN", 0, 4]]], ["The Coronaviridae, henceforth referred to as CoVs, infect a broad range of vertebrates including mammals and birds.", [["CoVs", "GENE_OR_GENE_PRODUCT", 45, 49], ["birds", "ORGANISM", 109, 114]]], ["Of the six CoV strains isolated from humans, four strains (HCoV-229E, HCoV-NL63, HCoV-HKU1, and HCoV-OC43) cause a usually mild self-limiting upper respiratory infection accounting for an estimated 15\u201329% of common colds [1].", [["respiratory", "ANATOMY", 148, 159], ["respiratory infection", "DISEASE", 148, 169], ["colds", "DISEASE", 215, 220], ["CoV", "ORGANISM", 11, 14], ["humans", "ORGANISM", 37, 43], ["HCoV-229E", "ORGANISM", 59, 68], ["HCoV-NL63", "ORGANISM", 70, 79], ["HCoV-HKU1", "ORGANISM", 81, 90], ["HCoV-OC43", "ORGANISM", 96, 105], ["upper respiratory", "ORGANISM_SUBDIVISION", 142, 159], ["humans", "SPECIES", 37, 43], ["humans", "SPECIES", 37, 43], ["HCoV-229E", "SPECIES", 59, 68], ["the six CoV strains", "PROBLEM", 3, 22], ["four strains", "TEST", 45, 57], ["HCoV", "TEST", 59, 63], ["HCoV", "TEST", 70, 74], ["HCoV", "TEST", 81, 85], ["HKU1", "TEST", 86, 90], ["HCoV", "TEST", 96, 100], ["a usually mild self-limiting upper respiratory infection", "PROBLEM", 113, 169], ["common colds", "PROBLEM", 208, 220], ["six CoV", "OBSERVATION_MODIFIER", 7, 14], ["mild", "OBSERVATION_MODIFIER", 123, 127], ["upper", "ANATOMY_MODIFIER", 142, 147], ["respiratory", "ANATOMY", 148, 159], ["infection", "OBSERVATION", 160, 169]]], ["Two other human CoV strains have produced more serious respiratory disease epidemics in recent years.", [["respiratory", "ANATOMY", 55, 66], ["respiratory disease epidemics", "DISEASE", 55, 84], ["human", "ORGANISM", 10, 15], ["CoV", "ORGANISM", 16, 19], ["human", "SPECIES", 10, 15], ["human CoV", "SPECIES", 10, 19], ["Two other human CoV strains", "PROBLEM", 0, 27], ["serious respiratory disease epidemics", "PROBLEM", 47, 84], ["CoV strains", "OBSERVATION", 16, 27], ["more", "OBSERVATION_MODIFIER", 42, 46], ["serious", "OBSERVATION_MODIFIER", 47, 54], ["respiratory disease", "OBSERVATION", 55, 74]]], ["Severe acute respiratory syndrome (SARS)-CoV originated in China in 2002 and 2003 and spread to a total of 37 countries, causing more than 8000 cases of SARS with an estimated fatality rate of 9% [2].", [["acute respiratory syndrome (SARS)-CoV", "DISEASE", 7, 44], ["SARS", "DISEASE", 153, 157], ["Severe acute respiratory syndrome (SARS)-CoV", "SPECIES", 0, 44], ["Severe acute respiratory syndrome", "PROBLEM", 0, 33], ["SARS", "PROBLEM", 35, 39], ["CoV", "PROBLEM", 41, 44], ["SARS", "PROBLEM", 153, 157], ["an estimated fatality rate", "TEST", 163, 189], ["acute", "OBSERVATION_MODIFIER", 7, 12], ["respiratory syndrome", "OBSERVATION", 13, 33]]], ["The cause of an ongoing epidemic of Middle East respiratory syndrome, MERS-CoV was first identified in Saudi Arabia in 2012 and to date has caused more than 2374 cases in 27 countries with a fatality rate >34% [3,4].", [["Middle East respiratory syndrome", "DISEASE", 36, 68], ["MERS-CoV", "ORGANISM", 70, 78], ["Middle East respiratory syndrome, MERS-CoV", "SPECIES", 36, 78], ["Middle East respiratory syndrome", "PROBLEM", 36, 68], ["a fatality rate", "TEST", 189, 204], ["Middle", "ANATOMY_MODIFIER", 36, 42], ["respiratory syndrome", "OBSERVATION", 48, 68]]], ["The use of human host cell receptors by both human and bat CoVs supports predictions of significant risk for emergence of new potential pandemic zoonotic CoVs [5,6].", [["cell", "ANATOMY", 22, 26], ["human", "ORGANISM", 11, 16], ["host cell", "CELL", 17, 26], ["human", "ORGANISM", 45, 50], ["bat CoVs", "ORGANISM", 55, 63], ["human host cell receptors", "PROTEIN", 11, 36], ["human", "SPECIES", 11, 16], ["human", "SPECIES", 45, 50], ["human", "SPECIES", 11, 16], ["human", "SPECIES", 45, 50], ["human host cell receptors", "TREATMENT", 11, 36], ["new potential pandemic zoonotic CoVs", "PROBLEM", 122, 158]]], ["Notably, no vaccines or antiviral compounds are approved for prevention or treatment of human or potential zoonotic CoVs.", [["zoonotic CoVs", "DISEASE", 107, 120], ["human", "ORGANISM", 88, 93], ["CoVs", "CANCER", 116, 120], ["human", "SPECIES", 88, 93], ["human", "SPECIES", 88, 93], ["vaccines", "TREATMENT", 12, 20], ["antiviral compounds", "TREATMENT", 24, 43], ["treatment", "TREATMENT", 75, 84], ["potential zoonotic CoVs", "PROBLEM", 97, 120], ["no", "UNCERTAINTY", 9, 11], ["vaccines", "OBSERVATION", 12, 20], ["antiviral compounds", "OBSERVATION", 24, 43], ["zoonotic CoVs", "OBSERVATION", 107, 120]]], ["Emerging CoVs have been accorded priority status by WHO and government agencies for development of prevention and treatment strategies due to severity of these infections and credible pandemic potential [7, 8, 9].", [["infections", "DISEASE", 160, 170], ["CoVs", "GENE_OR_GENE_PRODUCT", 9, 13], ["prevention", "TREATMENT", 99, 109], ["treatment strategies", "TREATMENT", 114, 134], ["these infections", "PROBLEM", 154, 170], ["infections", "OBSERVATION", 160, 170]]], ["This review will focus on opportunities for and challenges to development of antiviral nucleoside and nucleotide analogues targeting viral RNA synthesis as effective therapeutics against CoV infections.CoV antiviral strategiesDrugs currently under investigation for use against CoV disease include monoclonal antibodies; direct-acting antivirals (DAAs) including as protease, helicase, and polymerase inhibitors; and immunomodulators such as interferons and corticosteroids.", [["nucleoside", "CHEMICAL", 87, 97], ["nucleotide", "CHEMICAL", 102, 112], ["CoV infections", "DISEASE", 187, 201], ["CoV disease", "DISEASE", 278, 289], ["nucleoside", "CHEMICAL", 87, 97], ["nucleotide", "CHEMICAL", 102, 112], ["corticosteroids", "CHEMICAL", 458, 473], ["nucleoside", "SIMPLE_CHEMICAL", 87, 97], ["nucleotide analogues", "SIMPLE_CHEMICAL", 102, 122], ["CoV", "ORGANISM", 187, 190], ["CoV", "ORGANISM", 202, 205], ["CoV", "ORGANISM", 278, 281], ["direct-acting antivirals", "SIMPLE_CHEMICAL", 321, 345], ["DAAs", "SIMPLE_CHEMICAL", 347, 351], ["interferons", "GENE_OR_GENE_PRODUCT", 442, 453], ["corticosteroids", "SIMPLE_CHEMICAL", 458, 473], ["monoclonal antibodies", "PROTEIN", 298, 319], ["protease", "PROTEIN", 366, 374], ["helicase", "PROTEIN", 376, 384], ["interferons", "PROTEIN", 442, 453], ["CoV", "SPECIES", 187, 190], ["CoV", "SPECIES", 278, 281], ["antiviral nucleoside", "TREATMENT", 77, 97], ["nucleotide analogues", "TREATMENT", 102, 122], ["viral RNA synthesis", "TREATMENT", 133, 152], ["CoV infections", "PROBLEM", 187, 201], ["CoV antiviral strategiesDrugs", "TREATMENT", 202, 231], ["CoV disease", "PROBLEM", 278, 289], ["monoclonal antibodies", "TREATMENT", 298, 319], ["direct-acting antivirals (DAAs", "TREATMENT", 321, 351], ["protease", "TREATMENT", 366, 374], ["helicase", "TREATMENT", 376, 384], ["polymerase inhibitors", "TREATMENT", 390, 411], ["immunomodulators", "TREATMENT", 417, 433], ["interferons", "TREATMENT", 442, 453], ["corticosteroids", "TREATMENT", 458, 473]]], ["Challenges to CoV antivirals development are both general to RNA viruses and specific to CoVs.", [["CoV", "ORGANISM", 14, 17], ["CoVs", "GENE_OR_GENE_PRODUCT", 89, 93], ["CoVs", "DNA", 89, 93], ["CoV", "SPECIES", 14, 17], ["CoV antivirals development", "TREATMENT", 14, 40], ["CoV antivirals", "OBSERVATION", 14, 28]]], ["The replication of positive-sense RNA virus genomes is generally characterized by high error rates, high viral yields, short replication times, and abundant homologous and nonhomologous recombination [10].", [["positive-sense RNA virus genomes", "PROBLEM", 19, 51], ["high error rates", "PROBLEM", 82, 98], ["high viral yields", "PROBLEM", 100, 117], ["positive", "OBSERVATION_MODIFIER", 19, 27]]], ["In consequence, \u2018viral swarms\u2019 are generated which consist of a diverse population of genome mutants with varying degrees of fitness.", [["\u2018viral swarms", "TEST", 16, 29], ["diverse", "OBSERVATION_MODIFIER", 64, 71], ["population", "OBSERVATION", 72, 82], ["genome mutants", "OBSERVATION", 86, 100], ["varying degrees", "OBSERVATION_MODIFIER", 106, 121]]], ["This genetic plasticity challenges development of broadly useful antivirals by enabling rapid development of drug resistance while preserving overall viral fitness.CoV antiviral strategiesDevelopment of nucleoside analogue inhibitors of CoVs is further hampered by the novel RNA-dependent RNA proofreading activity of CoV nonstructural protein 14, a 3\u2032 to 5\u2032 exoribonuclease (nsp14-ExoN), which confers up to 20-fold increase in replication fidelity compared with other RNA viruses.", [["nucleoside", "CHEMICAL", 203, 213], ["CoVs", "CHEMICAL", 237, 241], ["nucleoside", "CHEMICAL", 203, 213], ["CoV", "ORGANISM", 164, 167], ["nucleoside analogue", "SIMPLE_CHEMICAL", 203, 222], ["CoVs", "SIMPLE_CHEMICAL", 237, 241], ["CoV nonstructural protein 14", "GENE_OR_GENE_PRODUCT", 318, 346], ["5\u2032 exoribonuclease", "GENE_OR_GENE_PRODUCT", 356, 374], ["nsp14-ExoN", "GENE_OR_GENE_PRODUCT", 376, 386], ["CoV nonstructural protein 14", "PROTEIN", 318, 346], ["3\u2032 to 5\u2032 exoribonuclease", "PROTEIN", 350, 374], ["nsp14", "PROTEIN", 376, 381], ["ExoN", "PROTEIN", 382, 386], ["broadly useful antivirals", "TREATMENT", 50, 75], ["drug resistance", "PROBLEM", 109, 124], ["CoV antiviral strategies", "TREATMENT", 164, 188], ["nucleoside analogue inhibitors", "TREATMENT", 203, 233], ["CoVs", "PROBLEM", 237, 241], ["CoV nonstructural protein", "TEST", 318, 343], ["replication fidelity", "PROBLEM", 429, 449], ["other RNA viruses", "PROBLEM", 464, 481], ["drug resistance", "OBSERVATION", 109, 124], ["viral fitness", "OBSERVATION", 150, 163], ["increase", "OBSERVATION_MODIFIER", 417, 425], ["replication fidelity", "OBSERVATION", 429, 449]]], ["The nsp14-ExoN activity is responsible for native CoV high resistance to many nucleoside analogues including ribavirin and 5-fluorouracil [11, 12, 13].", [["nucleoside", "CHEMICAL", 78, 88], ["ribavirin", "CHEMICAL", 109, 118], ["5-fluorouracil", "CHEMICAL", 123, 137], ["nucleoside", "CHEMICAL", 78, 88], ["ribavirin", "CHEMICAL", 109, 118], ["5-fluorouracil", "CHEMICAL", 123, 137], ["nsp14", "GENE_OR_GENE_PRODUCT", 4, 9], ["ExoN", "GENE_OR_GENE_PRODUCT", 10, 14], ["nucleoside analogues", "SIMPLE_CHEMICAL", 78, 98], ["ribavirin", "SIMPLE_CHEMICAL", 109, 118], ["5-fluorouracil", "SIMPLE_CHEMICAL", 123, 137], ["11, 12, 13]", "SIMPLE_CHEMICAL", 139, 150], ["nsp14", "PROTEIN", 4, 9], ["ExoN", "PROTEIN", 10, 14], ["The nsp14", "TEST", 0, 9], ["native CoV high resistance", "PROBLEM", 43, 69], ["many nucleoside analogues", "TREATMENT", 73, 98], ["ribavirin", "TREATMENT", 109, 118], ["fluorouracil", "TREATMENT", 125, 137], ["high resistance", "OBSERVATION", 54, 69]]], ["Nevertheless, the recent development of nucleotide and nucleoside analogue inhibitors with a high barrier for resistance, broad-spectrum activity against multiple CoVs, and the ability to inhibit WT CoVs in the presence of nsp14-ExoN holds promise for the treatment of CoV disease.Nucleotide and nucleoside analogue inhibitors for the treatment of CoV infectionsNucleotide and nucleoside analogue inhibitors, hereafter abbreviated NI, are chemically synthesized analogues of purines and pyrimidines in which the heterocyclic ring or sugar moiety has been altered.", [["nucleotide", "CHEMICAL", 40, 50], ["nucleoside", "CHEMICAL", 55, 65], ["nsp14-ExoN", "CHEMICAL", 223, 233], ["CoV disease", "DISEASE", 269, 280], ["Nucleotide", "CHEMICAL", 281, 291], ["nucleoside", "CHEMICAL", 296, 306], ["CoV infections", "DISEASE", 348, 362], ["nucleoside", "CHEMICAL", 377, 387], ["purines", "CHEMICAL", 475, 482], ["pyrimidines", "CHEMICAL", 487, 498], ["nucleotide", "CHEMICAL", 40, 50], ["nucleoside", "CHEMICAL", 55, 65], ["Nucleotide", "CHEMICAL", 281, 291], ["nucleoside", "CHEMICAL", 296, 306], ["Nucleotide", "CHEMICAL", 362, 372], ["nucleoside", "CHEMICAL", 377, 387], ["purines", "CHEMICAL", 475, 482], ["pyrimidines", "CHEMICAL", 487, 498], ["sugar", "CHEMICAL", 533, 538], ["nucleotide", "SIMPLE_CHEMICAL", 40, 50], ["nucleoside analogue", "SIMPLE_CHEMICAL", 55, 74], ["CoVs", "GENE_OR_GENE_PRODUCT", 163, 167], ["WT CoVs", "ORGANISM", 196, 203], ["nsp14", "GENE_OR_GENE_PRODUCT", 223, 228], ["ExoN", "GENE_OR_GENE_PRODUCT", 229, 233], ["CoV", "ORGANISM", 269, 272], ["nucleoside analogue", "SIMPLE_CHEMICAL", 296, 315], ["CoV", "ORGANISM", 348, 351], ["nucleoside analogue", "SIMPLE_CHEMICAL", 377, 396], ["purines", "SIMPLE_CHEMICAL", 475, 482], ["pyrimidines", "SIMPLE_CHEMICAL", 487, 498], ["sugar moiety", "SIMPLE_CHEMICAL", 533, 545], ["WT CoVs", "PROTEIN", 196, 203], ["nsp14", "PROTEIN", 223, 228], ["ExoN", "PROTEIN", 229, 233], ["CoV", "SPECIES", 269, 272], ["CoV", "SPECIES", 348, 351], ["nucleotide", "TREATMENT", 40, 50], ["nucleoside analogue inhibitors", "TREATMENT", 55, 85], ["a high barrier", "TREATMENT", 91, 105], ["multiple CoVs", "PROBLEM", 154, 167], ["WT CoVs", "PROBLEM", 196, 203], ["nsp14", "TREATMENT", 223, 228], ["ExoN holds promise", "TREATMENT", 229, 247], ["CoV disease", "PROBLEM", 269, 280], ["Nucleotide", "TREATMENT", 281, 291], ["nucleoside analogue inhibitors", "TREATMENT", 296, 326], ["CoV infections", "PROBLEM", 348, 362], ["Nucleotide", "TREATMENT", 362, 372], ["nucleoside analogue inhibitors", "TREATMENT", 377, 407], ["chemically synthesized analogues of purines", "TREATMENT", 439, 482], ["pyrimidines", "TREATMENT", 487, 498], ["the heterocyclic ring", "TREATMENT", 508, 529], ["sugar moiety", "PROBLEM", 533, 545], ["CoV disease", "OBSERVATION", 269, 280], ["CoV infections", "OBSERVATION", 348, 362], ["altered", "OBSERVATION_MODIFIER", 555, 562]]], ["Currently used to treat both chronic and acute viral infections, NIs are administered as nucleotide or nucleoside precursors or prodrugs, which are metabolized by host or viral kinases to their active triphosphate once inside the cell.Nucleotide and nucleoside analogue inhibitors for the treatment of CoV infectionsNIs exert inhibitory effects on viral replication by one or more non-mutually exclusive mechanisms (Figure 1).", [["cell", "ANATOMY", 230, 234], ["viral infections", "DISEASE", 47, 63], ["NIs", "CHEMICAL", 65, 68], ["nucleotide", "CHEMICAL", 89, 99], ["nucleoside", "CHEMICAL", 103, 113], ["triphosphate", "CHEMICAL", 201, 213], ["Nucleotide", "CHEMICAL", 235, 245], ["nucleoside", "CHEMICAL", 250, 260], ["CoV infections", "DISEASE", 302, 316], ["NIs", "CHEMICAL", 316, 319], ["nucleotide", "CHEMICAL", 89, 99], ["nucleoside", "CHEMICAL", 103, 113], ["triphosphate", "CHEMICAL", 201, 213], ["Nucleotide", "CHEMICAL", 235, 245], ["nucleoside", "CHEMICAL", 250, 260], ["NIs", "SIMPLE_CHEMICAL", 65, 68], ["nucleotide", "SIMPLE_CHEMICAL", 89, 99], ["nucleoside", "SIMPLE_CHEMICAL", 103, 113], ["prodrugs", "SIMPLE_CHEMICAL", 128, 136], ["triphosphate", "SIMPLE_CHEMICAL", 201, 213], ["cell", "CELL", 230, 234], ["nucleoside analogue", "SIMPLE_CHEMICAL", 250, 269], ["CoV", "ORGANISM", 302, 305], ["NIs", "SIMPLE_CHEMICAL", 316, 319], ["viral kinases", "PROTEIN", 171, 184], ["both chronic and acute viral infections", "PROBLEM", 24, 63], ["NIs", "TREATMENT", 65, 68], ["nucleotide", "TREATMENT", 89, 99], ["nucleoside precursors", "TREATMENT", 103, 124], ["prodrugs", "TREATMENT", 128, 136], ["viral kinases", "TREATMENT", 171, 184], ["their active triphosphate", "TREATMENT", 188, 213], ["Nucleotide", "TREATMENT", 235, 245], ["nucleoside analogue inhibitors", "TREATMENT", 250, 280], ["CoV infections", "PROBLEM", 302, 316], ["viral replication", "TREATMENT", 348, 365], ["chronic", "OBSERVATION_MODIFIER", 29, 36], ["acute", "OBSERVATION_MODIFIER", 41, 46], ["viral infections", "OBSERVATION", 47, 63], ["CoV infections", "OBSERVATION", 302, 316]]], ["First, mis-incorporation of foreign nucleotides in replicating viral genomes may cause chain termination and disrupt subsequent replication or transcription.", [["nucleotides", "CHEMICAL", 36, 47], ["replicating viral genomes", "DNA", 51, 76], ["foreign nucleotides", "TREATMENT", 28, 47], ["replicating viral genomes", "TREATMENT", 51, 76], ["chain termination", "PROBLEM", 87, 104], ["foreign nucleotides", "OBSERVATION", 28, 47], ["viral genomes", "OBSERVATION", 63, 76]]], ["Chain termination may be immediate (obligate) or may occur following a limited extent of continued RNA or DNA synthesis (non-obligate).", [["DNA", "CELLULAR_COMPONENT", 106, 109], ["continued RNA", "PROBLEM", 89, 102], ["DNA synthesis", "PROBLEM", 106, 119], ["may be", "UNCERTAINTY", 18, 24]]], ["Second, NIs may incorporate into elongating nucleotide chains, mispairing with and/or substituting natural nucleotides, thereby introducing mutations that potentially impair RNA synthesis, structure, or RNA\u2013protein interactions or protein functions.", [["nucleotide", "CHEMICAL", 44, 54], ["nucleotide", "CHEMICAL", 44, 54], ["nucleotides", "CHEMICAL", 107, 118], ["RNA\u2013protein", "GENE_OR_GENE_PRODUCT", 203, 214], ["NIs", "PROTEIN", 8, 11], ["elongating nucleotide chains", "PROTEIN", 33, 61], ["elongating nucleotide chains", "PROBLEM", 33, 61], ["substituting natural nucleotides", "TREATMENT", 86, 118], ["introducing mutations", "PROBLEM", 128, 149], ["RNA synthesis", "PROBLEM", 174, 187], ["RNA\u2013protein interactions or protein functions", "PROBLEM", 203, 248]]], ["Accumulation of mutations and loss of virus viability are referred to as lethal mutagenesis and error catastrophe [14].", [["error catastrophe", "DISEASE", 96, 113], ["mutations", "PROBLEM", 16, 25], ["loss of virus viability", "PROBLEM", 30, 53], ["error catastrophe", "PROBLEM", 96, 113], ["mutations", "OBSERVATION", 16, 25], ["loss", "OBSERVATION_MODIFIER", 30, 34], ["virus viability", "OBSERVATION", 38, 53]]], ["Through these mechanisms, NIs alter the genetic makeup of the virus, leading to a decrease in viral fitness with every consecutive replication cycle.", [["NIs", "GENE_OR_GENE_PRODUCT", 26, 29], ["the virus", "PROBLEM", 58, 67], ["a decrease in viral fitness", "PROBLEM", 80, 107], ["decrease", "OBSERVATION_MODIFIER", 82, 90], ["viral fitness", "OBSERVATION", 94, 107]]], ["Finally, NIs may cause depletion of pools of naturally occurring nucleotides by mimicking [15].Nucleotide and nucleoside analogue inhibitors for the treatment of CoV infectionsNIs demonstrate a relatively high barrier to resistance emergence because the structural conservation of the binding site of their polymerase targets is high among virus families, and resistance mutations generally incur a fitness cost for the enzyme and the virus [16].", [["NIs", "CHEMICAL", 9, 12], ["Nucleotide", "CHEMICAL", 95, 105], ["nucleoside", "CHEMICAL", 110, 120], ["CoV infections", "DISEASE", 162, 176], ["nucleotides", "CHEMICAL", 65, 76], ["Nucleotide", "CHEMICAL", 95, 105], ["nucleoside", "CHEMICAL", 110, 120], ["NIs", "SIMPLE_CHEMICAL", 9, 12], ["nucleoside analogue", "SIMPLE_CHEMICAL", 110, 129], ["CoV", "ORGANISM", 162, 165], ["binding site", "DNA", 285, 297], ["enzyme", "PROTEIN", 420, 426], ["depletion of pools", "PROBLEM", 23, 41], ["Nucleotide", "TREATMENT", 95, 105], ["nucleoside analogue inhibitors", "TREATMENT", 110, 140], ["CoV infections", "PROBLEM", 162, 176], ["the binding site", "PROBLEM", 281, 297], ["resistance mutations", "PROBLEM", 360, 380], ["the enzyme", "TEST", 416, 426], ["CoV infections", "OBSERVATION", 162, 176]]], ["For CoVs, amino acid conservation of the viral RdRp ranges from 70 to near 100% and is maintained across genera, suggesting NIs could potentially serve as broad-spectrum inhibitors of CoV infection [17\u2022\u2022].", [["amino acid", "CHEMICAL", 10, 20], ["NIs", "CHEMICAL", 124, 127], ["infection", "DISEASE", 188, 197], ["amino acid", "CHEMICAL", 10, 20], ["CoVs", "GENE_OR_GENE_PRODUCT", 4, 8], ["amino acid", "AMINO_ACID", 10, 20], ["NIs", "SIMPLE_CHEMICAL", 124, 127], ["CoV", "ORGANISM", 184, 187], ["CoVs", "PROTEIN", 4, 8], ["viral RdRp", "PROTEIN", 41, 51], ["CoVs", "PROBLEM", 4, 8], ["amino acid conservation", "TREATMENT", 10, 33], ["the viral RdRp", "TEST", 37, 51], ["NIs", "PROBLEM", 124, 127], ["broad-spectrum inhibitors", "TREATMENT", 155, 180], ["CoV infection", "PROBLEM", 184, 197], ["viral RdRp", "OBSERVATION", 41, 51]]], ["However, proofreading activity of nsp14-ExoN activity protects CoVs from many NIs effective against other RNA viruses [12,18].", [["nsp14", "GENE_OR_GENE_PRODUCT", 34, 39], ["ExoN", "GENE_OR_GENE_PRODUCT", 40, 44], ["CoVs", "SIMPLE_CHEMICAL", 63, 67], ["NIs", "CANCER", 78, 81], ["nsp14", "PROTEIN", 34, 39], ["ExoN", "PROTEIN", 40, 44], ["nsp14", "TREATMENT", 34, 39], ["CoVs", "PROBLEM", 63, 67], ["other RNA viruses", "PROBLEM", 100, 117]]], ["To effectively inhibit CoVs, an NI needs to either evade recognition by ExoN or undergo uptake into the elongating strand at a rate exceeding ExoN excision kinetics.", [["ExoN", "CHEMICAL", 72, 76], ["CoVs", "GENE_OR_GENE_PRODUCT", 23, 27], ["ExoN", "GENE_OR_GENE_PRODUCT", 72, 76], ["ExoN", "SIMPLE_CHEMICAL", 142, 146], ["CoVs", "PROTEIN", 23, 27], ["ExoN", "PROTEIN", 72, 76], ["ExoN", "PROTEIN", 142, 146], ["ExoN excision kinetics", "TREATMENT", 142, 164]]], ["We will next discuss several antiviral NIs described in the literature and evidence supporting their efficacy against CoVs.Nucleotide and nucleoside analogue inhibitors for the treatment of CoV infections", [["Nucleotide", "CHEMICAL", 123, 133], ["nucleoside", "CHEMICAL", 138, 148], ["CoV infections", "DISEASE", 190, 204], ["Nucleotide", "CHEMICAL", 123, 133], ["nucleoside", "CHEMICAL", 138, 148], ["CoVs", "SIMPLE_CHEMICAL", 118, 122], ["nucleoside analogue", "SIMPLE_CHEMICAL", 138, 157], ["CoV", "ORGANISM", 190, 193], ["several antiviral NIs", "TREATMENT", 21, 42], ["CoVs", "PROBLEM", 118, 122], ["Nucleotide", "TREATMENT", 123, 133], ["nucleoside analogue inhibitors", "TREATMENT", 138, 168], ["CoV infections", "PROBLEM", 190, 204], ["CoV infections", "OBSERVATION", 190, 204]]]], "58b50225971b9e2a91e4c94d6f478978b904a3c3": [["IntroductionSARS-CoV-2 infections have reached global pandemic proportions in early 2020, affecting over 2M people worldwide (as of this writing) and showing no signs of easing, except in a few jurisdictions where strict quarantine measures were implemented early on.", [["infections", "DISEASE", 23, 33], ["IntroductionSARS-CoV-2", "ORGANISM", 0, 22], ["people", "ORGANISM", 108, 114], ["people", "SPECIES", 108, 114], ["IntroductionSARS", "TEST", 0, 16], ["2 infections", "PROBLEM", 21, 33], ["strict quarantine measures", "TREATMENT", 214, 240]]], ["The resulting coronavirus disease (COVID-19) has a relatively high (\u223c3.4%) mortality rate [1] -a figure that varies widely between jurisdictions due to factors yet to be determined.", [["coronavirus disease", "DISEASE", 14, 33], ["coronavirus", "ORGANISM", 14, 25], ["The resulting coronavirus disease", "PROBLEM", 0, 33], ["COVID", "TEST", 35, 40], ["mortality rate", "TEST", 75, 89], ["-a figure", "PROBLEM", 94, 103], ["coronavirus disease", "OBSERVATION", 14, 33], ["high", "OBSERVATION_MODIFIER", 62, 66]]], ["Currently, no vaccines or effective treatments are available.", [["vaccines", "TREATMENT", 14, 22], ["effective treatments", "TREATMENT", 26, 46], ["no", "UNCERTAINTY", 11, 13]]], ["Most current data analysis efforts are, understandably, focused on the virus itself for the purpose of vaccine development and tracking its evolution for diagnostics and infection monitoring purposes.IntroductionCuriously, it is estimated that as high as 18-30% or more of the population may be asymptomatic to SARS-CoV-2 infections [2] [3] , while other affected individuals exhibit mild to severe to critical symptoms of infection.", [["infection", "DISEASE", 170, 179], ["SARS", "DISEASE", 311, 315], ["infections", "DISEASE", 322, 332], ["infection", "DISEASE", 423, 432], ["CoV-2", "ORGANISM", 316, 321], ["individuals", "ORGANISM", 364, 375], ["SARS-CoV", "SPECIES", 311, 319], ["vaccine development", "TREATMENT", 103, 122], ["diagnostics", "TEST", 154, 165], ["infection monitoring purposes", "TEST", 170, 199], ["asymptomatic", "PROBLEM", 295, 307], ["SARS", "PROBLEM", 311, 315], ["CoV-2 infections", "PROBLEM", 316, 332], ["other affected individuals", "PROBLEM", 349, 375], ["mild to severe to critical symptoms of infection", "PROBLEM", 384, 432], ["mild", "OBSERVATION_MODIFIER", 384, 388], ["severe", "OBSERVATION_MODIFIER", 392, 398], ["infection", "OBSERVATION", 423, 432]]], ["Thus, gaining insights on host susceptibility to the coronavirus is clearly another important aspect that needs to be worked on and understood.", [["coronavirus", "DISEASE", 53, 64], ["coronavirus", "ORGANISM", 53, 64]]], ["One would expect a link between host immunity genes and susceptibility or resistance to infection.", [["infection", "DISEASE", 88, 97], ["host immunity genes", "DNA", 32, 51], ["resistance to infection", "PROBLEM", 74, 97], ["infection", "OBSERVATION", 88, 97]]], ["The Human Leukocyte Antigen (HLA) gene complex includes two classes of such genes, which encode the Major Histocompatibility Complex (MHC).", [["Human Leukocyte Antigen", "GENE_OR_GENE_PRODUCT", 4, 27], ["HLA", "GENE_OR_GENE_PRODUCT", 29, 32], ["Major Histocompatibility Complex", "GENE_OR_GENE_PRODUCT", 100, 132], ["Human Leukocyte Antigen (HLA) gene complex", "DNA", 4, 46], ["Major Histocompatibility Complex", "PROTEIN", 100, 132], ["MHC", "PROTEIN", 134, 137], ["Human", "SPECIES", 4, 9], ["The Human Leukocyte Antigen", "TEST", 0, 27], ["Human Leukocyte", "ANATOMY", 4, 19]]], ["Proteins of the MHC present (class I) internally-or (class II) externally-derived antigenic determinants (epitopes) to T cells, which upon recognition of the epitope-complex, will mount an immune response to defend against viral and bacterial infections.", [["T cells", "ANATOMY", 119, 126], ["viral and bacterial infections", "DISEASE", 223, 253], ["T cells", "CELL", 119, 126], ["MHC", "PROTEIN", 16, 19], ["antigenic determinants", "PROTEIN", 82, 104], ["epitopes", "PROTEIN", 106, 114], ["T cells", "CELL_TYPE", 119, 126], ["epitope", "PROTEIN", 158, 165], ["the epitope-complex", "PROBLEM", 154, 173], ["viral and bacterial infections", "PROBLEM", 223, 253], ["bacterial", "OBSERVATION_MODIFIER", 233, 242], ["infections", "OBSERVATION", 243, 253]]], ["HLA genes are therefore cornerstone to acquired immunity in humans.", [["HLA", "GENE_OR_GENE_PRODUCT", 0, 3], ["humans", "ORGANISM", 60, 66], ["HLA genes", "DNA", 0, 9], ["humans", "SPECIES", 60, 66], ["humans", "SPECIES", 60, 66]]], ["HLA alleles have also been shown to be factors in susceptibility or resistance to certain diseases, and their frequency and composition in human populations vary widely (http://allelefrequencies.net).", [["HLA", "GENE_OR_GENE_PRODUCT", 0, 3], ["human", "ORGANISM", 139, 144], ["HLA alleles", "DNA", 0, 11], ["human", "SPECIES", 139, 144], ["human", "SPECIES", 139, 144], ["HLA alleles", "PROBLEM", 0, 11], ["certain diseases", "PROBLEM", 82, 98]]], ["A previous study found HLA class I genes HLA-B54:01 to be associated with the 2003 severe acute respiratory syndrome (SARS) coronavirus infections in Taiwan [4] -a related disease to the current pandemic.IntroductionFor over a decade, high-throughput transcriptome sequencing (RNA-Seq) has proven a worthy instrument for measuring changes of gene expression in human diseases and beyond [5] .", [["acute respiratory syndrome", "DISEASE", 90, 116], ["SARS) coronavirus infections", "DISEASE", 118, 146], ["HLA class I", "GENE_OR_GENE_PRODUCT", 23, 34], ["HLA-B54:01", "GENE_OR_GENE_PRODUCT", 41, 51], ["human", "ORGANISM", 361, 366], ["HLA class I genes", "DNA", 23, 40], ["HLA", "DNA", 41, 44], ["B54:01", "DNA", 45, 51], ["human", "SPECIES", 361, 366], ["SARS) coronavirus", "SPECIES", 118, 135], ["human", "SPECIES", 361, 366], ["A previous study", "TEST", 0, 16], ["HLA", "TEST", 41, 44], ["severe acute respiratory syndrome", "PROBLEM", 83, 116], ["SARS) coronavirus infections", "PROBLEM", 118, 146], ["-a related disease", "PROBLEM", 161, 179], ["gene expression in human diseases", "PROBLEM", 342, 375], ["severe", "OBSERVATION_MODIFIER", 83, 89], ["acute", "OBSERVATION_MODIFIER", 90, 95], ["respiratory syndrome", "OBSERVATION", 96, 116]]], ["Transcriptome analysis has the potential to reveal key genes that are modulated in response to infections, but also to reveal the HLA composition of affected individuals.", [["infections", "DISEASE", 95, 105], ["Transcriptome analysis", "TEST", 0, 22], ["key genes", "PROBLEM", 51, 60], ["infections", "PROBLEM", 95, 105], ["affected individuals", "PROBLEM", 149, 169], ["infections", "OBSERVATION", 95, 105]]], ["A few years ago, our group developed an approach for mining high-throughput next-generation shotgun sequencing data for the purpose of HLA determination [6] , which has since been applied in a broader clinical context [7] .IntroductionHere, we report our initial observations based on transcriptome sequencing libraries prepared from the bronchoalveolar lavage fluid samples of five patients at the early stage of the Wuhan seafood market pneumonia coronavirus outbreak (see Methods).", [["bronchoalveolar lavage fluid samples", "ANATOMY", 338, 374], ["pneumonia coronavirus", "DISEASE", 439, 460], ["bronchoalveolar lavage fluid samples", "ORGANISM_SUBSTANCE", 338, 374], ["patients", "ORGANISM", 383, 391], ["patients", "SPECIES", 383, 391], ["Wuhan seafood market pneumonia coronavirus", "SPECIES", 418, 460], ["an approach", "TREATMENT", 37, 48], ["HLA determination", "TEST", 135, 152], ["transcriptome sequencing libraries", "TREATMENT", 285, 319], ["the bronchoalveolar lavage fluid samples", "TEST", 334, 374], ["pneumonia coronavirus outbreak", "PROBLEM", 439, 469], ["bronchoalveolar lavage", "OBSERVATION", 338, 360]]], ["We identified the HLA class I group A allele A24:02 is common in some populations, the prevalence observed (80%) is higher than the allele frequency in the Chinese population (17.2%).MethodsWe downloaded Illumina HiSeq 3000 paired RNA-Seq reads from libraries prepared from the bronchoalveolar lavage fluid samples of five patients (https://www.ebi.ac.uk/ena/data/view/PRJNA605983 Accessions: SRX7730880-SRX7730884 denoted in the table below as Patient 1-5, respectively).", [["bronchoalveolar lavage fluid samples", "ANATOMY", 278, 314], ["bronchoalveolar lavage", "ORGANISM_SUBSTANCE", 278, 300], ["patients", "ORGANISM", 323, 331], ["HLA class I group A allele A24:02", "DNA", 18, 51], ["patients", "SPECIES", 323, 331], ["paired RNA", "TEST", 224, 234], ["the bronchoalveolar lavage fluid samples", "TEST", 274, 314], ["common", "OBSERVATION_MODIFIER", 55, 61], ["some", "OBSERVATION_MODIFIER", 65, 69], ["populations", "OBSERVATION_MODIFIER", 70, 81], ["higher", "OBSERVATION_MODIFIER", 116, 122], ["bronchoalveolar", "ANATOMY", 278, 293]]], ["We note that these are metagenomics samples, and, although not explicitly noted, we think that they were prepared for the primary purpose of identifying and characterizing the novel coronavirus at the outbreak epicentre.", [["coronavirus", "ORGANISM", 182, 193], ["metagenomics samples", "TEST", 23, 43], ["the novel coronavirus", "PROBLEM", 172, 193], ["coronavirus", "OBSERVATION", 182, 193]]], ["On each dataset, we ran HLAminer [6] in targeted assembly mode with default values (v1.4; contig length \u2265200bp, seq. identity \u226599%, score \u22651000), and report 4-digit (HLA allele/protein) resolution when top-scoring predictions are unambiguous.", [["default values", "TEST", 68, 82], ["v", "TEST", 84, 85], ["contig length", "TEST", 90, 103], ["bp", "TEST", 108, 110], ["identity", "TEST", 117, 125], ["score", "TEST", 132, 137], ["HLA allele/protein)", "TREATMENT", 166, 185]]], ["Otherwise the 2-digit (allele group) resolution is reported.ResultsWe predicted and compiled the likely HLA class I alleles for five patients at the early stage of the COVID-19 outbreak in Wuhan, China (Table 1) .", [["HLA class I", "GENE_OR_GENE_PRODUCT", 104, 115], ["patients", "ORGANISM", 133, 141], ["HLA class I alleles", "DNA", 104, 123], ["patients", "SPECIES", 133, 141]]], ["Although the bronchoalveolar lavage (BAL) fluid samples were initially utilized to identify and characterize the novel coronavirus (similar justification in [8] ), BAL metagenomics samples are expected to contain host cells / nucleic acids (DNA/RNA).", [["bronchoalveolar lavage (BAL) fluid samples", "ANATOMY", 13, 55], ["samples", "ANATOMY", 181, 188], ["cells", "ANATOMY", 218, 223], ["nucleic acids", "CHEMICAL", 226, 239], ["bronchoalveolar lavage", "MULTI-TISSUE_STRUCTURE", 13, 35], ["fluid samples", "ORGANISM_SUBSTANCE", 42, 55], ["coronavirus", "ORGANISM", 119, 130], ["host cells", "CELL", 213, 223], ["nucleic acids", "SIMPLE_CHEMICAL", 226, 239], ["DNA", "CELLULAR_COMPONENT", 241, 244], ["host cells", "CELL_TYPE", 213, 223], ["nucleic acids", "PROTEIN", 226, 239], ["the bronchoalveolar lavage (BAL) fluid samples", "TEST", 9, 55], ["the novel coronavirus", "PROBLEM", 109, 130], ["BAL metagenomics samples", "TEST", 164, 188], ["nucleic acids", "TEST", 226, 239], ["DNA/RNA", "TREATMENT", 241, 248], ["bronchoalveolar lavage", "OBSERVATION", 13, 35], ["coronavirus", "OBSERVATION", 119, 130], ["host cells", "OBSERVATION", 213, 223], ["nucleic acids", "OBSERVATION", 226, 239]]], ["Because HLA genes are expressed at the surface of all human nucleated cells, RNA-Seq data can be employed to determine HLA profiles from BAL samples.ResultsWe observe the HLA-A24 is a common group of alleles in Southeastern Asian populations, and the frequency of HLA-A24:02 frequency in Chinese population is typically 17.2%, a value that is statistically significantly less than our observed frequency of 80% (p< 10 \u22124 , 1-sided z-test).Discussion and ConclusionsA24:02, notably with diabetes [10] [11] [12] [13] , which is a reported potential risk factor in COVID-19 patients [14] .", [["surface", "ANATOMY", 39, 46], ["nucleated cells", "ANATOMY", 60, 75], ["BAL samples", "ANATOMY", 137, 148], ["diabetes", "DISEASE", 486, 494], ["HLA", "GENE_OR_GENE_PRODUCT", 8, 11], ["surface", "CELLULAR_COMPONENT", 39, 46], ["human", "ORGANISM", 54, 59], ["nucleated cells", "CELL", 60, 75], ["BAL samples", "CANCER", 137, 148], ["HLA-A24", "GENE_OR_GENE_PRODUCT", 171, 178], ["HLA-A24:02", "GENE_OR_GENE_PRODUCT", 264, 274], ["[10] [11] [12] [13]", "SIMPLE_CHEMICAL", 495, 514], ["patients", "ORGANISM", 571, 579], ["HLA genes", "DNA", 8, 17], ["human nucleated cells", "CELL_TYPE", 54, 75], ["human", "SPECIES", 54, 59], ["patients", "SPECIES", 571, 579], ["human", "SPECIES", 54, 59], ["HLA-A24", "SPECIES", 171, 178], ["all human nucleated cells", "TREATMENT", 50, 75], ["RNA", "TEST", 77, 80], ["HLA profiles", "TEST", 119, 131], ["BAL samples", "TEST", 137, 148], ["HLA", "TEST", 264, 267], ["Chinese population", "TEST", 288, 306], ["a value", "TEST", 327, 334], ["sided z-test", "TEST", 425, 437], ["diabetes", "PROBLEM", 486, 494], ["COVID", "TEST", 562, 567], ["nucleated cells", "OBSERVATION", 60, 75]]], ["HLA also informs vaccine development.", [["HLA", "GENE_OR_GENE_PRODUCT", 0, 3]]], ["This knowledge would help prioritize SARS-CoV-2 derived epitopes predicted to be stable HLA binders [15] .", [["SARS-CoV-2 derived epitopes", "PROTEIN", 37, 64], ["SARS", "TEST", 37, 41], ["CoV", "TEST", 42, 45]]], ["Future studies into host susceptibility and resistance to SARS-CoV-2 infections are sorely needed as they may help us better manage and mitigate risks of infections.", [["SARS", "DISEASE", 58, 62], ["infections", "DISEASE", 69, 79], ["infections", "DISEASE", 154, 164], ["SARS-CoV-2", "ORGANISM", 58, 68], ["SARS-CoV", "SPECIES", 58, 66], ["Future studies", "TEST", 0, 14], ["host susceptibility", "TEST", 20, 39], ["SARS", "PROBLEM", 58, 62], ["CoV", "PROBLEM", 63, 66], ["2 infections", "PROBLEM", 67, 79], ["infections", "PROBLEM", 154, 164], ["infections", "OBSERVATION", 154, 164]]], ["We chose to communicate our early findings in this domain to facilitate rapid development of response strategies.Grant informationThis work was supported by Genome BC and Genome Canada [281ANV]; and the National Institutes of Health [2R01HG007182-04A1].", [["response strategies", "TREATMENT", 93, 112], ["response strategies", "OBSERVATION", 93, 112]]]], "0e0b400da3e013335e2263619fbc9d5d558ca5fe": [["IntroductionThe COVID-19 (SARS-CoV-2) pandemic has changed the social environment in which people live and work, as well as the social systems they rely on.", [["SARS-CoV-2", "ORGANISM", 26, 36], ["people", "ORGANISM", 91, 97], ["people", "SPECIES", 91, 97], ["The COVID", "TEST", 12, 21], ["pandemic", "PROBLEM", 38, 46]]], ["39, 88 To contain the spread of coronavirus and to prepare for a dramatic increase in demand for limited hospital/medical facilities and resources, societies have enforced physical distancing measures.", [["coronavirus", "DISEASE", 32, 43], ["coronavirus", "ORGANISM", 32, 43], ["coronavirus", "PROBLEM", 32, 43]]], ["Furthermore, access to vital, but nonurgent, healthcare services (including pain management services) has been restricted.", [["pain", "DISEASE", 76, 80], ["pain management services", "TREATMENT", 76, 100]]], ["These changes have affected the way people connect with each other, manage their health and wellbeing, and fulfil their social roles.", [["people", "ORGANISM", 36, 42], ["people", "SPECIES", 36, 42]]], ["For others, however, these social changes can also represent significant threats to health and wellbeing.IntroductionThe negative impact of social changes prompted by the COVID-19 crisis may disproportionately affect individuals living with longterm painful conditions.", [["longterm painful conditions", "PROBLEM", 241, 268], ["negative", "OBSERVATION", 121, 129]]], ["Living with chronic pain can threaten an individuals' fundamental social needs for autonomy (agency or independence), belonging (social connection), and justice (fairness).", [["chronic pain", "DISEASE", 12, 24], ["chronic pain", "PROBLEM", 12, 24]]], ["In turn, for some, experiencing heightened social threat can maintain and exacerbate chronic pain.", [["chronic pain", "DISEASE", 85, 97], ["chronic pain", "PROBLEM", 85, 97], ["chronic", "OBSERVATION_MODIFIER", 85, 92], ["pain", "OBSERVATION", 93, 97]]], ["48 In this review, we draw attention to the potential for social and systemic changes associated with attempts to contain the spread of COVID-19 to precipitate, maintain, and exacerbate pain by increasing the social threats faced by individuals with chronic pain ( \u00bdF1 Fig. 1 ).", [["pain", "DISEASE", 186, 190], ["chronic pain", "DISEASE", 250, 262], ["COVID-19", "CHEMICAL", 136, 144], ["social and systemic changes", "PROBLEM", 58, 85], ["COVID", "TREATMENT", 136, 141], ["exacerbate pain", "PROBLEM", 175, 190], ["chronic pain", "PROBLEM", 250, 262]]], ["We also suggest strategies for mitigating the social impact of COVID-19 on those living with chronic pain, for instance by learning from the resilience demonstrated by people in pain who have found ways to deal with social threat.", [["chronic pain", "DISEASE", 93, 105], ["pain", "DISEASE", 178, 182], ["COVID-19", "CHEMICAL", 63, 71], ["people", "ORGANISM", 168, 174], ["people", "SPECIES", 168, 174], ["chronic pain", "PROBLEM", 93, 105], ["pain", "PROBLEM", 178, 182]]], ["Finally, we suggest several time-critical, high-impact research questions for further investigation (Fig. 1 ).Social disconnection and lonelinessOne of the most immediate effects of the pandemic on our social lives is the introduction of physical distancing measures and restriction of travel.", [["further investigation", "TEST", 78, 99], ["physical distancing measures", "TREATMENT", 238, 266], ["disconnection", "OBSERVATION", 117, 130]]], ["It is well known that spontaneous social interactions with others and participation in social roles can build and maintain a generalised sense of trust in others (social capital), promote feelings of wellbeing, 76 provide protection from the harmful effects of stress, 95 promote social connectedness, and reduce pain sensitivity.", [["pain", "DISEASE", 313, 317], ["pain sensitivity", "PROBLEM", 313, 329]]], ["91 Conversely, social isolation is associated with loneliness, higher levels of depression and anxiety, poorer health behaviours, poorer sleep, higher blood pressure, poorer immune function, and pain.", [["blood", "ANATOMY", 151, 156], ["depression", "DISEASE", 80, 90], ["anxiety", "DISEASE", 95, 102], ["pain", "DISEASE", 195, 199], ["blood", "ORGANISM_SUBSTANCE", 151, 156], ["loneliness", "PROBLEM", 51, 61], ["depression", "PROBLEM", 80, 90], ["anxiety", "PROBLEM", 95, 102], ["poorer health behaviours", "PROBLEM", 104, 128], ["poorer sleep", "PROBLEM", 130, 142], ["blood pressure", "TEST", 151, 165], ["poorer immune function", "PROBLEM", 167, 189], ["pain", "PROBLEM", 195, 199]]], ["40, 42 Chronic pain conditions place individuals at an increased risk of social isolation, smaller social network size, and reduced social role functioning, 37, 38, 78 all of which have negative implications for pain interference and pain intensity over time.", [["Chronic pain", "DISEASE", 7, 19], ["pain", "DISEASE", 212, 216], ["pain", "DISEASE", 234, 238], ["social network", "MULTI-TISSUE_STRUCTURE", 99, 113], ["Chronic pain conditions", "PROBLEM", 7, 30], ["social isolation", "TREATMENT", 73, 89], ["pain interference", "PROBLEM", 212, 229], ["pain intensity", "PROBLEM", 234, 248], ["Chronic", "OBSERVATION_MODIFIER", 7, 14], ["pain", "OBSERVATION", 15, 19], ["social isolation", "OBSERVATION", 73, 89], ["smaller", "OBSERVATION_MODIFIER", 91, 98], ["size", "OBSERVATION_MODIFIER", 114, 118]]], ["7, 31, 47 Indeed, disruption to social roles and relationships is one of the most distressing aspects of living with chronic pain.", [["chronic pain", "DISEASE", 117, 129], ["chronic pain", "PROBLEM", 117, 129], ["chronic", "OBSERVATION_MODIFIER", 117, 124], ["pain", "OBSERVATION", 125, 129]]], ["81 Physical distance from others and reduced participation in work and social activities can cause people to feel lonely or socially distanced from others, 73 and there are concerns that the COVID-19 pandemic will lead to a steep rise in the prevalence of loneliness.", [["loneliness", "DISEASE", 256, 266], ["people", "ORGANISM", 99, 105], ["people", "SPECIES", 99, 105]]], ["5, 22, 35, 39 People living with chronic pain, who may have entered the pandemic with fewer social resources than others, may be particularly vulnerable to feelings of loneliness and social disconnection at this time.", [["chronic pain", "DISEASE", 33, 45], ["loneliness", "DISEASE", 168, 178], ["People", "ORGANISM", 14, 20], ["People", "SPECIES", 14, 20], ["chronic pain", "PROBLEM", 33, 45], ["social disconnection", "PROBLEM", 183, 203], ["chronic", "OBSERVATION_MODIFIER", 33, 40], ["pain", "OBSERVATION", 41, 45]]], ["Unless individuals have the ability and means to maintain meaningful connections with others despite physical distancing measures, being physically isolated from others threatens to exacerbate pain and associated disability.Risk of increased social proximityThe paradox of COVID-19 is that being physically isolated from one's community can mean living in closer proximity to one's household members.", [["pain", "DISEASE", 193, 197], ["disability", "DISEASE", 213, 223], ["physical distancing measures", "TREATMENT", 101, 129], ["pain", "PROBLEM", 193, 197], ["increased", "OBSERVATION_MODIFIER", 232, 241], ["social proximity", "OBSERVATION", 242, 258]]], ["People living with chronic pain conditions may benefit from more frequent contact with family members because closer proximity offers more opportunity to improve social bonds.", [["chronic pain", "DISEASE", 19, 31], ["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6], ["chronic pain conditions", "PROBLEM", 19, 42]]], ["Although social support can help buffer against pain, 14, 15, 18, 56 an increase in solicitous behaviours in such close proximity might unintentionally contribute to the chronicity of pain.", [["pain", "DISEASE", 48, 52], ["pain", "DISEASE", 184, 188], ["social support", "TREATMENT", 9, 23], ["pain", "PROBLEM", 48, 52], ["an increase in solicitous behaviours", "PROBLEM", 69, 105], ["pain", "PROBLEM", 184, 188], ["increase", "OBSERVATION_MODIFIER", 72, 80]]], ["34, 43, 72 For example, in households where a child is in pain, increased social proximity could lead to increased exposure to protective parental behaviours and reductions in child autonomy and activity.", [["pain", "DISEASE", 58, 62], ["pain", "PROBLEM", 58, 62]]], ["Conversely, family members could become desensitised to the pain of others, or even become avoidant, risking further isolation for individuals living with pain.", [["pain", "DISEASE", 60, 64], ["pain", "DISEASE", 155, 159], ["the pain", "PROBLEM", 56, 64], ["avoidant", "PROBLEM", 91, 99], ["risking further isolation", "TREATMENT", 101, 126], ["pain", "PROBLEM", 155, 159]]], ["Those living with pain may experience increased feelings of guilt in response to increased support, especially if they perceive themselves to be a burden.", [["pain", "DISEASE", 18, 22], ["pain", "PROBLEM", 18, 22], ["guilt", "PROBLEM", 60, 65], ["increased support", "TREATMENT", 81, 98]]], ["50, 75 Alternatively, fear of rejection could lead to masking pain from others in shared living spaces, preventing individuals with pain from asking for help to meet their needs.", [["pain", "DISEASE", 62, 66], ["pain", "DISEASE", 132, 136], ["rejection", "PROBLEM", 30, 39], ["masking pain", "PROBLEM", 54, 66], ["pain", "PROBLEM", 132, 136], ["rejection", "OBSERVATION", 30, 39]]], ["13, 65 There is also a risk that for people living with chronic pain, living in close proximity and enclosed environments could increase exposure to interpersonal conflict, 63, 69 which is known to amplify PAIN \u00ae pain and disability.", [["chronic pain", "DISEASE", 56, 68], ["pain", "DISEASE", 213, 217], ["disability", "DISEASE", 222, 232], ["people", "ORGANISM", 37, 43], ["people", "SPECIES", 37, 43], ["chronic pain", "PROBLEM", 56, 68], ["PAIN \u00ae pain", "PROBLEM", 206, 217], ["chronic", "OBSERVATION_MODIFIER", 56, 63], ["pain", "OBSERVATION", 64, 68]]], ["21 Many people are struggling to juggle multiple social roles and responsibilitiessupporting children with schoolwork, working from home, and parenting-leading to emotional exhaustion.", [["people", "ORGANISM", 8, 14], ["children", "ORGANISM", 93, 101], ["people", "SPECIES", 8, 14], ["children", "SPECIES", 93, 101], ["emotional exhaustion", "PROBLEM", 163, 183]]], ["Women, in particular, are likely to carry a greater social burden and greater responsibility for childcare during COVID-19.", [["Women", "ORGANISM", 0, 5], ["Women", "SPECIES", 0, 5], ["COVID", "TEST", 114, 119]]], ["1,92 Critically, domestic abuse has increased during the COVID-19 lockdown, 10 which has also been shown to contribute to chronic pain.", [["domestic abuse", "DISEASE", 17, 31], ["chronic pain", "DISEASE", 122, 134], ["the COVID", "TEST", 53, 62], ["chronic pain", "PROBLEM", 122, 134], ["increased", "OBSERVATION_MODIFIER", 36, 45], ["chronic", "OBSERVATION_MODIFIER", 122, 129], ["pain", "OBSERVATION", 130, 134]]], ["Reduced access to high-quality pain management COVID-19 potentially poses a significant challenge for patients seeking to access pain management.", [["pain", "DISEASE", 31, 35], ["COVID-19", "CHEMICAL", 47, 55], ["pain", "DISEASE", 129, 133], ["patients", "ORGANISM", 102, 110], ["patients", "SPECIES", 102, 110], ["high-quality pain management COVID", "TREATMENT", 18, 52], ["a significant challenge", "TREATMENT", 74, 97], ["pain management", "TREATMENT", 129, 144], ["high", "OBSERVATION_MODIFIER", 18, 22]]], ["Although pain management is a fundamental right, 23 the health system responses to mitigate the impact of COVID-19 may significantly affect access for patients with complex medical conditions (eg, people with comorbid mental health conditions and addiction) and widen existing inequities in relation to pain management for socially disadvantaged populations.", [["pain", "DISEASE", 9, 13], ["COVID-19", "CHEMICAL", 106, 114], ["pain", "DISEASE", 303, 307], ["COVID-19", "CHEMICAL", 106, 114], ["patients", "ORGANISM", 151, 159], ["patients", "SPECIES", 151, 159], ["people", "SPECIES", 197, 203], ["pain management", "TREATMENT", 9, 24], ["COVID", "TREATMENT", 106, 111], ["comorbid mental health conditions", "PROBLEM", 209, 242], ["pain management", "TREATMENT", 303, 318], ["right", "ANATOMY_MODIFIER", 42, 47]]], ["90 For some people with chronic pain, the pandemic might bring life stressors that result in pain flare-ups, and increase the need for pain services.", [["chronic pain", "DISEASE", 24, 36], ["pain", "DISEASE", 93, 97], ["pain", "DISEASE", 135, 139], ["people", "ORGANISM", 12, 18], ["people", "SPECIES", 12, 18], ["chronic pain", "PROBLEM", 24, 36], ["pain flare", "PROBLEM", 93, 103], ["pain services", "TREATMENT", 135, 148], ["chronic", "OBSERVATION_MODIFIER", 24, 31], ["pain", "OBSERVATION", 32, 36]]], ["77 Furthermore, individual pain experiences may not be considered as immediately important when compared to the need to treat lifethreatening symptoms associated with COVID-19, 12 leading to less help-seeking and psychological distress.Risk of increased social proximityPain management during this pandemic for clinicians involves balancing access to care with minimising safety risk from exposure to COVID-19 for vulnerable patients and clinicians themselves.", [["pain", "DISEASE", 27, 31], ["psychological distress", "DISEASE", 213, 235], ["Pain", "DISEASE", 270, 274], ["COVID-19", "CHEMICAL", 401, 409], ["COVID-19", "CHEMICAL", 401, 409], ["patients", "ORGANISM", 425, 433], ["patients", "SPECIES", 425, 433], ["individual pain", "PROBLEM", 16, 31], ["lifethreatening symptoms", "PROBLEM", 126, 150], ["COVID", "TEST", 167, 172], ["psychological distress", "PROBLEM", 213, 235], ["Pain management", "TREATMENT", 270, 285], ["increased", "OBSERVATION_MODIFIER", 244, 253], ["social proximity", "OBSERVATION", 254, 270]]], ["79 Cancelled elective surgeries, closure of pain management services, and redeployment of clinicians to other areas of care all result in limited access to high-quality care.", [["pain", "DISEASE", 44, 48], ["elective surgeries", "TREATMENT", 13, 31], ["closure of pain management services", "TREATMENT", 33, 68]]], ["Consequently, the increased burden on healthcare workers may result in a greater focus on biomedical management (eg, opioid prescribing), rather than psychological and interdisciplinary treatment approaches.", [["biomedical management", "TREATMENT", 90, 111], ["interdisciplinary treatment approaches", "TREATMENT", 168, 206], ["increased", "OBSERVATION_MODIFIER", 18, 27], ["burden", "OBSERVATION_MODIFIER", 28, 34]]], ["Although this may be deemed necessary in the context of the pandemic due to heightened needs from patients for pain relief, clinicians and patients may not agree on opioid prescription/deprescription.", [["pain", "DISEASE", 111, 115], ["patients", "ORGANISM", 98, 106], ["patients", "ORGANISM", 139, 147], ["patients", "SPECIES", 98, 106], ["patients", "SPECIES", 139, 147], ["pain relief", "PROBLEM", 111, 122], ["opioid prescription", "TREATMENT", 165, 184]]], ["66 In addition, the individual assessment required to address the risks and benefits of opioid use and the monitoring of its use 85 may be complicated by a lack of access to face-to-face pain services.Risk of increased social proximityIn the absence of the availability of face-to-face contact, telehealth is increasingly being recommended as a first line of care for patients, 19 including those with chronic pain.", [["pain", "DISEASE", 187, 191], ["chronic pain", "DISEASE", 402, 414], ["patients", "ORGANISM", 368, 376], ["patients", "SPECIES", 368, 376], ["the individual assessment", "TEST", 16, 41], ["opioid use", "TREATMENT", 88, 98], ["the monitoring", "TEST", 103, 117], ["face pain services", "TREATMENT", 182, 200], ["chronic pain", "PROBLEM", 402, 414], ["increased", "OBSERVATION_MODIFIER", 209, 218], ["social proximity", "OBSERVATION", 219, 235], ["chronic", "OBSERVATION_MODIFIER", 402, 409], ["pain", "OBSERVATION", 410, 414]]], ["29 The rapid transition to telehealth in response to physical distancing regulations allows people to access high-quality care without travelling, potentially increasing patient access to care.", [["people", "ORGANISM", 92, 98], ["patient", "ORGANISM", 170, 177], ["people", "SPECIES", 92, 98], ["patient", "SPECIES", 170, 177], ["The rapid transition", "PROBLEM", 3, 23], ["physical distancing regulations", "TREATMENT", 53, 84], ["rapid", "OBSERVATION_MODIFIER", 7, 12]]], ["It also opens up new opportunities and enables us to think about new ways of delivering pain management.", [["pain", "DISEASE", 88, 92], ["pain management", "TREATMENT", 88, 103]]], ["However, this mode of delivery may be particularly challenging for vulnerable groups due to poor health status and low technological literacy.", [["delivery", "TREATMENT", 22, 30], ["vulnerable groups", "PROBLEM", 67, 84], ["poor health status", "PROBLEM", 92, 110]]], ["71 Even when services are delivered through telehealth, the fear of sharing confidential information from home and juggling multiple social responsibilities, particularly for women, pose further barriers to engaging in high-quality care.", [["women", "ORGANISM", 175, 180], ["women", "SPECIES", 175, 180]]], ["64 In the context of delivery, practical challenges in conducting multidisciplinary treatment through telehealth 77 may lead to a prioritising of individual over multidisciplinary approaches.", [["delivery", "TREATMENT", 21, 29], ["practical challenges", "TREATMENT", 31, 51]]], ["This is despite evidence that care delivered through telehealth can be as effective as face-to-face care for people experiencing pain conditions.", [["pain", "DISEASE", 129, 133], ["people", "ORGANISM", 109, 115], ["people", "SPECIES", 109, 115], ["pain conditions", "PROBLEM", 129, 144]]], ["55Exacerbation of social injustice and social inequalitiesCOVID-19 is exacerbating existing social injustices and inequalities.", [["Exacerbation of social injustice", "DISEASE", 2, 34]]], ["Extreme events such as terrorist attacks and natural disasters 32, 44, 96 are known to undermine the fundamental belief that the world is just, stable, orderly, and predictable, 52 with ramifications for perceived life control, future prospects, and wellbeing.", [["Extreme events", "PROBLEM", 0, 14], ["perceived life control", "TREATMENT", 204, 226], ["stable", "OBSERVATION_MODIFIER", 144, 150]]], ["67, 86 This is particularly relevant to chronic pain because commitment to the belief in a just world can buffer against its adverse effects.", [["pain", "DISEASE", 48, 52], ["chronic pain", "PROBLEM", 40, 52], ["its adverse effects", "PROBLEM", 121, 140], ["chronic", "OBSERVATION_MODIFIER", 40, 47], ["pain", "OBSERVATION", 48, 52]]], ["57 A pandemic-initiated violation of just-world beliefs could exacerbate perceived injustices associated with pain.", [["pain", "DISEASE", 110, 114], ["A pandemic", "PROBLEM", 3, 13], ["perceived injustices", "PROBLEM", 73, 93], ["pain", "PROBLEM", 110, 114]]], ["16 For example, physical distancing policies could further increase social isolation and potentially worsen perceived injustices, 80 while disrupting social networks that are sources of justice and support 74 may heighten perceptions of invalidation among those with pain, driven by the sense that one does not matter to others.", [["pain", "DISEASE", 267, 271], ["social isolation", "TREATMENT", 68, 84], ["pain", "PROBLEM", 267, 271]]], ["17 Variation in the effect of COVID-19 illustrates social inequalities around pain, and health care more generally.", [["pain", "DISEASE", 78, 82], ["COVID", "TEST", 30, 35], ["pain", "PROBLEM", 78, 82], ["Variation", "OBSERVATION_MODIFIER", 3, 12]]], ["There are known individual differences in pain associated with social identities, including sex, ethnicity, and age.", [["pain", "DISEASE", 42, 46], ["known individual differences in pain", "PROBLEM", 10, 46], ["individual", "OBSERVATION_MODIFIER", 16, 26], ["differences", "OBSERVATION_MODIFIER", 27, 38], ["pain", "OBSERVATION", 42, 46]]], ["6, 33 There are also social inequalities and biases, which can affect pain burden 25 and access to pain care.", [["pain", "DISEASE", 70, 74], ["pain", "DISEASE", 99, 103], ["pain burden", "PROBLEM", 70, 81], ["pain care", "TREATMENT", 99, 108]]], ["24, 82 Structural and individual biases towards minority and marginalized groups that are heightened by uncertainty, stress, and fear 49 are likely to be exacerbated by COVID-19.", [["COVID-19", "CHEMICAL", 169, 177], ["COVID", "TEST", 169, 174]]], ["Discrimination experienced by marginalized groups can affect peripheral and central processes, including immune functioning, 20,28,83 thus compounding the negative effects associated with the stigmatization of chronic pain.", [["chronic pain", "DISEASE", 210, 222], ["peripheral", "TISSUE", 61, 71], ["peripheral and central processes", "PROBLEM", 61, 93], ["immune functioning", "TEST", 105, 123], ["chronic pain", "PROBLEM", 210, 222], ["central", "ANATOMY_MODIFIER", 76, 83], ["chronic", "OBSERVATION_MODIFIER", 210, 217], ["pain", "OBSERVATION", 218, 222]]], ["26 Those living in poorer and/or more remote communities have higher rates of chronic pain and comorbidities 60, 62 and limited access to health care, which can lead to greater unmanaged pain and disability.", [["pain", "DISEASE", 86, 90], ["pain", "DISEASE", 187, 191], ["disability", "DISEASE", 196, 206], ["chronic pain", "PROBLEM", 78, 90], ["greater unmanaged pain and disability", "PROBLEM", 169, 206], ["chronic", "OBSERVATION_MODIFIER", 78, 85], ["pain", "OBSERVATION", 86, 90]]], ["3, 4 Reduced access to health care, higher costs, and language might form additional barriers to pain management in these communities (eg, refugees).", [["pain", "DISEASE", 97, 101], ["health care", "TREATMENT", 23, 34], ["pain management", "TREATMENT", 97, 112]]], ["For example, disabling chronic pain can be more prevalent in Indigenous populations, who are also less likely to access support services.", [["chronic pain", "DISEASE", 23, 35], ["disabling chronic pain", "PROBLEM", 13, 35], ["disabling", "OBSERVATION_MODIFIER", 13, 22], ["chronic", "OBSERVATION_MODIFIER", 23, 30], ["pain", "OBSERVATION", 31, 35]]], ["3, 4, 8 Travel restrictions imposed to limit the spread of COVID-19 into remote communities are likely to disrupt the provision of nonessential services, further limiting access to pain care.", [["COVID-19", "CHEMICAL", 59, 67], ["pain", "DISEASE", 181, 185], ["nonessential services", "TREATMENT", 131, 152], ["pain care", "TREATMENT", 181, 190]]], ["Socioeconomic disadvantage also increases vulnerability to disease, including COVID-19, through many potential pathways including lower social support, 89 overcrowding, poorer sanitation, neighbourhood, and housing conditions, and poorer health behaviours (eg, smoking, diet, alcohol consumption, and reduced exercise).", [["alcohol", "CHEMICAL", 276, 283], ["alcohol", "CHEMICAL", 276, 283], ["alcohol", "SIMPLE_CHEMICAL", 276, 283], ["Socioeconomic disadvantage", "PROBLEM", 0, 26], ["COVID", "TEST", 78, 83], ["lower social support", "TREATMENT", 130, 150]]], ["9, 70 Furthermore, although people from lower socioeconomic backgrounds are overrepresented in \"essential\" employment sectors, which have been largely spared from COVID-19-related redundancies, many of these employees are now facing longer working hours under more demanding conditions.", [["people", "ORGANISM", 28, 34], ["people", "SPECIES", 28, 34]]], ["All these factors could not only lead to increased risk of exposure to COVID-19, but also, if left untreated, exacerbate other conditions, including chronic pain.", [["COVID-19", "CHEMICAL", 71, 79], ["chronic pain", "DISEASE", 149, 161], ["COVID-19", "CHEMICAL", 71, 79], ["COVID", "TEST", 71, 76], ["chronic pain", "PROBLEM", 149, 161], ["chronic", "OBSERVATION_MODIFIER", 149, 156], ["pain", "OBSERVATION", 157, 161]]], ["In short, COVID-19 has disproportionately affected socially disadvantaged groups, and the ensuing global economic fallout could magnify these inequalities in pain further.", [["pain", "DISEASE", 158, 162], ["pain", "PROBLEM", 158, 162]]], ["90 The concern is that the most economically disadvantaged will be most likely to be exposed to the hazard, most susceptible to harm from it, and most likely to experience negative outcomes from it.", [["most likely", "UNCERTAINTY", 146, 157]]], ["88Responding to social threats posed by COVID-19The wide range of social threats that COVID-19 brings to those in pain means that no one response will address all these issues.", [["COVID-19", "CHEMICAL", 40, 48], ["pain", "DISEASE", 114, 118], ["COVID-19", "CHEMICAL", 40, 48], ["wide", "OBSERVATION_MODIFIER", 52, 56], ["range", "OBSERVATION_MODIFIER", 57, 62]]], ["For example, just as some treatments have moved online, it may also be possible to mitigate some of the impacts of physical distancing and social isolation using technology.", [["may also be possible", "UNCERTAINTY", 59, 79]]], ["Social media platforms, due to their wide reach and penetration, can help disseminate key information about COVID-19, providing virtual support to enhance social connectedness.", [["virtual support", "TREATMENT", 128, 143]]], ["58 People with pain already report using digital peersupport groups to connect with similar others and derive benefits from feeling validated and heard.", [["pain", "DISEASE", 15, 19], ["People", "SPECIES", 3, 9], ["pain", "PROBLEM", 15, 19], ["digital peersupport groups", "TREATMENT", 41, 67]]], ["Increasing digital social connectedness might afford people with chronic pain more social contact and accessibility than is possible face-to-face because it does not require physical mobility.", [["pain", "DISEASE", 73, 77], ["people", "ORGANISM", 53, 59], ["people", "SPECIES", 53, 59], ["chronic pain", "PROBLEM", 65, 77]]], ["However, we also need to ensure that the use of social platforms is beneficial, and do not increase risk (eg, due to the exposure to poor-quality health information that reinforces disability or propagating unproven and potentially harmful approaches).", [["disability", "DISEASE", 181, 191]]], ["Online technology can be used to facilitate the delivery of healthcare interventions, under the guidance of healthcare professionals.", [["Online technology", "TREATMENT", 0, 17], ["healthcare interventions", "TREATMENT", 60, 84]]], ["For example, cognitive behavioural therapies for loneliness delivered online can decrease loneliness and improve mental wellbeing.", [["loneliness", "DISEASE", 49, 59], ["cognitive behavioural therapies", "TREATMENT", 13, 44], ["loneliness", "PROBLEM", 49, 59]]], ["45, 46 Online pain management programs seem to hold promise, 29 particularly when patients have contact with healthcare providers, albeit remotely.", [["pain", "DISEASE", 14, 18], ["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90], ["Online pain management programs", "TREATMENT", 7, 38]]], ["54 Online resources can disseminate pain education, and online training programs on pain self-management can be developed for healthcare professionals, those with pain, and their close others.", [["pain", "DISEASE", 36, 40], ["pain", "DISEASE", 84, 88], ["pain", "DISEASE", 163, 167], ["pain education", "TREATMENT", 36, 50], ["online training programs", "TREATMENT", 56, 80], ["pain self", "TREATMENT", 84, 93], ["pain", "PROBLEM", 163, 167]]], ["30, 41, 84 However, these novel digital interventions might not be accessible for all and may even put up new barriers to those who require them the most (eg, socially disconnected individuals with limited digital literacy).Responding to social threats posed by COVID-19We also need to think beyond technology.", [["COVID-19We", "CHEMICAL", 262, 272], ["these novel digital interventions", "TREATMENT", 20, 53]]], ["The COVID-19 pandemic served to highlight the upstream social determinants of health, many of affect chronic pain directly.", [["chronic pain", "DISEASE", 101, 113], ["chronic pain", "PROBLEM", 101, 113]]], ["68, 87, 94 At the local level, online technologies could mitigate the social threat of existing social inequalities and injustices, providing access to relatively inexpensive, location-independent treatment, and social connection.", [["independent treatment", "TREATMENT", 185, 206]]], ["Coupled with systemic interventions such as increased government funding to telehealth services, reducing the costs and barriers to internet access, and making computers and mobile devices available to those who otherwise might not have access to them can further reduce these disparities.", [["systemic interventions", "TREATMENT", 13, 35], ["telehealth services", "TREATMENT", 76, 95], ["internet access", "TREATMENT", 132, 147], ["mobile devices", "TREATMENT", 174, 188], ["increased", "OBSERVATION_MODIFIER", 44, 53]]], ["97Conclusions and future directionsThe current pandemic has exacerbated existing sources of social threat for people with chronic pain.", [["chronic pain", "DISEASE", 122, 134], ["people", "ORGANISM", 110, 116], ["people", "SPECIES", 110, 116], ["chronic pain", "PROBLEM", 122, 134], ["chronic", "OBSERVATION_MODIFIER", 122, 129], ["pain", "OBSERVATION", 130, 134]]], ["To prevent a population-level increase in the severity and impact of chronic pain, it is critical to devote scientific attention to the assessment, mitigation, and prevention of sources of social threat for people with chronic pain.", [["chronic pain", "DISEASE", 69, 81], ["chronic pain", "DISEASE", 219, 231], ["people", "ORGANISM", 207, 213], ["people", "SPECIES", 207, 213], ["a population", "PROBLEM", 11, 23], ["level increase", "PROBLEM", 24, 38], ["the severity", "PROBLEM", 42, 54], ["chronic pain", "PROBLEM", 69, 81], ["the assessment", "TEST", 132, 146], ["mitigation", "TREATMENT", 148, 158], ["chronic pain", "PROBLEM", 219, 231], ["population", "OBSERVATION", 13, 23], ["increase", "OBSERVATION_MODIFIER", 30, 38], ["chronic", "OBSERVATION_MODIFIER", 69, 76], ["pain", "OBSERVATION", 77, 81], ["chronic", "OBSERVATION_MODIFIER", 219, 226], ["pain", "OBSERVATION", 227, 231]]], ["Table 1 outlines several high-impact areas for research to this end.", [["several", "OBSERVATION_MODIFIER", 17, 24], ["high", "OBSERVATION_MODIFIER", 25, 29]]], ["Crucially, COVID-19 should not only be regarded as a challenge but also as a unique opportunity for researchers and clinicians to develop new ways to deliver social support and pain management, as well as understand the impact of social adjustment among individuals with chronic pain.Conflict of interest statementThe authors have no conflicts of interest to report.", [["pain", "DISEASE", 177, 181], ["chronic pain", "DISEASE", 271, 283], ["social support", "TREATMENT", 158, 172], ["pain management", "TREATMENT", 177, 192], ["chronic pain", "PROBLEM", 271, 283]]], ["Priorities for research on social factors resulting from the COVID-19 pandemic. the social consequences of the pandemic for people with chronic pain. a.", [["chronic pain", "DISEASE", 136, 148], ["people", "ORGANISM", 124, 130], ["people", "SPECIES", 124, 130], ["a.", "SPECIES", 150, 152], ["the COVID", "TEST", 57, 66], ["pandemic", "PROBLEM", 70, 78], ["chronic pain", "PROBLEM", 136, 148], ["chronic", "OBSERVATION_MODIFIER", 136, 143], ["pain", "OBSERVATION", 144, 148]]], ["Assess nature and cohesion of family and wider social support networks and emotional connectedness of people with chronic pain during physical distancing. b.", [["chronic pain", "DISEASE", 114, 126], ["people", "ORGANISM", 102, 108], ["people", "SPECIES", 102, 108], ["chronic pain", "PROBLEM", 114, 126], ["chronic", "OBSERVATION_MODIFIER", 114, 121], ["pain", "OBSERVATION", 122, 126]]], ["Assess how minority and marginalised groups with chronic pain are accessing pain support during the pandemic, identifying possible facilitators and barriers. c.", [["chronic pain", "DISEASE", 49, 61], ["pain", "DISEASE", 76, 80], ["chronic pain", "PROBLEM", 49, 61], ["pain support", "TREATMENT", 76, 88], ["chronic", "OBSERVATION_MODIFIER", 49, 56], ["pain", "OBSERVATION", 57, 61]]], ["Assess different forms of social threat for people with chronic pain such as loneliness, experiences of injustice, victimization, and invalidation. d.", [["chronic pain", "DISEASE", 56, 68], ["loneliness", "DISEASE", 77, 87], ["people", "ORGANISM", 44, 50], ["people", "SPECIES", 44, 50], ["chronic pain", "PROBLEM", 56, 68]]], ["Examine the effects of social distancing measures in the workplace, and on job prospects after the COVID-19 pandemic for employees with chronic pain.Demographic and longitudinal studies on2.", [["chronic pain", "DISEASE", 136, 148], ["social distancing measures", "TREATMENT", 23, 49], ["chronic pain", "PROBLEM", 136, 148], ["longitudinal studies", "TEST", 165, 185], ["chronic", "OBSERVATION_MODIFIER", 136, 143], ["pain", "OBSERVATION", 144, 148]]], ["Fundamental research on biological, psychological, and/or social working mechanisms on the bidirectional relationship between social factors and pain. a.", [["pain", "DISEASE", 145, 149], ["a.", "SPECIES", 151, 153], ["pain", "PROBLEM", 145, 149]]], ["Assess the immediate and long-term effects of physical distancing on relevant pain outcomes and pain management strategies. b.", [["pain", "DISEASE", 78, 82], ["pain", "DISEASE", 96, 100], ["physical distancing", "TREATMENT", 46, 65], ["relevant pain outcomes", "TREATMENT", 69, 91], ["pain management strategies", "TREATMENT", 96, 122], ["long-term effects", "OBSERVATION_MODIFIER", 25, 42]]], ["Investigate whether pain-related stigma, discrimination, social isolation, or perceptions of injustice increase vulnerability to COVID-19 infection or affect risk-related behaviour. c.", [["pain", "DISEASE", 20, 24], ["COVID-19", "CHEMICAL", 129, 137], ["infection", "DISEASE", 138, 147], ["pain", "PROBLEM", 20, 24], ["stigma", "PROBLEM", 33, 39], ["social isolation", "TREATMENT", 57, 73], ["injustice increase vulnerability", "PROBLEM", 93, 125], ["COVID", "TEST", 129, 134], ["19 infection", "PROBLEM", 135, 147], ["infection", "OBSERVATION", 138, 147]]], ["Investigate the role of social learning in times of uncertainty and the effect on pain behaviour.Demographic and longitudinal studies on3.", [["pain", "DISEASE", 82, 86], ["pain behaviour", "PROBLEM", 82, 96], ["longitudinal studies", "TEST", 113, 133]]], ["Clinical and fundamental research on digital social support for chronic pain. a.", [["chronic pain", "DISEASE", 64, 76], ["a.", "SPECIES", 78, 80], ["digital social support", "TREATMENT", 37, 59], ["chronic pain", "PROBLEM", 64, 76], ["chronic", "OBSERVATION_MODIFIER", 64, 71], ["pain", "OBSERVATION", 72, 76]]], ["Study the potential limitations (eg, less physical activity, lower quality of social relationships) and strengths (eg, lower threshold for engagement) of digital social support compared to face-to-face social support on pain outcomes. b.", [["pain", "DISEASE", 220, 224], ["digital social support", "TREATMENT", 154, 176], ["pain outcomes", "PROBLEM", 220, 233]]], ["Conduct theory-based studies on mediators that influence the effectiveness of online social support for chronic pain complaints.", [["chronic pain", "DISEASE", 104, 116], ["online social support", "TREATMENT", 78, 99], ["chronic pain complaints", "PROBLEM", 104, 127]]], ["Clinical research on the effectiveness of digital pain management interventions for chronic pain. a.", [["pain", "DISEASE", 50, 54], ["chronic pain", "DISEASE", 84, 96], ["a.", "SPECIES", 98, 100], ["digital pain management interventions", "TREATMENT", 42, 79], ["chronic pain", "PROBLEM", 84, 96], ["chronic", "OBSERVATION_MODIFIER", 84, 91], ["pain", "OBSERVATION", 92, 96]]], ["Clinical trials comparing the effectiveness of digital vs face-to-face interventions. b.", [["Clinical trials", "TREATMENT", 0, 15], ["digital vs face-to-face interventions", "TREATMENT", 47, 84]]], ["Research on the quality of social relationships, communication and trust between professionals delivering online interventions and chronic pain patients. c.", [["chronic pain", "DISEASE", 131, 143], ["patients", "ORGANISM", 144, 152], ["patients", "SPECIES", 144, 152], ["online interventions", "TREATMENT", 106, 126], ["chronic pain patients", "PROBLEM", 131, 152]]], ["Identify barriers and facilitators for access to online treatments, especially for marginalized populations with chronic pain.5.Research into possible individual resilience mechanisms (eg, increased social cohesions, revaluation of values and priorities, increased uptake of online pain management) buffering against the effects of the pandemic on chronic pain.", [["chronic pain", "DISEASE", 113, 125], ["pain", "DISEASE", 282, 286], ["chronic pain", "DISEASE", 348, 360], ["online treatments", "TREATMENT", 49, 66], ["chronic pain", "PROBLEM", 113, 125], ["online pain management", "TREATMENT", 275, 297], ["chronic pain", "PROBLEM", 348, 360], ["chronic", "OBSERVATION_MODIFIER", 113, 120], ["pain", "OBSERVATION", 121, 125], ["chronic", "OBSERVATION_MODIFIER", 348, 355], ["pain", "OBSERVATION", 356, 360]]], ["Systemic research on the effects of multilevel social determinants of health on chronic pain and policies to address them (eg, labour relations, income inequality, neighbourhood deprivation, racism, sexism, ageism, access to health care, etc.), to strengthen population resilience to the impact of heightened social threats on chronic pain. a.", [["chronic pain", "DISEASE", 80, 92], ["chronic pain", "DISEASE", 327, 339], ["a.", "SPECIES", 341, 343], ["chronic pain", "PROBLEM", 80, 92], ["chronic pain", "PROBLEM", 327, 339], ["chronic", "OBSERVATION_MODIFIER", 327, 334], ["pain", "OBSERVATION", 335, 339]]], ["Research into integrated methods of intervention or analysis (eg, dynamic systems modelling) across micro (ie, families, partnerships), meso (ie, community, city, organizations), and macro (ie, nations, civilizations) levels of the social system.", [["intervention", "TREATMENT", 36, 48], ["analysis", "TEST", 52, 60], ["social system", "ANATOMY", 232, 245]]]], "703d99a1e7443b2ef48a334fe6b46145766a8d07": [["S136Abstracts / Journal of Biotechnology 136S (2008) S130-S139 teins.", [["Journal of Biotechnology 136S (2008) S130-S139 teins", "DNA", 16, 68]]], ["A fusion protein, human cytotoxic T-lymphocyte antigen 4-immunoglobulin (hCTLA4Ig) was strongly induced by sugar starvation using rice alpha-amylase 3D (RAmy3D) promoter in transgenic rice cell suspension cultures.", [["cell", "ANATOMY", 189, 193], ["cultures", "ANATOMY", 205, 213], ["sugar", "CHEMICAL", 107, 112], ["human", "ORGANISM", 18, 23], ["cytotoxic T-lymphocyte antigen 4", "GENE_OR_GENE_PRODUCT", 24, 56], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 57, 71], ["hCTLA4Ig", "GENE_OR_GENE_PRODUCT", 73, 81], ["sugar", "SIMPLE_CHEMICAL", 107, 112], ["alpha-amylase 3D", "GENE_OR_GENE_PRODUCT", 135, 151], ["RAmy3D", "GENE_OR_GENE_PRODUCT", 153, 159], ["fusion protein", "PROTEIN", 2, 16], ["human cytotoxic T-lymphocyte antigen 4", "PROTEIN", 18, 56], ["immunoglobulin", "PROTEIN", 57, 71], ["hCTLA4Ig", "PROTEIN", 73, 81], ["rice alpha-amylase 3D (RAmy3D) promoter", "DNA", 130, 169], ["transgenic rice cell suspension cultures", "CELL_LINE", 173, 213], ["human", "SPECIES", 18, 23], ["rice", "SPECIES", 130, 134], ["rice", "SPECIES", 184, 188], ["human", "SPECIES", 18, 23], ["rice", "SPECIES", 130, 134], ["rice", "SPECIES", 184, 188], ["A fusion protein", "TEST", 0, 16], ["human cytotoxic T", "TEST", 18, 35], ["lymphocyte antigen", "TEST", 36, 54], ["rice alpha-amylase 3D (RAmy3D) promoter", "TREATMENT", 130, 169], ["transgenic rice cell suspension cultures", "TREATMENT", 173, 213], ["rice cell suspension", "OBSERVATION", 184, 204]]], ["Nevertheless, there are some considerations which this inducible promoter system caused cell death because of sugar depletion during production phase.", [["cell", "ANATOMY", 88, 92], ["death", "DISEASE", 93, 98], ["sugar", "CHEMICAL", 110, 115], ["cell", "CELL", 88, 92], ["sugar", "SIMPLE_CHEMICAL", 110, 115], ["cell death", "PROBLEM", 88, 98], ["sugar depletion", "PROBLEM", 110, 125], ["sugar depletion", "OBSERVATION", 110, 125]]], ["Delay of the production due to existence of the residual sugar was an indispensable problem during the induction period by medium exchange in bioreactor.", [["sugar", "CHEMICAL", 57, 62], ["sugar", "SIMPLE_CHEMICAL", 57, 62], ["the residual sugar", "PROBLEM", 44, 62], ["medium exchange in bioreactor", "TREATMENT", 123, 152]]], ["In addition, loss of productivity associated with scale-up in flasks or bioreactors was related with hydrodynamic stress.", [["loss of productivity", "PROBLEM", 13, 33], ["bioreactors", "TREATMENT", 72, 83], ["hydrodynamic stress", "PROBLEM", 101, 120], ["loss", "OBSERVATION_MODIFIER", 13, 17], ["productivity", "OBSERVATION_MODIFIER", 21, 33], ["hydrodynamic stress", "OBSERVATION", 101, 120]]], ["In this study, the effects of inoculation methods and flask size on production of hCTLA4Ig were confirmed.", [["hCTLA4Ig", "GENE_OR_GENE_PRODUCT", 82, 90], ["hCTLA4Ig", "PROTEIN", 82, 90], ["this study", "TEST", 3, 13], ["inoculation methods", "TREATMENT", 30, 49], ["flask size", "PROBLEM", 54, 64], ["production of hCTLA4Ig", "TREATMENT", 68, 90], ["size", "OBSERVATION_MODIFIER", 60, 64]]], ["Different flask sizes (0.1, 0.25, 0.5, 1, 2 and 5 L) and inoculation methods (suspension and filtered cells) were applied to investigate their effects during production phase in Erlenmeyer flasks.", [["cells", "ANATOMY", 102, 107], ["cells", "CELL", 102, 107], ["Different flask sizes", "TEST", 0, 21], ["inoculation methods (suspension and filtered cells", "TREATMENT", 57, 107], ["flask", "OBSERVATION_MODIFIER", 10, 15], ["sizes", "OBSERVATION_MODIFIER", 16, 21]]], ["It was found that the volume ratio of spent medium containing residual sugar and settled cells, and flask size specifically influenced hCTLA4Ig expression pattern, cell viability and protease activity.", [["cells", "ANATOMY", 89, 94], ["cell", "ANATOMY", 164, 168], ["sugar", "CHEMICAL", 71, 76], ["sugar", "SIMPLE_CHEMICAL", 71, 76], ["cells", "CELL", 89, 94], ["hCTLA4Ig", "GENE_OR_GENE_PRODUCT", 135, 143], ["cell", "CELL", 164, 168], ["settled cells", "CELL_TYPE", 81, 94], ["hCTLA4Ig", "PROTEIN", 135, 143], ["protease", "PROTEIN", 183, 191], ["the volume ratio", "TEST", 18, 34], ["residual sugar and settled cells", "PROBLEM", 62, 94], ["flask size", "PROBLEM", 100, 110], ["influenced hCTLA4Ig expression pattern", "PROBLEM", 124, 162], ["cell viability", "PROBLEM", 164, 178], ["protease activity", "TREATMENT", 183, 200], ["settled cells", "OBSERVATION", 81, 94], ["size", "OBSERVATION_MODIFIER", 106, 110], ["cell viability", "OBSERVATION", 164, 178]]], ["In conclusion, it was essential to minimize the residual sugar in suspensions and hydrodynamic stress by scale-up for the enhancement of the production with RAmy3D promoter system.", [["sugar", "CHEMICAL", 57, 62], ["sugar", "SIMPLE_CHEMICAL", 57, 62], ["RAmy3D", "GENE_OR_GENE_PRODUCT", 157, 163], ["RAmy3D promoter", "DNA", 157, 172], ["the residual sugar in suspensions", "PROBLEM", 44, 77], ["hydrodynamic stress", "PROBLEM", 82, 101], ["RAmy3D promoter system", "TREATMENT", 157, 179], ["residual sugar", "OBSERVATION", 48, 62], ["hydrodynamic stress", "OBSERVATION", 82, 101]]], ["Porcine epidemic diarrhea virus (PEDV) is coronavirus and a causative agent for diarrhea in pigs, particularly in neonates.", [["Porcine epidemic diarrhea virus", "DISEASE", 0, 31], ["coronavirus", "DISEASE", 42, 53], ["diarrhea", "DISEASE", 80, 88], ["Porcine epidemic diarrhea virus", "ORGANISM", 0, 31], ["coronavirus", "ORGANISM", 42, 53], ["pigs", "ORGANISM", 92, 96], ["neonates", "ORGANISM", 114, 122], ["Porcine epidemic diarrhea virus", "SPECIES", 0, 31], ["coronavirus", "SPECIES", 42, 53], ["pigs", "SPECIES", 92, 96], ["Porcine epidemic diarrhea virus", "SPECIES", 0, 31], ["PEDV", "SPECIES", 33, 37], ["pigs", "SPECIES", 92, 96], ["Porcine epidemic diarrhea virus", "PROBLEM", 0, 31], ["PEDV", "PROBLEM", 33, 37], ["coronavirus", "PROBLEM", 42, 53], ["diarrhea", "PROBLEM", 80, 88]]], ["The propagation of the PEDV in cell culture was developed in 1988.", [["cell culture", "ANATOMY", 31, 43], ["PEDV", "CELL", 23, 27], ["cell", "CELL", 31, 35], ["PEDV", "DNA", 23, 27], ["the PEDV in cell culture", "TEST", 19, 43], ["PEDV", "OBSERVATION", 23, 27]]], ["PED disease vaccine is produced from Vero cells by using lively attenuated virus strain (Hofmann and Wyler, 1988) .", [["Vero cells", "ANATOMY", 37, 47], ["PED disease", "DISEASE", 0, 11], ["Vero cells", "CELL", 37, 47], ["Vero cells", "CELL_LINE", 37, 47], ["PED disease vaccine", "PROBLEM", 0, 19], ["Vero cells", "PROBLEM", 37, 47], ["lively attenuated virus strain", "PROBLEM", 57, 87], ["disease", "OBSERVATION", 4, 11]]], ["Industrially important viruses such as viral vaccines have been typically produced using anchorage-dependent cell lines in host cell culture systems (Lee et al., 1995) .", [["cell lines", "ANATOMY", 109, 119], ["cell culture", "ANATOMY", 128, 140], ["cell lines", "CELL", 109, 119], ["host cell", "CELL", 123, 132], ["anchorage-dependent cell lines", "CELL_LINE", 89, 119], ["Industrially important viruses", "PROBLEM", 0, 30], ["viral vaccines", "TREATMENT", 39, 53], ["anchorage-dependent cell lines", "TREATMENT", 89, 119], ["viruses", "OBSERVATION", 23, 30], ["dependent cell lines", "OBSERVATION", 99, 119], ["host cell", "OBSERVATION", 123, 132]]], ["The accumulation of ammonium ion in culture media is inevitable because ammonium ion is excreted as a byproduct of glutamine metabolism which is essential to mammalian cells.", [["cells", "ANATOMY", 168, 173], ["ammonium ion", "CHEMICAL", 20, 32], ["ammonium", "CHEMICAL", 72, 80], ["glutamine", "CHEMICAL", 115, 124], ["ammonium", "CHEMICAL", 20, 28], ["ammonium", "CHEMICAL", 72, 80], ["glutamine", "CHEMICAL", 115, 124], ["ammonium ion", "SIMPLE_CHEMICAL", 20, 32], ["ammonium ion", "SIMPLE_CHEMICAL", 72, 84], ["glutamine", "AMINO_ACID", 115, 124], ["mammalian cells", "CELL", 158, 173], ["mammalian cells", "CELL_TYPE", 158, 173], ["ammonium ion in culture media", "TREATMENT", 20, 49], ["ammonium ion", "PROBLEM", 72, 84], ["glutamine metabolism", "TREATMENT", 115, 135], ["accumulation", "OBSERVATION_MODIFIER", 4, 16], ["ammonium ion", "OBSERVATION", 20, 32], ["mammalian cells", "OBSERVATION", 158, 173]]], ["The inhibitory effect of ammonium ion is common to most animal cells.", [["cells", "ANATOMY", 63, 68], ["ammonium ion", "CHEMICAL", 25, 37], ["ammonium", "CHEMICAL", 25, 33], ["ammonium ion", "SIMPLE_CHEMICAL", 25, 37], ["cells", "CELL", 63, 68], ["animal cells", "CELL_TYPE", 56, 68], ["ammonium ion", "PROBLEM", 25, 37]]], ["Ammonium ion inhibits not only cell growth but also product formation such as interferon and vaccine.", [["cell", "ANATOMY", 31, 35], ["Ammonium", "CHEMICAL", 0, 8], ["Ammonium", "CHEMICAL", 0, 8], ["Ammonium ion", "SIMPLE_CHEMICAL", 0, 12], ["cell", "CELL", 31, 35], ["interferon", "GENE_OR_GENE_PRODUCT", 78, 88], ["interferon", "PROTEIN", 78, 88], ["Ammonium ion inhibits", "PROBLEM", 0, 21], ["cell growth", "PROBLEM", 31, 42], ["interferon and vaccine", "TREATMENT", 78, 100], ["only cell", "OBSERVATION_MODIFIER", 26, 35]]], ["Therefore, high cell density and high vaccine productivity could be achieved if ammonium ions were removed from the media as soon as they formed.", [["cell", "ANATOMY", 16, 20], ["ammonium ions", "CHEMICAL", 80, 93], ["ammonium", "CHEMICAL", 80, 88], ["cell", "CELL", 16, 20], ["ammonium ions", "SIMPLE_CHEMICAL", 80, 93], ["high cell density", "PROBLEM", 11, 28], ["high vaccine productivity", "PROBLEM", 33, 58], ["ammonium ions", "TREATMENT", 80, 93], ["high cell density", "OBSERVATION", 11, 28], ["high", "OBSERVATION_MODIFIER", 33, 37]]], ["In this study, the PEDV vaccine was produced by immobilized Vero cell in spinner flask coupled with in situ removal of ammonium ion.", [["cell", "ANATOMY", 65, 69], ["PEDV", "CHEMICAL", 19, 23], ["ammonium", "CHEMICAL", 119, 127], ["ammonium", "CHEMICAL", 119, 127], ["PEDV", "ORGANISM", 19, 23], ["Vero cell", "CELL", 60, 69], ["ammonium ion", "SIMPLE_CHEMICAL", 119, 131], ["Vero cell", "CELL_LINE", 60, 69], ["PEDV", "SPECIES", 19, 23], ["this study", "TEST", 3, 13], ["the PEDV vaccine", "TREATMENT", 15, 31], ["immobilized Vero cell in spinner flask", "TREATMENT", 48, 86], ["situ removal of ammonium ion", "TREATMENT", 103, 131], ["spinner flask", "OBSERVATION", 73, 86]]], ["A synthetic zeolite of membrane type was used as an ammonia adsorbents (Park et al., 1998) .ReferencesThe optimum operation variables such as multiplicity of infection (MOI), infection time, and harvest time was investigated before the in situ removal system was applied.", [["membrane", "ANATOMY", 23, 31], ["zeolite", "CHEMICAL", 12, 19], ["ammonia", "CHEMICAL", 52, 59], ["infection", "DISEASE", 158, 167], ["infection", "DISEASE", 175, 184], ["zeolite", "CHEMICAL", 12, 19], ["ammonia", "CHEMICAL", 52, 59], ["ammonia", "SIMPLE_CHEMICAL", 52, 59], ["A synthetic zeolite of membrane type", "TREATMENT", 0, 36], ["an ammonia adsorbents", "TREATMENT", 49, 70], ["The optimum operation", "TREATMENT", 102, 123], ["infection", "PROBLEM", 158, 167], ["infection", "PROBLEM", 175, 184], ["harvest time", "TREATMENT", 195, 207], ["the in situ removal system", "TREATMENT", 232, 258], ["membrane type", "OBSERVATION", 23, 36], ["infection", "OBSERVATION", 158, 167]]], ["The optimum operation variables for PEDV vaccine production in a spinner culture were MOI of 0.01 cell \u22121 , infection time of 72 h and harvest time of 48 h.", [["PEDV", "CHEMICAL", 36, 40], ["infection", "DISEASE", 108, 117], ["PEDV", "ORGANISM", 36, 40], ["PEDV", "SPECIES", 36, 40], ["The optimum operation", "TREATMENT", 0, 21], ["PEDV vaccine production", "TREATMENT", 36, 59], ["a spinner culture", "TEST", 63, 80], ["MOI", "TEST", 86, 89], ["infection time", "TEST", 108, 122]]], ["The optimum time for zeolite addition to 100 ml spinner flask in terms of volumetric virus productivity and specific virus productivity were 72 h and 48 h, respectively.", [["zeolite", "CHEMICAL", 21, 28], ["zeolite", "CHEMICAL", 21, 28], ["zeolite", "SIMPLE_CHEMICAL", 21, 28], ["zeolite addition", "TREATMENT", 21, 37], ["volumetric virus productivity", "PROBLEM", 74, 103]]], ["The volumetric virus productivity with zeolite treatment system was 2.6 times higher than that without zeolite treatment system in the media supplemented with 2.5 mM glutamine.", [["zeolite", "CHEMICAL", 39, 46], ["glutamine", "CHEMICAL", 166, 175], ["zeolite", "CHEMICAL", 39, 46], ["zeolite", "CHEMICAL", 103, 110], ["glutamine", "CHEMICAL", 166, 175], ["glutamine", "AMINO_ACID", 166, 175], ["The volumetric virus productivity", "PROBLEM", 0, 33], ["zeolite treatment system", "TREATMENT", 39, 63], ["zeolite treatment system", "TREATMENT", 103, 127], ["2.5 mM glutamine", "TREATMENT", 159, 175]]], ["The results showed that the integrated cell culture system coupled with immobilized cell culture and in situ removal of ammonium ion was very effective for the production of PEDV vaccine.", [["cell", "ANATOMY", 39, 43], ["cell", "ANATOMY", 84, 88], ["ammonium ion", "CHEMICAL", 120, 132], ["PEDV", "CHEMICAL", 174, 178], ["ammonium", "CHEMICAL", 120, 128], ["cell", "CELL", 39, 43], ["cell", "CELL", 84, 88], ["ammonium ion", "SIMPLE_CHEMICAL", 120, 132], ["PEDV", "SIMPLE_CHEMICAL", 174, 178], ["immobilized cell culture", "CELL_LINE", 72, 96], ["PEDV", "SPECIES", 174, 178], ["the integrated cell culture system", "TEST", 24, 58], ["immobilized cell culture", "TEST", 72, 96], ["situ removal of ammonium ion", "TREATMENT", 104, 132], ["PEDV vaccine", "TREATMENT", 174, 186]]]]}